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Abstract 
Acute and chronic pain is a common symptom of many diseases. Therapy is 
often not effective or is associated with significant adverse effects; the development 
of novel analgesic drugs with high therapeutic index is an urgent unmet clinical 
need. Several lines of evidence converge to show that pain is mostly signalled by 
activity in peripheral unmyelinated (C) or thinly myelinated (Aδ) sensory fibres, 
called nociceptors. A drug selectively affecting the conduction of nociceptors without 
interfering with the function of other peripheral nerve fibres (Aα, Aβ, Aγ) or cells in 
the central nervous system and heart would be an ideal pain therapeutic. 
We recently discovered that WIN17317-3, a small molecule 
iminodihydroquinoline, previously reported as a high affinity, state-dependent 
sodium channel (Nav) blocker, can produce such a selective nociceptor block. 
Specifically, WIN17317-3 blocks the conduction of nociceptive C-fibers, leaving A-
fibers, mainly involved in motor control and non-painful sensations, largely 
unaffected. To the best of our knowledge no other small molecule has been reported 
to exhibit such a selective blocking effect. This thesis describes the development of 
iminodihydroquinolines as novel analgesic candidate drugs with selective action on 
pain-signalling neurons. 
Following the traditional “hit” to “lead” drug discovery approach, a library of 
WIN17317-3 derivatives was synthesized. The compounds were screened using 
state of the art electrophysiological assays to determine their effects on the human 
Nav1.7 isoform, and selected structures were further characterized in a functional 
assay using rodent peripheral sensory nerves. Voltage-gated sodium channels are 
responsible for the generation and propagation of action potentials in all electrically 
excitable cells; Nav1.7 channels are highly expressed in nociceptors, but are 
sparsely expressed or absent in non-nociceptive neurons. The 
iminodihydroquinolines described, were found to potently inhibit Nav1.7 channels 
and nociceptor conduction leaving non-nociceptive fibers largely unaffected. A 
selected lead preclinical drug candidate was subjected to in vivo pharmacokinetic 
profiling and toxicity studies in rodents. The results suggest that 
iminodihydroquinolines may be suitable analgesic drugs for topical, local, or regional 
administration with a wide safety margin. 
To achieve selective blockade of nociceptors clinically without interfering with 
the action of motor neurons would be a major breakthrough for the treatment of pain 
disorders and anesthesia.  
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1. Voltage-Gated Sodium Channels as Targets for 
Pain Therapy 
 
1.1. Pain, an unmet clinical challenge 
Pain is one of the most important human experiences, and one of the most 
complex. It is defined as the “unpleasant sensory and emotional experience 
associated with actual or potential tissue damage” (International Association for the 
Study of Pain- ISAP).4 The definition recognizes pain as a multidimensional 
phenomenon involving sensory, affective and cognitive components, which are not 
necessarily correlated to tissue damage. 
Conventionally, pain is broadly categorized into two classes mainly on the 
basis of the arbitrary time interval from onset: acute and chronic pain.5 Acute pain is 
typically the result of soft tissue injury or inflammation notifying the presence of 
physical insult, is of sudden onset, and usually lasts for a short period of time (less 
than three months). It subsides when the underlying cause resolves. Acute pain can 
be successfully managed for the majority of patients with non-steroidal anti-
inflammatory drugs (NSAIDs), opioids, local anesthetics (LAs) and anticonvulsants. 
Chronic pain, by contrast, long outlasts the initial insult to tissues, lasts greater than 
six months and rarely serves any biological function.6 Although improvement maybe 
observed, for many patients complete cure can be rarely achieved using the current 
analgesic treatments.7 
Additionally, pain is classified as of three types according to its etiology: 
nociceptive, neuropathic and psychogenic.8, 9 Nociceptive pain arises due to noxious 
external or inflammatory stimuli activating free peripheral nerve endings, 
nociceptors, which transmit the signal to the central nervous system (CNS).10 
Neuropathic pain, which is also known as dysfunctional pain, is indicative of 
dysfunction or damage to the nervous system with some of the probable causes 
including mechanical factors (e.g. nerve compression), toxicity (e.g. from 
chemotherapeutic drugs), metabolic diseases (e.g diabetes), post-inflammatory 
changes or idiopathic causes. Its mechanisms are entirely different from that of 
normal - nociceptive pain as apart from the detection of inflammatory mediators by 
nociceptors, it also involves peripheral and central sensitization.11 Psychogenic pain 
most often has a physical origin (tissue damage or nerve damage) however in this 
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case the pain caused by the actual damage is increased or prolonged by 
psychological factors such as fear, depression, stress, or anxiety; it can also 
originate from purely psychological conditions. 
By any measure, pain is an enormous global health problem.12 The overall 
annual prevalence of chronic pain in Europe has been estimated to around 20% of 
the general population, significantly affecting the patients’ social and working lives.13 
Very few (2%) are managed by pain specialists and only half report receiving 
adequate pain treatment. Pain is the leading cause for absenteeism from work with 
nearly 500 million working days lost per annum costing the European economy at 
least €34 billion. Approximately 10% of the population use analgesic medications on 
a regular basis leading to substantial direct and indirect (because of the plethora of 
adverse events of these compounds) costs. This is highlighted by the fact that the 
fatality associated with the use of NSAIDs exceeds 5 per 100,000, number higher 
than that for cervical cancer or malignant melanoma.14 According to the official data 
of the American Academy of Pain Medicine, pain affects more Americans than 
diabetes, heart disease and cancer combined, and the annual cost of pain ($560- 
$635 billion) is nearly 30% higher than the combined cost of cancer and diabetes.15 
Evidently, pain management remains to date largely ineffective and the currently 
available pharmacological treatments are associated with significant adverse 
events. Development of novel, efficacious, analgesics with less serious adverse 
events is evidently an urgent unmet clinical need. 
 
1.2. The perception and modulation of pain: a brief overview 
The word “pain” comes from the Latin poena meaning penalty. Physiologists 
distinguish between the terms pain and nociception. Nociception refers to the 
signals arriving in the CNS as a result of activation of specialized sensory neurons, 
nociceptors, providing information about tissue damage. Pain is the unpleasant 
emotional experience that usually accompanies nociception.16 
The gate control theory of pain, proposed by Ronald Melzack and Patrick 
David Wall in 1965, was the first model explaining the variability between the input 
and output in the sensory system of pain, describing the relationship between 
nociceptive and non-nociceptive afferents in the dorsal horn as an electronic switch 
(Fig. 1).17,18 Despite flaws in the presentation of neural architecture, the model was 
the first to account for the physical and psychological aspects of pain perception; 
whilst more recent detailed mechanisms have been added to the model, the general 
framework remains intact to date. 
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Figure 1. Gate control theory of pain. This model proposed that inhibitory interneurons 
located in the substantia gelatinosa (yellow, GS) determine whether nociceptive input from 
the periphery is relayed through the spinal transmission system (pink, T) to the higher CNS 
for pain to be consciously received.
19
 
The sequence of events by which a painful stimulus is perceived involves 
four key processes: (a) transduction, (b) transmission, (c) modulation, and (d) 
perception (Fig. 2). Transduction occurs in the peripheral terminals of primary 
afferents where different forms of stimuli (mechanical, heat, chemical) are converted 
to electrical signals (action potential, AP).20, 1 The generated AP is transmitted 
through the nervous system via three major components. The peripheral sensory 
neurons will first transfer the impulse from the transduction site to the spinal cord, 
where their central terminals synapse with second-order neurons. The latter will 
subsequently send projections to the 
thalamus and various brainstem and 
diencephalic structures where neurons 
will finally project to various cortical sites. 
Modulation is the process by which 
neural activity can be altered along the 
pain transmission pathway.21 The major 
site for modulation is the dorsal horn. 
The process involves a multitude of 
neurotransmitter systems and can have 
both inhibitory and facilitator effects. 
Perception is the final stage of the pain 
signaling process. It is presumed to be 
the result of concerted activation of 
primary and secondary somatosensory 
and limbic cortices leading to the 
subjective sensation of pain. 
  
Figure 2. Schematic representation of pain 
signaling mechanisms showing ascending 
and descending modulatory pathways. 
Adapted from reference 1.
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In the following sections the peripheral pain nervous system is discussed in 
more detail. Further information for the central mechanisms of pain and other 
general aspects of pain can be found in all fundamental pain textbooks.1, 22, 23 
 
1.3. Peripheral mechanisms of pain 
Afferent neurons of the somatosensory system continuously “taste their 
environment”.24 They convey information about the external environment and the 
state of the organism itself to the CNS. Primary sensory neurons are classified into 
two main groups based on anatomical and functional criteria: (a) the myelinated A-
fibers which are subdivided into Aβ- and Aδ-fibers, and (b) the non-myelinated C-
fibers (Table 1). Each fiber class is responsible for transmitting a specific type of 
sensory information. 
Table 1. Anatomical and functional characteristics of sensory neuronal fibers. 
 Αβ-fibers Αδ-fibers C-fibers 
Schematic 
 
 
 
Threshold low medium High 
Axon diameter 6-14 μm 1-6 μm 0.1-1 μm 
Myelination yes Yes, thin No 
Velocity 36-90 ms
-1 
5-36 ms
-1
 0.1-1 ms
-1
 
Receptor type mechanoreceptor* mechanoreceptor 
nociceptor 
nociceptor 
Receptive field small Small small 
Quality touch* sharp “first” pain dull “second” pain 
*for the majority of fibers 
The two major types of afferents transmitting nociceptive information, named 
nociceptors, are the medium diameter myelinated Aδ-fibers which convey what is 
called “fast” pain (the initial component of acute pain) and the small diameter 
unmyelinated C-fibers, that mediate “slow” pain. In their vast majority Aβ fibers 
detect innocuous stimuli applied to skin, muscle and joints and thus do not 
contribute to pain.25 
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Like all primary sensory neurons, the cell bodies of nociceptors are located 
in the dorsal root ganglia (DRG) or the trigeminal ganglia for the innervation of the 
face. They have a peripheral axonal branch that innervates the target tissue (free 
nerve ending) and a central axon branch that enters the spinal cord to synapse with 
the CNS second order neurons (Fig. 3).26 
 
 
Figure 3. Anatomy of nociceptors. The central projections of nociceptors are highly 
organized with different types of fiber terminating within specific dorsal horn laminae. (A) 
Unmyelinated C-fibers project to superficial laminae I and II. (B) Myelinated A-fibers project 
to superficial laminae I and V. Adapted from reference 26.26 
Nociceptors can be found in any area of the body capable of sensing pain, 
either externally or internally, such as the skin, muscles, joints (somatic pain)27 and 
the internal organs (visceral pain).28, 29 Depending on the tissue they innervate they 
feature distinct anatomical and functional characteristics. Skin nociceptors, also 
known as cutaneous nociceptors, are the most thoroughly studied class of 
nociceptors. The neurophysiology of cutaneous nociceptors is discussed in more 
detail below. 
 
1.4. Neurochemistry of cutaneous nociceptors 
Peripheral nociceptors have four key operational components: 
(a) The free nerve ending, which is the peripheral terminal responsible for 
transducing external stimuli into APs 
(b) The axon responsible for transmitting APs 
(c) The cell body that controls the identity and the integrity of the neuron and 
(d) The central terminal which is the presynaptic elements of the first synapse, 
responsible for transmitting the information to the CNS. 
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1.4.1. Transduction 
Cutaneous nociceptor transduction is the process of detection of painful 
stimuli (hot and cold thermal stimuli, intense noxious mechanical stimuli, harmful 
chemical stimuli) by the nociceptive free nerve ending.30 The peripheral terminal 
sensitivity to the various stimulus modalities is mediated by multiple specialized 
receptors which upon activation lead to membrane depolarization and in effect to AP 
generation (Fig. 4). 
Briefly, thermal sensitivity is mostly mediated by transient receptor potential 
(TRP) channels, large ligand-gated cationic channels (Ca2+), that open in response 
to thermal fluctuations and certain chemical modulators.31 The vanilloid-1 (TRPV1)32 
subtype senses heat (> 43 °C) and can also be stimulated by capsaicin (the pungent 
ingredient of chili peppers) and protons. The ankyrin-1 (TRPA1)33, 34 and melastatin-
8 (TRPM8)35 subtypes sense cold as well as mustard oil and menthol respectively. 
Mechanotransduction is the least understood of the stimulus modalities, with 
different lines of evidence providing conflicting data.36, 37 The acid-sensing ion 
channels (ASIC),38 the Piezo 1 and 2 channels,39 and the TRPA140 are some of the 
transducers that appear to be implicated in the process. Lastly nociceptors can be 
stimulated by a wide range of chemicals that are either released as part of the 
inflammatory response or are external irritants (e.g. plant or insect stings). 
 
 
Figure 4. Potential mediators for nociceptor stimulation and the corresponding transducer 
receptors and ion channels in the peripheral free nerve ending. Adapted from reference 23.23  
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These mediators can act directly to alter the sensitivity of peripheral 
nociceptors or indirectly via coupling to one or more membrane bound receptors 
(TRP, ASICs, purinergic receptors (P2X), G-protein coupled receptors (GPCR), two-
pore potassium channels (K2P), and receptor tyrosine kinase (RTK)). Binding of 
ligands to their corresponding receptors can initiate a cascade of events that 
includes activation of second-messenger systems and alteration of gene regulation. 
Many, if not most, of the transducer receptors and ion channels can respond 
to more than one stimulus modality and are therefore named polymodal. The 
relative expression of transducer elements in specific subset of nociceptor sensory 
neurons defines their modality sensitivity. Nociceptors capable of detecting a wide 
range of stimulus modalities are defined as polymodal.26 
1.4.2. Action potential generation and axonal conduction 
Nociceptor stimulation at the free nerve ending and transducer activation as 
described above leads to local membrane depolarization, in graded response to the 
strength of the applied stimulus, named as the generator potential. This generator 
potential is passively propagated to a site with a high density of voltage-gated 
sodium channels (Nav) known as the AP initiation site. Depending on the size of the 
generator potential and the electrophysiological properties of the nociceptor 
terminal, an AP can be generated at the AP initiation site which will be subsequently 
propagated along the peripheral axon towards the CNS. 
Voltage-gated sodium channels (Navs) and potassium channels are the key 
players for the generation and transmission of neuronal APs (Fig. 5). Navs are 
responsible for the rising phase of the AP. The role of Navs in nociception is 
described extensively in section 1.7, these being the precise pharmacological 
targets of this study. 
 
Figure 5. Contribution of voltage-gated ion channels in neuronal action potential firing.  
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Potassium channels are responsible for the falling phase of the AP leading to 
cell membrane repolarization and hyperpolarization, which limits AP generation and 
the AP firing rate. Certain potassium channels do not inactivate at resting membrane 
potential, thereby a steady voltage-dependent outward current is generated, 
responsible for the stabilization of the membrane potential in the presence of small 
depolarizing currents. Potassium channels are classified into four groups: voltage-
gated (Kv), two-pore (K2P), calcium-activated (KCA), and inward rectifying (Kir).
41 Their 
most prominent expression patterns in peripheral neurons, as reported in literature, 
are depicted in Figure 6. 
 
Figure 6. Subcellular localization of potassium channel isoforms in unmyelinated and 
myelinated murine DRG neurons. Adapted from reference 42. 42 
 
1.4.3. CNS terminal - synaptic transmission 
Voltage-gated calcium channels (Cav), amongst their other crucial 
physiological roles, are the key mediators of synaptic transmission responsible for 
the initial influx of calcium into the nerve terminal that is required for 
neurotransmitter release.43 When an AP reaches the nociceptive central terminal, 
the membrane is depolarized, activating Cavs; calcium flux initiates a cascade of 
events leading to neurotransmitter release via synaptic vesicle exocytose 
(glutamate,44 substance P45). Cavs are classified into two groups based on their 
electrophysiological properties: low-voltage (T-type) and high-voltage (L, N, P/Q and 
R-type) activation threshold Cavs.
43 
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All Cav types are found in the dorsal horn, 
yet evidence suggests that the high-
threshold N and P/Q type Cavs are the 
ones predominantly expressed on the 
central terminals of presynaptic 
afferents.46 A number of excitatory 
ionotropic receptors as well as excitatory 
and inhibitory GPCRs appear to modulate 
(facilitate or inhibit) the neurotransmitter 
release (Fig. 7). 
 
 
1.5. Nociceptor sensitization 
Sensitization -increased excitability- is a characterizing and important 
property of nociceptors. It typically develops as a consequence of tissue insult and 
inflammation and can be expressed and defined as a reduction in the threshold of 
nociceptor activation or/and an increase in the magnitude of a response to noxious 
stimulation (hyperalgesia).47 Naturally ineffective stimuli may become effective 
(allodynia) and can also be accompanied by the development of ongoing, 
spontaneous activity. Furthermore, nociceptor sensitization may include a decrease 
in the response adaptation something that is commonly observed when a certain 
stimulus is applied for a prolonged period of time. Peripheral nociceptor sensitization 
can also trigger increased excitability of central neurons in the nociceptive pathway, 
an event termed “central sensitization”.48 This is found to contribute both in acute 
chemogenic but also neuropathic chronic pain.49 
Mechanistically, sensitization is a reflection of changes in the behavior of 
voltage-gated and/or ligand-gated ion channels, resulting from the release of 
endogenous substances that are either synthesized or attracted at the site of tissue 
insult.2 Endogenous substances typically contributing to nociceptor sensitization 
include the inflammatory mediators described in section 1.4.1. Arachidonic acids, 
prostanoids,50 and the tumor necrosis factor-α (TNF-α), appear to play a particularly 
important role in nociceptor sensitization.51 
  
Figure 7. Release of neurotransmitters and 
neuromodulators, upon AP arrival at the pre-
synaptic nociceptive terminal, in the superficial 
dorsal horn of the spinal cord or the brainstem. 
Adapted from reference 2.
2
 
Introduction 
 
10 
1.6. Pain pharmacology 
Several classes of pharmacological agents are currently used for pain 
management. The most commonly used system for classifying analgesic drugs is 
the world health organization (WHO) ladder which separates them into three groups 
based on increasing strength of analgesic properties: non-opioid drugs, weak 
opioids and strong opioids (Fig. 8). 
 
Figure 8. The adapted WHO analgesic ladder. The classic 1986 version of the WHO 
analgesic ladder, originally applied to management of cancer pain, proposed the treatment 
should begin with non-opioid medication, followed by the use of weak and strong opioids if 
pain is not controlled. The updated bidirectional version of the ladder (vide supra) is 
applicable for the treatment of both acute and chronic (including cancer) pain conditions, and 
it integrates a fourth step with invasive analgesic techniques.
52
 
The most widely prescribed drugs in the world are the non-opioid analgesics 
NSAIDs and acetaminophen (paracetamol), valuable in the management of both 
acute and chronic painful and inflammatory conditions, administered both 
systemically and locally. NSAIDs act via inhibition of cyclo-oxygenase (COX), a key 
enzyme of the arachidonic acid 
metabolic pathway (Fig. 9). There are 
two COX isoforms, COX-1 and COX-2. 
COX-1 is constitutively expressed and 
has a homeostatic role (blood fluidity and 
blood pressure) and a protective role in 
the gastro-intestinal (GI) mucosa. COX-2 
expression is inducible in inflamed 
tissues and leads to prostaglandin E2 
(PGE2) production, which is known to 
Figure 9. Non-selective NSAIDs and their 
molecular mechanism of action at the 
arachidonic acid metabolic pathway. 
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sensitize the peripheral terminals of sensory afferents. NSAIDs mediate their 
analgesic, antipyretic and anti-inflammatory effects via COX-2 blockade.53 Early 
NSAIDs (such as aspirin) are non-selective for the two enzymes, and are associated 
with serious GI side effects; in the last decade, COX-2 selective NSAIDs (e.g. 
rofecoxib) have been introduced as a safer alternative in terms of GI effects,54 
however at the expense of cardiovascular safety.55 Acetaminophen is a para-
aminophenol derivative with analgesic and antipyretic properties like NSAIDs. Its 
mechanism of action is largely unknown with recent reports suggesting that the 
analgesic effects may be mediated via the serotogenic pathway.56 It has no effect on 
peripheral PG synthetase inhibition hence lacks the useful peripheral anti-
inflammatory activity of NSAIDs, however it is much better tolerated. 
Opioids are the most effective treatment for patients with moderate and 
severe pain. Opioids bind to specific GPCRs, the opioid receptors, which are found 
in the periphery, at pre- and post-synaptic sites in the dorsal horn, in the brain stem, 
thalamus and cortex (ascending pain pathways) and in structures of the descending 
inhibitory pain system.57 Opioid receptors are divided in three principle classes: μ, κ 
and δ. Clinically used opioids (e.g. morphine, codeine, tramadol) are predominantly 
μ-receptor agonists. At cellular level, opioid receptor activation inhibits Cavs 
reducing neurotransmitter release, and also certain Kvs leading to hyperpolarization 
of postsynaptic neurons. A third mechanism of opioid action is the activation of 
descending inhibitory pain transmission, via inhibition of γ-aminobutyric acid (GABA) 
modulatory interneurons.58 Given their ubiquitous expression in the nervous system, 
opioid receptors influence numerous physiological functions such as reward, stress, 
respiration, and GI motility; opioid use is therefore associated with multiple adverse 
effects. 
Several other pharmacological classes are used in pain management, mainly 
in efforts to alleviate chronic conditions such as neuropathic and cancer pain.59 The 
antidepressants,60 the anticonvulsants,61, 62 the muscle relaxants and the LAs are 
frequently employed for pain relief; as their primary indication is other than pain 
relief, these are often referred to as adjuvant analgesics. The analgesic effects of 
these drugs are mediated, for the vast majority of cases, via Nav inhibition or Cav 
modulation. Clinically used Nav blockers are discussed in detail in section 1.7.6. 
Analgesic drugs with different molecular mechanisms of action are often 
administered together, aiming at superior efficacy and safety compared to the drugs 
acting alone. 
The insufficient effectiveness for the treatment of several types of pain and 
the adverse effects associated with currently marketed analgesic drugs are the two 
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driving forces for the development of novel pain therapeutics.63 A large number of 
potential pain targets have emerged in the last decade and extensive efforts are 
being made for exploiting those as novel strategies for treating pain.64 However, 
their probability of success cannot be determined until these are evaluated in Phase 
2 (efficacy) clinical trials. 
Analgesic drugs currently in development (already in or very close to 
entering clinical studies) include drugs that have arisen as a result of improvements 
in drugs/targets that are already used clinically (e.g. variations on the theme of 
NSAIDs, COX-2 and opioid inhibitors), as well as chemical entities targeting novel 
pain targets (e.g. voltage-gated ion channels and TRP channels). The use of 
biologics for the treatment of pain is also being evaluated. This topic is extensively 
described in the Wall and Melzack’s, Textbook of pain.23 
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1.7. The voltage-gated sodium channel (Nav) as therapeutic 
target for pain 
Voltage gated sodium channels (Navs) play a key role in the neuronal 
network, by initiating and propagating APs rapidly throughout neurons and other 
electrically excitable cells. Navs in multicellular organisms are responsible for the 
communication and the coordination of higher processes, such as cognition and 
locomotion, where fast signal transmission is of essence. Variation in the expression 
of Navs has been linked with multiple diseases like epilepsy, cancer, multiple 
sclerosis, stroke and pain.65 Recent clinical and experimental data validate the 
Nav1.7 isoform as a potential therapeutic target for pain. 
 
1.7.1. Structure 
Navs are dynamic transmembrane proteins present in all eukaryotic cells, as 
well as certain types of prokaryotes, though their exact role in the latter is still to be 
understood. They consist of a principal α-subunit (~260 kDa) which folds to shape 
the ion-conducting pore, and one or more smaller auxiliary β-subunits (~39 kDa) 
which assist in the integration of the α-subunit into the membrane and modulate the 
biophysical properties of the channel. 
 
Figure 10. Schematic representation of the generic structure of the mammalian Nav α-
subunit. The α-subunit is composed of four pseudo homologous domains (I to IV), each 
comprised by six transmembrane segments (1 to 6) presented as cylinders. The S4 
segments serve as the voltage sensor (+). Pink circles indicate the positions of amino acids 
important for ion conductance and selectivity. Green circles indicate the positions of 
hydrophobic amino acids part of the inactivation gate, which is thought to fold into and block 
the ion-conducting pore. Side view (left) and top view (right). Adapted from references 66, 67.66, 
67
 
Introduction 
 
14 
The α-subunit comprises of four pseudo homologous domains (I-IV) sharing 
approximately 90% sequence identity. Each of the four domains corresponds to six 
segments (S1-S6) which traverse the membrane in the form of α-helices (Fig. 10). 
The S1-S4 segments comprise the voltage-sensing region whereas S5-S6 
segments and the re-entrant loop, consist the pore forming region. Residues in the 
S5-S6 unit determine the channel’s selectivity and ion permeation properties.66, 68, 69 
The mammalian Nav channel, being a large amphipathic membrane, is 
exceptionally difficult to crystalize therefore no direct three-dimensional (3D) 
structural information is available to date. The molecular model currently available 
for the α-subunit relies largely on information provided by the crystal structure of the 
structurally related Kv channel, by studies using mammalian Nav chimeras and point 
mutation experiments. The crystal structure of a bacterial voltage-gated sodium 
channel (NaChBac) from Arcobacter bultzeri, a homotetramer with similar 
pharmacological profile to the mammalian Nav channel, was solved in 2011 (2.7 Å 
resolution) with the channel being in a pre-open conformation.70 Later work revealed 
structures of the channel in two inactivated states.71 Since then, two additional 
NaChBacs crystal structures became available, altogether providing significant new 
information about the architecture of the pore, the selectivity filter, and probable 
interaction sites with channel modulators.72, 73 
 
1.7.2. Function 
The opening and closing of Navs requires their transit between different 
conformational states depending on the voltage gradient across the membrane, a 
model first proposed by Hodgins and Huxley in 1952 termed as voltage-gating.74 At 
resting membrane potential (~ -70 mV), the channels exist in a resting, closed, non-
conducting state (Fig. 11). In response to an electrical stimulus that depolarizes 
sufficiently the membrane (> -50 mV), positively charged residues in the S4 voltage-
sensor region (in particular arginines), induce changes to the tertiary structure of the 
protein, allowing the opening of the pore and the selective passage of sodium ions 
inside the cell; this constitutes the upstroke of the AP. On sustained depolarization 
(~ +35 mV) the channel enters an inactivated closed state, which leaves the channel 
refractory, i.e, unable to open again for a period of time. Two types of inactivation 
processes exist, the “classical” fast inactivation (in the ms range) and a slow 
inactivation that can last much longer (up to seconds).75 The two types of 
inactivation have different underlying mechanisms, located in different parts of the 
channel and consequently respond differently to bio/chemical agents. Subsequent to 
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inactivation and membrane depolarization, the channel re-enters the closed resting 
state. Changes in the activation/inactivation properties of the channel have profound 
effects on the onset, frequency and duration of APs and hence on neuronal 
signaling. 
 
Figure 11. Classic Nav channel current profile. When the membrane is at resting potential,    
-90 mV, the channel is at its closed (resting state). Upon depolarization (shift of membrane 
potential to +30 mV), the channel becomes activated and sodium ions enter the cell through 
the Nav channel pore. Within a few ms the inactivation loop “enters” the pore and the 
channel inactivates. When the membrane is repolarized to –50 mV, the channel partially 
recovers from inactivation, yet no current flows. Upon further repolarization to -90 mV the 
channel returns to its resting (closed) state. Adapted from reference 76.76 
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1.7.3. Nav subtypes, tissue distribution, and channelopathies 
Since the cloning of the first α-subunit in 1984, ten mammalian Nav subtypes 
have been identified, sharing 50% sequence identity within their transmembrane 
and extracellular domains.77 Nav isoforms are conventionally classified in two 
groups: those that are sensitive to block by the pufferfish toxin tetrodotoxin (TTX), 
exhibiting nanomolar potencies (Nav1.1, 1.2, 1.3, 1.4, 1.6, 1.7), and those that are 
resistant (Nav1.5, 1.8, 1.9) The ten Nav isoforms vary in terms of their 
pharmacology, their biophysical properties and their tissue distributions (Table 2). 
Table 2. Cloned Nav α-subunit genes, their major expression sites and the effect of their 
mutation.
78
 
79
 
Subunit Gene 
TTX 
sensitivity 
Major 
expression 
Effects of mutation (human) 
Nav1.1 SCN1A   CNS, PNS epilepsy, migraine, autism, 
episodic ataxia 
Nav1.2 SCN2A   CNS, PNS epilepsy, autism 
Nav1.3 SCN3A   CNS, PNS epilepsy 
Nav1.4 SCN4A   skeletal muscle hyperkalaemic periodic paralysis, 
paramyotonia congenita 
Nav1.5 SCN5A × cardiac muscle brugada syndrome, long QT 
syndrome 3, atrial fibrillation 
Nav1.6 SCN8A   CNS, PNS, 
smooth muscle 
mental retardation, pancerebellar 
atrophy, ataxia, infantile 
experimental encephalopathy 
Nav1.7 SCN9A   PNS congenital indifference in pain, 
erythromalalgia, paroxysomal 
extreme pain disorder, anosmia 
Nav1.8 SCN10A × PNS, heart idiopathic painful small-fiber 
neuropathy. 
Nav1.9 SNC11A × PNS painful peripheral neuropathy 
 Nax SNC6/7A non 
functional 
circumventricular 
organs 
Unknown 
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1.7.4. Localization of Nav isoforms in nociceptors and their 
biophysical characteristics 
Each Nav channel subtype has distinct electrophysiological properties, 
exhibiting specific voltage thresholds and transition kinetics for channel opening, 
inactivation, and recovery from inactivation, that determine the AP firing pattern of 
the cell type in which they are expressed. The precise anatomical distribution of Nav 
isoforms in sensory afferents is far from clear; channels are differentially distributed 
within a given afferent and between subpopulations of afferents.80 Out of the ten 
cloned Nav isoforms, five have been linked to nociceptor responses: Nav1.3, Nav1.6, 
Nav1.7, Nav1.8, and Nav1.9. Out of these, isoforms Nav1.7, Nav1.8, and Nav1.9, are 
almost exclusively expressed in nociceptors and hence their selective blockade is 
currently one of the most prominent novel strategies for the development of new 
analgesic drugs. The localization of Nav isoforms in nociceptors, as reported in 
literature, is discussed below alongside the isoforms’ salient characteristics. 
The Nav1.3 isoform is highly expressed in developing neurons, yet is not 
detectable in the adult nervous system. It has however been shown to be 
upregulated in DRG neurons following peripheral nerve injury.81 It exhibits fast 
activation and inactivation kinetics, characteristic of TTX-sensitive (TTX-S) 
channels, and recovers rapidly from inactivation thereby supporting repetitive 
neuronal firing. It is known to mediate a persistent current (INaP), a steady-state 
sodium current that is involved in AP initiation at membrane voltages near the 
threshold of firing.82 It responds to small depolarizations, close to the resting 
membrane potential, thus amplifying small current inputs.83 
The Nav1.6 isoform also exhibits fast kinetics and recovers rapidly from 
inactivation therefore sustaining high firing frequencies. It has the unique property of 
mediating resurgent currents (INaR), currents that occur during membrane 
repolarization due to unusual channel reopening, also contributing to high-frequency 
firing. Nav1.6 is the predominant Nav isoform in the nodes of Ranvier in both PNS 
and CNS myelinated neurons, supporting saltatory conduction. It has recently been 
demonstrated to also be a significant component of non-myelinated nociceptive 
neurons, contributing to AP propagation.84 
The Nav1.7 isoform is present along the entire trajectory of nociceptive DRG 
neurons, highly expressed in the cell body as well as in the peripheral and centrally 
directed axons and terminals.85 It exhibits fast kinetics but slow recovery from 
inactivation thus preventing high frequency firing. This is consistent with studies 
showing that the maximal firing rate of C-fibers is significantly lower than that of A-
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fibers. It exhibits slow onset of closed state-inactivation (negative membrane 
potential), which leads to the generation of large currents during slow ramp 
depolarizations. Overall the biophysical properties of Nav1.7 channels closely 
resemble those of the predominant TTX-S current in small diameter DRG sensory 
neurons. Nav1.7 channels have an important role both in setting the threshold for the 
generation of APs but also in AP conduction.86 
Nav1.8 is one of the two isoforms generating the TTX-resistant (TTX-R) 
current recorded from DRG nociceptors, the other one being Nav1.9. Nav1.8 
currents exhibit ∼10-fold slower rates of activation and fast inactivation than TTX-S 
currents and their voltage-dependence of activation and inactivation is typically 30-
40 mV more depolarized. Nav1.8 channels are therefore likely to be activated 
subsequent to Nav1.7 in response to stimuli, and are hence less likely to contribute 
to setting the threshold for the generation of action potentials. Nav1.8 produces most 
of the inward current responsible for the AP upstroke and supports repetitive firing in 
depolarized DRG neurons.87 Nav1.8 is predominately localized in the cell body and 
the peripheral terminal of nociceptors.88 
Nav1.9, the second neuronal TTX-R channel, has been cloned almost 20 
years ago yet it has been proven extremely difficult to express and study in 
heterologous expression systems. Nav1.9 is distributed throughout the nociceptive 
afferents. It activates at hyperpolarized potentials close to the resting membrane 
potential (-60 to -70 mV). It does not contribute to the action potential upstroke but 
rather depolarizes the neurons and prolongs and enhances small depolarizations, 
thus setting the resting membrane potential and increasing excitability.83, 89, 90  
Changes in the biophysical properties or the expression levels of these 
channels have been associated with a number of pathological pain conditions. 
Evidence for the contribution of each of the above isoforms in pain is provided 
below. 
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1.7.5. Implication of Nav isoforms in pain 
“A Holy Grail of pain research has been the discovery of ‘peripheral’ sodium 
channels.” 
        Prof. Stephen Waxman 
 
Consideration of Nav1.3 as a potential pain target was triggered by the 
demonstration that the channel is undetectable in the healthy adult rodent nervous 
system, yet it is upregulated in DRG neurons following peripheral nerve injury and is 
highly expressed in secondary and third order CNS neurons of the pain signaling 
pathway.91 Studies using antisense Nav1.3 knockout models gave controversial 
results: whilst a certain construct led to amelioration of pain behavior in an animal 
model of peripheral nerve injury,91 the use of a different construct showed no pain 
attenuation.92 The use of a different, virus mediated, knockout strategy in a rodent 
neuropathic model led to pain behavior improvement.93 The development of Nav1.3 
selective blockers is important from a scientific point of view, for evaluating the 
isoform’s contribution in pain however it is not as yet clear whether these will be 
clinically useful.94 
Despite the low Nav1.6 abundance in nociceptors, recent studies pinpoint 
this isoform as the underlying cause of multiple painful conditions. It has been 
shown to mediate chemotherapy induced pain,95 and RNA-mediated knockout of the 
channel in vivo has been demonstrated to prevent localized inflammation of the 
lumbar DRG.96 Furthermore, local knockdown of Nav1.6 in a rodent model of 
neuropathic pain was found to reduce pain behaviors, neuronal excitability and 
sympathetic sprouting.97 These studies suggest that Nav1.6 may have a value as a 
therapeutic target for pain, yet its abundant expression in large myelinated fibers 
may compromise the therapeutic window. 
A large body of preclinical data identify Nav1.7 as the major isoform 
implicated in the pathophysiology of pain.86 Brief exposure of rat pheochromocytoma 
cells to an inflammatory stimulus (nerve growth factor), leads to increased 
expression levels of Nav1.7.
98 Global Nav1.7 gene deletion in mice is lethal, yet 
nociceptor-specific Nav1.7 gene deletion leads to viable mice, exhibiting reduced or 
completely abolished responses to inflammatory induced pain and thermal 
hyperalgesia induced by burn injury.99, 100 
Recent genetic studies and functional profiling of mutant channels in 
individuals with rare hereditary pain disorders has validated the Nav1.7 isoform as a 
target for pain therapy and led to the big urge by the scientific community and the 
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pharmaceutical industries for the discovery of Nav1.7 selective inhibitors as the next 
generation pain therapeutics.101 Erythermalgia (IEM) is a rare autosomal dominant 
disorder in which the patient experiences episodes of very painful burning sensation 
and red hot skin, usually in the extremities. IEM is attributed to a gain-of-function 
mutation which hyperpolarizes the Nav1.7 activation threshold, increasing the 
response of the channel to depolarizing stimuli.102 Paroxysomal extreme pain 
disorder (PEPD) is another Nav1.7 gain-of-function attributed hereditary disease, 
characterized by episodes of burning pain in the rectum, ocular and mandibular 
regions. PEPD has been linked to slow channel inactivation (hundreds of ms) in 
some cases, to complete failure of inactivation in others, and in some to more 
negative activation thresholds.103 On the other end of the spectrum, Nav1.7 loss-of-
function mutations lead to disorders where individuals are unable to perceive or 
interpret the intensity of painful stimuli. Congenital indifference to pain (CIP) is one 
such autosomal recessive disorder result of non-sense or frame-shift mutations in 
the SCN9A gene which make the Nav1.7 channel completely dysfunctional and 
unable to pass a current.104 
Despite the compelling evidence for Nav1.7’s crucial role in acute 
inflammatory and chronic pain conditions associated with channelopathies, it is still 
not clear whether the isoform is necessary for the presentation of other forms of pain 
e.g. neuropathic pain. Nociceptor specific deletion of Nav1.7, for example, revealed 
the isoform is not implicated in oxaliplatin-induced neuropathic pain.105, 106 On a 
similar note, a different study showed that spinal nerve ligation (SNL)-induced pain 
can still be perceived after Nav1.7 deletion from sensory neurons.
106 The above data 
suggest that Nav1.7 inhibition could potentially provide effective analgesia clinically, 
for a number of painful conditions, yet given the numerous Nav isoforms involved in 
the pathophysiology of pain, Nav1.7 selective blockers are unlikely to be the one-
treats-all pain medicines that many seem to propose. 
Nav1.8 is the second Nav isoform that received much attention as a potential 
pain target. The expression and biophysical properties of Nav1.8 channels have 
been shown to be largely modulated by nociceptive inputs. Intraplantar 
administration of complete Freund’s adjuvant,107 or carrageenan,108 resulted in 
increased Nav1.8 expression in the rat digital nerve and DRG respectively. 
Additional evidence for the role of Nav1.8 in normal pain function and inflammatory 
pain is derived from knockout109 and knockdown studies in rodents using small-
molecule blockers110 and antisense oligonucleotides.111 The recent functional 
profiling of patients with small fiber neuropathies, revealed gain-of-function 
mutations in Nav1.8 which produced hyper-excitability and inappropriate 
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spontaneous firing in DRG neurons; the study provided a strong link between Nav1.8 
and painful neuropathy.112 
The contribution of Nav1.8 currents to neuropathic pain conditions however, 
like for Nav1.7, remains controversial. Antisense mediated knockdown of Nav1.8 was 
found to reverse neuropathic pain behavior after L5/L6 SNL, and direct L5/L6 SNL 
nerve injury led to immunocytochemical and electrophysiological changes in 
Nav1.8.
113 On the contrary studies using Nav1.8-null mice have concluded that 
Nav1.8 is not involved in neuropathic pain.
105 In one study Nav1.8 mRNA, protein 
and current were found to be substantially decreased in axotomized DRG 
neurons.114 
The role of the Nav1.9 isoform in the pathophysiology of pain has been less 
explored mainly due to difficulties in expressing and studying the channel in 
heterologous expression systems. Inflammatory mediators have been shown to 
cause an increase in Nav1.9 mediated current and Nav1.9 knockout mice display 
attenuated responses in inflammatory pain.115, 116 In addition, Nav1.9 has been 
demonstrated to be implicated in the perception of noxious cold-induced pain with 
Nav1.9 null mice and knockdown rats exhibiting increased cold pain thresholds.
117 
Strong evidence for the role of Nav1.9 in neuropathic pain comes from the recent 
discovery that Nav1.9 gain-of-function mutations cause painful peripheral 
neuropathy by increasing the resting membrane potential and reducing in the 
current threshold required to trigger an AP.118 
 
1.7.6. Nav blockers as pain relief medicines 
Nav blockers have been used in pain medicine for over a century now. Drugs 
like cocaine and procaine have been used for analgesia long before their actual 
pharmacological properties were defined; whilst widely known for their serotonine-
norepinephrine-dopamine reuptake inhibition properties, they also act as Nav 
blockers.119 Over the years, more specific Nav blockers have dominated the field of 
pain therapeutics. The local anesthetics (e.g. lidocaine, bupivacaine and 
ropivacaine) and the anticonvulsants (e.g. carbamazepine, phenytoin, lamotrigine), 
are nowadays regularly used for the treatment of several acute and chronic pain 
conditions. 
Both LAs and the anticonvulsants are low potency Nav blockers, that exhibit 
no particular selectivity between the different Nav isoforms yet they are reasonably 
tolerated for use in certain clinical settings. They share overlapping binding sites 
localized at the inner vestibule of the pore on the S6 helix of the Nav domain IV (Fig. 
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12), yet they exhibit different pharmacological properties.120, 121 The key for their 
relatively safe therapeutic profile and distinct pharmacology lies in their preferential 
binding to specific Nav conformational states, with different kinetics, altering the 
channels’ biophysical properties. 
As described above, Navs transit between different conformational states in 
response to changes in the membrane potential (resting, activated, inactivated). 
Drugs that bind to Nav with affinity independent to the conformational state, or to a 
site that is accessible in any channel conformation are known as tonic blockers. 
State-dependent blockers on the other hand bind preferentially to one or more 
conformational states. 
The LAs and the anticonvulsants are state-dependent blockers exhibiting 
preferential binding to the inactivated state; this is either due to higher affinity of the 
blocker for this particular state (anticonvulsants) or to higher accessibility of the 
binding site when at this state (LAs). As a consequence, the channel is stabilized at 
a non-conducting state which slows down its repriming time (return to the resting 
state). Hyper-excitability in chronic pain diseases is characterized by neuronal 
membrane depolarization (that increases with the frequency of firing), which means 
more channels enter the inactivated state; in effect, state-dependent blockers lead 
to a greater block in such diseased rather than normal firing neurons. 
The functional consequences of state-dependent binding are the voltage-
dependent block (amount of block versus voltage) and the use-dependent block 
(amount of block versus frequency of stimulation/firing). Anticonvulsants exhibit high 
voltage-dependence, but only moderate use-dependence due to their fast drug 
dissociation after repolarization. Therefore, anticonvulsants are best at inhibiting 
high-frequency firing, allowing normal action potential firing in the presence of the 
drug. LAs on the other hand, dissociate with a slower time constant than they 
associate to the binding site leading to accumulation of inhibition, making potency 
dependent on the opening frequency (use-dependence). In effect, LAs tend to be 
more effective in blocking low-frequency firing. 
The development of state-dependent Nav blockers remains to date one of 
the most pursued strategies for the discovery of novel analgesic drugs. 
A more recent strategy, currently pursued by numerous pharmaceutical 
companies, is the development of subtype-selective blockers specifically targeting 
the Nav isoforms of the periphery (Nav1.3, Nav1.7, Nav1.8, and Nav1.9). 
A combination of site-directed mutagenesis, binding and electrophysiological 
studies have identified at least seven distinct binding sites in addition to the LA 
binding site, located in and around the pore region of the α–subunit (Fig. 12).78 
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These were identified using toxins and alkaloids as pharmacological probes, several 
of which exhibit high Nav isoform selectivity. The clinical usefulness of such toxins is 
often limited by their large molecular weight however they are invaluable 
pharmacological tools, used as therapeutic leads in many drug discovery programs. 
 
Figure 12. Nav channel homology model illustrating the postulated toxin binding sites (1-6) 
and the LAs binding site; side view (left) and top view (right). (1) TTX (2) batrachotoxin (BTX) 
(3) scorpion α-toxin (4) scorpion β-toxin (5) brevetoxins (6) δ-conotoxin (7) pyrethroids.
122
 
Several studies examining the analgesic properties of toxins that selectively 
block peripheral Nav isoforms have been published. ProTx II, a selective Nav1.7 
blocker derived from the tarantula venom (site 4), completely blocks AP propagation 
in nociceptors at concentrations that have little effect on other sensory fibers when 
applied to desheathed cutaneous nerves.123 Sadly, it has no activity when applied to 
intact nerves as it is connective-tissue impermeant. More recently, μ-SLPTX-Ssm6a, 
another Nav1.7 selective inhibitor isolated from centipede venom, was found more 
potent than morphine in a rodent model of chemical-induced pain and it was 
equipotent with morphine in rodent models of thermal and acid-induced pain.124 
In the past decade, a very large number of studies/patents have been 
published reporting small molecule Nav1.7 and Nav1.8 specific inhibitors, with 
efficacy in animal models of pain; however, in the vast majority, the compounds’ 
activity against other Nav isoforms is not being reported in a native neuronal 
environment and the results should therefore be interpreted with care. Table 3 
describes compounds targeting Navs for pain relief currently in clinical development. 
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Table 3. Nav channel modulators that have reached clinical development for the treatment of 
pain.
122
 
Compound Company Pharmacology Phase Therapeutic indication 
AZD3161  AstraZeneca Nav1.7 I Neuropathic/inflammatory 
pain (IV, intradermal) 
CNV1014802 Convergence Nav1.7 II Neuropathic pain, 
Trigeminal neuralgia (oral) 
DSP-2230 Dainippon 
Sumitoto 
Nav1.7/1.8 I Neuropathic pain (oral) 
NKTR-171 Nektar Broad Nav I Neuropathic pain (oral) 
PF-04531083 Pfizer Nav1.8 I Neuropathic/inflammatory 
pain (oral) 
PF-05089771 Pfizer Nav1.7 II Neuropathic/inflammatory 
pain erythermalgia (oral) 
TTX WEX TTX-S Nav III Neuropathic/inflammatory 
cancer pain (IV) 
XEN402 Xenon/Teva Nav1.7 II Neuropathic/inflammatory 
pain erythermalgia 
(topical) 
XEN403 Xenon Nav1.7 I Neuropathic/inflammatory 
pain erythermalgia (oral) 
 
 
 
Figure 13. Nav channel modulators in clinical development for the treatment of pain. 
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A third, currently less exploited strategy, for improving the side effect profile 
of non-selective Nav inhibitors, is to restrict their action to the desired target tissue 
i.e. in the periphery, aiming to increase tolerability by reducing action on the CNS.125 
Two different approaches have been explored to date: (a) a passive approach 
where compounds are prevented from penetrating the blood-brain barrier and (b) a 
more active approach where compounds are specifically delivered to nociceptors. 
One example of the first approach is the development of BZP;126 BZP is a 
small molecule Nav1.7 blocker developed by Merck, producing substantial reversal 
of inflammatory hyperalgesia and mechanical allodynia on rat models of 
inflammatory and neuropathic pain, comparable to that of clinically used drugs; due 
to its poor brain-penetrance it confers fewer sedative, and motor-coordination 
impairments. Limitations of this approach remain the plausible adverse effects from 
cross activity at cardiac Navs and the unsuited use of such compounds in conditions 
which compromise the blood-brain or the blood-spinal cord barrier.127 
 
 
Figure 14. Structures of the TRPV1 agonist, capsaicin, and the tertiary lidocaine derivative, 
QX-313 (left). TRPV1 agonist–Nav antagonist effects at nociceptors. Activation of TRPV1 by 
capsaicin allows QX314 internalization and binding to the Nav LA site blocking Nav current 
passage (right).
128
 
The concept of the second approach is well described by the cell-specific 
targeting of QX-314, a quaternary lidocaine derivative, into nociceptors.129 QX-314 is 
a charged molecule, hence cannot access its intracellular LA binding site by passive 
diffusion. Its neuronal internalization has been made possible via TRPV1 receptors 
which upon prolonged activation and pore dilation allow the passage of large cations 
such as QX-314 into the cell. TRPV1 activation allows QX-314 to reach its active 
site and mediate its Nav blocking effects (Fig. 14). Indeed, co-administration of a 
TRPV1 agonist (e.g. capsaicin, lidocaine) and QX-314 in rodents has been shown to 
produce long lasting inhibition to painful mechanical and thermal stimuli. TRPV1 is 
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selectively expressed in nociceptive neurons therefore QX-314 pain-signalling 
blockade proceeds without the motor deficits normally associated with the use of LA 
drugs. 
Unfortunately, several limitations have been associated with the 
development of TRPV1 agonists-Nav antagonists as pain therapeutics. Intrathecal 
application of QX-314 caused serious irritation and death in mice,130 something not 
observed after subcutaneous, or perineural administration even at high doses. 
Systematically, it is twice as toxic as lidocaine.131 In addition, the initial activation of 
TRPV1 is accompanied by an intense pain sensation which lasts until the onset of 
the Nav-mediated analgesic effect. It therefore does not appear as the most 
appealing strategy for producing analgesia however, it provides proof-of-concept 
evidence for the significant therapeutic advantages of selective nociceptor blockade. 
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1.8. Previous studies related to this work: 
Iminodihydroquinolines as Nav blockers for pain 
therapy 
The small molecule iminodihydroquinoline 
WIN17317-3 (1, Fig. 15) was the first, high affinity, 
tissue selective Nav inhibitor to be reported.
132 The 
compound was initially described as a selective Kv1.3 
and Kv1.4 blocker;
133 when however, in a subsequent 
study a radiolabeled analogue of WIN17317-3 
([3H]WIN17317-3, Merck) was employed to probe 
neuronal Kv1 channels in rat brain synaptic membranes, its binding interactions 
were found insensitive to any of the well-characterized potassium channel ligands. 
Instead, [3H]WIN17317-3 binding was blocked by a number of Nav modulators, such 
as the neurotoxins (TTX, BTX), the LAs (lidocaine) and the antiarrhythmics; it was 
found to bind saturably and reversibly to a single neuronal binding site (Kd 2.2 ± 0.3 
nM; Bmax 5.4 ± 0.2 pmol/mg of protein) that corresponded pharmacologically to the 
Nav1.2. Importantly, autoradiography of rat brain sections incubated with 
[3H]WIN17317-3 revealed high specific binding to sites that correspond with the 
known distribution of Navs in the CNS (Fig. 16). Similar experiments, in rabbit 
skeletal muscle microsomal membranes revealed that WIN17317-3 also interacts 
with skeletal muscle Navs via an analogous allosteric interaction, but interacts much 
more weakly with the cardiac Navs. This suggested that WIN17317-3 possesses 
selectivity for neuronal and skeletal muscle Nav isoforms over isoforms expressed in 
the heart. WIN17317-3 was found to block the binding of [3H]BTX-B via an allosteric 
mechanism of action. 
 
Figure 16. Autoradiographic localization of [
3
H]WIN17317-3 binding sites in rat brain. Brain 
sections were incubated with the tracer (2-3 nM) in the absence (A) and the presence (B) of 
non-radiolabeled WIN17317-3.
132
 
  
Figure 15. Chemical structure 
of WIN177317-3. 
A 
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In the following years, Merck laboratories have evaluated a diverse spectrum 
of chemical structures as Nav inhibitors for various clinical indications, yet no further 
studies were reported exploiting the structural class of iminodihydroquinolines.134, 135 
The favorable physicochemical properties of WIN17317-3, and its ability to depict 
the Nav distribution in vitro led our group to pursue a 
125I-labeled 
iminodihydroquinoline, 2, as tracer 
for imaging Navs in the brain.
3 In 
vivo imaging of Navs can 
potentially provide insights to the 
activation of neuronal pathways 
and aid the diagnosis of a 
number of neurological diseases. 
To evaluate the suitability of [125I]2 for imaging Navs in vivo, its 
pharmacokinetic profile and tissue distribution were examined after iv administration 
in mice (Fig. 17). Unfortunately, both biodistribution studies and whole body 
SPECT/CT imaging showed very low brain uptake (0.48 ± 0.04% ID/g) with no sign 
of retention, and quick clearance from the liver and kidneys, paralleled by an 
increased uptake in the intestines, consistent with hepatobiliary excretion. The 125I-
labeled tracer also suffered from rapid metabolism, with less than 5.5% of the intact 
tracer remaining in the circulation 30 minutes post injection, with the rest of the 
activity observed as a highly polar metabolite. The results suggested that 
iminodihydroquinolines are poorly suited for tracer development. 
 
Figure 17. Biological evaluation of [
125
I]2 after iv administration in mice. (A) Tissue 
distribution expressed as % ID/g ± SD (n≥3) (B) SPECT/CT summation image from 15-35 
min after injection.
3
 
  
Scheme 1. Radiosynthesis of [
125
I]2.
3
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As part of the same study, WIN17317-3 and 2 were evaluated in an 
automated patch clamp electrophysiology assay for their activity at the panel of 
human Nav isoforms. Comparison of the two suggested that the Nav blocking 
potency of WIN17317-3 is fully retained by the newly developed iodinated analogue. 
Based on the previously reported data, suggesting preferential binding of 
WIN17317-3 at the neuronal and skeletal muscle tissues over the cardiac tissue, 
higher potency was anticipated for the Nav1.2 and Nav1.4 isoforms over Nav1.5; 
unexpectedly, both compounds showed higher affinity binding to the Nav1.4, Nav1.5 
and Nav1.7 isoforms over the Nav1.2 (10-fold), Nav1.6 (10-fold) and Nav1.8 (80-fold) 
isoforms (Table 4). 
Table 4. hNav isoform profiling of iminodihydroquinolines WIN17317-3 and 2.* 
 hNav IC50 (μΜ) 
      Isoform 
Cpd 
1.2 
3
 
CNS 
1.4 
Skeletal muscle 
1.5 
Heart 
1.6 
PNS 
1.7 
PNS 
1.8 
PNS 
WIN17317-3 2.2 ± 1.2 0.2 ± 0.2 0.3 ± 0.1 1.9 ± 0.7 0.2 ± 0.1 15.0 ± 5.8 
2 1.5 ± 0.5 0.1 ± 0.1 0.2 ± 0.1 0.6 ± 0.2 0.2 ± 0.1 5.5 ± 4.1 
*Årstad group, unpublished data. 
The most powerful known method of blocking pain while retaining 
consciousness, is to inject LAs, like lidocaine, regionally into areas of the body 
generating pain. However, as previously discussed, LAs are non-selective Nav 
blockers, causing apart from Nav blockade in nociceptors also blockade of Navs in 
the heart, brain as well as non-nociceptive sensory, sympathetic and motor fibers 
leading to adverse side effects. 
Re-evaluating the results obtained from the iodinated iminodihydroquinoline 
study, we envisioned that iminodihydroquinolines could potentially be clinically 
useful as locally administered pain therapeutics with reduced side effect burden 
compared to the currently available analgesic treatments. The high affinity Nav1.7 
inhibition could lead to effective pain-signaling blockade (C-fibers), with less 
prominent effects on other sensory and motor fibers (A-fibers), as suggested by the 
lower potency exhibited for their predominately expressed isoform, Nav1.6. In 
addition, the low brain uptake and the restriction of [125I]2 in the periphery, as well as 
the 10-fold selectivity over the brain isoform Nav1.2 suggest iminodihydroquinolines 
are less likely to exhibit serious CNS side effects. The quick blood metabolism is 
anticipated to minimize the drug concentration in circulation thereby reducing the 
probability for cardiovascular toxicity.  
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The first step towards validating the above hypothesis was to examine the 
iminodihydroquinolines efficacy in blocking pain signaling. In collaboration with the 
Koltzenburg group, UCL Neurology, WIN17317-3 was evaluated in the rodent skin-
nerve assay for its in vitro effects on peripheral sensory neurons. The skin-nerve 
assay is one of the most powerful methods for investigating pain-signaling as it 
allows direct recording of AP conduction from the several types of neuronal fibers 
independently, as well as provides a quantifiable measure of their responses upon 
pharmacological intervention. The rodent skin-nerve assay is described in depth in 
chapter 5.1. 
 
Figure 18. WIN17317-3 evaluation in the rat skin-nerve assay. Saphenous nerve A- (■) and 
C-fiber (●) CAP blockade as a function of WIN17317-3 concentration. Data points are shown 
as mean ± S.E.M (n = 9), fitted dose-response curves are presented as solid lines. 
(Koltzenburg group, unpublished data). 
The results of the assay were overwhelming (Fig. 18). WIN17317-3 blocked 
nociceptive C-fibers with moderate potency (EC50 = 34.6 μΜ) yet with remarkable 
selectivity over the non-nociceptive A-fibers; less than 40% of the A-CAP signal was 
blocked at the EC90 for C-fibers (149.2 μΜ). To the best of our knowledge, only two 
examples of such differential fiber block have been reported in literature, by proTx-II 
or co-administration of QX-314 with a TRPV1 agonist. Τhe effects of the tarantula 
toxin ProTx-II, a highly potent and selective Nav1.7 blocker, were evaluated on the 
exact same skin-nerve assay by the Koltzenburg group; selective C-CAP blockade 
was obtained however only when applied to the desheathed nerve (Fig. 19).123 Due 
to its large molecular weight proTx-II is not connective tissue penetrant and hence is 
of limited therapeutic potential.  
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Figure 19. (A) Aminoacid sequence of the tarantula T. Prurien peptide, ProTx-II. (B) 3D-
structure model of ProTx-II, constructed using the optimal docking area method by homology 
modeling with ICM-PRO (Molsoft) based on the NMR structure of GsMTx2 (PDB:1lup). Blue, 
green, yellow, red and purple represent positively charged, aromatic, hydrophobic, 
negatively charged and polar residues respectively. The locations of aminoacid residues 
important for Nav1.5 binding as revaled by mutation experiments are indicated.
136
 (C) ProTx-
II effects on the isolated nerve preparation. Saphenous nerve Aβ- (●) and C-fiber (■) CAP 
blockade as a function ProTx-II concentration. Data points are shown as mean ± S.E.M (n = 
9). (D) Block of hNav1 subtypes by ProTx-II examined by whole-cell voltage clamp. IC50 
values: Nav1.2, 41 nM; Nav1.3, 102 nM; Nav1.4, 41 nM; Nav1.5, 79 nM; Nav1.6, 26 nM; 
Nav1.7, 0.3 nM; Nav1.8, 146 nM.
123
 
Internalization of the permanently charged lidocaine derivative QX-314 
through activation of ion channels selectively expressed in nociceptors (TRPV1, 
TRPA1), as previously discussed in section 1.7.6, was also shown to produce 
selective and prolonged conduction block of C-fibers.137 The Koltzenburg group 
investigated the possibility of WIN17317-3 eliciting its nociceptive effects via an 
analogous mechanism of action: acting as a TRPV1/TRPA1 agonist, resulting in the 
opening of the channel(s) and to its internalization in the nociceptor terminal, where 
action at Navs would mediate C-CAP conduction blockade. Calcium imaging 
experiments138 performed on HEK293 cells transfected with the TRPV1 and TRPA1 
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channels of interest, showed no increase in Ca2+ flux upon WIN17317-3 application 
at the concentration range this causes C-CAP blockade (Fig. 20). This suggested 
the two TRP channels are not activated by WIN17317-3 therefore the proposed 
mechanistic hypothesis was disapproved. 
 
 
Figure 20. WIN17317-3 effects on (A) TRPV1- and (B) TRPA1-transfected HEK293 cells 
examined using live cell ratiometric calcium imaging. A control agonist was administered 
prior to and after WIN17317-3 administration to confirm the expression of functional 
channels. Koltzenburg group, unpublished data. 
The selective action of WIN17317-3 on nerve conduction was therefore 
considered to be mediated most likely via the selective blockade of Nav isoforms, in 
particular Nav1.7, or by another unknown mechanism. 
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1.9. Research aim and objectives 
The aim of this work was to develop small molecule iminodihydroquinolines 
as novel local analgesic drug candidates with high therapeutic index for progression 
into clinical development. To achieve this, the traditional medicinal chemistry 
approach of ‘hit’ to ‘lead’ development, commonly used in drug discovery programs 
for optimizing newly identified chemical entities for their activity against a certain 
biological/therapeutic target, was employed. According to this, the following 
objectives were set: 
(a) Design and synthesis of a compound library based on the structure of the ‘hit’ 
molecule WIN17317-3. Synthetic routes were to be developed for accessing 
structurally-diverse analogues of WIN17317-3. 
(b) Pharmacological characterization of compounds using a combination of Nav 
screening assays and evaluation at peripheral sensory neurons. 
(c) Development of a pharmacophore model. Understanding the compounds’ 
SARs for the binding site is essential for optimizing activity at the target. 
(d) Mechanistic investigation of the molecular mode of action. Diverse 
pharmacological characterization and analysis was endeavoring to unravel the 
relationship between Nav inhibition and nociceptor blockade and explain the 
underlying mechanism for the observed preferential nociceptor block. 
(e) Characterization of a lead compound in early preclinical safety studies, 
including pharmacokinetic profiling and evaluation of toxicity. The lead 
compound was to be selected on the basis of its efficacy towards potently 
blocking nociceptors without interfering with other neuronal fibers or blocking 
off-target Nav isoforms. 
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2. The Design of an Iminodihydroquinoline 
Compound Library 
 
The underlying principle of the compound library design, part of this work, 
was the effective exploration of the structure-activity relationships (SARs) of the 
iminodihydroquinoline class for Nav isoform blockade, in particular Nav1.7, and the 
description of the respective pharmacophore, with the minimum required number of 
ligands. A pharmacophore, as defined by the International Union of Pure and 
Applied Chemistry (IUPAC), is the ensemble of steric and electronic features that is 
necessary to ensure the optimal supramolecular interactions with a specific 
biological target structure, and to trigger or block its biological response.139 
Drug design is conventionally characterized as being of two types:140 
a. Structure-based drug design (SBDD)141, 142 which exploits the three-
dimensional (3D) structure of a biomolecular target (X-ray crystallography, 
NMR spectroscopy) for the design of complementary ligands according to 
the electronic and steric requirements of the active site, and 
b. Ligand-based drug design (LBDD) which uses the relationship between the 
structure of ligands and their paired activity at the target, for building a 
pharmacophore model identifying the optimal physicochemical properties for 
binding.143, 144 
Despite the continuing efforts of the scientific community, the crystal 
structure for the mammalian Nav channel has not as yet been characterized; 
consequently, the design of Nav ligands has traditionally followed the LBDD 
approach. Accordingly, in this study, efforts were concentrated on generating new 
ligands based on the structure of the hit molecule, WIN17317-3. By systematically 
altering molecular features and measuring the impact of these on Nav1.7 activity, we 
aimed to create a pharmacophore model defining those structural characteristics 
leading to high affinity binding. 
Structural modifications were methodically introduced in four areas of the 
parent WIN17317-3 molecule: the 4-imino substituent (R1), the N-1 substituent (R2), 
the 7-chloro substituent (R3) and the core heterocyclic scaffold (Fig. 21). Only one 
molecular feature was altered at a time in order for results to be conclusive 
regarding the specific parameter varied. 
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Figure 21. Characterization of the WIN17317-3 pharmacophore. 
Multiple molecular characteristics can contribute to the SAR of a compound 
class, like the size and shape, the stereochemical arrangement and distribution of 
functional groups, and the chemical reactivity and electronic effects. Substituents 
were introduced at the four pharmacophoric areas defined above, with the aim to 
collectively investigate activity trends implied by the following descriptors: 
a. Molecular weight, size and shape 
 Both parameters are of high importance for the 
discovery of novel ion channel ligands. The mechanism 
of action of several Nav toxins largely relies on their bulky 
structure. The TTX binding site for example is located in 
short proximity from the opening of the channels pore so 
as when bound it physically obstructs the passage of 
sodium ions.145 In contrast, the LA binding site is situated in the lumen of the 
channel hence the introduction of large/bulky groups could be in this case 
detrimental for activity, since ligands could be prevented from reaching their active 
site.120 The shape of the drug should be in general complementary to the active site 
(key and lock relationship) for optimum activity to be achieved. 
b. Lipophilicity 
 This parameter refers to a compound’s ability to dissolve in oils, lipids, and 
non-polar solvents versus polar, aqueous, environments. It reflects molecular 
desolvation in transfer from aqueous phases to cell membranes and binding sites, 
hence plays an important role to the pharmacokinetics/pharmacodynamics (PK/PD) 
and toxicity profile of a drug.146 The partition coefficient (logP) is the most widely 
used measure of lipophilicity and it can be either measured experimentally or 
predicted using algorithms (cLogP). For charged molecules, the distribution 
coefficient (logD) at a set pH, is rather measured, reflecting the net result of all 
intermolecular forces involved between the solute (ionized plus unionized forms) 
and the two phases between which it partitions.  
Figure 22. The chemical 
structure of TTX. 
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 𝑙𝑜𝑔 𝑃𝑜𝑐𝑡/𝑤𝑎𝑡 = 𝑙𝑜𝑔 (
[𝑠𝑜𝑙𝑢𝑡𝑒]𝑜𝑐𝑡𝑎𝑛𝑜𝑙
𝑢𝑛𝑖𝑜𝑛𝑖𝑠𝑒𝑑
[𝑠𝑜𝑙𝑢𝑡𝑒]𝑤𝑎𝑡𝑒𝑟
𝑢𝑛𝑖𝑜𝑛𝑖𝑠𝑒𝑑)  𝑙𝑜𝑔𝐷𝑜𝑐𝑡/𝑤𝑎𝑡 = 𝑙𝑜𝑔 (
[𝑠𝑜𝑙𝑢𝑡𝑒]𝑜𝑐𝑡𝑎𝑛𝑜𝑙 
𝑖𝑜𝑛𝑖𝑠𝑒𝑑 + [𝑠𝑜𝑙𝑢𝑡𝑒]𝑜𝑐𝑡𝑎𝑛𝑜𝑙 
𝑢𝑛𝑖𝑜𝑛𝑖𝑠𝑒𝑑
𝑠𝑜𝑙𝑢𝑡𝑒]𝑤𝑎𝑡𝑒𝑟 
𝑖𝑜𝑛𝑖𝑠𝑒𝑑+ [𝑠𝑜𝑙𝑢𝑡𝑒]𝑤𝑎𝑡𝑒𝑟 
𝑢𝑛𝑖𝑜𝑛𝑖𝑠𝑒𝑑 ) 
Figure 23. LogP and LogD equations. 
c. Acidity/Basicity 
 The presence of ionizable functional groups in a drug can serve two principal 
functions: it can lead to direct specific interactions/bonds with the biomolecular 
target, and/or can increase the molecule’s overall polarity thereby influencing other 
key physicochemical properties such as solubility and lipohilicity.147 The prerequisite 
of two basic centers at the pharmacophore, these being the quinoline and imine 
functionalities of the hit WIN17317-3, was to be examined, by tuning the acid-base 
dissociation constants (pKa) of the two, using different substitution patterns. 
d. Topological polar surface area (tPSA) 
 tPSA is defined as the sum of the contributions to the molecular (usually van 
der Walls) surface area of all the polar atoms in a molecule such as oxygen, 
nitrogen and their attached hydrogens. It is a convenient measure of the polarity of a 
ligand, as it avoids the need for 3D structure calculations, or determination of the 
biologically relevant conformations of ligands. A recently published study by 
Prasanna et al., demonstrates that tPSA and pharmacological activity are correlated 
(positively or negatively) in many of the drug classes examined.148 
e. Hydrogen-bond donors and acceptors 
 The hydrogen bond interactions between a ligand and its target protein are 
known to play a critical role in the overall affinity between the two. In addition, the 
number of hydrogen bonds in a molecule is known to affect pharmacokinetic 
properties such as tissue absorption and penetration across the blood-brain barrier; 
according to the Lipinski’s rule of five a compound is more likely to be membrane 
permeable, by passive diffusion, if it contains less than five hydrogen bond donors 
and less than ten hydrogen bond acceptors.149 Hydrogen bond donors and 
acceptors of variable strengths were to be incorporated in all four pharmacophoric 
areas under investigation. 
The molecular descriptors described above were used to guide the Nav 
ligand design in this study. In many cases, a single structural modification induced 
changes in more than one molecular descriptor hence a careful assessment of all 
plausible properties altered was performed for every new compound examined. 
Of particular interest was the introduction of fluorine-containing ligands in the 
library. Fluorine substitution is routinely used in medicinal chemistry as depicted by 
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the large number of fluorine-containing drugs currently in the pharmaceutical 
pipeline (>20%).150 Fluorine, due to its small size (van der Waals radius 1.47 Å), can 
serve as a hydrogen bioisostere (van der Waals radius 1.20 Å), yet as the most 
electronegative element in the periodic table (3.98 Pauling scale) it can have 
profound effects on a compound’s biological activity. In multiple real-life examples, 
the introduction of fluorine substitution in pharmaceutical entities has led to 
enhanced binding affinity (direct interaction of fluorine with the target), improved 
physicochemical properties (lipohilicity and basicity), and increased metabolic 
stability.151 In addition, radioactive18F-tags are increasingly introduced as 
pharmacological tools for characterizing the pharmacokinetic profile of drug 
candidates using positron emission tomography (PET) imaging in the early stages of 
clinical development.152 In this study, fluorine substitution was used as a tool for (a) 
probing the SARs of the class, (b) optimizing the properties of a lead drug candidate 
and (c) identifying sites suitable for potential 18F-fluorination. 
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3. Chemical Approaches and Reactions 
 
In this chapter the synthetic methods and chemical transformations 
employed for the synthesis of a library of 25 novel structural analogues of 
WIN17317-3 are described. For convenience of representation, the data are 
classified in three sections according to the nature of the heterocyclic scaffold 
incorporated (quinolines, naphthyridines, purines and pyridines) and subcategorized 
according to the synthetic building blocks and chemical routes used. The rationale 
behind compound design and the biological activity of compounds are discussed in 
separate chapters. The second part of this chapter describes the radiosynthesis of a 
selected lead compound labeled with fluorine-18 for pharmacokinetic profiling in 
vivo. 
 
 
Figure 24. The heterocyclic compounds composing the WIN17317-3 library, for which the 
chemical synthesis is described in this chapter. From left to right: quinolines, naphthyridines, 
purines and pyridines and an [
18
F]labelled selected lead compound. 
 
3.1. Synthesis of a WIN17317-3 Compound Library 
3.1.1. N-substituted-4-imino-1,4-dihydroquinolines 
Based on the structure of ‘hit’ WIN17317-3 (1), 22 novel 
iminodihydroquinoline analogues were designed bearing diverse substitution 
patterns (Fig. 25). To access these, three synthetic routes were developed; Route A 
starting from 4-chloroquinolines, route B starting from 4-quinolones and route C 
starting from benzoic acids. The route employed for each compound was selected 
based on the commercial availability of building blocks and the reactivity of those 
with the desired R1- and R2-containing functionalities. 
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Figure 25. General structure of N-substitued-4-imino-1,4-dihydroquinolines and the three 
building blocks used for their synthesis. 
3.1.1.1. Route A: From 4-chloroquinolines 
The first synthetic approach involved a two-step reaction sequence using 
commercially available 4-chloroquinoline building blocks and was adapted from 
previously described literature methods (Scheme 2).133,132 According to these, 4-
chloroquinoline is heated with an alkyl or aryl amine to install the 4-alkylamino group 
of a 4-(alkylamino)-quinoline intermediate; the quinolone nitrogen is subsequently 
substituted by treatment with an alkyl or benzyl halide to afford the target 
iminodihydroquinoline system. 
 
Scheme 2. Literature route to iminodihydroquinolines. 
Reagents and conditions: (i) EtOH, reflux, 18-24 h (ii) NaI, acetone, reflux, 18-24 h 
 
The first step of the above procedure was optimized by altering the reagent 
stoichiometry and the reaction conditions (Scheme 3). In the optimized procedure, 
4-chloroquinolines were heated with 5.5 equivalents of the neat amines. The higher 
effective concentration of amines, in combination with the use of higher reaction 
temperatures, led to higher reaction rates and improved reaction times. In addition, 
the excess of amine used, quenched the hydrogen chloride released as reaction by 
product; this significantly simplified the work-up procedure, avoiding alkaline washes 
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and allowing for the majority of cases pure product isolation through precipitation 
from ice-cold water. 
 
Scheme 3. Optimized synthesis to 4-alkylaminoquinoline intermediates.  
Reagents and conditions: (i) No solvent, reflux, 18-24 h 
 
Table 5 summarizes the reaction of 7-substituted 4-chloroquinolines with various 
aliphatic and aromatic amines. The 4-alkylaminoquinoline intermediates (3 - 11) 
were obtained in excellent yields, exceeding 90% for the majority of cases. 
 Table 5. Synthesis of (4-alkylamino)quinoline intermediates 3 - 11. 
 
Product        -R
1 
-R
3
  Time (h) Temp. (°C) Yield (%) 
3  Cl 18 120 96 
4  Cl 5 120 99 
5  Cl 5 110 90 
6  Cl 3 120 91 
7 
 
Cl 24 90 35 
8 
 
Cl 1.5 110 60 
9  H 24 110 88 
10 
 
H 24 110 90 
11  OMe 48 110 81 
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Two intermediates, 5 and 6, were further functionalized to attain the desired 
R1 motifs of the target iminodihydroquinolines. The primary amine in quinoline 5 was 
treated with acetic anhydride, to afford amide 12 in 85% yield (Scheme 4). 
 
Scheme 4. Synthesis of amide 12. 
Reagents and conditions: (i) DCM, 0 °C → rt, 3 h, 85% 
 
The primary alcohol of 6 was converted to the corresponding monofluoride in 
13 using diethylamino sulfur trifluoride (DAST) (Scheme 5). DAST is an organosulfur 
fluorinating reagent developed in the early 70s, widely used for the nucleophilic 
fluorination of oxidized organic compounds.153 
 
Scheme 5. Synthesis of intermediate 13. 
Reagents and conditions: (i) DAST, DCM, 0 °C → rt, 48 h, 63% 
 
The synthesis of two 4-(alkylamino)quinoline intermediates, 14 and 18 (vide 
infra), deviated from the established optimised reaction conditions (Schemes 6, 7). 
Stoichiometric amounts of quinolines and amines were used and reaction solvents 
were introduced in the mixture. The first case involved installation of the 4-(2,2,2-
trifluoroethyl)amino substituent in 14 (Scheme 6). 2,2,2-trifluoroethylamine, was 
purchased as the hydochloride salt therefore a base, excess triethylamine, in DMF 
was added to release the corresponding reactive free amine in situ. 
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Scheme 6. Synthesis of intermediate 14. 
Reagents and conditions: (i) NEt3, DMF, 110 °C, 4 h, 92% 
 
The second case involved the reaction of 4,7-dichloroquinoline with 3-amino-
1,3,4,5-tetrahydro-2H-benzo[b]azepin-2-one, 17 (Scheme 7). Both reagents were 
solids therefore DMF was introduced to solubilize the reaction mixture. Furthermore, 
with a limited amount of 17 available, only one equivalent of the amine was used 
and triethylamine was added to quench the hydrogen chloride released as reaction 
by product. 
 
Scheme 7. Synthesis of 1,3,4,5-tetrahydro-2H-benzo[b]azepin-2-one (bnza) intermediate 18. 
Reagents and conditions: (i) NEt3, DMF, 150 °C, 18 h, 26% 
 
Amine 17 was synthesized according to literature procedures from racemic 
3-bromo-1,3,4,5-tetrahydro-benzo[b]azepin-2-one (15) in two steps (Scheme 8). 
According to these, 15 was reacted with sodium azide in the presence of sodium 
iodide to afford azide 16 in 93% yield.154 18 was subsequently reduced to amine 17, 
following a facile method using a mixture of zinc and ammonium chloride as the 
reducing agent and mild reaction conditions.155 
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Scheme 8. Synthesis of bnza-containing amine 17. 
Reagents and conditions: (i) NaN3, NaI, DMF, rt, 24 h, 93% (ii) Zn powder, NH4Cl, EtOH/ 
H2O (3:2), 80 °C, 20 min, 61% 
 
Following the synthesis for all (4-alkylamino)quinoline intermediates, the final 
step of this route involved alkylation of the quinoline nitrogen to furnish the target 
iminodihydroquinolines (Scheme 9). 
 
Scheme 9. Second step of iminodihyroquinoline synthesis. 
Reagents and conditions: (ii) NaI, acetone, reflux, 18-24 h 
 
4-(alkylamino)quinoline intermediates were heated to reflux with the selected 
alkyl or aryl bromides in the presence of sodium iodide in acetone to improve the 
leaving group character (Finkelstein ion exchange)132 (Table 6). All reactions 
proceeded to completion. 4-(alkylamino)-quinolines 12 and 15, exhibited poor 
solubility in acetone therefore the two reactions were performed in DMSO and DMF 
respectively. The target iminodihydroquinolines were recrystallized and isolated in 
high purity (>98%) for submission to pharmacological assays. The reaction yields 
reflect the compounds ability to crystallize from the selected solvent system rather 
than the efficiency of the reaction. Given the low amount of material required for 
biological testing, enough material was obtained with the first crystal crop, therefore 
recrystallization from the mother liquor for yield improvement purposes was not 
attempted, to avoid compromising purity. 
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 Table 6. N-benzylation of (4-alkylamino)quinolines 19 - 27. 
 
Starting 
material A 
Product R
1 
R
3
 X Yield (%) 
4 19  Cl H 17 
8 20 
 
Cl H 98 
9 21  H H 86 
 22   F 71 
 23   I 79 
11 24  OMe H 42 
12 25 
 
Cl H 25
a 
14 26 
 
Cl H 73 
18 27 
 
Cl H 49
b 
(i) NaI, acetone, reflux, 3-18 h (a) DMSO, NEt3, 110 °C, 24 h (b) DMF, 100 °C, 24 h 
 
The same method was applied for the installation of alkyl groups as N-1 
substituents (Table 7). The reactivity of (4-alkylamino)quinolines with benzylic 
halides was markedly higher than with alkyl halides, fact mirrored in the longer 
reaction times for the latter. 
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  Table 7. N-alkylation of (4-alkylamino)quinolines 7-10. 
 
 (i) NaI, acetone, reflux, 32 h (a) NaH, THF, 0 °C, 0.5 h → 65 °C, 72 h 
The reaction of (4-aminophenyl)quinoline, 7, with 1-bromopentane did not 
proceed under the established reaction conditions. The decreased reactivity was 
attributed to conjugation of the quinoline’s nitrogen electron lone pair to the R1 
aniline ring. To compensate for this, the amine was deprotonated with NaH prior to 
alkylation; the increased nucleophilicity allowed alkylation to proceed with the target 
compound 28 obtained in 24% yield. 
Apart from alkyl chains, cycloalkyl rings were also introduced as N-1 
substituents (Scheme 10). Reaction of 3 with 3-bromocyclohexene afforded 
compound 31 in 28% yield. Similarly 13 was reacted with 
(bromomethyl)cyclohexane to afford compound 32 in 27% yield. 
 
 
 
Scheme 10. Synthesis of iminodihydroquinolines 31 and 32. 
Reagents and conditions: (i) 3-Bromocyclohexene, NaI, DMF, 80 °C, 4 days, 28% (ii) 
(Bromomethyl)cyclohexane, NaI, DMF, 120 °C, 4 days, 27%.   
 Starting 
material 
 
Product       -R
1
 -R
3
 Yield (%) 
 
 7  28 
 
Cl 24
a
 
 
 8  29 
 
Cl 92 
 
 10  30 
 
H 51 
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3.1.1.2. Route B: From 4-quinolones 
The second synthetic approach to iminodihydroquinolines relied on 
commercially available 4-quinolones as building blocks, which were assembled in a 
two-step reaction sequence (Scheme 11). 
 
Scheme 11. Second route to iminodihydroquinolines starting from 4-quinolones. 
Reagents and conditions: (i) NaH, 0 °C, 15 min (ii) R
2
-Br, DMF, 80 -110 °C, 18-24 h (iii) 
POCl3, 110 °C, 3 h (iv) R
1
-NH2, MeOH, rt, 5-18h 
 
The first step involved the R2 alkylation of 4-quinolones to afford N-
substituted quinolone intermediates. 4-quinolones exist exclusively in their carbonyl 
tautomeric form (Scheme 12). N-H deprotonation generates ambident anions that 
can react at either oxygen or nitrogen depending on the exact reaction conditions. 
Selective N-alkylation/benzylation has been previously reported by means of N-H 
deprotonation using a strong base such as sodium hydride or potassium hydroxide 
prior to reaction with alkyl/benzyl halides;156 O-alkylation has been reported for 
reactions performed in the presence of silver carbonate.157 
 
Scheme 12. 4-Quinolone tautomerization. Equilibrium lies heavily in the carbonyl form as the 
hydroxyl tautomer lacks a favorable polarized resonance state.
158
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Reaction of 4-quinolones with sodium hydride, followed by treatment with 
benzyl bromide or n-pentyl bromide, afforded N-substituted quinolones 33, 34 and 
35 (Table 8). Alkylation at the nitrogen atom was verified by 
analysis of the NOESY spectra of the three compounds. 
Hydrogen correlation was observed between the benzylic 
protons and the quinolone protons at positions 2 and 8 
suggesting these nuclei are spatially close (Fig. 26). 
Table 8. N-alkylation of 4-quinolones. 
 
Starting material Product R
3 
R
2 
Yield (%) 
7-chloro-4-quinolone 33 Cl 
 
57 
7-chloro-4-quinolone 34 Cl 
 
31 
4-quinolone 35 H 
 
68 
(i) NaH, 0 °C, 15 min (ii) Benzyl/alkyl bromide, DMF, 80-110 °C, 18-24 h 
 
The second and final step of this route involved installation of the R1 4-
iminoalkyl group. The N-substituted quinolones were reacted with phosphorous 
oxychloride in a Vilsmeier-type reaction to afford highly reactive haloquinolinium 
ions. These were subsequently treated with the selected amine to furnish the target 
iminodihydroquinolines (Scheme 13).159 
 
Scheme 13. Proposed mechanism for carbonyl to imine transformation via a 
chloroquinolinium intermediate.  
Figure 26. Key NOESY 
interactions (↔) 
coorelations (       ) in 
x,x 
Chemical approaches and reactions 
 
48 
This second synthetic approach was applied for the synthesis of six 
iminodihydroquinolines, 1 and 36 - 40 (Table 9, Scheme 14). It was considered 
advantageous over the 4-chloroquinoline route for a number of cases. Firstly, the 
use of a highly reactive chloroquinolinium intermediate allowed the incorporation of 
low nucleophilicity amines as R1-imino substituents; N-benzyl-4-quinolone (33) was 
treated with O-phenylhydroxylamine (pKa=1.96)
160 at ambient temperature, yielding 
compound 36 in an excellent 74% yield. In addition, installation of the 4-imino 
substituent in the last step of the reaction sequence allowed the synthesis of a 
series of iminodihydroquinolines with the same R2 substituents via a common N-
substituted-4-quinolone intermediate; for example compounds 37 and 38 were both 
accessed via quinolone 35. This effectively translates to a more labor-, time- and 
cost-efficient library synthesis. 
 Table 9. Synthesis of iminodihydroquinolines 1, and 36 - 38. 
 
4-Quinolone Product R
1 
R
2
 R
3 
Yield (%) 
33 1 
 
 
Cl 51 
 36 
  
Cl 74 
35 37 
  
H 57 
 38 
  
H 88 
(i) POCl3, 110
 
°C, 3 h (ii) R
2
-NH2, MeOH, rt, 5-18h 
 
Furthermore, the reaction sequence was used for the installation of 
benzylsulfonyls as R1 substituents (Scheme 14). According to a previously 
described procedure, quinolones 33 and 34 were reacted with benzylsulfonyl 
isocyanate to afford the target iminodihydroquinolines 39 and 40, in 70% and 85% 
yield respectively.161 
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Scheme 14. Synthesis of iminodihydroquinolines 39 and 40. 
Reagents and conditions: (i) CH3CN, 70 °C, 24 h, 39 → 70%, 40 → 85%. 
 
 
3.1.1.3. Route C: From substituted benzoic acids via ring annulation 
The third synthetic approach, as the previously described route B, also 
involved substituted 4-quinolones as synthetic intermediates; however, in this case, 
the quinolone biaryl scaffold had to be constructed from single aryl units in 
multistage reactions (Scheme 15). Two reasons led us pursue this otherwise time- 
and labor- intensive synthetic route: 
a) Limited availability of building blocks for use in routes A and B: in certain 
cases the building blocks with the desired R3 substitution pattern were not 
commercially available or were too expensive for practical applications (for 
example where R3 = F). 
b) The need to access compounds bearing cycloalkyl or aryl R2 groups: direct 
nucleophilic addition at the quinoline or quinolone nitrogen using aryl halides 
or secondary alkyl halides was not feasible via the previously described 
routes. 
 
Scheme 15. Third route to iminodihydroquinolines from substituted benzoic acids denoting 
the key 4-quinolone intermediate. 
  
Chemical approaches and reactions 
 
50 
4-Quinolones are particularly interesting scaffolds from a biological point of 
view, dominating the class of antibacterial agents for more than four decades 
(ciprofloxacin).162 Recent studies have demonstrated they are multi-faceted drugs 
also exhibiting antiischaemic (flosequinan), antiviral (elvitegravir) and antitumor 
properties (Fig. 27).163 
 
Figure 27. Structures of marketed 4-quinolone drugs. 
Their synthesis has therefore been the subject of extensive research with 
flexible routes developed, allowing access to highly substituted and diverse 
quinolone libraries. The recent review by Boteva and Krasny, provides an excellent 
summary of preceding methods to substituted 4-quinolones.164 The selected 
synthetic approach to 4-quinolones was based on the Grohe-Heitzer synthesis of 4-
quinolone-3-carboxylic acids (46) (Scheme 16).165 
 
Scheme 16. The Grohe-Heitzer synthesis (pink) and the modified Grohe-Heitzer synthesis 
employed as part of the third synthetic route (C) to 4-iminodidydroquinolines (black). 
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According to this, an acid chloride, 41, is initially condensed with the active 
methylene of ethyl 3-(N,N-dimethylamino)acrylate to form enamine 44 (Scheme 16). 
This is subjected in situ to an addition-elimination reaction by the action of primary 
amines making it possible to introduce diverse R2 substituents at the N-1 position.166 
Enamine 45 is cyclized, through intramolecular nucleophilic aromatic substitution 
with the ortho halogen leaving group with respect to the activating carbonyl group, to 
afford after ester hydrolysis, the quinolone carboxylic acid 46. Having furnished the 
biaryl core, the final steps of the sequence involve acid decarboxylation to generate 
the N-1 substituted quinolone 47 which can be successively transformed to the 
target 4-iminodihydroquinoline. 
 
Scheme 17. Synthesis of iminodihydroquinolines 55 and 56. 
Reagents and conditions: (i) (COCl)2, DMF (cat.), DCM, rt, 2h, quant. (ii) ethyl 3-(N,N-
dimethylamino)acrylate, NEt3, CH3CN, 70 °C, 3-5 h (iii) NH2-R
2
, 70 °C, 18 h, 52(a) → 31%, 
52(b) → 61% (iv) NaH, THF, reflux, 4-6.5 h (v) NaOH, THF/EtOH (6:1), 50-60 °C, 6 h, 53(a) 
→ 58%, 53(b) → 43% (vi) HCl (aq.), biphenyl ether, 260 °C, 7 h, 54(a) → 18%, 54(b) → 24% 
(vii) POCl3, 100 °C, 2 h (viii) n-pentylamine, rt, 2-3 h, 55 → 68%, 56 → 96% 
 
The route was successfully applied for the synthesis of 
iminodihydroquinolines 55 and 56 (Scheme 14). Commercially available 2,6-
dichlorobenzoic acid (49) was treated with oxalyl chloride in the presence of a 
catalytic amount of DMF to form acid chloride 50 in quantitative yield. 50 was 
reacted with ethyl 3-(N,N-dimethylamino)acrylate to afford enamine 51. 
Transamination using aniline or cyclohexylamine resulted in formation of enamines 
52(a) and 52(b) in 31% and 61% yield respectively. The enamines were obtained as 
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racemic mixtures of the E and Z isomers, in 77:23 ratio for 52(a) and in 83:17 ratio 
for 52(b), as determined by the 1H NMR spectra. The results are in agreement with a 
previously published study by Kędzia, J. et al. which demonstrated that in similar 
systems the E isomer is preferentially formed, due to the Z isomer being 
destabilized by steric interactions between the diethoxycarbonyl and the amino 
alkyl/aryl groups.167 Ring cyclisation in the presence of NaH, followed by ester 
hydrolysis under basic conditions furnished the biaryl core generating carboxylic 
acids 53(a) and 53(b).These were subsequently decarboxylated via harsh heating in 
acidic pH to afford 4-quinolones 54(a) and 54(b) in 18% and 24% yield. The final 
steps involved installation of the 4-imino substituent, via reaction of a 
chloroquinilinum ion intermediate with n-pentylamine as previously described for 
route B. The target compounds 55 and 56 were obtained in overall yields of 2% and 
6% respectively. 
The lowest yielding step in the above reaction sequence was the thermal 
decarboxylation of the quinolone-3-carboxylic acids. In an attempt to improve the 
overall yield, the synthesis of iminodihydroquinoline 61, was modified to circumvent 
this step (Scheme 18). 
 
Scheme 18. Synthesis of iminodihydroquinoline 61. 
Reagents and conditions: (i) N,N-dimethylformamide dimethyl acetal, toluene, reflux, 24 h, 
61% (ii) 3-fluorobenzyl amine, acetic acid, 60 °C, 8 h, 48% (iii) NaH, DMF, 0 → 80 °C, 3 h, 
14% (iv) POCl3, 100 °C, 2.5 h (v) n-pentylamine, MeOH, rt, 5 h, 50% 
 
The first step of the sequence, involved condensation of commercially 
available 2-chloro-4-fluoroacetophenone with N,N-dimethyl formamide dimethyl 
acetal at 110°C, to afford intermediate enamine 58 in 61% yield. N,N-dimethylamino 
group substitution of 58 using 3-flurobenzylamine in acetic acid provided 
intermediate 59 as a single isomer in 48% yield. This was subsequently treated with 
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NaH to furnish the biaryl quinolone core in 60 in 14% yield. It is worth noting that the 
reaction yield was significantly lower compared to the ones previously obtained for 
the ester-containing compounds 52(a) and 52(b) (Scheme 17). The ease of 
cyclization is known to be dependent on the nature of the substituent at the enamine 
nitrogen. Reaction of 60 sequentially with phosphorous oxychloride and n-
pentylamine, afforded the target iminodihydroquinoline 61 in 50% yield. The overall 
reaction yield was 2%. The sequence was eventually proven to be as low yielding as 
the one initially described (Scheme 17); it is however by one synthetic step shorter. 
 
3.1.2. N-substituted-4-imino-1,4-dihydro-naphthyridines 
The naphthyridines are aromatic heterocyclic compounds members of the 
chemical class of diazanaphthalenes, increasingly applied in medicinal chemistry as 
quinoline bioisosteres.168 Their framework consists of a naphthalene ring at which 
one carbon per ring has been replaced with a nitrogen atom (Fig. 27). 
 
Figure 28. The chemical family of diazanapthalenes. 
Traditionally, synthetic approaches to naphthyridines involved extension of 
established routes to quinolines with the benzyl building blocks of the latter being 
replaced with appropriately substituted pyridines. Two out of the six possible 
naphthyridine isomeric scaffolds, and in particular the 1,5- and 1,8-isomers, were 
introduced giving rise to two novel structural analogues in the library, 69 and 82. The 
N-1, 4-imino substitution pattern met in the parent WIN17317-3 and the synthesized 
iminodihydroquinoline series was retained. 
1,2 1,3 1,4 2,3 
1,5 1,6 1,7 1,8 
2,6 2,8 
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The modified Grohe-Heitzer iminodihydroquinoline synthesis (route C, vide 
supra), was adapted for the synthesis of the 4-imino-1,5-naphthyridine analogue 69 
(Scheme 19). 
 
Scheme 19. Synthesis of the substituted naphthyridine 69. 
Reagents and conditions: (i) (COCl)2, DMF (cat.), DCM, rt, 2 h, quant. (ii) Ethyl 3-(N,N-
dimethylamino)acrylate, NEt3, CH3CN, 65 °C, 3.5 h (iii) Benzylamine, 70 °C, 18 h, 45% (d) 
NaH, THF, 50 °C, 4 h, 94% (iv) NaOH, THF, 60 °C, 3 h, 90% (v) HCl (aq.), biphenyl ether, 
280 °C, 7 h, 74% (vi) POCl3, 110 °C, 2 h (vii) n-pentylamine, rt → 18 h, 80 °C → 6 h, 59% 
 
Commercially available picolinic acid (62) was the utilized building block. The 
acid chloride derivative 63 was reacted with ethyl 3-(N,N-dimethylamino)acrylate, 
and the resulting enamine 64 was transaminated with benzylamine to afford a 
mixture of 65 isomers (83:17 ratio). 65 was cyclized following treatment with NaH, to 
furnish the 1,5-naphthyridine scaffold in 66 in an excellent 94% yield. Ester 
hydrolysis and decarboxylation afforded intermediate 68 in 74% yield. Reaction with 
POCl3 followed by treatment with an excess of n-pentylamine led to the doubly 
alkylated analogue 69.This was not surprising as naphthyridine rings are π-electron 
deficient and hence highly susceptible to nucleophilic attack, particularly at the ortho 
and para positions.169 
A different approach was employed for the synthesis of the 4-imino-1,8-
naphthyridine analogue 82. The synthesis was based on a recent report of a one-pot 
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method to naphthyridines via a modified Friedländer reaction.170 The archetypal 
Friedländer quinoline synthesis involves condensation of an aromatic o-amino 
aldehyde or ketone (70) with an aldehyde or a ketone containing an active 
methylene group (71), followed by acid catalyzed cyclisation to furnish the quinolne 
core (72, Scheme 20.A).171 The advanced method uses more accessible 2-pyridyl 
pivalamides or tert-butylcarbamates (73) as building blocks that are subjected to 
ortho-metalation before being reacted with the active methylene of a β-
dimethylamino or β-alkoxy acrolein derivative (74) (Scheme 20.B). Acid mediated 
cyclisation gives access to the naphthyridine core (75). 
Scheme 20. The archetypal Friedländer quinoline synthesis (A) and the adopted 1,8-
naphthyridine synthesis (B). 
 
An efficient four-step route to the target 4-iminonaphthyridine 82 was 
designed integrating the advanced Friedländer method (Scheme 21). The required 
tert-butylcarbamade starting material 77 was synthesized from commercially 
available 4-chloro-2-aminopyridine (76). In a one-pot procedure, 77 was treated with 
n-butyllithium to form the dilithiated intermediate 78 which was subsequently reacted 
with β-dimethylaminoacrolein and heated in refluxing aqueous hydrochloric acid to 
furnish the 1,8-naphthyridine scaffold. Two products, 79 and 80, were isolated in 
39% and 17% yields respectively, the latter being the hydrolysis product of 79. The 
final steps in the sequence involved N-1 benzylation of 80 to afford compound 81 
which was subsequently reacted with POCl3 and n-pentylamine to afford the target 
compound 82 in 90% yield. 
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Scheme 21. Synthesis of the substituted naphthyridine 82. 
Reagents and conditions: (i) Di-tert-butyl dicarbonate, LiHMDS, THF, -5–0 °C, 2 h, 77% (ii) 
n-BuLi, HMPA, THF, -78 °C, 1 h (iii) β-dimethylaminoacrolein, -78 °C, 1.5 h (iv) HCl (aq.), 
100 °C, 3 h, 79 → 39%, 80 → 17% (v) CH3COOH, 125 °C, 1.5 h, 92% (vi) Benzyl bromide, 
K2CO3, DMF, 80 °C, 3 h, 80% (vii) POCl3, 110 °C, 1.5 h (viii) n-pentylamine, MeOH, rt, 18 h, 
90% 
 
Mechanistic insights to the one-pot transformation of carbamate 77 to 4-
chloronapthyridine 79 are given in Scheme 22. The suggested mechanism is based 
on the findings of Cho et al. who investigated similar transformations of ortho-
lithiated N-acylanilines to quinolines.172 According to these, the reaction of dilithiated 
tert-butylcarbamade 83 with dimethylaminoacrolein leads to the formation of a 
primary adduct 84 which upon hydrolysis generates aldehyde 85. 85 can form 4-
chloronaphthyridine 79 via two plausible pathways. The first (blue pathway) involves 
cyclisation to hemiamidal 86, followed by loss of a dimethylamine molecule, 
aromatization, and Boc-deprotection under acidic conditions, to yield the target 
naphthyridine 79. The second viable pathway (purple) involves elimination of 
dimethylamine from 85 generating the α,β-unsaturated E-aldehyde 87. 87 
isomerizes to the corresponding Z aldehyde 88, which sets all substituents in place 
for intramolecular cyclisation to hemiamidal 89. 89 undergoes aromatization by the 
loss of a water molecule, and Boc-deprotection under acidic conditions, to form 4-
chloroquinoline 79. 
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Scheme 22. Proposed mechanisms for the one-pot transformation of tert-butylcarbamates to 
1,8-naphthyridines.
172
 
 
3.1.3. N9-substitued-6-aminoaryl-purines and N-substituted-4-
imino-1,4-dihydro-pyridines 
With the aim to introduce more structurally diverse scaffolds as part of the 
library, two more heterocyclic ring systems - purine and pyridine - were 
incorporated, giving rise to three additional structural analogues of WIN17317-3.  
Purines consist of a pyrimidine ring fused to an imidazole ring; they are the 
most widely occurring nitrogen-containing heterocycles in nature, ubiquitous motifs 
of significant biomolecules such as adenine, guanine (nucleic acid bases), 
adenosine (neuromodulator) and adenosine triphosphate (ATP) (coenzyme-energy 
transfer) (Fig. 29).173 The purine framework is found in drugs with various 
pharmacological activities such as caffeine (CNS stimulant, adjuvant analgesic), 
fludarabine and thioguanine (chemotherapeutics). 
 
Figure 29. Structures of purine-containing biomolecules and drugs.  
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Two purine analogues 93 and 94 were synthesized via a two-step reaction 
sequence using commercially available 6-chloropurine (90) as the starting material 
(Scheme 23). Base promoted N-alkylation of purine 90, as previously described in 
literature, afforded a mixture of two products: the N7-isomer 92 isolated in 13% 
yield, and the desired N9-isomer (91) constituting the major product isolated in 48% 
yield.174 The increased polarity of the N7-isomer relative to its N9 alkylated 
counterpart allowed separation of the two by standard flash chromatography on 
silica gel. Nucleophilic aromatic substitution in 91 by aniline and benzylamine 
afforded the final compounds 93 and 94 in 75% and 90% yields respectively. 
 
Scheme 23. Synthesis of substituted purines 93 and 94. 
Reagents and conditions: (i) NaH, DMF, rt, 24 h, 91 → 48%, 92 → 13% (ii) Aniline, NEt3, n-
pentanol, 110 °C, 24 h, 75% (iii) Benzylamine, EtOH, reflux, 3 h, 90% 
 
Shifting away from a fused bicyclic core, analogue 97 featuring a 1,4-
dihydropyridine scaffold was synthesized (Scheme 24). The halogen substitution - 
N-alkylation reaction sequence applied for the synthesis of iminodihydroquinolines 
(route A) was used (see Section 3.1.1.1). 4-chloroquinoline (95) was treated with n-
pentylamine to afford 4-aminoalkylpyridine intermediate 96, which was subsequently 
reacted with benzyl bromide under Finkelstein reaction conditions to afford the 
target compound 97 in an overall 32% yield. 
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Scheme 24. Synthesis of substituted pyridine 97. 
Reagents and conditions: (i) n-Pentylamine, 110 °C, 48 h, 51% (ii) Benzyl bromide, NaI, 
acetone, reflux, 8 h, 62% 
 
3.2. Synthesis of an 18F-labeled lead drug candidate 
The synthesized compounds were submitted to pharmacological assays to 
determine their activity as Nav inhibitors and as nociceptor blockers, with several 
members of the library found efficacious in blocking pain signaling (see Chapters 4 
and 5). Appreciating the importance of an 
integrated PK/PD strategy in the drug 
development process, a selected compound from 
the library, 22, designated as the ‘lead,’ was to be 
submitted in early pharmacokinetic profiling and 
safety pharmacology studies in vivo in rodents 
(Fig. 30). 
Nuclear imaging methods, explicitly positron emission tomography (PET) 
and single-photon emission computed tomography (SPECT) are increasingly 
applied for the determination of the PK/PD properties of novel drug candidates.175 
Briefly portraying the methods’ principles, a radioactive tag is inserted into the 
selected drug candidate; the radiolabeled molecule is subsequently administered to 
a living subject and is detected in vivo as a function of time, with high sensitivity and 
specificity by the appropriate nuclear imaging modality. The two modalities, PET and 
SPECT, vary on the type of radionuclides they can accommodate. 
3.2.1. The choice of radionuclide 
In this event, the synthesis of an isotopically labeled version of lead 
compound 22 was pursued. Isotopically labeled tracers are labeled by replacement 
of the stable isotope of an element in the compound with the corresponding 
radionuclide; they thus retain all chemical and biological properties of the non-
labeled molecule. The nature of the radionuclide incorporated, and hence the 
Figure 30. Lead structure 22 and 
the corresponding [
18
F]radiotracer. 
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imaging modality employed, were therefore dictated by the chemical composition of 
22. Out of all possible isotopic substitutions (H, C, N, F), fluoride replacement by 
positron emitting fluoride-18 was selected for [18F]22 imaging with PET. Fluoride-18, 
with a half-life of 110 min, offers a reasonable time frame for radiosynthesis, 
administration and visualization of the distribution and metabolism profile of the 
radiolabeled drug candidate in vivo, limiting unnecessary radiation burden. 
 
3.2.2. The triarylsulfonium salt method for 18F-labeling of 
aromatic compounds 
Historically, direct [18F]fluorination of activated aromatic rings (containing 
electron-withdrawing groups, EWG), has been achieved by nucleophilic aromatic 
substitution (SNAr) of one of the following leaving groups: trimethylammonium (-
NMe3+), nitro (-NO2), halogen (-F, -Cl, -Br), and sulfonium salts (-SAr2
+).176 
[18F]fluorination of electron neutral or non-activated aromatic rings, like the benzylic 
moiety of interest, has been diachronically challenging; the few methods reported 
require the use of palladium, nickel, and copper or hypervalent iodine complexes in 
procedures posing a number of practical difficulties and harsh reaction conditions.177 
The practical utility of such reactions for the preparation of biologically relevant 18F-
labeled molecules remains to be demonstrated. 
Sulfonium salts were first 
proposed as leaving groups for [18F] 
nucleophilic aromatic fluorination in 
the late 1980s; dimethylsulfonium 
ions were employed for the labelling 
of strongly activated aromatic rings 
(Fig. 31).178 Difficulties however in 
synthesizing dimethylsulfonium derivatives of complex aromatic compounds, their 
high reactivity, and the formation of [18F]fluorination side products during labeling 
(methyl fluoride), made this a poor general method for the labeling of aromatic 
compounds with fluorine-18.  
Two decades later, the method was reassessed, this time using 
diarylsulfonium leaving groups (Figure 32.B).179 Triarylsulfonium salts exhibit high 
thermal and chemical stability and allow highly efficient labeling of activated 
aromatic rings. [18F]fluoride preferentially reacts at the most electron poor of the 
three sulfonium-substituted carbons. Our group exploited this reactivity trend further, 
Figure 31. 
18
F-Labeling of dimethylsulfonium 
salts.  
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engineering novel electron rich sulfonium leaving groups bearing electron-donating 
spectator ligands (OMe, CH3) aiming to direct fluorination at non-activated, electron-
neutral aromatic rings (Figure 32.C). The applicability of such sulfonium salts for the 
highly efficient and regioselective aromatic [18F]fluorination of non-activated aromatic 
scaffolds bearing drug-like functionalities has been demonstrated.180 
 
 
Figure 32. Timeline of sulfonium salt development as leaving groups for aromatic 
[
18
F]fluorination. 
 
3.2.3. Synthesis of a triarylsulfonium salt precursor for 
aromatic 18F-fluorination 
Based on the above principle, triarylsulfonium salt 100 bearing a di(4-
methoxyphenyl)sulfonium leaving group, was designed as the precursor for the 18F-
labeling of 22. The retrosynthetic approach to 100 is illustrated in Scheme 25. 
According to this, sulfonium salt 100 could potentially be accessed via arylation of 
thioether 98, which could in turn be obtained from the reaction of a suitably 
substituted aryl halide with 4-methoxythiophenol. 
 
Scheme 25. Retrosynthetic analysis of triarylsulfonium salt 100.  
2012 
    
1987 2014 
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The first step in the sequence involved the preparation of thioether 98. 
Amongst multiple routes explored,181 palladium-catalysed cross coupling of aryl 
iodide 23 with (4-methoxy)thiophenol was proved to be the most efficient and 
reliable route to 98 (Scheme 26).182 Full conversion of starting materials to product 
was essential as 23 and 98 exhibited similar retention factors meaning the two were 
inseparable by standard chromatographic means. The iodinated 
iminodihydroquinoline 23 was synthesized via N-alkylation of 4-
pentylaminoquinoline (9) as described in section 3.1.1.1 (page 43). 
 
Scheme 26. Synthesis of thioether 98. 
Reagents and conditions: (i) Pd2dba3 (cat., 1%), bis[(2-diphenylphosphino)phenyl] ether, 
tBuOK, toluene, reflux, 3 h, 63% 
 
A highly versatile method recently developed by the group was employed for 
the synthesis of triarylsulfonium salt 100 (Scheme 27).183 The functionalized 
thioether 98 was reacted with a diaryliodonium triflate salt under copper(II) catalysis, 
an approach first introduced by Crivello et al.184 According to our group’s advanced 
method, the imine functionality was masked prior to reaction by protonation using 
triflic acid, avoiding coordination with the copper(II) hence allowing the reaction to 
proceed. Gratifyingly, the corresponding triflate salt of 98 reacted cleanly with bis(4-
methoxyphenyl)iodonium triflate affording the desired sulfonium salt 100 in 32% 
yield. 100 was isolated by column chromatography on silica gel in high purity. To 
enable labeling, the free base was liberated after purification using aqueous sodium 
hydroxide. 
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Scheme 27. Synthesis of triarylsulfonium salt 100. 
Reagents and conditions: (i) TFSA, Cu(II)benzoate, chlorobenzene, reflux, 2 h (ii) NaOH 
(2M), basic workup, 32% 
 
The diaryliodonium salt reagent 99 used in the reaction above, was 
synthesized according to a previously described procedure (Scheme 28).185 The 
one-pot synthesis involved reaction of anisole with elemental iodine and 3-
chloroperoxybenzoic acid (mCPBA) and tosic acid as the oxidizing agent to afford 
an iodonium tosylate intermediate; this which was subsequently treated with triflic 
acid, to afford by in situ anion exchange, the desired iodonium triflate 99 in 80% 
yield. 
 
Scheme 28. Synthesis of di(methoxyphenyl)iodonium triflate, 99. 
Reagents and conditions: (i) mCPBA, TsOH, DCM, 40 °C, 15 min (ii) TfOH, rt, 1 h, 80% 
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3.2.4. Radiolabeling of [18F]22 
Screening of bases and solvents commonly used for nucleophilic 
[18F]fluoride substitution reactions, revealed potassium bicarbonate and dimethyl 
sulfoxide (DMSO) to be optimal for triarylsulfonium salt labeling, in a study 
performed by Dr. Kerstin Sander.180 [18F]fluorination of 100 was performed under 
these optimized established reaction conditions (Scheme 29).180 According to these 
(5 mg precursor, 0.5 ml DMSO, 120 °C, 15 min), sulfonium salt 100 was reacted 
with dried [18F]fluoride to give [18F]22 in 47% analytical radiochemical yield (RCY) 
and 30% decay-corrected isolated RCY. 
 
Scheme 29. Labeling of [
18
F]22. 
Reagents and conditions: (i) [18F]Fˉ, KHCO3, K222, DMSO, 15 min, 120 °C, analytical RCY: 
47 ±6%, decay-corrected isolated RCY: 30 ±6%, (±SD) (n = 6). 
 
The identity of the radiochemical product [18F]22 was confirmed by co-elution with 
the non-radioactive analogue 22 (Fig. 33). 
 
Figure 33. HPLC chromatogram of the isolated compound [
18
F]22, co-injected with the non-
labelled reference 22. 
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4. Sodium Channel Blockade by WIN17317-3 
Analogues (in Vitro) 
One of the key objectives of this study, as discussed in chapter 1 (page 32), 
was the elucidation of the structure-activity requirements of 4-
iminodihydroquinolines for blocking Nav isoforms, in particular Nav1.7. In this 
chapter, the human Nav blocking efficiencies of iminodihydroquinolines, as 
measured in automated patch clamp electrophysiology assays, are described. The 
first ever pharmacophore model for the iminodihydroquinoline class at Navs is 
defined. 
 
4.1. Electrophysiological assays, and their use, for 
measuring Nav activity 
Multiple functional assays have been developed for studying the function and 
pharmacology of Nav channels (ion flux, fluorescent dyes, radioligand binding, patch 
clamp) exploiting either the actual Na+ ion flux across the cell membrane or the 
concomitant transient changes in membrane potential.186 Out of these, the 
electrophysiological patch clamp technique has progressively stood out as the gold 
standard.187 The technique is a refinement of the traditional voltage clamp method, 
developed by Erwin Neher and Bert Sakmann in 1976, for which they were awarded 
the Nobel Prize in Physiology or Medicine in 1991. 
In a simplified description of the method’s principles, a patch of membrane is 
electrically isolated from the external solution by pressing a glass pipette, ﬁlled with 
an electrolyte solution, against the surface of the cell (Fig. 34.A). By applying light 
suction, a seal is formed (electrical resistance >10 GΩ), with the glass pipette and 
the cell membrane being less than 1 nm apart. Currents fluxing through the 
channel(s) in this patch flow into the pipette and are recorded by an electrode 
connected to a highly sensitive differential amplifier. To prevent alterations in the 
membrane potential, a compensating current that resembles the current flowing 
through the membrane is generated by the amplifier as a negative feedback 
mechanism and injected into the cell. The current is recorded, allowing conclusions 
to be drawn regarding the membrane conductance. The advantage of this method is 
that the membrane potential can be precisely controlled independent of the fluxing 
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ionic currents. Patch clamp is the only available method suitable for investigating the 
function of channels at specific voltage states (resting, open inactivated). 
Despite its ubiquitous use in academic research for drug discovery, the 
technique holds significant drawbacks. It has low throughput, it is labor intensive and 
requires highly skilled operators, all factors making it not amenable to screening 
large compound libraries. The recent development of automated patch 
electrophysiology technologies in the last decade has resolved these issues and has 
since revolutionized the field of ion channel research allowing the screening of 
hundreds of compounds per day.188 
 
Figure 34. Schematic representation of the general features of a conventional patch clamp 
chip (A) and a planar patch clamp chip (B). (C) Illustration of a 16 well planar patch clamp 
configuration allowing parallel patch clamping. Adapted from reference 189.189 
Automated patch clamp assays share the principles of the manual method, 
yet the experimental set up was adapted to allow automation. The traditional glass 
pipette has been replaced by a planar plastic substrate in what are named as planar 
patch screening platforms. The planar substrate is perforated with small micron-
sized holes mimicking the tip of the glass electrode (Fig. 34.B). An automated liquid 
handling device is used to deliver both cells and test compounds into the planar 
patch clamp chip and a mobile electronic head stage is automatically positioned into 
the wells to establish the voltage-clamp and record fluxing currents. 
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Five planar system platforms have been commercialized to date; QPatch 
(Sophion Bioscience), PatchXpress (Molecular Devices), IonWorks -HT, -Quattro, -
Barracuda (Molecular devices), Patchliner (Nanion Technologies), and Cytopatch 
(Cytocentrics), with divergent chip constructions and technologies resulting in 
differences in the compound throughput capacity and the quality of data obtained 
from each one. An in depth description of the available automated planar-array 
electrophysiology platforms can be found in the review by Dunlop et al., as well as a 
comparison of those to the conventional patch clamp method.190 
In this study, the Nav screening assay employed was selected on the basis of 
the following considerations: (a) cost- and (b) time-efficiency, given the large 
number of compounds to be screened, and (c) consistency/reproducibility as 
subsets of the compound library would be tested sequentially in different runs/time 
periods. After examining all possible options, the assay was decided to be 
outsourced to Cambridge Bioscience®, in collaboration with a U.S. company, 
ChanTest® Corporation. In consultation with one of Chan Test’s® ion channel expert 
scientists, the IonWorks QuattroTM planar electrophysiology platform was selected. 
 
4.2. The IonWorks Quattro screening platform 
IonWorks QuattroTM (IWQ) is the screening platform with the highest 
compound throughput (up to 10,000 data points per day), each plate being a 
multiplex of 384 individual chips.191 Each chip has 64 engraved cavities (population 
patch chip, PPC) meaning up to 64 cells can be simultaneously sealed and voltage 
clamped. This statistically increases the probability of forming a viable seal and 
hence successfully recording a data point from a chip. Indeed, more than 95% 
success rate is associated with IWQ in terms of data point collection. Furthermore, 
the PCC chip allows averaging of cell-to-cell variations in current amplitude and 
therefore accounts for cell variability factors in the current measurement.192 The use 
of the IWQ platform for studying the pharmacology of Nav channels has been 
validated. 
Despite the high throughput and high success rate, the IWQ platform holds 
certain limitations. It is the only one of the newly automated systems incapable of 
GΩ seals, although the measurements show good consistency with manual patch 
clamp data. It is incapable of performing ligand application with simultaneous 
voltage clamping, a significant drawback in particular for slowly desensitizing ligand-
gated channels. Lastly, in certain studies examining the effects of highly lipophilic 
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compounds right-shifting of activities has been observed (higher IC50s), which was 
attributed to compounds adhering to the plastic surface of the plate.193 
For the purpose of this study, the IWQ platform was operated at a voltage 
protocol validated for evaluating the state-dependent interactions of pharmacological 
agents with human Nav1.7 channels cloned in Chinese hamster ovarian (CHO) cells 
(Fig. 35). The protocol consists of a series of depolarizing pulses delivered at 
precise time intervals. 
 
Figure 35. Voltage protocol for measuring hNav1.x blockade. The test pulse (TP) pattern 
was repeated twice: before (-control) and 5 minutes after compound (cpd) addition. The peak 
current amplitudes at TP1, TP11 and TP12 were measured and used for calculating the 
percentage inhibitions at resting and inactivate states, and use-dependency respectively. 
Four replicates were performed for each compound concentration tested. Lidocaine (3 mM) 
and DMSO (0.3%) were included in each plate as positive and negative control, respectively. 
The voltage protocol consists of three phases of stimulation. During phase 1, 
the membrane is hyperpolarized from -80 mV (holding potential) to -120 mV, at 
which potential the Nav1.7 isoform is known to completely recover from inactivation. 
A single pulse (TP1) is subsequently applied, allowing the measurement of tonic 
block, mainly reflecting the effect of drug binding to channels in the resting state. 
The maximum depolarization-evoked current for Nav1.7 occurs at ~0 mV. During 
phase 2, a train of short pulses (TP1 - TP10) is applied at 10 Hz frequency serving 
as the conditioning step for assessing use-dependent inhibition at TP11. At the 
same time, TP11 serves as the long inactivating conditioning pulse for assessing 
inactivation-dependent inhibition at phase 3. After a brief stop at -60 mV which is the 
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midpoint of Nav1.7 steady-state inactivation, to allow partial recovery of unblocked 
channels from inactivation, inactivation-dependent inhibition is measured at TP12. 
The test pulse protocol of Figure 35 was successful in determining the state- 
and use-dependent block induced by lidocaine at hNav1.7 (Fig. 36). In addition, the 
pufferfish toxin TTX produced similar levels of block at all three phases consistent 
with previous findings demonstrating that this is insensitive to changes in membrane 
potential or channel gating. 
 
Figure 36. Concentration-response relationships for lidocaine and TTX at hNav1.7 measured 
using the IWQ platform operated at the voltage protocol of Fig. 35. IC50 values for lidocaine 
were 548 µM, 49 µM and 8 µM for the tonic, frequency-dependent and inactivated states 
respectively. Data are presented as mean ± SD (n = 3–5). TTX produced similar 
concentration-response curves at all three voltage states. 
The Nav screening of all first generation iminodihydroquinoline analogues, 
described in this chapter, was performed at the IWQ platform. From September 
2013, ChanTest® replaced IWQ with a higher efficiency second generation 
IonWorks instrument, the IonWorks™ Barracuda (IWB). Whilst IWQ records from 48 
recording wells at a time, the IWB allows recordings from all 384 wells at once. 
Furthermore IWB supports recordings during compound addition, but does not allow 
wash out of ligands, which reduces the efficiency for investigating ligand-gated ion 
channels since only one concentration per recording well can be obtained.191 The 
second generation iminodihydroquinoline analogues, the Nav characterization of 
which is described in chapter 5.4, were tested at the IWB platform. 
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4.3. Evaluation of a two concentration-response point 
approach for screening Nav activity using IonWorks 
Quattro 
Given the high cost of automated patch clamp electrophysiology assays 
(3900 GBP per IonWorks plate), a cost-efficient yet meaningful approach for 
screening our compound library with the minimum possible number of plates was 
required. After a search in literature, several studies were identified which used only 
one concentration-response point per compound for characterizing the Nav activity 
of large compound libraries. One such example is the study by Huang et al. where 
400 known drugs were screened at 10 µM concentration against hNav1.3 using a 
novel technology platform called the electrical stimulation voltage ion probe reader 
(E-VIPR); based on the percentage of hNav1.3 inhibition produced, compounds 
were classified as hNav1.3 blockers or not (Fig. 37). 
 
Figure 37. Screening results of 400 known drugs for blocking activity against hNav1.3 at 10 
µM using E-VIPR. Each plate contained four negative (DMSO, red) and four positive (100 
mM tetracaine, blue) controls. Drug-blocking activity was calculated according to the two 
controls, with hits defined as compounds producing more than 60% of the tetracaine block. 
Adapted from reference 194.
194 
The applicability of a similar screening approach using the IWQ platform has 
recently been assessed, as part of a study evaluating the use of automated patch 
clamp electrophysiology assays in Nav channel drug discovery.
189 12,000 
compounds were screened for their blocking activity against hNav1.7 at 10 µM 
concentration, with hits defined as compounds producing greater than 80% inhibition 
in two consecutive experiments (Fig. 38.A). 
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Figure 38. (A) Percentage inhibition of hNav1.7 channels by ~12,000 compounds (grey dots) 
tested at 10 µM in duplicate (Obs1 and Obs2) (Pearson r correlation coefficient = 0.66, r
2
 = 
0.44, P < 0.0001). (B) Compounds producing greater than 80% inhibition (square with 
dashed border) were re-evaluated at 10 µM in duplicate (Pearson r correlation coefficient = 
0.86, r
2
 =0.75, P < 0.0001). (C) Plot of IC50s, calculated from 8-point concentration-response 
curves, versus the percentage inhibition produced at 10 µM as determined from B. 
Compounds producing >50% inhibition at 10 µM in study B are depicted in black circles 
whilst those producing <50% are illustrated with open squares. Adapted from reference 189.189 
Unfortunately, when re-submitting the selected hits to the same assay for 
confirmation purposes, although correlation between duplicate observations was 
largely improved compared to the primary screen, there was an unexpected change 
in the compounds’ levels of inhibitions ranging from 5-80% (Fig. 38.B). Interestingly, 
the %inhibitions at 10 µM at this follow up study were found to correlate well with 
subsequently measured IC50s for the compounds (Fig. 38.C). The most potent 
compounds, IC50s less than1 µM, exhibited more than 80% inhibition at 10 µM. In 
contrast, more than 90% of the compounds showing less than 50% inhibition at 10 
µM were either inactive or had IC50s greater than 10 µM. This led us to conclude, 
that provided there is high confidence in the accuracy of the single concentration 
measurement, this can indeed be predictive of the relative blocking activity (IC50) of 
a compound. 
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Inspired by the findings of the study described above, a novel screening 
approach was designed for evaluating the Nav activity of WIN17317-3 analogues. 
The concentration-response relationships of WIN17317-3 and two of its structural 
analogues, 116* and 118*, were previously described using IWQ, as part of a study 
conducted by the Årstad group investigating novel Nav blockers as tracers for 
imaging fast neurotransmission. All compounds in this thesis given a star annotation 
were synthesised by PDRA Dr. Carlos Médina-Perez. IC50 values for the three 
compounds were calculated from 8-point concentration response curves (4 
replicates per data point) as shown in Table 10. 
Table 10. Concentration-response relationships and charactetization of WIN17317-3, 116* 
and 118* at hNav1.7. 
Compound WIN17317-3 116* 118* 
Structure 
 
 
  
Concentration (µM) % Channel block ± SD
* 
(n=2-4) 
0.03 7.5 ± 1.5  -0.2 ± 14.6  -9.2 ± 5.0 
0.1 31.3 ± 12.1 6.8 ± 3.6  -6.0 ± 4.2 
0.3 65.7 ± 6.9 13.0 ± 4.6  -12.0 ± 12.5 
1 74.6 ± 16.4 42.2 ± 11.3  8.9 ± 1.4 
3 76.8 ± 4.7 36.8 ± 3.5  -1.2 ± 8.2 
10 92.9 ± 2.9 60.7 ± 2.2  14.4 ± 3.1 
30 100.1 ± 6.4 80.0 ± 13.0  29.6 ± 11.6 
100 106 ± 2.6 88.9 ± 9.4  63.0 ± 12.2 
IC50 (µM) 0.21 ± 0.05 3.6 ± 0.98 54.8 ± 6.2 
Potency High Moderate Low 
Potency score II I 0 
*Peak current at tonic state 
On examining the dose-response data for the three iminodihydroquinolines, 
(vide supra) as well as the data of the Castle et al. study (Fig. 38), specific 
correlation trends became apparent between the percentage inhibitions produced at 
two concentrations, 1 µM and 10 µM, and the compounds’ IC50s. Based on this, it 
was decided for test compounds to be screened only at 1 µM and 10 µM 
concentrations and according to the %inhibitions produced, to estimate their Nav 
blocking potency.  
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More specifically, guided by the above findings, the classification criteria for 
predicting the potency of compounds based on the %Nav block at 1 and 10 µM were 
set as: 
i) > 50% block at 1 µM, and >80% at 10 µM  → Highly potent 
ii) 15-50% block at 1 µM and >50% at 10 µM → Moderately potent 
iii) < 15% block at 1 µM, and <50% at 10 µM → Inactive 
iv) Compounds failing to fulfil any of the above  → Outliers 
By measuring two points at the concentration-response curve, each being an 
average of four experiments, and by setting the double set of criteria for potency 
classification, compound misassignement due to experimental errors could be 
effectively reduced. Along these lines, the synthesised iminodihydroquinoline 
analogues were screened against hNav1.7, at 1 µM and 10 µM concentrations, and 
were classified as highly or moderately potent hNav1.7 blockers, as inactive or as 
outliers (Fig. 39). 
 
Figure 39. Screening of 41 first generation iminodihydroquinoline analogues against 
hNav1.7. Plot of %tonic inhibitions obtained at 1 µM and 10 µM concentrations. According to 
the pre-defined set of criteria compounds were classified as highly potent (green, 13 cpds), 
as moderately potent (blue, 14 cpds) as inactive (red, 12 cpds) or as outliers (grey, 2 cpds). 
The IC50 values for 20 of the iminodihydroquinoline analogues screened 
were subsequently measured in order to (a) evaluate the validity of the two-point 
screening method for predicting the Nav activity of test compounds and (b) define 
the range of IC50s anticipated for each of the activity categories set above. IC50 
values were calculated from 8-point concentration-response curves, measured at 
the IWQ using the same cell line and voltage protocol as for the screening study. 
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IC50s for compounds from all three potency categories were measured. 
These were plotted alongside the %inhibitions produced at 1 μM and 10 μΜ as 
illustrated in Figure 40. Two out of the four compounds examined from the ‘inactive’ 
category exhibited IC50s higher than 100 µM and are therefore not included in the 
graph. Gratifyingly, linear correlation was observed between the three variables 
suggesting that the inhibitions at the two concentrations are indeed predictive of the 
IC50 values of compounds. 
 
Figure 40. 3D Plot of hNav1.7 IC50s versus %tonic inhibitions measured at 1 µM and 10 µM 
concentrations. (A) Side view and (B) top view. Compounds are classified as potent (●), 
moderately potent (●) or inactive (●) according to the results of the screening at 1 and 10 μΜ 
and the predefined set of criteria. The % inhibitions at 1 μΜ and 10 μΜ shown, were part of 
the 8 point concentration-response curves used for determining the compounds’ IC50s. 
As clearly illustrated above, the IC50 values for the three activity categories 
can be divided in three concentration ranges, each being one order of magnitude 
apart. More specifically, the defined activity categories were found to correspond to 
the following IC50 values: 
a) highly potent →  IC50 < 1 µM 
b) moderately potent →  1 µM < IC50 < 10 µM 
c) inactive →  IC50 > 10 μM. 
The results of the study demonstrate that the suggested two concentration 
screening approach can successfully predict the relative blocking activity of 
iminodihydroquinoline analoques at Navs. The method is particularly useful in the 
context of this work where a new pharmacophore model is being built and qualitative 
information is initially sought for defining the acceptable substitution patterns at the 
active site.  
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4.4. Investigation for state- and use- dependency 
In the paper by Wanner et al., first describing the effects of WIN17317-3 at 
Navs, WIN17317-3 was reported as a highly potent state-dependent Nav blocker; in 
electrophysiological experiments using CHO cells transfected with rat brain Navs, 
WIN17317-3 exhibited higher affinity for inactivated channels (KD = 9.3 nM) 
compared to channels in the resting state (KD = 310 nM).
132 
The iminodihydroquinoline analogues were submitted to the voltage pulse 
protocol of section 4.2 (page 68) aiming to access information regarding their state 
and use-dependency at hNav1.7. Higher levels of inhibition were anticipated for the 
10 Hz and inactivation states than for the tonic state. The data obtained for each of 
the three voltage-states were analyzed separately as plotted in Figure 41. For each 
state, compounds were classified as potent, moderately potent, inactive, or outliers 
according to the previously defined set of criteria. 
 
 
Figure 41. Plots of tonic (A), use-dependent (B) and inactivation blocks (C) of first 
generation analogues against hNav1.7 at 1 μΜ and 10 μΜ concentrations. According to the 
defined set of criteria compounds were classified as highly potent (green), as moderately 
potent (blue), as inactive (red), or as outliers (╫). (D) Superposition of the data from all three 
blocking states showed no apparent differences amongst them.  
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Unexpectedly, no apparent differences were observed between the relative 
levels of inhibition exerted by compounds amongst the three states (Fig. 41). 
Although compounds showed a tendency for higher potency blockade (shift towards 
the right top corner) when subjected to the use-dependent and inactivation voltage 
pulses relative to tonic block, superposition of the three graphs revealed no clear 
differences amongst them. All compounds classified as inactive or outliers, with the 
exception of one, failed to produce activity at all three investigational states. 
Likewise, the vast majority of compounds exhibiting moderate or high potency 
showed similar levels of inhibition in the three states hence had identical activity 
classification at all three voltage states. 
The IC50 values for 20 iminodihydroquinoline analogues, as measured from 
8-point concentration-response curves, were also examined at the voltage states 
under investigation (Table 11). A two-fold difference between IC50s was set as the 
minimum requirement for classifying a compound as having a preference for any 
particular state. Disappointingly, in agreement with the findings of the screening 
study, WIN17317-3 (1) was found to exhibit equal blocking potencies in all three 
states and so did most of the iminodihydroquinoline analogues explored. Only four 
compounds, 111*, 114*, 116*, and 117*, appeared to show a preference for the 
inactivated state and use-dependency. Notably, all four have small and compact N-1 
imino substituents (R1). One compound, 102*, was found to exhibit higher potency 
blockade for resting channels than channels in the other two states. 
Given the previously published manual patch clamp data for WIN17317-7’s 
effects at Navs, it was considered highly unlikely for this to lack state- and use- 
dependency. It was instead considered plausible that the absence of selectivity 
amongst the three voltage states observed in this study could be related to an 
experimental limitation of the assay used; for example, the voltage-potential and test 
pulse protocol employed could be poorly suited for measuring the state-dependent 
interactions of this compound class with Navs. Further manual patch clamp 
experiments are required to clarify this result. 
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Table 11. IC50 values of first generation iminodihydroquinoline analogues for hNav1.7 
channels at tonic-, 10 Hz- and inactivated- voltage states. The structures of compounds 
exhibiting preference for a particular voltage state/s over other/s are illustrated to the right. 
Compound 
IC50 ±SE (µM) 
Structure 
Tonic 10 Hz Inactivated 
1 0.21 ± 0.05 0.22 ± 0.03 0.23 ± 0.04 
 
2 0.22 ± 0.04 0.27 ± 0.04 0.34 ± 0.05 
 
101* 0.42 ± 0.06 0.62 ± 0.10 0.74 ± 0.14 
 
102* 0.64 ± 0.08 1.2 ± 0.19 1.2 ± 0.29 
 
103* 1.6 ± 0.20 1.4 ± 0.22 1.2 ± 0.29 
104* 0.18 ± 0.03 0.22 ± 0.04 0.24 ± 0.05 
 
105* 0.16 ± 0.03 0.20 ± 0.03 0.21 ± 0.04 
 
106* 1.6 ± 0.40 1.9 ± 0.60 1.6 ± 0.74 
 
107* 94.4 ± 9042* 38.1 ± 471* 21.4 ± 10.6 
 
108* 0.25 ± 0.04 0.34 ± 0.05 0.40 ± 0.08 
 
109* 1.1 ± 0.19 1.3 ± 0.28 1.5 ± 0.48 
 
110* 13.8 ± 3.9 16.4 ± 4.5 18.5 ± 4.9 
111* 1.7 ± 0.26 0.36 ± 0.05 0.43 ± 0.06 
112* >100 >100 >100 
 
113* >100 91.3 ± 16.3 85.9 ± 9.6 
 
114* 3.6 ± 0.78 2.0 ± 0.40 1.9 ± 0.47 
 
115* 0.39 ± 0.10 0.41 ± 0.08 0.42 ± 0.10 
 
116* 3.6 ± 0.98 1.8 ± 0.48 1.6 ± 0.62 
117* 1.1 ± 0.16 0.63 ± 0.09 0.47 ± 0.09 
 
118* 54.8 ± 6.2 51.2 ± 6.7 44.6 ± 8.9 
*IC50 value determined based only one concentration 
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4.5. Structure-Activity Relationships for Nav1.7 
A series of 41 structural analogues of WIN17317-3 were designed and 
synthesized by systematically introducing substituents in the four defined 
pharmacophore regions of WIN17317-3 (Fig. 42). The compounds’ activity at 
hNav1.7 was evaluated at 1 μΜ and 10 μΜ concentrations and according to the 
%inhibitions produced these were classified as of high or moderate potency or as 
inactive. The deduced SARs for each of the pharmacophoric areas are sequentially 
described below, followed by an assessment of the effects of overall molecular 
properties such as lipophilicity and tPSA. The Nav activity data provided in this 
section represent the blocking efficiencies obtained for channels at the tonic state; 
however, since similar levels of inhibition were 
recorded for compounds at all voltage states 
explored, the deduced SARs can be considered as 
applicable to all. The IC50 values reported were 
calculated from 8-point dose-response curves, 
whereas estimated IC50 values refer to predicted 
values based on the %Nav block at 1 μΜ and 10 μΜ. 
The first pharmacophore region to be described is the R1 substituent (Table 
12). The spatial requirements of the R1 substituent were initially investigated using a 
series of analogues bearing straight and branched aliphatic chains, as well as 
aliphatic and aromatic rings. The progressive shortening of the alkyl chain length, 
from five carbons in 1, to three carbons in 117*, and to two carbons in 114*, led to a 
systematic drop in potency. The introduction of the branched isopropyl group in 
analogue 114* was found to be well tolerated with the noted decrease in potency 
most likely attributed to the concurrent shortening of the chain length. The 
conformationally restrained analogue 111* bearing a cyclopentyl ring, showed a ten-
fold drop in potency relative to its linear chain equivalent 1. On the contrary, the more 
flexible planar benzyl group in 20 produced equipotent inhibition to 1. 
As described in chapter 2, investigating the effects of fluoride containing 
derivatives was of particular interest in this study. Three fluorinated R1 analogues, 
115*, 116* and 26 were examined. The 5-fluoropentyl analogue 115* was found 
equipotent to the parent 1; likewise, β-fluorination at 116* produced similar levels of 
inhibition as the same chain length analogue 114*. The two positions were identified 
as plausible sites for [18F]fluorination.  
Figure 42. The WIN17317-3 
pharmacophore. 
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Table 12. Characterization of R
1
-series iminodihydroquinolines as hNav1.7 inhibitors. 
 
 
Compound R
1 %Inhibition ± SD  
1 µM, 10µM 
     Nav1.7 Activity 
IC50 (μΜ) 
Potency 
score
* 
WIN17317-3 
(1) 
 
79.2  ±  4.6 
76.0  ±  6.6 
0.21 II 
117*  
45.5 ± 4.9  
86.3  ±  6.9 
1.10 I 
114*  
32.5  ±  2.9 
69.9  ±  7.4 
3.60 I 
111*  
43.6  ±  30.2 
73.6  ±  26.2 
1.70 I 
20  
60.0  ±  6.9 
96.7  ±  4.7 
N/A II 
115*  
67.9  ±  2.1 
82.4  ±  4.1 
0.39 II 
116*  
42.2 ±  11.3 
60.7  ±  2.2 
3.60 I 
26  
4.2  ±  10.3 
24.5 ±  19.6 
N/A 0 
113*  
-5.6  ±  1.9 
7.0  ±  6.9 
>100 0 
19  
27.5  ±  9.6 
62.3  ±  4.8 
N/A I 
25  
20.8  ±  8.3 
12.5  ±  6.4 
N/A 0 
39 
 -2.5  ±  7.1 
7.6  ±  0.8 
N/A 0 
118*  
8.9  ±  1.4 
14.4  ±  3.1 
54.8 0 
27 
 2.7  ±  6.3 
19.4  ±  5.1 
N/A 0 
*Potency score: 0= Inactive, I= moderately potent, II= highly potent  
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Interestingly, replacement of the terminal CH2F group in 116* with a CF3 
group in 26 was found detrimental for activity. The van der Waals volume of the CF3 
group is comparable to that of an ethyl group195 hence the observed loss of activity is 
unlikely to be attributed to steric effects. The CF3 group is only inductively electron 
withdrawing, meaning the effect cannot be attributed to altered electron density of 
the imine nitrogen either; the methylene group between the CF3 and the imine 
nitrogen should diminish the effect leaving the σ-bonding of the imine nitrogen 
unaffected. Fluorine, with strong C-F and C-CF3 bond dipoles and three sets of lone 
pairs can also be involved in weak intra- or inter- molecular dipolar and hydrogen 
bond interactions.196 These however, were also regarded as an unlikely reason for 
the observed loss of activity for 26; the RCH2F group of 116* which is known to be a 
superior hydrogen-bond acceptor compared to the RCF3 moiety led to high potency 
inhibition.197 
The electronic requirements of the R1 pharmacophore region were 
investigated next. Various analogues bearing polar alkyl chain functionalities were 
examined. The incorporation of the amide and hydroxyl functionalities in compounds 
25 and 113*, respectively, was proved detrimental for activity. Hydroxyl group 
masking and conversion to the less polar ether functionality in 19 was found to 
restore activity. The tPSA of all R1-series analogues of table 13 were calculated, and 
paired with the corresponding Nav activity for each compound (Fig. 43). Notably all 
R1 series compounds exhibiting high Nav potency had tPSAs lower than 20 Å
2 and all 
inactive compounds, with the exception of one, had tPSAs higher than 38 Å2. These 
findings led us conclude that polar groups are 
not tolerated at the R1 pharmacophore region. 
This could be attributed to a number of reasons, 
such as electrostatic repulsion with groups at the 
active site, or hydrogen bonding of the molecule 
with either the channel preventing optimal 
compound binding at the active site, or with 
water molecules altering the compound’s 
solvation thermodynamics. 
 Expanding on the classical approach of systematically altering molecular 
properties for characterizing the pharmacophore, a more unconventional fragment-
based drug design approach was also employed.144 Small fragments from well-
established structurally diverse Nav inhibitors were incorporated as R
1 substituents 
aiming to identify common or overlapping pharmacophore regions between 
WIN17317-3 and the scaffolds from which the respective fragments originated. The 
Figure 43. Plot of tPSA - activity 
relationship. High potency (●), 
moderate potency (●), inactive (●). 
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benzene sulfonamide moiety198 of compound 39, the triazole ring199 of compound 
118* and the bnza200 moiety of compound 27 are all structures encountered in potent 
Nav blockers described in literature. Unfortunately, when part of the R
1 chain, all 
three fragments abolished activity. 
The second pharmacophore region to be explored was the N-1 benzyl 
substituent denoted as R2 (Table 13). The effects of introducing substituents at the 
various positions of the benzyl ring, such as electron withdrawing groups (-CN and –
F), were initially examined. The nitrile group is commonly introduced as a 
substituent on aromatic rings, and is present in numerous pharmaceutical 
compounds. It can inductively polarize aromatic rings thereby altering benzylic π-π 
interactions. In addition, nitriles can engage in polar interactions through hydrogen 
bonding. They are commonly used as ketone bioisosteres and in several cases they 
were demonstrated to increase metabolic stability towards oxidation.201 Ortho and 
meta nitrile group incorporation in analogues 101* and 102*, respectively, was found 
to be well tolerated, producing potent Nav inhibition. A nearly ten-fold drop in potency 
was observed with a nitrile substituent in the para position, as for 103*. Interestingly, 
the similarly π-deficient 4-pyridyl analogue 106* (large permanent pyridine dipole 
moment)202 also showed low Nav blocking efficiency suggesting that the para 
position of the phenyl ring cannot tolerate electron withdrawing groups. The meta 
fluoride substituent in analogue 104* was well tolerated and 104* was in fact one of 
the most potent compounds of the series. 
As part of a broader exploration of the R2 pharmacophore region, a variety of 
alkyl, heteroalkyl, aryl and heteroaryl groups with diverse physicochemical 
properties were introduced as R2 substituents. The introduction of a branched 
phenylethyl group led to the chiral analogue 108* which upon testing as a racemic 
mixture, produced equipotent inhibition to the parent compound 1. On the contrary, 
removal of the phenyl ring as for the methyl analogue 107*, abolished activity. 
Moving from aromatic to aliphatic substituents, benzyl ring replacement by the 
bulkier cyclohexyl ring in 105* was found to retain activity (IC50=0.16 µM). 
Incorporation of a polar heteroatom in the cyclohexyl ring as in 109* led to a nearly 
ten-fold drop in potency (IC50=1.1 µM). Decreasing the ring size by one carbon to 
the 5-membered THF group in 110*, led to a further drop in potency by one order of 
magnitude (IC50=13.8 µM). Finally, incorporation of the highly polar triazole ring, in 
analogue 112*, was proved detrimental for activity. These findings highlight the 
requirement for a large hydrophobic substituent at the R2 pharmacophore region.  
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   Table 13. Characterization of R
2
-series iminodihydroquinolines as hNav1.7 inhibitors. 
 
 
Compound R
2 %Inhibition ± SD  
1 µM, 10µM 
Nav1.7 Activity 
       IC50 (μΜ) 
Potency 
score
* 
WIN17317-3 
(1) 
 79.2  ±  4.6 
76.0  ±  6.6 
0.21 II 
101*  
60.2  ±  6.5 
92.4  ±  3.2 
0.42 II 
102*  
57.4  ±  10.0 
94.0  ±  1.6 
0.64 II 
103*  
36.1  ±  5.7 
88.6  ±  0.1 
1.60 I 
106*  
48.3  ±  2.1 
77.0  ±  1.8 
1.60 I 
104*  
72.1  ±  5.1 
100.2  ±  3.2 
0.18 II 
107*  
-5.5  ±  17.1 
-3.9  ±  6.9 
94.4 0 
108*  
72.4  ±  7.3 
93.6  ±  6.5 
0.25 II 
105*  
75.1  ±  9.4 
89.7  ±  9.8 
0.16 II 
109*  
47.0  ±  2.9 
80.6  ±  5.0 
1.10 I 
110*  
18.0  ±  4.2 
38.2  ±  6.3 
13.8 0 
112*  
-4.0  ±  4.9 
10.5  ±  3.1 
>100 0 
55 
 32.7  ±  2.3 
81.0  ±  5.4 
N/A I 
56 
 49.3  ±  7.4 
81.8  ±  2.4 
N/A II 
31  
31.7  ±  8.0 
66.7  ±  5.6 
N/A I 
 *Potency score: 0= Inactive, I= moderately potent, II= highly potent  
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It is widely accepted that the binding conformation of a pharmaceutical 
compound with many rotational degrees of freedom is not necessarily the lowest 
energy conformation of the molecule but rather the one that allows the highest 
number of stabilizing interactions with the active site. In order to investigate the 
active conformation of WIN17317-3, the methylene linker of the benzyl group was 
removed aiming to restrict molecular flexibility. Three analogues, 55, 56 and 31 
(table 14) were examined. All three analogues were found to maintain activity; 
analogue 56 bearing a cyclohexyl group produced high Nav inhibition (<1 µM) whilst 
analogues 55 and 31 bearing phenyl and cyclohexene substituents respectively, 
showed reduced activity with IC50 values estimated in the range of 1 and 10 µM. 
The third pharmacophore region to be explored was the R3 substituent at the 
seven position of the quinoline scaffold; this is a chloride substituent for the parent 
WIN17317-3 (Table 14). Chlorine and the heavier halogens have unique electronic 
properties when bound to aryl rings; apart from the electron withdrawing effects they 
exert, they can also form interactions (halogen bonds) with adjacent electrophiles, 
nucleophiles and other halogens at the binding pocket. Halogen bonds are weaker 
than hydrogen bonds yet their strength increases with the size of the halogen atom 
and is dependent on the electronegativity of the other carbon substituents and the 
density of the binding partner.203 Chlorine for iodine substitution in analogue 2 was 
found to be well tolerated with comparable IC50s obtained for the two compounds. 
Chlorine for hydrogen substitution in analogue 21 led to a considerable drop in 
potency, with an estimated IC50 value in the range of 1 - 10 µM. Interestingly, 
incorporation of the electron-donating methoxy group in 24 appears to lead to only a 
small drop in inhibition potency relative to the halogenated analogues 1 and 2, yet 
more experiments are required to verify this result. The small size of the library 
precludes the deduction of firm conclusions regarding the requirements for the R3 
pharmacophore region, yet the results suggest that the electronic nature of 
substituents at this position has limited effect on binding, and that the binding pocket 
tolerates substituents with a range of steric requirements. 
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    Table 14. Characterization of R
3
-series iminodihydroquinolines as hNav1.7 inhibitors. 
 
 
Compound R
3 %Inhibition ± SD  
1 µM, 10µM 
Nav1.7 Activity 
       IC50 (μΜ) Potency 
score
* 
WIN17317-3 
(1) 
-Cl 
79.2  ±  4.6 
76.0  ±  6.6 
0.21 II 
2 -I 
73.1  ±  8.3 
102.6  ±  2.9 
0.22 II 
21 -H 
33.8  ±  8.1 
59.5 ± 5.4 
N/A I 
24 -OCH3 
52.7  ±  N/A 
89.1  ±  14.0 
N/A II 
     *Potency score: 0= Inactive, I= moderately potent, II= highly potent 
The 1,4-iminodihydroquinoline heterocyclic scaffold was the fourth 
pharmacophore region to be investigated using analogues containing other, 
structurally diverse, nitrogen-containing heterocycles (Table 15). The effect of 
introducing additional nitrogen atoms to the quinoline scaffold was initally examined. 
Two naphthyridine analogues 69 and 82 were synthesized. The nitrogen at the 8th 
position of analogue 82 led to a drop in potency and to an estimated IC50 in the 
range of 1-10 μΜ. Interestingly, the 1,5-napthyridine 69, bearing an additional n-
pentyl alkyl chain at the 7 position maintained potency for Nav1.7 inhibition. This 
suggested that the nitrogen at the 5th position is well tolerated, and also that bulkier 
substituents than those previously explored for the R3 region, vide supra, can be 
accommodated at the site. The effects of a 5,6-biaryl system, were also examined 
through two purine analogues, 93 and 94. Purines are frequently referred to as 
privileged structures due to their profound ability to bind to multiple receptors hence 
having applications across a wide range of therapeutic areas. The structural 
similarities of purines and quinolines have been extensively exploited by recent 
medicinal chemistry studies; in several examples quinolines have been successfully 
employed as viable purine isosteres maintaining biological activity.204 Unfortunately, 
both purine analogues 93 and 94, although bearing similar substitution patterns to 
the parent WIN17317-3, failed to produce inhibition at Nav1.7. Quinoline substitution 
by pyridine in analogue 97 also led to abolished activity.   
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Table 15. Characterization of heterocyclic scaffold analogues (R
4
-series) as hNav1.7 
inhibitors. 
Compound Structure 
%Inhibition ± SD  
1 µM, 10µM 
Nav1.7 Activity 
IC50 (μΜ) Potency 
score
* 
WIN17317-3 
(1) 
 
79.2  ±  4.6 
76.0  ±  6.6 
0.21 II 
69 
 
48.9  ±  13.8 
76.2  ±  5.0 
N/A I 
82 
 
28.8  ±  5.0 
66.9  ±  13.8 
N/A I 
93 
 
-2.5  ±  7.1 
7.6  ±  0.8 
N/A 0 
94 
 -13.2  ±  9.8 
23.0  ±  2.3 
N/A 0 
97 
 
0.9  ±  9.9 
2.0  ±  5.9 
N/A 0 
  *Potency score: 0= Inactive, I= moderately potent, II= highly potent 
Examining the deduced SARs for the R1 and R2 pharmacophore regions it 
became apparent that the two areas share similar structural characteristics: both 
require large, hydrophobic substituents to achieve potent Nav1.7 blockade. Based 
on this, it was hypothesized that the molecule could potentially behave as a dimer 
allowing binding at the active site via two orientations. The use of 
homodimers/symmetrical ligands is a common practice in medicinal chemistry and 
usually aims at the production of more potent and/or more selective drugs compared 
to the single entity.205 The previously described analogue 20 presenting benzyl rings 
as both R1 and R2 substituents exhibited comparable levels of inhibition to the 
parent WIN17317-3 providing support to the suggested dual binding hypothesis 
(Table 16). Five analogues, bearing n-pentyl chains as R2 substituents were 
synthesized aiming to investigate this hypothesis further. The “reversed” substituent 
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analogue 29 produced highly potent inhibition similar to that of the parent 
WIN17317-3. Three highly conjugated analogues 28, 36, and 40 were additionally 
examined. Interestingly, the aniline analogue 28 produced high affinity inhibition 
whereas analogues 36 and 40 lacked activity at Nav1.7. The selected imino-
oxyphenyl ether and -phenyl sulfonamide moieties in analogues 36 and 40 
respectively, are motifs encountered in potent Nav blockers previously described in 
literature.198, 206 Possible explanations for the observed lack of efficacy for analogues 
36 and 40 are: (a) their high polarity, given the hydrophobic requirements of the R1 
pocket as established above, and/or (b) the altered pKas of the imine and quinoline 
nitrogen atoms due to the electron-withdrawing nature of the substituents. 
Table 16. Functional characterization of iminodihydroquinolines as hNav1.7 inhibitors. 
Compound Structure 
%Inhibition ± SD  
1 µM, 10µM 
Nav1.7 Activity 
IC50 (μΜ) Potency 
score
* 
WIN17317-3 
(1) 
 
79.2  ±  4.6 
76.0  ±  6.6 
0.21 II 
20 
 
60.0  ±  6.9 
96.7  ±  4.7 
N/A II 
28 
 
53.6  ±  5.6 
77.4  ±  13.9 
N/A I 
29 
 
62.9  ±  9.1 
87.8  ±  14.1 
N/A II 
36 
 
-2.7  ±  4.5 
3.2  ±  5.8 
N/A 0 
40 
 
0.2  ±  10.5 
-8.9  ±  4.9 
N/A 0 
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In an effort to obtain further information to support the development of a 
pharmacophore model, the effects of overall physical properties such as pKa, tPSA 
and logD on Nav1.7 inhibition were also to be examined. The pKa and logD values 
for iminodihydroquinolines were calculated using the Accelrys Accord for Excel 
software and tPSA values were calculated using ChemBioDraw Ultra 14.0. 
The published pKa value for WIN17317-3 is 11.5.
133 The pKa values 
calculated by the Accelrys software for WIN17317-3 were 5.38 for the imino nitrogen 
and 3.10 for the quinoline nitrogen. Given our experimental observations regarding 
the polarity and basicity of WIN17317-3 and the class of iminodihydroquinolines in 
general, the calculated pKa values were believed to be incorrect. The logD7.4 value of 
the iodinated iminiodihydroquinoline analogue 2 has been measured by a previous 
member of the group using the traditional n-octanol flask method to be 2.98 ± 0.08 (n 
= 3).3 The calculated logD7.4 value for the same compound was 5.60. Given that the 
logD calculation requires the concentration of ionized species in solution, and since 
the calculated pKa value predicted by the software was false, calculated logD values 
were also considered to be inaccurate. The effects of pKa and logD parameters on 
Nav1.7 inhibition could therefore not be assessed. 
The effects of the polar surface area on Nav1.7 activity were however 
examined (Fig. 44). Compounds acting as highly or moderately potent Nav1.7 
inhibitors were found to exhibit tPSA < 25 Å2; whereas inactive compounds were 
evidently far more polar with the majority (8/10) exhibiting tPSA > 25 Å2. 
 
Figure 44. tPSA – Nav1.7 inhibition relationship for first generation iminodihydroquinoline 
analogues. Compounds are classified as highly potent (●), as moderately potent (●) Nav1.7 
blockers or as inactive (●). 
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Overall, summarizing the results of the SAR study, the following are 
concluded regarding the WIN17317-3 pharmacophore: 
a) The R1 region can accommodate non-polar aliphatic or aromatic substituents. A 
noticeable decrease in potency is observed when the aliphatic chain is 
shortened and loss of biological activity is observed in the presence of polar 
functionalities.  
b) Similar to R1, the R2 region can also accommodate hydrophobic aliphatic and 
aromatic substituents. Substituents conjugated to the quinoline ring lead to a 
drop in potency and the introduction of polar substituents results in complete 
loss of biological activity.  
c) Despite the small number of R3 substituents investigated, the R3 region appears 
to tolerate both electron withdrawing and electron donating substituents, both 
yielding high potency Nav1.7 inhibition. Hydrogen, the halogens, and the larger 
aminopentyl chain are all well tolerated suggesting the presence of a large 
pocket with weak binding interactions. 
d) The R4 pharmacophore region requires the presence of a fused, 6+4 nitrogen 
containing heterocyclic scaffold, like the quinolines and naphthyridines. 
 
Figure 45. Structure-activity relationships of small molecule iminodihydroquinolines for 
hNav1.7. (high potency inhibition: ↑, low potency inhibition: ↓, abolished activity: ×). 
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4.6. Nav isoform profiling 
One of the key objectives of this study was to investigate the underlying 
mechanism for the observed selectivity of WIN17317-3 in blocking C-fibres with 
higher potency than A-fibres. As previously discussed, it was speculated that such 
selectivity could originate from WIN17317-3 inhibiting Nav isoforms expressed at C-
fibres (Nav1.7, Nav1.8, Nav1.9) with higher potency than the ones expressed at A-
fibres (Nav1.6). Our approach was based on developing pharmacophore hypotheses 
for the distinct Nav channels; divergent SARs for Nav1.7 and Nav1.8 from Nav1.6, 
would support an Nav isoform-based mechanism. Additionally, the screening of 
compounds against the wider range of Navs would provide information regarding 
potential off-target toxicity. The Nav1.2, Nav1.4, and Nav1.5 isoforms are expressed 
in the CNS, the muscles and the heart, respectively, hence their blockade in vivo 
could lead to serious adverse effects.207 
Ten selected iminodihydroquinolines from the library, with varying R1, R2 and 
R3 substituents, were screened for their blocking potency against the human Nav1.2, 
Nav1.4, Nav1.5, Nav1.6, Nav1.7 and Nav1.8 isoforms (Table 17). 
Table 17. Blocking potencies of ten selected iminodihydroquinolines against hNav isoforms. 
Cpd 
IC50 (µM) 
1.2 1.4 1.5 1.6 1.7 1.8 
1 2.2 ± 1.2 0.19 ± 0.08 0.33 ± 0.10 1.92 ± 0.72 0.21±0.05 15.03± 5.76 
2 1.5 ± 0.5 0.14 ± 0.06 0.23 ± 0.05 0.64 ± 0.21 0.22±0.04 5.47±4.05 
102* 4.8 ± 1.2 0.67 ± 0.26 1.51 ± 0.15 2.95 ± 0.85 0.64±0.08 3.98±1.21 
104* 2.8 ± 1.0 0.20 ± 0.26 0.46 ± 0.15 1.46 ± 0.85 0.18±0.03 14.26±1.21 
105* 4.3 ± 1.0 0.20 ± 0.07 0.45 ± 0.09 0.81 ± 0.38 0.16±0.03 12.62±5.74 
106* 17.9 ± 5.0 0.72 ± 0.22 4.38 ± 1.30 12.53± 2.87 1.6 ± 0.40 36.14±7.01 
107* >100 58.34 ±12.8 >100 98.43 94.4 >100 
108* 2.5 ± 0.4 0.25 ± 0.13 0.72 ± 0.16 0.99 ± 0.31 0.25±0.04 3.92±1.17 
109* 10.7 ± 2.1 0.89 ± 0.34 1.98 ± 0.33 4.48 ± 0.87 1.1 ± 0.19 12.18±1.86 
116* 53.4 ± 26.2 3.93 ± 1.57 4.72 ± 1.17 18.77 ±3.62 3.6 ± 0.98 41.31±3.95 
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Given the high cost associated with automated patch clamp 
electrophysiology assays the least relevant Nav1.1 and Nav1.3 isoforms were 
excluded at this stage from the screen. The Nav1.9 isoform, although of particular 
interest due to its selective expression in nociceptors,118 is not part of commercially 
available Nav screening portfolios due to difficulties in expressing, maintaining and 
recording from stable Nav1.9 cell lines; it was therefore also excluded from the 
screen. 
For comparison purposes, the selectivity of each compound towards 
blocking hNav1.7, the isoform of interest, over other hNavs, was calculated and is 
provided alongside the compounds’ structures in Table 18. Selectivity was 
measured as the ratio between the IC50 values for the respective isoforms: 
Selectivity for ℎNa𝑣1.7 over ℎNa𝑣1. x =
IC50(Na𝑣 1. 𝑥)
IC50(Na𝑣 1.7)
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Table 18. Selectivity of iminodihydroquinolines for blocking hNav1.7 over other hNavs. 
Compound 
Nav1.7 Selectivity 
Compound 
Nav1.7 Selectivity 
1.2 1.4 1.5 1.6 1.8 1.2 1.4 1.5 1.6 1.8 
 
10 1 2 9 72 
 
11 0 3 8 23 
1  106*  
 
7 1 1 3 25 
 
10 1 3 4 16 
2  108*  
 
8 1 2 5 6 
 
10 1 2 4 11 
102*  109*  
 
16 1 3 8 79 
 
15 1 1 5 11 
104*  116*  
 
27 1 3 5 79       
105*        
 
Interestingly, several iminodihydroquinolines were found to exhibit higher 
blocking potency for Nav1.7 over three particular Nav isoforms: the Nav1.2, Nav1.6 
and Nav1.8 isoforms (Fig. 46). Examining the highest selectivity achieved for Nav1.7 
over each of these isoforms, with respect to Nav1.2, up to 27-fold selectivity was 
observed for 105*, with the next most selective compounds 104* and 116* exhibiting 
15-fold selectivity. The remaining iminodihydroquinolines showed ~10 fold selectivity 
over Nav1.2. With respect to Nav1.6, WIN17317-3 and analogues 104* and 106* 
were the most selective (~10 fold), with the remaining compounds exhibiting 5-fold 
or lower selectivity. Three compounds stand out for their selectivity over Nav1.8: 1 
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(72-fold), 104* and 105* (~80 fold). The next most selective compounds were 2 and 
106*. All iminodihydroquinolines were essentially equipotent towards blocking 
Nav1.7 and the Nav1.4 and Nav1.5 isoforms. 
 
Figure 46. Iminodiydroquinolines’ selectivity for blocking hNav1.7 over other Nav isoforms. 
The radar charts’ axes represent the compounds’ selectivity for Nav1.7 as the ratio of 
IC50(Nav1.7) over IC50(Nav1.x). (A) Selectivity for Nav1.7 over Nav1.2, Nav1.4, Nav1.5, Nav1.6, 
and Nav1.8. (B) Focus in the three isoforms, Nav1.2, Nav1.6 and Nav1.8, that showed the 
highest Nav1.7 blocking selectivity. 
Despite the relatively small differences in the IC50 values of 
iminodihydroquinoloines for the various Nav isoforms, the results of this study 
suggest the presence of structural variations between the binding sites at the Nav1.7 
and the Nav1.2, Nav1.6, and Nav1.8 isoforms. Intriguingly, 104*, 105* and 116* were 
the three compounds that exhibited markedly higher selectivity for blocking Nav1.7 
over the three other isoforms. Unfortunately, given the small number of compounds 
investigated, there is insufficient data to draw any conclusions regarding the 
structural origin of this selectivity. 
 
4.7. Summary 
 To conclude, the blocking activities of iminodihydroquinolines at Navs have 
been described in this chapter. A cost- and time- effective screening approach was 
validated and used for predicting the in vitro potency of compounds at Navs by 
measuring only two concentration-response points, using the IonWorks Quattro 
automated patch clamp electrophysiology platform. The first ever SAR of the 
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iminodihydroquinoline class for the human Nav1.7 isoform has been defined using a 
4-region WIN17317-3 pharmacophore model. Compounds with varying Nav1.7 
potencies were identified, ranging in the low micromolar range for some compounds 
to others being completely inactive. Several members of the library were found to 
exhibit equipotent inhibition of all Nav isoforms explored, whilst certain compounds 
showed significantly higher potency for Nav1.7 relative to the Nav1.2, Nav1.6 and 
Nav1.8 isoforms. This diversity in the compound library provides suitable candidates-
tools for investigating (a) the relationship between Nav1.7 potency and pain 
signaling blockade and (b) the hypothesis that selective Nav isoform blockade is the 
underlying mechanism for the observed C/A-fiber selectivity exhibited by WIN17317-
3. 
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5. Selective blockade of C-fiber action potential 
propagation by iminodihydroquinolines in 
rodent peripheral sensory neurons in vitro 
 
The effects of iminodihydroquinolines at peripheral sensory neurons in vitro 
are described in this chapter. The potency of iminodihydroquinolines for blocking 
nociceptors, as well as their selectivity over non-nociceptive fiber blockade, as 
measured in the skin-nerve assay, are described herein; the role of Nav isoforms in 
the process is also examined. A ‘lead’ preclinical drug candidate with profound 
selectivity for nociceptor block has been selected from a second generation 
compound library, for further characterization in vivo. 
 
5.1. The skin-nerve preparation as an assay to measure 
pharmacological activity in peripheral endings of 
sensory neurons 
The rodent skin-nerve preparation is an increasingly used technique in the 
field of experimental pain medicine. It is a method for directly recording APs 
extracellularly from peripheral sensory nerve endings in vitro. It enables recording of 
propagated APs from single nerve fibers but also from groups of nerve fibers known 
as compound action potentials (CAP).208 Several studies have demonstrated that 
the responses are comparable to those obtained in vivo for the same species of 
rodent.209, 210 
As previously described in section 1.3, peripheral sensory nerves consist of 
a large number of sensory fibers, of different types, each type being responsible for 
transmitting a particular type of information. Each of the nerve fiber categories (Aβ, 
Aδ, C) has unique morphology (axonal diameter, level of myelination) and therefore 
conducts electrical signals, APs, at a specific unique speed. This neurophysiological 
principle is exploited by the skin-nerve assay; a peripheral nerve is stimulated at its 
distal end, the generated CAP is propagated along the nerve and the CAP signal is 
recorded at a defined proximal end. The CAP train signal is recorded, and then 
separated and assigned, according to the times electrical activity is reaching the 
recorder, as the CAPs of individual nerve fiber classes (Fig. 47). Precise 
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pharmacological manipulation at the preparation allows the examination of the 
modulatory effects of drugs on individual nerve fiber(s) classes.211, 212 
 
Figure 47. Example of six CAP signal overlays evoked by electrical stimulation (time 0) of 
the sciatic-tibial nerve of a mouse in vivo. Dashed lines indicate conduction velocity cutoffs 
for differentiation of the three major fiber types present (Aβ, Aδ, C). Note difference in 
vertical scales for A and C fibers. Aβ-Αδ fibers were evoked by a 100 μA stimulus and C 
fibers were evoked by 6 mA stimulus. Adapted from reference 209.209 
CAPs rather than individual neuronal fiber action potentials were recorded at 
this study; this allowed the simultaneous examination of the responses of several 
fiber categories within the nerve since the response of the peripheral nerve as a 
whole was of interest. 
 
5.1.1. Experimental set-up 
The saphenous nerve is the most commonly used tissue in the rodent skin-
nerve preparation; being a purely sensory nerve it provides a large sample of the 
somato-sensory neuronal fibers to be investigated.213, 214 The rat rather than mouse 
saphenous nerve was used in this study as it is easier to handle tissues of larger 
size. One of the advantages of the assay is that the nerve can be kept functional for 
many hours after dissection, under superfusion, meaning that both left and right 
nerves of an animal can be used and that a considerable number of recordings can 
be obtained from each nerve. 
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Figure 48. Anatomical context of the rat saphenous nerve (lower 
right leg). The saphenous nerve (yellow) is a terminal sensory 
branch of the femoral nerve, arising from the third lumbar root. At 
the level of the thigh it separates from the femoral nerve and 
descends on the lateral side of the femoral vessels (arteries: red, 
veins: blue) to lie on the medial side of the leg. It supplies the skin 
of the medial side and front of the knee. At the ankle, it passes 
anterior to the medial malleolus to innervate skin on the medial 
and dorsal aspects of the foot.
215
 Its superficial anatomical path, 
allows in vivo electrophysiological studies. Adapted from reference 
215. 
In brief, the saphenous nerve is dissected in continuity with the skin of the 
lower hind limb and is placed with the corium side facing up into a superfused skin-
nerve chamber (Fig. 49). The skin-nerve chamber consists of two compartments: 
the recording chamber accommodating the proximal end of the nerve, and the 
stimulation chamber accommodating the distal end of the nerve and the attached 
skin. 
The nerve is electrically stimulated at the distal end, by delivering a 
supramaximal stimulus (110% of the stimulus exerting the maximal response). The 
propagated electrical potentials are recorded at the proximal end using a pair of gold 
wire electrodes. These potentials are in the µV range and are therefore passed 
through two types of amplification before being measured at a commercially 
available system (Fig. 50). The stimulation protocol, as well as the materials and 
methods used in this assay are provided as experimental details in chapter 8. The 
components of the equipment and the set-up of the skin-nerve recording station are 
described in detail in the recently published Nature protocol by Reeh et al.215 
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Figure 49. The experimental set up for the skin-nerve preparation. (A) Schematic 
representation of the skin-nerve chamber illustrating fluid circulation. Adapted from reference 
215. (B) Top view of the skin-nerve chamber. The skin is placed in the stimulation chamber 
dermis side up (1), and the proximal end of the attached nerve is extended through a hole to 
the adjacent recording chamber (2). 
 
 
Figure 50. Schematic representation of the skin-nerve assay data capture. Electrical 
stimulation is administered to the receptive field. The recorded signal is fed into an AC-
coupled differential preamplifier that is connected in series with a second single ended 10
4 
–
gain amplifier and a band-pass filter (between 1 Hz and 1 kHz).The signal is subsequently 
fed to audio speakers and oscilloscope and processed through a DAP board, where the 
action potentials above set amplitudes are discriminated and fed into the computer. Adapted 
from reference 215.
215
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In experiments where the effects of pharmacological agents at the nerve are 
to be investigated, a metal ring is used to isolate the area of the nerve to be treated 
with the drug, from the fluid in the rest of the chamber (Fig. 51). An application 
system is used to deliver the drug solutions in the ring for the selected time periods. 
 
Figure 51. Schematic representation (A) and view (B) of the skin-nerve preparation with the 
metal ring. An application system’s tip is positioned within the ring to superfuse the isolated 
receptive field with the drug solution of interest. Labels: (1) pair of stimulation electrodes; (2) 
pair of wire electrodes used for recording the signal; (3) metal ring used to isolate the 
receptive field. 
 
5.1.2. Recordings and data analysis 
The recorded CAP traces in this study typically comprised of two waves 
arriving at latencies of ~2 ms and ~33 ms, with conducting velocities higher than 5 
ms-1 (fast conducting) and lower than 1 ms-1 (slow-conducting) respectively; these 
were assigned as the A- and C-fiber waves respectively (Fig. 52). This allocation 
was in accordance to literature reported CAP measurements from rats of similar age 
and weights in the same preparation.216, 216b, 217  The Aδ wave coincided with the 
falling phase of the Aβ wave, hence it was difficult to determine the amplitude of 
each in isolation. Recorded CAP signals were therefore analyzed as originating 
collectively from groups of A- and C-fibers. The CAP peak response was used as a 
measure of the CAP amplitude (Fig. 52 dotted lines). This was considered as a 
more accurate measurement of axonal activity compared to the area under the 
curve as it is formed by the spatio-temporal summation of many single unit action 
potentials fired by individual axons. 
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Figure 52. Typical CAP traces evoked by electrical stimulation of the saphenous nerve at 
time 0 as indicated by the open point arrows. (A) Shows all the components of the 
saphenous CAP while (B) and (C) focus in at specific settings for measuring Aβ and C-CAPs 
respectively. Dotted lines denote the peak responses recorded. 
The use of DMSO as vehicle for compound delivery at the skin-nerve 
preparation has been previously validated by the Koltzenburg group. The magnitude 
of CAPs remained stable over treatment with six ascending concentrations of DMSO 
(0.01, 0.1, 0.2, 0.5, 1, and 2% v/v), each circulated for 15 minutes, over the span of 
the recordings for 2-2.5 h. Changes in CAP magnitude did not exceed 10% of the 
initial values for up to 2.5 h of monitoring. Baseline control recordings of at least 20 
minutes were performed prior to each experiment to verify the stability of the 
recording and served as the normalizing control for quantitative evaluation of the 
action of the respective drug. 
Drug solutions were diluted in simulated intestinal fluid (SIF) from 10 mM or 
100 mM stock solutions in DMSO, with the maximum concentration of vehicle never 
exceeding 2% v/v. The experimental protocol of a single recording session involved 
the successive circulation of six ascending concentrations of the drug solution of 
interest, from 1 μM to 200 μΜ or from 100 μΜ to 1 mM, for 15 minutes intervals 
each. The amplitude of CAP block at each concentration was calculated as the 
percentage decrease in CAP relative to the initial measurement at baseline 
recording (Fig. 53). Each compound was tested on a minimum of three nerves and 
results are presented as mean CAP block ± standard error of the mean (SEM) in 
semi logarithmic plots. Wherever appropriate, dose-response curves were fitted 
using the Origin Pro9.0© software in DoseResp fitting mode. The EC50 for each 
compound was determined from the corresponding dose-response curve, as a 
summary measure of potency. Since no data are available to date regarding the 
percentage of C-fiber blockade in a sensory nerve required to produce pain relief, 
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EC90s were also determined, as a more cautious estimate of the drug concentration 
required for achieving effective analgesia. 
 
Table 19. Example of data recording and analysis of WIN17317-3 effects in the saphenous 
skin-nerve preparation. 
Conc. 
(µM) 
A-CAP C-CAP 
IPR  
(mV) 
%Block 
Average 
%block from 
9 expts 
SEM 
IPR 
(μV) 
%Block 
Average 
%block from 
9 expts 
SEM 
0 
Baseline 
4.96 0 0 0 76.3 0 0 0 
1 4.88 1.61 7.21 3.9 69.4 9.0 6.88 1.5 
10 4.96 0.00 11.24 5.3 68.8 9.8 17.60 3.5 
20 4.88 1.61 14.61 6.2 64.2 15.8 39.43 6.2 
50 4.88 1.61 18.00 6.5 56.9 25.4 69.33 9.8 
100 4.80 3.23 21.35 7.2 41.5 45.6 85.09 8.4 
200 4.72 4.84 39.48 8.4 0 100 100 0.0 
 
 
Figure 53. Data analysis of WIN17317-3 effects in the saphenous skin-nerve preparation. 
The %CAP blocks produced by ascending drug concentrations were calculated as % current 
reduction relative to baseline as depicted by the equation to the right. The data points are 
plotted on a concentration - %block semi-logarithmic plot, as means of nine recordings ± 
SEM. Dose-response curves were fitted and EC50, EC90 parameters were calculated using 
the Origin Pro9.0
©
 software in DoseResp fitting mode. 
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5.2. Effects of iminodihydroquinolines on C- and A-fiber 
conduction 
The skin-nerve preparation was used to elucidate the SAR of the 
iminodihydroquinoline class for C-fiber blockade; the identification of structural 
features contributing to the selective blockade of C- over A-fibers was of particular 
interest. Fourteen compounds from the library were initially screened using the skin-
nerve preparation and the effects of modifications in the R2 and R3 pharmacophore 
regions of WIN17317-3 were examined (Fig. 54). 
 
 
Figure 54. The WIN17317-3 pharmacophore. 
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5.2.1. SARs for C-fiber blockade 
Focusing at modifications in the R2 pharmacophore region first, the effects of 
nine compounds with various aryl, heteroaryl and alkyl R2 substituents, of diverse 
physicochemical properties, were examined (Fig. 55). The compounds were applied 
at six ascending concentrations, 1 μM, 10 μM, 20 μM, 50 μM, 100 μM and 200 µM, 
the same concentration range previously used for characterizing the dose-response 
relationship of WIN17317-3. Each concentration was applied for a period of 15 
minutes. 7 compounds from this series were tested by Dr. Mona Alqatari (PDRA, 
Koltzenburg group). 
The dose-response curves are plotted alongside the structure of the 
compounds in Figure 55. All compounds, with the exception of 107*, were found 
effective in largely blocking C-CAP conduction at the concentration range tested. 
The 1 μM concentration appeared to have no significant effect on C-CAP amplitude; 
for the majority of compounds 10 µM was the lowest concentration causing a 
decrease in the C-CAP current. Whilst for many compounds, full C-CAP blockade 
was achieved at the highest concentration investigated, that is 200 μΜ, some 
compounds (such as 101*, 102*, and 103*), did not produce full C-CAP block at this 
concentration. The top asymptote of the dose-response curves for the latter could 
therefore not be defined. Parameters determined from such incomplete dose-
response curves are usually associated with larger error values. EC50 values 
calculated from such data sets are clearly marked in potency tables, to highlight the 
increased error likely associated with the values. 
The R2 series analogues investigated, exhibited a range of C-CAP EC50s 
between 26-160 µM and EC90s in the range of 107-337 µM (Table 20). Interpreting 
the observed SAR for this series, introduction of substituents at the benzyl ring 
(nitrile and fluoride) was found to be well tolerated; the C-CAP blocking activity was 
maintained independent of the electronic nature and the position of the substituent 
at the ring. Nitrile containing compounds 101*, 102*, and 103* caused more than 
70% C-CAP block at the highest 200 µM concentration. Based on EC50s, the rank of 
potencies for nitrile containing analogues was ortho>meta>para (Table 20). The 
meta fluoro benzyl analogue 104*, was the second most potent compound in the R2 
series with a C-CAP EC50 of 39.5 (± 6.5) µM. The most potent compound of the 
series was the branched methyl benzyl analogue 108*, tested as a racemic mixture, 
with an EC50 of 26.2 ± 08 µM and EC90 of 106.8 ± 9.2 µM. Compound 106*, bearing 
a 2-pyridinyl ring as the R2 substituent proved particularly interesting; its dose-
response curve, unlike all other compounds explored, resembled the profile of a 
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partial rather than a full antagonist. The fitted dose-response curve appeared to 
reach a plateau at 65 (± 4)% of C-CAP block, suggesting that this is the maximal 
response that can be elicited by the drug. More experiments at a higher dose range 
are required to validate and investigate this result further. 
  Moving from aryl to alkyl R2 substituents, the methyl analogue 107* was the 
least active compound in the series, producing less than 40% C-CAP block at the 
200 µM concentration. Introduction of the bulkier methylcyclohexyl and cyclohexyl 
substituents in compounds 105* and 56, respectively, restored blocking activity 
which implies that lipophilicity and energetic interactions play an important role at 
the binding site, and that this region of the pharmacophore tolerates sterically 
demanding groups. Compound 105* exhibited essentially the same dose-response 
profile as the ‘hit’ WIN17317-3. This suggested that both alkyl and aryl groups could 
potentially be introduced as the R2 substituent of an investigational therapeutic 
agent. Having a pool of active compounds can be beneficial for a drug development 
program as other important molecular properties of a drug such as solubility and 
metabolic stability could be optimized by exploring different substituents whilst 
retaining the desired biological effect. 
 
Figure 55. (continued).  
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Figure 55. Effects of R
2
-series analogues in the skin-nerve preparation. Saphenous nerve 
Aβ (■) and C (●) fiber CAP blockade as a function of iminodihydroquinoline concentration. 
Data shown as mean ± S.E.M (n = ≥4, (a) n= 2), fitted dose-response curves presented as 
solid lines. 
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Table 20. Summary of half-maximal and maximal concentrations (EC50 and EC90) for C-CAP 
blockade as a result of modifications at the R
2
 substituent. 
Entry Cpd  EC50 (µM) S.E.  EC90 (µM) S.E. N 
1 1  34.6 5.1  149.2 49.7 9 
2 101*  69.1
a 
3.8  - - 4 
3 102*  89.4
a 
8.6  - - 5 
4 103*  156.3
a 
7.2  - - 4 
5 104*  39.5 6.5  243.4 99.6 4 
6 106*  49.1
a 
6.3  - - 4 
7 108*  26.2 0.8  106.8 9.2 4 
8 107*  - -  - - 4 
9 105*  38.4
a 
1.5  - - 5 
10 56  57.6 11.6  331.4 156.2 2 
a
Dose-response relationship fitted with a non-defined top asymptote. 
 
  The SARs of R3 substituents were investigated next. Examining the dose-
response curves of the R2-series analogues (vide supra) it became apparent that 
the concentration range used was not sufficient to produce complete C-fiber block in 
the majority of examples. The experimental method was therefore modified to 
include a concentration scouting run for each new compound tested. This involved 
an experiment run at a concentration range of 20 µM to 1 mM (20 µM, 50 µM, 100 
µM, 200 µM, 500 µM, 1 mM). Based on the outcome, the most appropriate out of 
two concentrations ranges was selected for evaluating the dose-response profile of 
the compound: (a) low: 1-200 µM or (b) high: 20-1000 µM. 
  Three analogues from the R3-series, 2, 21 and 24 were initially examined 
(Fig. 56). Chlorine substitution at the parent WIN17317-3 with the bulkier and more 
lipophilic iodine in 2 led to a two-fold drop in C-CAP EC50. Halogen substitution with 
hydrogen in 21 led to a further drop in potency and a C-CAP EC50 of 120.7 µM. 
Interestingly, incorporation of the electron-donating methoxy group in 24 led to 
equipotent C-CAP inhibition to the electron neutral hydrogen substituted compound 
21. 
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Figure 56. Effects of R
3
-series analogues in the skin-nerve preparation. Block of saphenous 
nerve Aβ (■) and C (●) fiber CAP as a function of drug concentration. Data are shown as 
mean ± S.E.M (n = ≥4). Fitted dose-response curves are presented as solid lines.  
 
Table 21. Summary of half maximal and maximal effective concentrations (EC50 and EC90) 
for C-fiber blockade in rat saphenous nerve as a result of modifications at the R
3
 substituent. 
Entry Cpd  EC50 (µM) S.E.  EC90 (µM) S.E. N 
1 1  34.6 5.1  149.2 49.7 9 
2 2  68.9 15.7  290.7 157.7 4 
3 21  120.7 5.8  269.6 28.2 4 
4 24  112.0 5.5  341.9 38.1 4 
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5.2.2. Selectivity for C- over A-fiber blockade 
In order to assess the compounds’ selectivity for blocking C-fibers over A-
fibers, the %A-CAP block produced at the concentration point where C-CAP 
reached maximal blockade (EC90) was measured. The selectivity for C- over A-fiber 
block was defined as the ratio between the %C-CAP and %A-CAP blocks at the 
EC90 concentration for C-CAP. The results are illustrated in Figure 57. The C- over 
A-fiber selectivity of compounds with incomplete C-CAP dose-response curves 
could not be quantified at this point. 
From the R2 series, two compounds, 104* and 108*, were found to exhibit 
superior C- over A-fiber selectivity relative to the hit WIN17317-3. The meta-fluoro 
substituted benzyl analogue 104* exhibited less than 15% A-CAP block at the C-
CAP EC90, 243.4 µM, translating to a nearly 8-fold selectivity for C- over A-fibers. 
Similarly the branched methyl benzyl analogue 105* exhibited a 9-fold C-over A-
fiber selectivity. The cyclohexyl analogue 56 was the least selective compound of 
the series with almost 50% of the A-CAP blocked at C-CAP EC90. 
 21 was the most selective compound of the R3 series with less than 20% A-
CAP block at C-CAP EC90. The iodinated analogue 2 was the next most selective 
with 22% block whilst the methoxy analogue 24 was the least selective compound of 
the R3 series with more than 50% of A-CAP blocked. 
 
Figure 57. C- over A-fiber selectivity for R
2
- and R
3
-series analogues. 90% C-CAP block for 
each compound is plotted alongside the simultaneously recorded value for % A-CAP. The C-
over A-fiber selectivity was calculated as the ratio between the two at the bottom of the chart.  
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 After screening 14 compounds in total, it became apparent that 
iminodihydroquinolines are potent, selective blockers of C-fibers whilst leave the A-
fibers largely unaffected. All attempted modifications at the R2 and R3 positions, with 
the exception of one (R2 = CH3), were found to cause potent C-CAP inhibition. 
Several compounds with C- over A-fiber selectivity superior to that of WIN17317-3 
were identified. Given the laborious nature of skin-nerve experiments, a lead 
compound from the first two series was selected and used as the basis for further 
investigations of the R1 pharmacophore region. 
 
5.3. Lead identification and development 
Prior to selecting a lead from a compound series, it is important to define the 
potential roles that this would be required to fulfill; these will in turn determine the 
molecular properties the lead should possess and hence dictate the selection 
process. The lead compound in this study was to be used (a) as an experimental 
tool for investigating the mechanistic origin of the C- over A-fiber selectivity and (b) 
as a lead drug candidate that upon further optimization would enter in vivo 
pharmacokinetic and toxicity studies in rodents and potentially human ex-vivo nerve 
conduction studies for future development as a local analgesic drug. 
As such, the most important property the lead should possess in terms of 
biological activity was maximal selectivity for blocking C- over A-fibers. This would 
facilitate the elucidation of its molecular mechanism of action at peripheral nerves, 
and at the same time minimize side effects and idiosyncratic toxicities when applied 
as a drug candidate at a therapeutic dose. The lead should exhibit high potency for 
its physiological target, the C-fibers, and in addition retain “drug-like” 
physicochemical properties. Accordingly, the optimal substituents from the R2 and R3 
series were selected and combined in a molecule to afford a new lead compound 
(Fig. 58). 
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Figure 58. Hit to lead development. Optimal R
2
 and R
3
 substituents were combined for the 
design of the lead compound 22. 
The meta-fluorobenzyl substituent of compound 104*, was selected as the 
optimal R2 substituent, on the basis of the high C- over A-fiber selectivity (8-fold) 
and also the high potency for C-fiber blockade (EC50 = 39.6 ±6.5 µM) exhibited by 
104*. In addition, the fluoride substituent provides a potential site for 
[18F]fluorination, which would facilitate pharmacokinetic profiling studies. From the 
R3 series, the compound demonstrating the highest C-over A-fiber selectivity was 21 
bearing hydrogen as the R3 substituent. 21 was less potent (EC50 = 120.7 ±5.8 µM) 
than WIN17317-3 (EC50 = 34.6 ±5.1 µM) towards blocking C-fibers, however it 
exhibited favorable “drug-like” physicochemical characteristics such as low melting 
point known to contribute to higher aqueous solubility. Hydrogen was therefore 
selected as the optimal R3 substituent. 
The proposed new lead compound, 22, bearing the optimal R2 and R3 
substituents described above, was synthesized and tested for its effects in the skin-
nerve preparation (Fig. 59). Gratifyingly, 22 was found to be the most selective of all 
compounds screened up to this point, with the C- over A-fiber selectivity exceeding 
those of both the hit WIN17317-3 and the “parent” molecules 104* and 21. Less 
than 5% of A-CAP block was observed at the C-CAP EC90 301 ± 45 µM. This 
translates to a 30-fold selectivity for C- over A-fibers at the anticipated therapeutic 
dose range. In terms of potency, 22 with an EC50 value of 160.4 ± 9.6 µM was an 
order of magnitude less potent than WIN17317-3. 
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Figure 59. Effects of Hit (WIN17317-3) and Lead (22) molecules in the skin-nerve 
preparation. Block of saphenous nerve Aβ (■) and C (●) fiber CAP as a function of drug 
concentration. Data are shown as mean ± S.E.M (n = ≥4). Fitted dose-response curves are 
presented as solid lines. 
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5.4. Second generation iminodihydroquinoline analogues 
 
A second generation library of compounds was designed and synthesized 
based on the structure of the lead 22 in an attempt to improve potency whilst further 
exploring the SARs of iminodihydroquinolines. Modifications were focused around 
the least explored R1 and R3 pharmacophore regions (Fig. 60). 
 
5.4.1. Effects on C- and A-fiber conduction 
All second generation compounds were tested at the high concentration 
range of 20 µM to 1 mM. This allowed the deduction of complete C-CAP dose-
response curves as well as determination of the corresponding A-CAP EC50s. 
 
Figure 60. Effects of second generation analogues in the skin-nerve preparation. Block of 
saphenous nerve Aβ (■) and C (●) fiber CAP as a function of drug concentration. Data are 
shown as mean ± S.E.M (n = ≥4, 
a
n = 3). Fitted dose-response curves are presented as solid 
lines. 
  
1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0
0
20
40
60
80
100
10 100 1000
P
e
rc
e
n
ta
g
e
 o
f 
B
lo
c
k
 
[22] (μM) 
1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0
0
20
40
60
80
100
 
10 100 1000
[37] (μM) 
1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0
0
20
40
60
80
100
 
0 1 0 1 00
P
e
rc
e
n
ta
g
e
 o
f 
B
lo
c
k
 
1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6 2.8 3.0
0
20
40
60
80
100
 
10 100 1000
[38] (μM) [61] (μM)a
 
Functional characterization 
 
112 
Table 22. Summary of half-maximal and maximal effective concentrations (EC50 and EC90) 
for C-fiber blockade in rat saphenous nerve by second generation analogues. 
Entry Cpd  EC50 (µM) S.E.  EC90 (µM) S.E. N 
1 22  160.4 9.6  301.4 45.0 4-9 
2 37  186.6 18.1  481.4 124.9 4 
3 38  71.8 2.0  136.7 6.4 4 
4 61  164.5 16.4  481.3 126.5 3 
 
Two compounds, 37 and 38, bearing benzyl and phenyl R1- substituents, 
respectively, were evaluated at the skin-nerve preparation to examine the 
requirements of the R1 pharmacophore region. Substitution of the pentyl chain in 22 
with the benzyl group in 37 maintained C-CAP blocking activity with the two 
compounds exhibiting similar potency values. The introduction of a phenyl ring as 
the R1 substituent in 38, on the other hand, led to a two-fold increase in potency and 
a C-CAP EC50 of 71.8 ± 2.0 µM. In terms of C- over A-fiber selectivity, both 
compounds were significantly less selective than the lead. 38 in particular, was the 
least selective compound from both libraries blocking more than 65% of A-CAP at 
C-CAP EC90 (Fig. 61). 
Further investigating the effects of modifications at the R3 pharmacophore 
region, fluoride, a commonly used hydrogen bioisostere, was introduced as the R3-
substituent in 61 (Fig. 60). Compound 61 exhibited lower potency (EC50= 164.5 ± 
16.4 μΜ) than the previously explored R3 halogenated analogues (-Cl and -I) for C-
CAP blockade, yet it was equipotent to the hydrogen substituted 22 (Table 22); this 
suggested spatial requirements are associated with the R3 pharmacophore region. 
Regarding C-over A-fiber selectivity, 61 blocked more than 45% of A-CAP at the C-
CAP EC90 meaning this is only two-fold selective (Fig. 61). 
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Figure 61. Effects of second generation analogues on C- and A-fiber conduction as 
measured in the skin-nerve preparation. 90% C-CAP block for each compound is plotted 
alongside the simultaneously recorded value for % A-CAP block at this concentration. C/A-
CAP block ratios, at the bottom of the chart, were calculated as a measure of the C/A-fiber 
selectivity. 
Comparing the EC50 values of C-CAP and A-CAP block for the second 
generation iminodihydroquinolines, confirmed that the selected lead compound from 
the first library, 22, was more selective than all the compounds of the second 
generation library (Fig. 62). At this point, 22 was appointed as the lead preclinical 
drug candidate for entering pharmacokinetic profiling studies. 
 
Figure 62. Half maximal effective concentrations (EC50 ± S.E., n ≥ 3) of second generation 
analogues for C- and A-CAP blockade as measured in the skin-nerve preparation. 
  
Functional characterization 
 
114 
5.4.2. Nav screening 
The in vitro effects of the second library of iminodihydroquinolines at Navs 
were evaluated using the IonWorks Barracuda platform (Table 23). Gratifyingly, 22, 
as well as analogue 38, exhibited state- and use-dependency, displaying two-fold 
lower IC50 values for channels in those states over resting Navs (tonic block). On the 
contrary, compound 37 inhibited Navs at all three voltage states with similar levels of 
potency. The effects of the lead were evaluated at Nav1.7, the molecular target of 
interest, but also at the Nav1.4, Nav1.5 and Nav1.6 isoforms aiming to assay 
potential off-target toxicity. Unfortunately, 22 was found to block non-selectively all 
of the Nav isoforms investigated. Interestingly, the most and least selective 
compounds for C- over A-fiber blockade, 22 and 38 respectively, displayed similar 
IC50 values for the Nav1.6 and Nav1.7 isoforms. The significance of this for 
unraveling the molecular mechanism of action of iminodihydroquinolines at 
peripheral nerves is discussed in section 5.7. 
Table 23: IC50 values of second generation iminodihydorquinolines for hNav inhibition. 
Cpd 
Nav 
Isoform 
IC50 ± SE (μΜ) 
Tonic block 
Use-dependent 
block 
State-dependent 
block 
22 Nav1.4 2.98 ± 0.41 1.57 ±0.20 1.32 ± 0.35 
 Nav1.5 9.90 ± 0.67 2.20 ± 0.08 4.03 ± 0.28 
 Nav1.6 4.70 ± 0.79 1.59 ± 0.10 1.30 ± 0.06 
 Nav1.7 5.42 ± 0.80 1.77 ± 0.11 2.15 ± 0.24 
37 Nav1.7 1.65 ± 0.18 1.01 ± 0.08 1.15 ± 0.08 
38 Nav1.6 6.59 ± 0.63 2.24 ± 0.12 1.34 ± 0.09 
 Nav1.7 6.45 ± 0.60 1.89 ± 0.07 1.78 ± 0.13 
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5.5. Nerve absorption and metabolism pharmacokinetics 
 The rapid metabolism and tissue clearance exhibited by [125I]labelled 
iminodihydroquinoline 2 after iv administration in mice (see page 28), suggested that 
the plausible routes of administration for this compound class are limited to those 
avoiding drug passage through the systemic circulation, i.e. local administration. 
Such routes are the local infiltration, epidural, spinal and topical/surface 
administration and peripheral nerve block, all widely used in clinical practice for the 
delivery of LA drugs.218 Local administration leads to drug deposition at the nerve 
surface, which upon a series of steps will reach the individual neuronal fibers to 
exert its effects. 
 Before assessing the rate of 22 nerve absorption and the impact of this on 
the onset and maintenance of nerve block, a description of the anatomical features 
of the rat saphenous nerve is given below to provide a brief overview over the 
anticipated drug movement pathway. The saphenous nerve consists of afferent Aβ, 
Aδ and C-fibers, tightly packed together in bundles known as fasciculi (Fig. 63). 
Each fiber is cased by a thin membrane, the endoneurium, and each bundle of 
fibers is surrounded by two to four layers of flattened connective tissue known as the 
perineurium. Saphenous nerves are in their majority monofasciculated, yet nerves 
consisting of two or more fascicles are also known to exist. The outermost layer of 
connective tissue is the epineurium and encloses the nerve fascicles and the blood 
vessels supplying the nerve. 
 
Figure 63. Cross sectional aspects of the rat saphenous nerve. A. Schematic representation 
of the nerve illustrating fascicles and individual nerve fibers. Components in an orderly 
fashion from the outermost layer to the inner most include the epineurium, perineurium, 
endoneurium and Swann cells surrounding the axon. B. Light micrograph of a 
monofasciculated nerve, enveloped by a well-defined perineurium (arrows), showing 
myelinated fibers and capillary blood vessels (*) in the endoneural space.
214
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 The average number of myelinated A-fibers in the saphenous nerve is 700 
and the ratio of unmyelinated C-fibers to A-fibers has been measured to 3.42:1.213 A 
recent study investigating the anatomy of young female rat saphenous nerves has 
demonstrated that these are longitudinally and laterally symmetrical with no 
morphological differences between proximal and distal segments, as well as 
between right and left sides. Myelinated and unmyelinated fibers are found 
intermingled in the endoneural space.214 
 Following drug administration into the soft tissues near the nerve, drug 
molecules will move from the extraneural site towards the inner layers of the nerve 
via diffusion according to the concentration gradient. They will first cross the 
epineurium to reach the perineurium, which is the greatest diffusional barrier, and 
from there move into the endoneurium to reach their site of action, the individual 
nerve fibers. 
 The first step towards assessing the local pharmacokinetics of 22 involved a 
quick stability study to identify to which degree the compound remained intact after 
administration.The solutions of 22 applied to the nerve, were analyzed by high 
performance liquid chromatography (HPLC) at the end of a dose-response 
experiment; the chromatograms revealed no additional species apart from the 
parent 22 in the solutions examined. This suggested 22 is stable under the 
experimental conditions and is most likely the active species for the pronounced 
effects at the saphenous nerve. 
 Two experiments were carried out to examine the effects of biological 
barriers on absorption, onset of nerve conduction blockade, and potency of 22. The 
first experiment involved nerve desheathing a procedure by which the outer 
epineurium and perineurium connective tissues are carefully detached from the 
nerve, uncovering the free neuronal fibers. The dose-response relationship of 22 at 
the desheathed nerve was determined by applying a series of ascending drug 
concentrations for 15 minute periods each, as previously described for the assay 
using intact nerves (Fig. 64). As expected, 22 was much more potent in blocking C-
CAPs in desheathed rather than intact nerves; a 20-fold increase in potency was 
observed and complete C-fiber blockade was achieved at 50 µM. This suggested 
slow diffusion of 22 through the various layers of connective tissue. Gratifyingly, A-
fiber conduction in the desheathed nerve preparation remained unaffected at the 
concentration point where full C-CAP blockade was achieved, suggesting that the 
source of differential C- over- A-fiber block is not related to the time course of drug 
diffusion into the nerve or the nerve’s anatomical features.  
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Figure 64. Effects of the lead compound 22 in intact (left) and desheathed (right) saphenous 
nerves. Block of Aβ (■) and C (●) fiber CAP as a function of drug concentration. Data are 
shown as mean ± S.E.M (n = 9 intact, n = 2 desheathed). Fitted dose-response curves are 
presented as solid lines. 
 The results of the experiment imply that a temporal component is associated 
with all dose-response data reported so far, and is a result of diffusion barriers. The 
rate of diffusion is governed by the concentration gradient, and the speed of overt of 
drug action is essentially proportional to the log of drug concentration. As a 
consequence, doubling the concentration of the drug will only marginally speed up 
the onset of block, although it is likely to block fibers more effectively and prolong 
the duration of block. Lipophilicity is one of the key molecular properties influencing 
the rate of diffusion and hence the speed of effect onset. The 
iminodihydroquinolines tested are likely to exhibit a range of diffusion rates 
according to their distinct logP values. 
 To explore the time course of diffusion of 22 into the nerve, a single 
concentration, just below the EC50, 130 µM, was applied to the intact saphenous 
nerve for a time period of 90 minutes (Fig. 65). At 15 minutes, 40% C-CAP blockade 
was observed, consistent with the previously obtained data for the dose-response 
relationship of 22. There was a linear increase in the %C-CAP block with time, from 
0 to 45 minutes, at which point complete block was reached. A-fiber conduction 
remained practically unaffected during the course of the experiment. This confirmed 
that the differential block observed for the two fiber classes is not a temporal 
phenomenon but rather a result of the axons being per se differentially sensitive to 
the block.  
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Figure 65. Effects of lead compound 22, applied at a single concentration, 130 µM, at the 
intact saphenous nerve for 1.5 h. Block of Aβ (■) and C (●) fiber CAP as a function of time. 
Data are shown as mean ± S.E.M (n = 4). 
The above experiments signify the clinical potential of 
iminodihydroquinolines as local analgesic drugs. Primarily, complete impulse 
inhibition and functional impairment of C-fibers has been achieved whilst 
maintaining conduction of myelinated Aβ afferents over an extended period of time. 
This may translate to effective pain relief in vivo without loss of the discriminative 
touch sensation. We anticipate that preferential block of C-fibers will also be exerted 
over the larger Aα myelinated fibers, responsible for motor control, hence also 
avoiding the paralysis side effects exerted by the currently used LAs. In terms of 
potency, the above experiments demonstrate that complete C-CAP blockade can be 
achieved at concentrations significantly lower than those initially estimated from the 
dose-response relationships. A balance is required for dosing, between a 
concentration high enough to produce effective C-CAP blockade within a reasonable 
period of time yet without compromising safety. 
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5.6. Comparative assessment towards local anesthetics 
 Peripheral nerve block induced by LA drugs, as observed clinically, can 
sometimes lead to differential functional blockade; pain is often alleviated whilst 
motor function and touch sensation are less affected. This is presumed to be the 
result of a complex behavior in vivo, with numerous investigational studies on the 
subject yielding contradicting data. Despite widespread belief that the effective 
concentration of local anesthetics simply increases as a function of larger fiber 
diameter, the so called “size-principle”, the relationship appears to be much more 
complex than initially appreciated.219 Other factors such as the type of fiber, the 
degree of myelination, the fiber length and the frequency dependence are also 
important. 
 With respect to the effects of lidocaine at single fiber APs, a consistent order 
of fiber block has been reported by many investigators, both in vitro and in vivo.220, 
221, 222, 223 The Aδ-fibers were found to be the most susceptible of all categories, 
followed by the larger Aβ-fibers, and the C-fibers being the least susceptible of all 
(Fig. 66). This could explain the clinical observation that pain sensation is numbed 
before motor function is affected, as the fast-pain transmitting Aδ-fibers are blocked 
first. The preferential block of Aδ-fibers however, over the prolonged-pain 
transmitting C-fibers, is not always beneficial in a clinical setting. It can often mislead 
an anesthesiologist about the extent of total block; if a region is falsely assigned as 
“anesthetized” while some C-fibers are still conducting, the residual afferent input 
might still be able to sensitize the CNS and thereby mediate post-operative pain. 
 
Figure 66. Effects of lidocaine in the rat sciatic nerve. (A) Tonic block of individual nerve 
fiber axons in vivo. All categories (Aβ, Αδ, C) are blocked over a range of concentrations 
from 0.2 to 0.8 mM yet nociceptive C-fibers are evidently significantly less susceptible.
220
 (B) 
Time course of impulse blockade as a response to a non-equilibrium percutaneous bolus 
injection of 0.5% lidocaine around the nerve.
223
 The differential rate and maximum degree of 
block exhibited by nerve fibers are consistent amongst the two studies. Adapted from 
references 220 and 223.  
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 The effects of three clinically used LAs, lidocaine, butamden, and dibucaine 
in C- and A-fiber CAPs were assessed in the skin-nerve preparation for purpose of 
comparison with the lead compound 22. Lidocaine is the gold standard for local 
analgesia and hence was examined first. C-fibers (EC50 value of 415.9 ± 90 µM) 
were found to be slightly more susceptible to lidocaine than A-fibers, EC50= 715.8 ± 
102.9 µM (Fig. 67, 68). At the concentration point causing 90% of C-CAP block, A-
CAP block reached approximately 70% (Fig. 69). An analogous study reported in 
literature, investigating the effects of lidocaine on the desheathed rat saphenous 
nerve, also reports a lower C-CAP EC50 (= 63 ± 6 µM) than A-CAP EC50 (= 119 ± 46 
µM). However, the difference was not statistically significant and lidocaine was 
classified as non-selective blocker of all CAP components.217 
 
Figure 67. Effects of lead 22 and local anesthetics lidocaine, butamben and dibucaine, in the 
skin-nerve preparation. Block of saphenous nerve Aβ (■) and C (●) fiber CAP as a function 
of drug concentration. Data are shown as mean ± S.E.M (n = ≥4, 
a
n = 3). Fitted dose-
response curves are presented as solid lines. 
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Figure 68. Half-maximal effective concentrations of lead 22 and local anesthetics lidocaine 
butamben and dibucaine (EC50 ± S.E., n ≥ 3) for C- and A-CAP blockade in the skin-nerve 
preparation. Asterisks (*) indicate the significance level of A and C-CAP EC50 difference, as 
calculated by the unpaired Students t-test (* P ≤ 0.05, *** P ≤ 0.001, **** P ≤ 0.0001). 
 
 
Figure 69. Effects of ‘lead’ 22 and local anesthetics on C- and A-fiber conduction in the skin-
nerve preparation. 90% C-CAP block for each compound is plotted alongside the 
simultaneously recorded value for % A-CAP. C/A ratios, at the bottom of the chart, were 
calculated as a measure of the C/A-fiber selectivity for each compound. 
 The second LA examined at the skin-nerve preparation was butyl 
aminobenzoate (butamben). Butamben was first patented in 1923 for topical use, 
Butesin Picrate. It was later on formulated as a 5% aqueous suspension by Abbot 
Laboratories suitable for epidural administration. Butamben was of particular interest 
in the context of this study. Its epidural administration has been reported to produce 
long-lasting sensory blockade to cancer patients, with a marked reduction or even 
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absence of pain obtained, whilst preserving motor, bowel and bladder function.224 
Perplexingly, epidural administration of aqueous butamben solutions in rats did not 
produce similar selectivity, with the authors of the study attributing this to differences 
in the physicochemical properties of the suspension, rather than the butamben 
molecule per se.225 A more recent study by Thériault et al. suggests that the 
observed selectivity could be partially due to enhanced and selective 
responsiveness of Nav channels in nociceptive neurons to butamben.
226 In the skin-
nerve preparation butamben caused a dose-dependent inhibition of all phases of the 
CAP in a concentration range of 0.05 to 1 mM (Fig. 67). A slight preference was 
observed for A- over C-fiber blockade in terms of EC50s (Fig. 68), yet the compound 
was found to be non-selective at higher concentration dose-response points (C-CAP 
EC90) (Fig. 69). 
 The last LA evaluated in the skin-nerve assay was cinchocaine also known 
under the name dibucaine. Cincochaine was the first LA of the quinoline group to be 
synthesized and was introduced into medical practice in 1932. Its high CNS and 
CVS toxicity limited its clinical use yet it remains the subject of several recent 
medical studies.227, 228, 229 It has been the starting point for the exploration of other 
quinoline based derivatives as LAs.230 Appreciating the common structural origin of 
iminodihydroquinolines and cinchocaine, its effects on CAP conduction were 
explored (Fig. 67). Interestingly cinchocaine, exhibited a reversed selectivity relative 
to iminodihydroquinolines, with A-fibers (EC50= 5.1 ± 0.6 µM) being more 
susceptible to block than C-fibers (EC50= 14.8 ± 1.5 µM) (Fig. 68). Like butamben, 
cinchocaine was non-selective at higher concentration dose-response points (Fig. 
69). 
Overall, the above findings suggest that the lead compound of this study, 22, is 
far superior to all LAs examined, both in terms of C- over A-fiber block selectivity but 
also, with the exception of dibucaine, in terms of potency for blocking C-fibers. 
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5.7. Unraveling the molecular mechanism of 
iminodihydroquinoline action at nociceptors 
5.7.1. Relationship between Nav1.7 inhibition and C-fiber 
conduction block 
One of the key objectives of the study was to elucidate the molecular 
mechanism of action of iminodihydroquinolines at nociceptors. As previously 
described in chapter 1.7, Nav channels play a crucial role in the electrophysiology of 
nerve conduction, as they are responsible for the depolarization phase of the action 
potential. The Nav1.7 is one of the Nav isoforms predominantly expressed in 
nociceptors. Having established that iminodihydroquinolines are potent Nav1.7 
blockers, a positive correlation was anticipated between the levels of Nav1.7 
inhibition and C-fiber blockade by members of the compound library. To investigate 
this hypothesis, the iminodihydroquinolines examined in the skin-nerve preparation 
were selected to represent a range of Nav1.7 potencies. The IC50 values of the 14 
compounds tested, spanned the range of < 1 μΜ (7 compounds), 1-10 μΜ (6 
compounds), and > 10 μΜ (1 compound). The logarithmic relationship between the 
IC50s for Nav1.7 and the EC50s for C-CAP blockade of iminodihydroquinolines is 
plotted in Figure 70. The compound with Nav1.7 IC50 higher than 10 µM (IC50= 94.4 
µM) was found inactive in the skin-nerve preparation at the concentration range 
tested, hence it is not included in the plot. 
 
Figure 70. Logarithmic relationship between IC50 of hNav1.7 at resting state, and EC50 of C-
fiber blockade as determined by the automated patch clamp and the skin-nerve assays 
respectively. Standard deviations and standard errors are plotted as relative log error 
bars.
231
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As can be seen from the graph above, the potency for C-CAP blockade 
appears to increase with increasing Nav1.7 potency. In an attempt to quantify this 
relationship, a linear regression model was applied to the data set (Fig. 71.A). The 
line of ‘best fit’ had a calculated adjusted R2 value of 0.40 meaning only 40% of the 
variability could be accounted for by this relationship. Visually there was a trend with 
data points appearing to be divided into two groups of different gradients as 
illustrated in Figure 71.B. Indeed, when applying linear regression models to the 
newly assigned data sets, the R2 values of the two were improved compared to the 
previously applied model A, meaning these relationships were better fitted for 
describing the data. 
 
Figure71. Linear regression models for describing the activity of iminodihydroquinolines at 
Nav1.7 and at sensory C-fibers. (A) The linear model characterizing the relationship between 
all data points, adj. R
2
= 0.40 (B) Two linear models, applied at two group subsets, display 
increased R
2
 values (0.91, 0.68) and are therefore more appropriate predictors of the 
log(IC50)/ log(EC50) relationship. Models and adjusted R
2
 values were calculated using the 
OriginPro software at linear fitting mode with no weighting. 
 It was hypothesized that the distinct correlations observed for the two groups 
of Fig. 71.B, could be attributed to differences in the diffusion rates of the 
compounds. Comparing several physical properties known to affect the diffusion 
rate of a compound, in particular the logD, the molecular weight, the pKa and the 
polar surface area, no apparent differences were found to exist between the two 
groups with respect to these parameters. 
 In summary, the above data provide evidence that Nav1.7 inhibition is the 
underlying mechanism of iminodihydroquinolines’ sensory C-fiber blockade, yet the 
possibility of other targets also being engaged in the process cannot be ruled out.  
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5.7.2. Nav isoform selectivity and C- over A-fiber selectivity 
We hypothesized that the selective C-fiber conduction blockade exhibited by 
iminohydroquinolines could potentially be mediated via selective inhibition of the Nav 
isoforms predominantly expressed in this category of somatosensory neurons. More 
precisely, the C- over A-fiber selectivity was considered to originate from selective 
inhibition of the Nav1.7 over the Nav1.6 isoform. 
The selectivity of compounds for blocking Nav1.7 over Nav1.6 isoforms was 
measured as the ratio between their IC50 values, as previously described in page 90. 
Compounds exhibiting a range of Nav1.7 over Nav1.6 selectivity were tested in the 
skin-nerve preparation, with some being equipotent for the two, to others showing 
up to 10-fold selectivity. The C- over A-fiber selectivity for each compound is plotted 
alongside its Nav1.7 over Nav1.6 selectivity in Figure 72. Unexpectedly, no 
correlation was found to exist between the two variables. Lead compound 22, with 
the highest selectivity for C-over A-CAP blockade, blocked both Nav1.7 and Nav1.6 
channels with similar levels of potency (hNav1.6/hNav1.7 IC50~ 1). In addition, the 
most and least C-fiber selective compounds of the library, 22 and 38 respectively, 
showed essentially the same Nav isoform inhibition profile. The results suggest that 
the selective action of iminodihydroquinolines on nerve conduction is not likely to 
originate from selective inhibition of Nav channels predominantly expressed in 
nociceptors, but is rather due to another, currently unknown mechanism. 
 
Figure 72. Selectivity for Nav1.7 over Nav1.6 isoform blockade, as calculated from the 
relative potencies at tonic state in automated patch clamp assays, plotted alongside the 
selectivity for C- over A-fiber blockade for each compound, calculated as the ratio of 90% C-
CAP blockade over the corresponding A-CAP block in the skin nerve preparation.  
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5.8. Summary 
In conclusion, iminonidihydroquinolines are potent, selective blockers of C-
CAPs in peripheral sensory neurons. Their evoked responses in the skin-nerve 
preparation and their levels of Nav inhibition as determined with automated patch 
clamp assays, suggest that the C-CAP blockade is largely mediated via Nav1.7 
inhibition, although other molecular mechanisms or targets may also contribute. The 
underlying mechanism of the selective C- over A-CAP conduction blockade was 
found to be unrelated to increased responsiveness of Nav isoforms selectively 
expressed in nociceptors, but rather to be due to another, currently unknown 
mechanism. 
Compound 22 exhibited the highest C- over A-fiber selectivity of the 
compound series and was therefore selected as the lead preclinical drug candidate 
for further characterization in vivo. The physicochemical properties of the lead 22 as 
well as its functional characterization at Nav1.7 and the sensory neuronal fibers are 
summarized in Table 24, alongside those of the ‘hit’ compound WIN17317-3 and the 
local anesthetic lidocaine. 
Table 24. Physicochemical properties and functional characterization of 22, WIN17317-3 
and the marketed drug lidocaine. 
Compound 22 WIN17317-3 Lidocaine 
Chemical structure 
  
 
Name 
[1-(3-Fluoro-benzyl)-
1H-quinolin-4-ylidene]-
pentyl-amine 
(1-Benzyl-7-chloro-
1H-quinolin-4-
ylidene)-pentyl-amine 
2-Diethylamino-
N-(2,6-dimethyl-
phenyl)-
acetamide 
Chemical formula C21H23FN2 C21H23ClN2 C14H22N2O 
Molecular weight 322.42 338.87 234.34 
Melting point 64-65 
o
C 102-103 
o
C 68
o
C 
Nav1.7 IC50 (μΜ) 
5.42 ± 0.80 (tonic) 
1.77 ± 0.11 (10 Hz) 
2.15 ± 0.24 (inact.) 
0.21 ±0.05 (tonic) 
0.22 ±0.03 (10 Hz) 
0.23 ±0.04 (inact.) 
548 (tonic) 
49 (10 Hz) 
8 (inact.) 
C-CAP EC50 (μΜ) 160.4 ± 9.7 34.6 ± 5.1 415.9 ± 90.4 
C- over A-CAP 
selectivity
a 30 2.7 1.3 
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Table 24: Continued. 
Compound 22 WIN 17317-3 Lidocaine 
Solubility 
(mg/mL)
b 
H2O 1.4 ± 0.4  0.8 ± 0.2  3.42 ± 0.02
232
 
PB
 
2.6 ± 0.3  1.7 ± 0.1  NA 
25%PG:PB 4.0± 0.4  1.8 ± 0.3  NA 
a 
C/A-CAP selectivity = 90/(%A-CAP at [C-CAP EC90]); 
b
 Compounds tested in the free base 
form, PB = phosphate buffer (pH= 7.4), PG= propylene glycol, 32
o
C. 
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6. In vivo characterization of a lead preclinical 
drug candidate in rodents 
 
The two main reasons drug candidates fail during clinical development are 
that (a) they are not efficacious or (b) they do not exhibit the required safety profile. 
Experts in the field emphasise the importance of implementing a proactive testing 
paradigm, conducting the relevant predictive in vitro and in vivo studies early in the 
drug discovery process to avoid spending resources on molecules with soon-to-be 
discovered limiting liabilities.233, 234 While in silico and in vitro models are continually 
being developed and refined, in vivo preclinical safety models remain the gold 
standard for assessing human risk.  
The toxicity of any drug is strongly dependent on its absorption, distribution, 
metabolism and excretion (ADME) profile which in turn is influenced by the selected 
route of administration. Given the quick metabolism and clearance of [125I]2 from the 
blood, iminodihydroquinolines were developed as candidate analgesic drugs 
suitable for local administration. As such, they are intended to produce their effects 
at or near their site of deposition, without requiring transit through the blood to a 
blood-perfused site. Subsequent to administration, the efficacy as well as the 
potential toxicity of a given iminodihydroquinoline will depend on its concurrent 
distribution and dissipation from the site of administration. The potential sources of 
toxicity can be broadly divided into local and systemic (Fig. 73). Localised toxicity 
could potentially arise from drug action at neuronal tissues, apart from the intended 
nociceptors, leading to sensory and motor deficits. Such effects are, however, 
unlikely to occur in the case of iminodihydroquinolines given the class’s high 
selectivity for C- over A-neuronal fibres. Other local side effects could involve drug 
action on skeletal muscles; given that iminodihydroquinolines also act as potent 
Nav1.4 inhibitors this parameter must be assessed. 
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Figure 73. A conceptual model depicting the fate of local drugs injected perineurally 
indicating potential sites for toxicity effects (*). 
Locally administered drugs are cleared from their site of action mainly via 
systemic absorption. In fact, the main adverse effects of clinically used LAs are 
associated with high plasma concentrations leading to CNS and cardiovascular 
complications (Fig. 74). Given the high Nav1.2 (brain) and Nav1.5 (heart) inhibition 
exhibited by iminodihydroquinolines in vitro, systemic side effects were the main 
concern for their potential development as local analgesics. 
 
Figure 74. Relationship of plasma concentration and signs and symptoms of toxicity for 
lidocaine. Adapted from reference 219.219 
The pharmacokinetic profile of [125I]2 showed no significant retention of 
radioactivity in the mouse brain and heart after iv administration suggesting that the 
concentration of iminodihydroquinolines will be relatively low in these vital organs 
even in the case they enter systemic circulation. Given that the lead compound 22 is 
structurally different to 2, these parameters had to be reassessed. 
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To provide preliminary data, two experiments were designed for evaluating 
the safety profile of 22. The first involved pharmacokinetic profiling of 18F-labelled 22 
using PET/CT aiming to assess the excretion pathway and the retention of 22, if 
any, in vital and potentially responsive tissues (heart, brain). The second experiment 
involved assessment of the acute toxicity of the compound in vivo. A five stage dose 
escalation study was designed aiming to determine the maximum tolerated dose for 
22 and obtain an indication of the safety dose margin. 
 
6.1. Assays 
6.1.1. Positron emission tomography (PET) for 
pharmacokinetic profiling 
PET is a non-invasive imaging technique increasingly applied in the field of 
drug discovery for evaluating the PK/PD of new drug candidates both at preclinical 
and clinical development stages.235 The introduction of new radiochemical 
techniques along with advances in PET technology have been the key contributing 
factors in the increasing prevalence of PET.175 
PET relies on unstable radioisotopes undergoing positron decay via the 
release of a positron and a neutrino from the nucleus. The released positron travels 
a short distance (typically 1 mm - 2 cm depending on its kinetic energy) before 
annihilating with an electron; their rest masses are converted into two 511 keV 
photons which are released simultaneously and in opposite directions (Fig. 75). 
Coincident detection of these photons by a pair of radiation detectors in a PET 
scanner determines the so called line of response which provides information about 
the spatial location of the radionuclide. Upon counting millions of annihilation events, 
a final source map can be reconstructed in the form of a 3D-image.236 
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Figure 75. Principles of PET. A. A positron (e
+
) and a neutrino (ν) are ejected from an atom 
that undergoes positron decay. Two 511 keV photons are produced when the positron 
annihilates with an electron (e
-
). B. If both protons are detected within a set timing window, 
as determined by the PET scanner coincidence timing processor, then a line of response is 
registered. 
The main advantage of PET relative to other molecular imaging modalities 
(SPECT, MRI) is that it is fully quantitative. It has high sensitivity and it allows 
emission scans to be acquired as dynamic series and be presented in the form of a 
motion picture. The series of static recordings are separated in time frames, each 
depicting a map of the radioactivity concentration in the subject for a certain time 
interval after tracer injection. This means tracer distribution can be monitored 
quantitatively at each of the tissues of interest as a function of time. The time frames 
can be specifically defined according to the needs of each study; in studies requiring 
pharmacokinetic profiling for example, time frames are selected according to the 
anticipated tissue kinetics of the ligand under investigation. 
For the purpose of this study, [18F]22 was synthesised as previously 
described in section 3.2.3. [18F]22 (specific activity: 2.9 GBq/μmol) was administered 
intavenously to a mouse via the tail-vein and dynamic PET imaging was performed 
for 2 hours using a nanoScan® PET-CT system at the UCL Centre of Advanced 
Biomedical Imaging. The PET study was performed by PDRAs Dr. Kerstin Sander 
and Dr. Thibault Gendron. 
  
Preliminary safety study 
 
132 
6.1.2. The “up-and-down” method for determining acute lethal 
toxicity 
The median lethal dose, LD50, a concept first introduced by Trevan in 
1927,237 has been used for many decades as the standardized approach for 
determining the acute lethal toxicity of new chemical entities. Limitations of LD50 
testing procedures, coupled with increased concern over the use of animals in 
testing, led to the recent development of alternative approaches using fewer animals 
and with more humane endpoints.238, 239 
The “up-and-down method” (Dixon, 1948),240 also known as the “staircase 
bioassay”, was employed for the toxicity study of the lead compound 22. The 
method has been extensively used in a variety of experimental settings and has 
been shown to be equally effective as the conventional LD50 method, while 
significantly reducing the number of animals used.241, 240, 242 In brief, the study design 
involves the selection of an initial dose for administration from the concentration 
range where this is speculated to produce an effect. Experimental endpoints 
(positive results) are clearly defined prior to the beginning of the study and a 
specified time-period, usually seven days, is allowed for these to occur. If no effect 
is observed during this period, the dose is increased by a defined (log) increment 
and a new subject is dosed. Alternatively, if a positive result is obtained with the 
initial dose, the next dosing is decreased accordingly. This procedure is repeated 
until sufficient data is obtained to answer the imposed question. 
According to regulatory requirements, preclinical acute toxicity should 
ordinarily be examined using two routes of drug administration: (a) the route 
intended for human administration, and (b) intravenously. Studies should be 
conducted in at least two mammalian species, including a non-rodent species when 
reasonable. In this study the effects of iv administration were investigated first. 
Knowledge regarding the compounds “toxic” blood concentration, and information 
about systemic absorption and clearance, would help to determine the therapeutic 
window, and the likelihood of a systemic toxic reaction following a high drug 
concentration locally, or prolonged drug exposure. Most incidents currently 
associated with the use of LAs arise from accidental intravascular administration 
rather than overdose. As it was recently stated “it is not a question of ‘if’ an 
intravascular injection occurs is a question of when”.243, 244 
Lethality was the defined endpoint for this study, whilst CNS and cardiac 
toxicity were set as secondary endpoints. The study was outsourced to Charles 
River laboratories, Wilmington USA, as our group does not hold a valid project 
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license for performing such procedures. Male Wistar Han rats were injected with 22 
dosed as discussed above via the tail vein. 
 
6.2. Pharmacokinetic profile of [18F]22 
The biodistribution of [18F]22 after iv administration is depicted by the series 
of PET/CT images in Figure 76. Immediately after injection the 18F-labelled lead 
compound 22 can be traced moving up the tail vein and reaching the compartments 
of the heart. From there, it enters the general circulation reaching the lungs and the 
brain via the pulmonary and carotid arteries and the rest of the body tissues via the 
aorta. Rapid clearance can be seen even at the early time points, with no apparent 
retention in critical organs, i.e. the brain, heart and lungs. From 2-5 minutes there is 
gradual accumulation in the liver and kidneys, followed by excretion to the GI tract 
and bladder. At 30 minutes post injection onwards, the radioactivity is largely limited 
to the GI tract, bladder and gall bladder. The results confirm clearance via renal and 
hepatobiliary excretion. 
 
Figure 76. Representative PET/CT images illustrating the biodistribution of [
18
F]22 in wild-
type albino (Balb/C) mouse after iv administration. The radiotracer retention is presented as 
a percentage of the injected dose per unit tissue volume (%ID/ml).  
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Overall, [18F]22 showed no significant brain or heart retention as evident by 
the two hour summed PET/CT image (Fig. 77). The data are in accordance with the 
previously described pharmacokinetic profile of [125I]2.3 This confirmed the 
requirement for a local route of administration 
and at the same time provided confidence 
regarding the compounds’ therapeutic index, 
as systemic toxicity is likely to be limited by 
the rapid clearance from circulation. 
 
6.3. Maximum tolerated dose of the lead 22 after iv 
administration in rats 
Administration of an initial dose of 3 mg·kg-1 of 22 in rats, led to no apparent 
signs of toxicity, neither did the increased dose of 7.5 mg·kg-1. Escalating to 30 
mg·kg-1, immediately post injection, the animal exhibited laboured and irregular 
breathing and arrhythmic heartbeat. It became non-responsive, ataxic, had some 
muscle spasms (seizure- like activity) and died soon after dosing. Decreasing the 
dose by half, to 15 mg·kg-1, led to similar signs of toxicity and the animal also died 
soon after dosing. Reducing the dose further, to 10 mg·kg-1, caused the animal 
immediately post dose to exhibit increased heart rate and increased effort for 
respiration; the animal was hypoactive yet responsive to stimulation. Within an hour 
of dosing the animal recovered, returning to normal breathing rhythms and became 
much more responsive. Based on the results of this initial sighting study, the 
maximum tolerated dose of 22 was estimated in the range of 7.5 - 10 mg·kg-1, with 
the first signs of CNS and cardiovascular toxicity appearing at 10 mg·kg-1. Table 25 
provides a summary on the “up-and-down” test series results. 
Table 25. “Up-and-down” test series to determine the CNS, cardiovascular toxicity and 
lethality in rats after iv administration of 22. 
Dose 
(mg·kg
-1
) 
Test results
a 
CNS tox. CVS tox Lethality 
3 O O O 
7.5 O O O 
10 X X O 
15 X X X 
30 X X X 
a
X= positive result; O= negative result.  
Figure 77. Biodistribution of [
18
F]22. 
Summed PET/CT image, 2 hours. 
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The LA lidocaine, produces systemic CNS and cardiac toxicity in mice with 
an ED50 of 19.5 and 21.2 mg·kg
-1 respectively;131 these values are in accordance 
with those obtained for other species (dog, monkey).245, 246  22 with a C-CAP EC50 = 
160.4 ± 9.7 μΜ is 3-fold more potent in blocking C-fibers relative to lidocaine, C-CAP 
EC50 = 415.9 ± 90.4 μΜ. Taking into account the relative potencies and the 
maximum tolerated doses for the two compounds, collectively the results suggest 
that 22 has similar, or superior, safety profile to lidocaine when administered 
systematically. Nonetheless, the administration of LAs that have higher systemic 
toxicity than lidocaine but have other therapeutic benefits, for example are longer 
acting, is commonplace in clinics as exemplified by bupivacaine. 
It is worth noting that oral administration of a 100 mg·kg-1 dose of the parent 
compound, WIN17317-3, twice daily in mice and hamsters, as part of a study 
investigating the antiparasitic activity of iminodihydroquinolines, proceeded with no 
lethality for the five day period of the study.247 However, administration of 200 
mg·kg-1 twice daily in mice was not tolerated (2/2 animal died). 
 
6.4. Summary 
To conclude, in this last part of the study, the safety profile of 22 was 
investigated in preliminary assays. Safety evaluation is a critical step in the 
preclinical drug discovery process and of particular importance to regulatory 
authorities for granting permission for the use of more advanced animal models or 
human tissues. Using an isotopically 18F-labelled analogue, the pharmacokinetic 
profile of the lead compound 22 was assessed after iv administration in mice. The 
results of the study, in combination with those previously obtained for [125I]2, suggest 
that iminodihydroquinolines are rapidly metabolised and largely cleared from the 
blood within ten minutes post injection, showing no significant retention in any of the 
vital organs (brain, heart), with renal and hepatobiliary being their main routes of 
excretion. The maximum tolerated dose of 22 after iv administration in rats has been 
estimated at 7.5 – 10 mg·kg-1, allowing a considerable safety margin, given the 
anticipated slow rate of systemic absorption from a peripheral tissue administration 
site. 
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7. Conclusions 
Of all neurological diseases, pain is one of the most challenging with respect 
to understanding the relationships between symptoms and mechanisms and 
rationalizing approaches towards treatment. There is currently a great unmet clinical 
need for novel, more efficacious and safer pain therapies.248 The most powerful 
known method of blocking pain while retaining consciousness is to inject LAs, Nav 
blockers, regionally into areas of the body generating pain. LAs like lidocaine, 
provide effective pain relief by blocking conduction of pain-signalling neurons; 
however, adverse effects including action on the CNS (e.g. seizures), on heart’s 
excitable tissue (arrhythmias, conduction defects) and on non-nociceptive fibres of 
the PNS (anaesthesia, motor- or vaso-paralysis) limit their clinical utility. The work in 
this thesis describes the development of small molecule iminodihydroquinolines as 
new generation local analgesic drugs with selective action on pain-signalling 
neurons. 
Previous work by our group has demonstrated that the high affinity, state-
dependent Nav blocker, WIN17317-3, can potently block nociceptive C-fibers whilst 
leaving non-nociceptive A-fibers largely unaffected. In the present work, a library of 
structural analogues of WIN17317-3 was designed, synthesized and evaluated for 
their effects at human Navs and rodent peripheral sensory neurons in vitro. The 
results revealed selective nociceptor blockade to be a functional property 
characterizing the iminodihydroquinoline class of compounds. Nociceptor blockade 
was demonstrated to be mediated, at least partially, through inhibition of the Nav1.7 
isoform. Intriguingly, the profound C- over A-fiber selectivity could not be explained 
by selective inhibition of ion channels known to be predominantly expressed at 
nociceptors (TRPA1, TRPV1, Nav1.7, Nav1.8,) as it was initially hypothesised. 
The selective nociceptor blockade exhibited by iminodihydroquinolines could 
in a clinical setting translate to effective analgesia without the complete sensory and 
motor block currently produced by LA drugs. This would be beneficial in a number of 
clinical situations. For example, analgesia without loss of proprioception or motor 
function would allow patients undergoing neurosurgery to provide instant feedback 
on sensation and the ability to control movement thus limiting possible nerve 
damage. Also, it would enable early mobilization in patients receiving peripheral 
nerve block or plexus block in cases such as following knee or hip joint 
replacement.129 Furthermore, epidural administration for pain relief during labour 
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would allow the mother to actively participate in the delivery of the child. In a 
different scenario, the unpleasant loss of sensation and prolonged numbness 
following dentistry and cosmetic procedures could be avoided. 
Appreciating the clinical potential associated with the use of 
iminodihydroquinolines as local analgesic drugs, a lead compound from the library, 
22, exhibiting excellent C-over A-fiber selectivity and “drug-like” physicochemical 
properties, was selected for further characterization in vivo. 22 was submitted to 
preliminary safety studies in rodents; the pharmacokinetic profile of 18F-labelled 22 
showed rapid clearance and excretion after iv administration and the maximum 
tolerated systemic dose of 22 was estimated to be in the range of 7.5-10 mgkg-1. 
Both studies provided confidence regarding the potential safety margin of 22. 22 
was denoted as the lead preclinical drug candidate for entering human nerve 
conduction studies ex vivo, analogous to the rodent skin-nerve preparation studies. 
The human nerve conduction studies will objectively and quantifiably evaluate 
whether the remarkable peripheral nerve effects observed in rodents are also 
exerted in human tissues. If successful, we envision 22, upon further toxicological 
studies, progressing to first-in-man microdosing studies for future clinical 
development as a local analgesic drug. 
The discovery of iminodihydroquinolines as selective nociceptor blockers 
opens new exciting opportunities for the field of pain medicine. Presently, there is a 
feeling that success in the development of new pain therapeutics is quite limited, 
lacking real breakthrough analgesic drugs despite improvements in our 
understanding of pain mechanisms.63 Whilst many efforts and resources have been 
concentrated on the selective targeting of peripheral Navs, the clinical usefulness of 
such agents after a decade of extensive research is still to be demonstrated. Having 
excluded all known mechanisms to confer C-over A-fiber selectivity (selective Nav or 
TRP isoform inhibition), the elucidation of the molecular mechanism of action of 
iminodihydroquinolines could provide a completely novel target for analgesia 
revolutionizing the field of analgesic drug discovery. 
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8. Experimental 
 
8.1. Experimental for Chapter 3 
All chemistry and radiochemistry experiments were performed at the UCL 
Department of Chemistry. 
General experimental 
Reagents were purchased from Sigma-Aldrich, Acros Organics or Fluorochem and 
were used without further purification. Purification of compounds by column 
chromatography was performed on BDH silica gel (40-60 μM) unless otherwise 
specified. Analytical thin layer chromatography was carried out using Merck 
Keiselgel aluminium-backed plates coated with silica gel. Components were 
visualized using combinations of ultra-violet lights, ninihydrin, phosphomolybdic acid 
and potassium permanganate. For compound characterization, 1H and 13C NMR 
spectra were recorded at room temperature unless otherwise specified. The 
respective instruments, Bruker Avance 400, 500 or 600 were operated at a 
frequency of 400, 500 or 600 MHz for 1H and 100, 125 or 150 MHz for 13C, 
respectively. Proton decoupled 19F NMR spectra were recorded on a Bruker Avance 
300 instrument at a frequency of 282 MHz. All spectra were internally referenced to 
the respective deuterated solvents. Chemical shifts are reported in ppm using the 
following abbreviations: s, singlet; d, doublet; t, triplet; q, quintet; m, multiplet; br, 
broad or a combination of these. Coupling constants (J) are given in Hertz (Hz). Full 
NMR assignment was performed with the aid of multidimensional and long range 
experiments. Infrared (IR) spectra were recorded on a Perkin-Elmer 1605 Fourier 
transform spectrometer or a Perkin-Elmer spectrum 100 FT-IR spectrometer as thin 
films. High resolution mass spectra were recorded on either a Thermo Finnigan 
MAT900xp (CI, EI) or a MALDI microMX (TOF) mass spectrometer. Melting points 
were determined using a Gallenkamp heating block and are uncorrected. 
All labelling reactions were performed manually using [18F]fluoride in [18O]H2O. 
Radio-HPLC was performed with an Agilent 1200 HPLC system equipped with a 
1200 Series Diode Array Detector and a GABI Star NaI (Tl) scintillation detector. 
The system was used for purification as well as characterization of the radiotracer. 
The decay-corrected isolated RCY was calculated by relating the amount of isolated 
radioactive product to the initial amount of [18F]fluoride in [18O]H2O. The analytical 
RCY was determined by integrating the area under the curve in the preparative 
radio-HPLC chromatogram. No corrections were made to account for losses during 
the preparative procedure. 
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8.1.1. Synthesis of N-substitued-4-imino-1,4-dihydroquinolines. 
 
Route A: 
 
Scheme 30. Synthesis of N-substituted-4-imino-1,4-dihydorquinolines from 4-
chloroquinolines. 
Reagents and Conditions: (i) 90-120 °C, 2-48 h; (ii) Acetic anhydride, DCM, 0 °C → rt, 3 h; 
(iii) DAST, DCM, 0 °C → rt, 48 h; (a) modified reaction conditions; (iv) NaI, acetone, reflux, 3-
18 h. 
 
(4-alkylamino)quinoline intermediates 3 - 18: 
(7-Chloro-quinolin-4-yl)-pentyl-amine (3) 
White feathery solid 
 Chemical formula: C14H17ClN2 
 Molecular weight: 248.75 g.mol-1 
 Yield: 96% 
A solution of 4,7-dichloroquinoline (1.00 g, 0.05 mol) in amylamine (2.70 ml, 0.15 
mol) was heated at 120 oC to reflux for 18 h under Ar atmosphere. The resulting 
solution was allowed to cool at R.T. and was then transferred to ice/water (~40 cm3) 
while stirring vigorously. The precipitate formed was filtered, washed with water (2 x 
15 ml) and pentane (2 x 15 ml) and dried in vacuo to afford pure 3 as a white 
feathery solid (1.19 g, 96%). 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.53 (1H, d, J= 5.3, CH-2), 7.96 (1H, d, J= 2.2, CH-8), 
7.66 (1H, d, J= 9.0, CH-5), 7.36 (1H, dd, J= 9.0, 2.2, CH-6), 6.39 (1H, d, J= 5.3, CH-3), 7.98 
(1H, t, J= 5.1, NH), 3.30 (2H, td, J= 7.3, 5.1, NHCH2), 1.77 (2H, qn, J= 7.3, NHCH2CH2), 
1.47-1.35 (4H, m, CH2CH2CH3), 0.95 (3H, t, J= 7.2, CH3) 
13
C NMR (150 MHz, CDCl3) δ ppm: 152.0 (CH-2), 149.9 (CQ-4), 149.1 (CQ-8’), 134.9 (CQ-7), 
128.8 (CH-8), 125.3 (CH-6), 120.9 (CH-5), 117.6 (CQ-4’), 99.1 (CH-3), 43.3 (NHCH2), 29.3 
(CH2CH2CH3), 28.7 (NHCH2CH2), 22.6 (CH2CH3), 14.1 (CH3) 
HRMS (CI) m/z: Calcd. [M-H]
+
 249.1159 
 Measured  249.1160 
LRMS (CI) m/z:  251 (32), 249 (100, [M-H]
+
) 
IR vmax (neat/cm
-1
): 3205 (N-H), 3058 (Ar C-H), 2920 (Alkyl C-H), 2854, 1573 (Ar C=C) 
m.p.: 117 - 118 
o
C  
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(7-Chloro-quinolin-4-yl)-(2-ethoxy-ethyl)-amine (4) 
Off white powder 
 Chemical formula: C13H15ClN2O 
 Molecular weight: 250.72 g.mol-1 
 Yield: quantitative 
A solution of 4,7-dichloroquinoline (0.40 g, 2.02 mmol) in 2-ethoxyethylamine (1 ml, 
9.54 mmol) was heated at 120 oC to reflux for 5 h under Ar atmosphere. The 
resulting solution was allowed to cool at R.T. and was then transferred into an 
ice/water mixture (~20 cm3) whilst stirring vigorously. The resulting off-white 
precipitate was filtered, washed with water (2 x 15 ml) and pentane (2 x 15 ml) and 
dried in vacuo to afford pure 4 as an off white powder (0.52 g, quantitative yield). 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.53 (1H, d, J= 5.3, CH-2), 7.96 (1H, d, J= 2.3, CH-8), 
7.69 (1H, d, J= 8.9 CH-5), 7.37 (1H, dd, J= 8.9, 2.3, CH-6), 6.41 (1H, d, J= 5.3, CH-3), 5.47 
(1H, b, s, NH), 3.76 (2H, t, J= 5.4, NHCH2CH2), 3.59 (2H, q, J= 7.0, OCH2CH3), 3.47 (2H, q, 
J= 5.4, NHCH2), 1.26 (3H, t, J= 7.0, CH3)  
13
C NMR (150 MHz, CDCl3) δ ppm: 152.1 (CH-2), 149.9 (CQ-4), 149.1 (CQ-8’), 135.0 (CQ-7), 
128.8 (CH-8), 125.5 (CH-6), 121.2 (CH-5), 117.4 (CQ-4’), 99.4 (CH-3), 68.0 (NHCH2CH2), 
66.8 (OCH2CH3), 42.9 (NHCH2), 15.3 (CH3) 
HRMS (CI) m/z:  Calcd. [M-H]
+
 251.0951 
    Measured 251.0954 
LRMS (CI) m/z:  253 (33), 251 (100, [M-H]
+
) 
IR vmax (neat/cm
-1
): 3234 (NH), 2965 (Alkyl C-H), 2855, 2799, 1607, 1578 (Ar C=C), 
1546 
m.p.: 114 –115 
o
C 
 
 
N1-(7-chloroquinolin-4-yl)ethane-1,2-diamine (5) 
White powder 
 Chemical formula: C11H12ClN3 
 Molecular Weight: 221.69 g.mol-1 
 Yield: 90% 
A mixture of 4,7-dichloroquinoline (1.50 g, 7.57 mmol) and ethylenediamine (2.81 
ml, 42.05 mmol) was heated to reflux at 110 °C for 5 h. After cooling at R.T., the 
mixture was poured onto an ice (~50 cm3) and NaOH (2M, 50 ml) mixture while 
stirring vigorously. The precipitate formed was filtered, was washed with water (2 x 
100 ml) and pentane (2 x 100 ml) and was dried in vacuo to afford 5 as white solid 
(1.52 g, 90%). 
1
H NMR (600 MHz, DMSO-d6) δ ppm: 8.37 (1H, d, J= 5.3, CH-2), 8.27 (1H, d, J= 9.0, CH-5), 
7.77 (1H, d, J= 2.6, CH-8), 7.43 (1H, dd, J= 9.0, 2.6, CH-6), 7.32 (1H, s, br, NH), 6.50 (1H, d, 
J= 5.3, CH-3), 3.31-3.23 (2H, m, NHCH2), 2.84 (2H, t, J= 6.5, CH2NH2), (NH2 hidden below 
H2O peak) 
13
C NMR (150 MHz, DMSO-d6) δ ppm: 151.9 (CH-2), 150.3 (CQ-4), 149.0 (CQ-8’), 133.5 (CQ-
7), 127.4 (CH-8), 124.2 (CH-5), 124.1 (CH-6), 117.4 (CQ-4’), 98.7 (CH-3), 45.4 (NHCH2), 
39.7 (CH2NH2) 
HRMS (EI) m/z: Calcd. [M]
+   
221.0714 
 Measured     221.0716 
LRMS (EI) m/z:  223 (7), 221 (21, [M]
+
), 193 (37), 192 (53), 191 (100, [M-CH2NH2]
+
), 163 
(51), 156 (74, [M-CH2NH2-Cl]
+
), 155 (71), 135 (38) 128 (21)  
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2-(7-Chloro-quinolin-4-ylamino)-ethanol (6) 
White feathery solid 
 Chemical formula: C11H11ClN2O 
 Molecular Weight: 222.67 g.mol-1 
 Yield: 91% 
A solution of 4,7-dichloroquinoline (1.50 g, 7.57 mmol) in ethanolamine (15 ml, 0.25 
mol) was heated at 120 oC under argon atmosphere for 3 h. After cooling at R.T., 
the solution was transferred to an ice/water mixture (~40 cm3) while stirring 
vigorously. The precipitate formed was filtered, washed with water (3 x 10 ml) and 
pentane (3 x 10 ml), and dried in vacuo to afford pure 6 as a white feathery solid 
(1.53 g, 91%). 
1
H NMR (600 MHz, DMSO-d6) δ ppm: 8.38 (1H, d, J= 5.4, CH-2), 8.26 (1H, d, J= 9.0, CH-5), 
7.78 (1H, d, J= 2.0, CH-8), 7.44 (1H, dd, J= 9.0, 2.0, CH-6), 7.30 (1H, t, J= 5.7, NH), 6.49 
(1H, d, J= 5.4, CH-3), 4.89 (1H, br, s, OH), 3.65 (2H, t, J= 5.7, CH2OH), 3.35 (2H, q, J= 5.7, 
NHCH2) 
13
C NMR (150 MHz, DMSO-d6) δ ppm: 151.9 (CH-2), 150.3 (CQ-4), 149.1 (CQ-8’), 133.40 
(CQ-7), 127.5 (CH-8), 124.1 (CH-5), 124.0 (CH-6), 117.5 (CQ-4’), 98.7 (CH-3), 58.7 (CH2OH), 
45.2 (NHCH2) 
HRMS (EI) m/z: Calcd. [M]
+   
   222.0560 
 Measured      222.0565 
LRMS (EI) m/z:  224 (16), 222 (55, [M]
+
), 193 (30), 191 (91, [M-CH2OH]
+
), 156 (100, [M-
CH2OH-Cl]
+
), 155 (76), 135 (21), 99 (21) 
IR vmax (neat/cm
-1
): 3300 (OH), 3062 (Ar C-H), 2960 (Alkyl C-H), 2811, 1575 (Ar C=C), 
1535 (Ar C=C) 
m.p.: 218 - 219 
o
C 
 
 
(7-Chloro-quinolin-4-yl)-phenyl-amine (7) 
Pale pink powder 
 Chemical formula: C15H11ClN2 
 Molecular Weight: 254.71 g.mol-1 
 Yield: 60% 
 
A solution of 4,7-dichloroquinoline (0.40 g, 2.00 mmol) in aniline (0.82 ml, 9.00 
mmol), was heated at 110 oC for 1.5 h. The resulting mixture was cooled at R.T. and 
was then poured onto ice/water (~20 cm3) while stirring vigorously. The resulting 
precipitate was filtered, washed with water and pentane and dried in vacuo to afford 
pure 7 (0.31 g, 60%) as pale pink powder. 
1
H NMR (600 MHz, DMSO-d6) δ ppm: 9.63 (1H, s, br, NH), 8.52 (1H, d, J= 9.0, CH-5), 8.48 
(1H, d, J= 5.8, CH-2), 7.94 (1H, d, J= 2.2, CH-8), 7.66 (1H, dd, J= 9.0, 2.2, CH-6), 7.48 (2H, 
t, J= 7.8, meta Ph-CH), 7.40 (2H, d, J= 7.8, ortho Ph-CH), 7.25 (1H, t, J= 7.8, para Ph-CH), 
6.89 (1H, d, J= 5.8, CH-3) 
13
C NMR (150 MHz, DMSO-d6) δ ppm: 149.8 (CH-2), 146.8 (CQ-4), 139.3 (Ph-CQ), 135.1 
(CQ-7), 129.7 (meta Ph-CH), 125.6 (CH-6 or CH-8), 125.5 (CH-6 or CH-8), 125.1 (para Ph-
CH), 124.9 (CH-5), 123.4 (ortho Ph-CH), 117.7 (CQ-4’), 101.4 (CH-3), [CQ-8’ hidden] 
HRMS (CI) m/z: Calcd. [M-H]
+
 255.0689  
   Measured  255.0686 
LRMS (CI) m/z:  257 (34), 255 (98, [M-H]
+
), 219 (30, [M-Cl]
+
) 
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IR vmax (neat/cm
-1
): 3165 (NH), 3096 (Ar C-H), 3048, 2995, 2939, 1607 (C=N-), 1591, 
1562 (Ar C=C) 
m.p.: 190 – 191
o
C 
 
 
Benzyl-(7-chloro-quinolin-4-yl)-amine (8) 
Pale yellow solid 
 Chemical formula: C16H13ClN2 
 Molecular Weight: 268.74 g.mol-1 
 Yield: 35% 
To 4,7-dichloroquinoline (0.40 g, 1.61 mmol), benzylamine (0.90 ml, 8.25 mmol) was 
added and the resulting solution  was stirred at 90 oC for 24 h. After cooling at R.T, 
the solution was transferred in ice/water (~40 cm3) and the mixture was stirred for 15 
min. The pale brown precipitate was filtered and was washed with water (2 x 25 ml) 
and pentane (2 x 25 ml). Purification via flash column chromatography (1:1 
EtOAc:petroleum ether) afforded pure 8 as a pale yellow solid (0.15 g, 35 %). 
1
H NMR (CDCl3, 500 MHz) δ ppm: 8.45 (1H, d, J= 5.5, CH-2) 7.99 (1H, d, J= 2.0, CH-8) 7.84 
(1H, d, J= 8.9, CH-5) 7.30-7.42 (6H, m, CH-6, Ph-CH), 6.43 (1H, d, J= 5.5, CH-3), 5.98 (1H, 
s, br, NH), 4.56 (2H, d, J= 4.9, NHCH2) 
 13
C NMR (CDCl3, 125 MHz) δ ppm: 150.8, 150.4, 147.8, 137.0, 135.6, 129.1, 128.1, 127.8, 
127.6, 125.9, 121.6, 117.0, 99.6, 47.6 
HRMS (ES+) m/z: Calcd. [M-H]
+
 269.0846  
   Measured  269.0839 
LRMS (ES+) m/z:  271 (35), 269 (100, [M-H]
+
) 
m.p.: 166 - 167 
o
C 
 
 
Pentyl-quinolin-4-yl-amine (9) 
White powder 
 Chemical formula: C14H18N2 
 Molecular Weight: 214.31 g.mol-1 
 Yield: 88% 
A solution of 4-chloroquinoline (1.00 g, 6.11 mmol) in amylamine (3.90 ml, 33.62 
mmol) was heated at 110 oC for 24 h under Ar atmosphere. The solution was 
allowed to cool at R.T. and was then transferred to an ice/water mixture (~40 cm3) 
while stirring vigorously. The precipitate formed was filtered, was washed with water 
(2 x 20 ml) and pentane (2 x 20 ml), and was dried in vacuo to afford pure 9 as a 
white powder (1.15 g, 88%). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 8.56 (1H, d, J= 5.3, CH-2), 7.98 (1H, d, J= 8.4, CH-5), 
7.73 (1H, d, J= 8.4, CH-8), 7.63 (1H, ddd, J= 8.4, 6.8, 1.5, CH-6), 7.43 (1H, ddd, J= 8.4, 6.8, 
1.5, CH-7), 6.43 (1H, d, J= 5.3, CH-3), 5.04 (1H, t, J= 5.2, NH), 3.32 (2H, td, J= 7.2, 5.2, 
NHCH2), 1.78 (2H, qn, J= 7.2, NHCH2CH2), 1.49-1.36 (4H, m, CH2CH2CH3), 0.95 (3H, t, J= 
7.2, CH3) 
13
C NMR (150 MHz, CDCl3) δ ppm: 151.2 (CH-2), 149.8 (CQ-4), 148.5 (CQ-8’), 130.1 (CH-5), 
129.1 (CH-6), 124.7 (CH-7), 119.3 (CH-8), 118.8 (CQ-4’), 98.9 (CH-3), 43.4 (NCH2), 29.4 
(CH2CH2CH3), 28.8 (NCH2CH2), 22.6 (CH2CH3), 14.2 (CH3) 
HRMS (EI) m/z: Calcd. [M]
+
 214.1464 
   Measured   214.1471 
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LRMS (EI) m/z:  214 (27, [M]
+
), 157 (100, [M-CH2(CH2)2CH3]
+
), 156 (22) 
m.p.: 102 – 103 
o
C 
 
 
N-benzylquinolin-4-amine (10) 
Pale yellow solid 
Chemical Formula: C16H14N2 
Molecular Weight: 234.30 
Yield: 90% 
A solution of 4-chloroquinoline (0.46 g, 2.84 mmol) in benzylamine (1.70 ml, 16.49 
mmol) was heated at 110 °C for 24 h. After cooling to room temperature, the 
solution was poured into ice (~100 cm3) while stirring vigorously. The organic 
products were extracted with DCM (2 x 100 ml), the organic extracts were dried over 
anh. MgSO4 and were evaporated in vacuo. Purification via column chromatography 
(1:19 MeOH:EtOAc) afforded 10 (0.60 g, 90%) as pale yellow solid. 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.55 (1H, d, J= 5.3, CH-2), 8.01 (1H, dd, J= 8.5, 1.4, CH-
8), 7.77 (1H, dd, J= 8.5, 1.4, CH-5), 7.65 (1H, td, J= 8.5, 1.4, CH-7), 7.46-7.42 (1H, m, CH-
6), 7.42-7.37 (4H, m, ortho Ph-CH, meta Ph-CH), 7.36-7.32 (1H, m, para Ph-CH), 6.46 (1H, 
d, J= 5.3, CH-3), 5.39 (1H, s, br, NH), 4.54 (2H, d, J= 5.3, CH2) 
13
C NMR (150 MHz, CDCl3) δ ppm: 151.2 (CH-2), 149.5 (CQ-4), 148.5 (CQ-8’), 137.6 (Ph-
CQ), 130.2 (CH-8), 129.2 (CH-7), 129.1 (meta Ph-CH), 128.0 (para Ph-CH), 127.7 (ortho Ph-
CH), 124.9 (CH-6), 119.4 (CH-5), 118.8 (CQ-4’), 99.5 (CH-3), 47.69 (CH2) 
HRMS (CI) m/z: Calcd. [M+H
+
] 235.1230 
   Measured  235.1231 
LRMS (CI) m/z:  235 (100, [M+H]
+
) 
IR vmax (neat/cm
-1
): 3190 (N-H), 3057 (Ar C-H), 3019, 2971, 2911, 1567 (Ar C=C), 1536 
m.p.: 130 – 131 °C 
 
 
(7-Methoxy-quinolin-4-yl)-pentyl-amine (11) 
Beige solid 
Chemical formula: C15H20N2O 
Molecular weight: 244.34 g.mol-1 
Yield: 81% 
A solution of 4-chloro-7-methoxyquinoline (0.50 g, 2.58 mmol) in amylamine (2.45 
ml, 21.08 mmol) was heated to reflux at 110 °C for 48 h. After cooling at ambient 
temperature, the mixture was poured onto an ice (~ 100 cm3) and NaOH (100 ml, 
2M) mixture while stirring vigorously. The precipitate formed was filtered, was 
washed with water (2 x 100 ml) and petrol (2 x 100 ml) and was dried in vacuo to 
afford 11 as beige solid (0.51 g, 81%). 
1
H NMR (CDCl3, 400 MHz) δ ppm: 8.49 (1H, d, J= 5.4, CH-2), 7.63 (1H, d, J= 9.2, CH-5), 
7.35 (1H, d, J= 2.6, CH-8), 7.08 (1H, dd, J= 9.2, 2.6, CH-6), 6.36 (1H, d, J= 5.4, CH-3), 4.91 
(1H, s, br, NH), 3.94 (3H, s, OCH3), 3.55-3.28 (2H, m, NCH2), 1.77 (2H, q, J= 7.3, 
NCH2CH2), 1.52-1.37 (4H, m, CH2CH2CH3), 0.96 (3H, t, J= 7.1, CH3) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 160.3 (CQ-7), 151.5 (CH-2), 150.4 (CQ-4 or CQ-8’), 149.9 
(CQ-4 or CQ-8’), 120.6 (CH-5), 117.1 (CH-6), 113.3 (CQ-4’), 108.3 (CH-8), 98.0 (CH-3), 55.5 
(OCH3), 43.3 (NHCH2), 29.4 (CH2CH2CH3), 28.9 (NHCH2CH2), 22.6 (CH2CH3), 14.2 
(CH2CH3) 
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HRMS (EI) m/z: Calcd. [M+H]
+ 
244.1570 
 Measured     244.1567 
LRMS (EI) m/z:  244 (13, [M]
+
), 187 (13, [M-CH2(CH2)2CH3]
+
), 88 (11), 86 (65, 
[NHCH2(CH2)3CH3]
+
), 84 (100) 
IR vmax (neat/cm
-1
): 3357 (N-H), 3078, (Ar C-H), 2999, 2958, 2931, 2858 (aliphatic C-H), 
1618 (C=N), 1583, 1535 
m.p.: 118-119 °C 
 
 
N-[2-(7-Chloro-quinolin-4-ylamino)-ethyl]-acetamide (12) 
White powder 
 Chemical formula: C13H14ClN3O 
 Molecular Weight: 263.72 g.mol-1 
 Yield: 85% 
To 5 (1.52 g, 6.85 mmol) and NEt3 (2.60 ml, 18.50 mmol) in DCM (3 ml) at 0 °C, 
acetic anhydride (0.84 ml, 8.87 mmol) was added under argon atmosphere. The 
mixture was stirred at 0 °C for 1 h and then at ambient temperature for 2 h further. 
NaHCO3 (1 M, 15 ml) was added to the reaction mixture. The organic products were 
extracted with EtOAc (3 x 15 ml) and the organic extracts were dried over anh. 
MgSO4 and evaporated in vacuo to afford 12 as white crystalline solid (1.55 g, 85%). 
1
H NMR (600 MHz, DMSO-d6) δ ppm: 8.40 (1H, d, J= 5.4, CH-2), 8.18 (1H, d, J= 9.0, CH-5), 
8.13 (1H, s, br, NHCOCH3), 7.79 (1H, d, J= 2.4, CH-8), 7.46 (1H, dd, J= 9.0, 2.4, CH-6), 7.43 
(1H, s, br, NHCH2CH2NHCO), 6.53 (1H, d, J= 5.4, CH-3), 3.35-3.29 (4H, m, NHCH2CH2), 
1.83 (3H, s, CH3) 
13
C NMR (150 MHz, DMSO-d6) δ ppm: 170.0 (C=O), 152.0 (CH-2), 150.0 (CQ-4), 149.1 (CQ-
8’), 133.4 (CQ-7), 127.6 (CH-8), 124.2 (CH-5 or CH-6), 123.9 (CH-5 or CH-6), 117.4 (CQ-4’), 
98.6 (CH-3), 42.3 (NHCH2 or NHCH2CH2), 37.3 (NHCH2 or NHCH2CH2), 22.7 (CH3) 
HRMS (EI) m/z: Calcd. [M]
+   
263.0820 
 Measured     263.0807 
LRMS (EI) m/z:  265 (17), 263 (50, [M]
+
), 205 (19), 205 (20), 204 (56), 193 (33), 191 
(100, [M-CH2NHCOCH2]
+
), 156 (41, [M-CH2NHCOCH2-Cl]
+
), 155 (22), 
135 (11) 
IR vmax (neat/cm
-1
): 3323 (N-H), 3181 (N-H), 2951 (Ar C-H), 2929, 2845 (Alkyl C-H), 1645 
(C=N), 1607, 1577 (Ar C=C), 1543 
m.p.: 215 – 216 °C 
 
 
(7-Chloro-quinolin-4-yl)-(2-fluoro-ethyl)-amine (13) 
Off white powder 
Chemical formula: C11H10ClFN2 
Molecular weight: 224.66 g.mol-1 
Yield: 63% 
To a suspension of 6 (0.30 g, 1.35 mmol) in anhydrous DCM (5 ml) cooled at 0 oC, 
DAST (0.60 ml, 4.71 mmol) was added under Ar atmosphere. The resulting mixture 
was stirred at R.T. for 2 days. The reaction was quenched at 0 oC by the slow 
addition of cold NaOH (1M, 15 ml). The organic products were extracted with DCM 
(3 x 20 ml). The organic extracts were dried over anh. Na2SO4 and concentrated in 
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vacuo. The resulting precipitate was purified by flash column chromatography 
(EtOAc) to afford pure 13 (0.19 g, 63%) as an off white powder. 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.58 (1H, d, J= 5.3, CH-2), 7.99 (1H, d, J= 2.2, CH-8), 
7.71 (1H, d, J= 9.0, CH-5), 7.39 (1H, dd, J= 9.0, 2.2, CH-6), 6.45 (1H, d, J= 5.3, CH-3), 5.37 
(1H, br, s, NH), 4.77 (2H, dt, 
2
JHF= 46.9 
3
JHH= 5.0, CH2F), 3.66 (2H, dq, 
3
JHF= 26.8 
3
JHH= 5.0, 
NHCH2) 
13
C NMR (150 MHz, CDCl3) δ ppm: 152.0 (CH-2), 149.4 (CQ-4 or CQ-8’), 149.2 (CQ-4 or CQ-
8’), 135.2 (CQ-7), 128.9 (CH-8), 125.8 (CH-6), 121.0 (CH-5), 117.3 (CQ-4’), 99.3 (CH-3), 81.7 
(d, 
1
JCF= 168.1, CH2F), 43.5 (d, 
2
JCF= 20.3, CH2CH2F) 
19
F NMR (282 MHz, CDCl3) δ ppm: -224.24 
HRMS (EI) m/z: Calcd. [M]
+
 224.0511 
    Measured 224.0509 
LRMS (EI) m/z:  226 (26), 224 (100, [M]
+
), 193 (28), 191 (81, [M-CH2F]
+
), 156 (75, 
[M-CH2F-   Cl]
+
), 155 (49), 88 (66) 
IR vmax (neat/cm
-1
): 3213 (NH), 3053(C=CH), 3001, 2964 (Alkyl C-H), 1608, 1578 (Ar 
C=C), 1542 
m.p.: 165-166 
o
C 
 
 
7-chloro-N-(2,2,2-trifluoroethyl)quinolin-4-amine (14) 
White crystalline solid 
 Chemical formula: C11H8ClF3N2 
 Molecular Weight: 260.64 g.mol-1 
 Yield: 92% 
A mixture of 4,7-dihydroquinoline (0.40 g, 2.01 mmol), 2,2,2-trifluroethylamine 
hydrochloride (1.37 g, 10.1 mmol) and triethylamine (1.27 ml, 10.1 mmol) in DMF 
(1.5 ml) was heated at 100 oC for 4 h. The resulting solution was allowed to cool at 
R.T. and was then transferred to an ice/water (~30 cm3) and NaOH mixture (2M, 5 
ml) while stirring vigorously. The precipitate formed was filtered, was washed with 
water (2 x 10 ml) and pentane (2 x 10 ml) and was dried in vacuo to afford a white 
solid. Re-crystallization (CHCl3, MeOH) afforded pure 14 as a white crystalline solid 
(0.47 g, 92%). 
1
H NMR (600 MHz, DMSO-d6) δ ppm: 8.49 (1H, d, J= 5.4, CH-2), 8.31 (1H, d, J= 9.1, CH-5), 
7.86 (1H, d, J= 2.3, CH-8), 7.80 (1H, t, J= 6.7, NH), 7.53 (1H, dd, J= 9.1, 2.3, CH-6), 6.83 
(1H, d, J= 5.4, CH-3), 4.24 (2H, qd, 
3
JCF= 9.9, 
3
JHH=6.7, NHCH2) 
13
C NMR (150 MHz, DMSO-d6) δ ppm: 151.9 (CH-2), 149.7 (CQ-4), 149.0 (CQ-8’), 133.8 (CQ-
7), 127.7 (CH-8), 125.5 (q, 
1
JCF= 279.9, CF3), 124.9 (CH-6), 123.9 (CH-5), 117.3 (CQ-4’), 
99.9 (CH-3), 43.2 (q, 
2
JCF= 32.8, NCH2) 
19
F NMR (282 MHz, DMSO-d6) δ ppm: -69.8 
HRMS (ES+) m/z: Calcd. [M-H]
+
 261.0406  
   Measured  261.0414 
LRMS (ES+) m/z:  263 (28), 261 (98, [M-H]
+
) 
m.p.: 201 - 202 
o
C 
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3-azido-1,3,4,5-tetrahydro-2H-benzo[b]azepin-2-one (16) was synthesized by 
PDRA Dr. Carlos Perez Medina according to a previously described procedure.154 
 
 
3-amino-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one (17) 
White powder 
 Chemical formula: C10H10N2O 
 Molecular Weight: 176.21 g.mol-1 
 Yield: 61% 
 
To a solution of 16 (0.60 g, 2.97 mol) and NH4Cl (0.37 g, 7.00 mmol), in EtOH (8 ml) 
and H2O (2.7 ml), zinc powder (0.26 g, 4.00 mmol) was added and the resulting 
mixture was heated to reflux at 80 oC for 20 min with vigorous stirring. After cooling 
at R.T., EtOAc (15 ml) was added followed by NH3 (aq., 32%, 1 ml). The mixture 
was filtered, and the filtrate was washed with brine and dried over anh. Na2SO4. The 
solvents were evaporated in vacuo to afford pure 17 as a white powder (0.32 g, 
61%). 
1
H NMR (600 MHz, CDCl3) δ ppm: 7.83 (1H, s, br, NH-1), 7.22-7.23 (2H, m, CH-6, CH-8), 
7.14 (1H, td, J= 7.5, 1.4, CH-7), 6.99 (1H, dd, J= 8.3, 1.1, CH-9), 3.43 (1H, dd, 
3
JH-3, H-4 AXIAL= 
11.4, 
3
JH-3, H-4 EQUATORIAL= 8.1, CH-3), 2.92 (1H, td, 
2
JH5-AX, H5-EQ= 13.6, 
3
JH5-AX, H4-AX= 13.6, 
3
JH5-
AX, H4-EQ= 7.8, CH-5AX), 2.65 (1H, dd, 
2
JH5-AX, H5-EQ= 13.9, 
3
JH5-EQ, H4-AX= 7.8, CH-5EQ), 2.52 (1H, 
tt, 
2
JH4-AX, H4-EQ= 13.1, 
3
JH4-AX, H5-AX= 13.6, 
3
JH4-AX, H5-EQ= 7.6, 
3
JH4-AX, H3= 7.6, CH-4AX), 1.93 (1H, 
ddd, 
2
JH4-AX, H4-EQ= 13.0, 
3
JH4-EQ, H3= 11.5, 
3
JH4-EQ, H5-AX= 7.9), 1.64 (2H, s, br, NH2) 
13
C NMR (150 MHz, CDCl3) δ ppm: 177.1 (CQ-2), 136.7 (CQ-9’), 134.7 (CQ-5’), 129.8 (CH-6), 
127.7 (CH-8), 126.2 (CH-7), 122.1 (CH-9), 51.6 (CH-3), 39.2 (CH2-4), 29.16 (CH2-5) 
HRMS (EI) m/z: Calcd. [M]
+   
 176.0944 
 Measured    176.0947 
LRMS (EI) m/z:  176 (36, [M]
+
), 159 (45), 147 (17, [M-CH2NH2]
+
), 130 (100), 118 (21), 
106 (52) 
IR vmax (neat/cm
-1
): 3356 (NH2), 3296, 3025 (Ar C-H), 2945, 2849 (Alkyl C-H), 1662, 1582 
m.p.: 160-162 
o
C 
 
 
3-((7-chloroquinolin-4-yl)amino)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one (18) 
Beige powder 
 Chemical formula: C19H16ClN3O 
 Molecular Weight: 337.80 g.mol-1 
 Yield: 26% 
 
To a mixture of 17 (0.19 g, 1.11 mmol) and 4,7-dichloroquinoline (0.22 g, 1.11 
mmol) in DMF (1.5 ml), NEt3 (0.30 ml, 2.16 mmol) was added and the resulting 
mixture was heated at 150 °C for 18 h. After cooling at R.T. the mixture was poured 
onto an ice (~30 cm3) and NaOH (2M, 20 ml) mixture and was stirred for 15 min. 
The precipitate formed was filtered and was washed with water (2 x 50 ml) and 
pentane (2 x 50 ml). Purification via flash column chromatography (EtOAc → 1:20 
MeOH:EtOAc) afforded 18 as a beige solid (97 mg, 26%). 
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1
H NMR (600 MHz, DMSO-d6) δ ppm: 10.03 (1H, s, NHCO), 8.42 (1H, d, J= 9.0, quin CH-5), 
8.34 (1H, d, J= 5.4, quin CH-2), 7.80 (1H, d, J= 2.3, quin CH-8), 7.50 (1H, dd, J= 9.0, 2.3, 
quin CH-6), 7.34 (1H, dd, J= 7.6, 1.6, bnza CH-6), 7.33-7.29 (2H, m, CHNH, bnza CH-8), 
7.17 (1H, td, J= 7.6, 1.6, bnza CH-7), 7.13 (1H, dd, J= 7.6, 1.6, bnza CH-9), 5.93 (1H, d, J= 
5.4, quin CH-3), 4.06 (1H, dt, J= 11.3, 7.7, bnza CH-3), 2.85-2.78 (2H, m, bnza CH2-5), 2.61-
2.51 (2H, m, bnza CH2-4) 
13
C NMR (150 MHz, DMSO-d6) δ ppm: 171.2 (CQ=O), 151.9 (quin CH-2), 149.6 (quin CQ-4), 
149.0 (quin CQ-8’), 137.6 (bnza CQ-9’), 133.6 (bnza CQ-5’ and quin CQ-7), 129.7 (bnza CH-6), 
127.6 (bnza CH-8), 127.5 (quin CH-8), 125.3 (bnza CH-7), 124.6 (quin CH-5), 124.4 (quin 
CH-6), 122.1 (bnza CH-9), 117.5 (quin CQ-4’), 99.6 (quin CH-3), 52.8 (bnza CH-3), 34.6 
(bnza CH2-4), 28.2 (bnza CH2-5) 
HRMS (EI) m/z: Calcd. [M]
+   
 337.0976 
 Measured    337.0973 
LRMS (EI) m/z:  339 (17), 337 (44, [M]
+
), 132 (100) 
IR vmax (neat/cm
-1
): 3361 (N-H), 3039 (Ar C-H), 2955, 2850 (Alkyl C-H), 1664 (C=N-), 1609, 
1579 (Ar C=C), 1535 
 
 
4-Imino-1,4-dihydroquinolines 19 - 32: 
(E)-N-(1-benzyl-7-chloroquinolin-4(1H)-ylidene)-2-ethoxyethanamine (19) 
  
 Dark yellow/orange crystals 
 Chemical formula: C20H21ClN2O 
 Molecular weight: 340.85 g.mol-1 
 Yield: 17% 
 
To a solution of 4 (0.60 g, 2.40 mmol) and NaI (0.43 g, 2.86 mmol) in acetone (5 ml), 
benzyl bromide (0.30 ml, 2.64 mmol) was added and the resulting mixture was 
heated to reflux at 80 oC for 12 h under Ar atmosphere. The solution was allowed to 
cool at R.T and was then transferred to an ice/water (~30 cm3) and NaOH (2 M, 20 
ml) mixture whilst stirring vigorously. The precipitate formed was filtered, washed 
with water (2 x 20 ml) and pentane (2 x 20 ml), and dried in vacuo. Recrystallization 
(CH3CN: petroleum ether) afforded pure 19 as dark yellow/orange crystals (0.14 g, 
17%). 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.44 (1H, d, J= 8.6, CH-5), 7.35 (2H, t, J= 7.4, meta Ph-
CH), 7.30 (1H, t, J= 7.4, para Ph-CH), 7.17 (2H, d, J= 7.4, ortho Ph-CH), 7.12 (1H, d, J= 8.6, 
CH-6), 7.02 (1H, d, J= 7.9, CH-2), 7.00 (1H, s, CH-8), 6.07 (1H, d, J= 7.9, CH-3), 5.04 (2H, 
s, CH2Ph), 3.82 (2H, t, J= 6.8, NCH2CH2), 3.62 (2H, q, J= 7.0, CH2CH3), 3.53 (2H, t, J= 6.8, 
NCH2CH2), 1.24 (3H, t, J= 7.0, CH3) 
13
C NMR (150 MHz, CDCl3) δ ppm: 154.9 (CQ-4), 139.6 (CQ-7), 139.5 (CH-2), 136.5 (CQ-8’), 
135.5 (Ph-CQ), 129.3 (meta Ph-CH), 128.3 (para Ph-CH), 127.4 (CH-5), 126.2 (ortho Ph-
CH), 123.8 (CH-6), 114.9 (CH-8), 99.9 (CH-3), 71.6 (NCH2CH2), 66.7 (CH2CH3), 55.6 
(CH2Ph), 50.0 (NCH2CH2), 15.4 (CH3), (CQ-4’ hidden) 
HRMS (ES+) m/z: Calcd. [M-H]
+
 341.1404 
   Measured 341.1421 
LRMS (ES+) m/z:  343 (35), 341 (100, [M-H]
+
) 
IR vmax (neat/cm
-1
): 3031 (Ar C-H), 2967 (Alkyl C-H), 2901, 2824, 1635 (C=N-), 1596            
(Ar C=C), 1569 
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m.p.: 111-112 
o
C 
 
 
(E)-N,1-dibenzyl-7-chloroquinolin-4(1H)-imine hydroiodide (20) 
Dark yellow crystals 
 Chemical formula: C23H19Cl2 ∙ HI 
 Molecular Weight: 486.78 g.mol-1 
 Yield: 98% 
 
 
To a solution of 8 (0.90 g, 3.35 mmol) and NaI (0.60g, 4.02 mmol) in acetone (15 
ml), benzyl bromide (0.44 ml, 3.70 mmol) was added and the mixture was heated at 
60 °C for 18 h. The mixture was allowed to cool to ambient temperature and was 
then poured into an ice (~ 100 cm3) and NaOH (2M, 100 ml), mixture while stirring 
vigorously. The precipitate formed was filtered, was washed with water (2 x 100 ml) 
and petrol (2 x 100 ml) and was dried in vacuo. Recrystallization (MeOH) afforded 
the hydroiodide salt 20, as yellow crystalline solid (1.60 g, 98%). 
1
H NMR (CDCl3, 600 MHz) δ ppm:
 
11.04-10.89 (1H, m, =NH
+
), 9.45 (1H, d, J= 8.9, CH-5), 
8.10-8.04 (1H, m, CH-2), 7.61 (1H, d, J= 1.9, CH-8), 7.56 (1H, dd, J= 8.9, 1.9, CH-6), 7.46 
(2H, d, J= 7.5, CH-12, CH-16), 7.41-7.35 (3H, m, CH-20, CH-22, CH-24), 7.30 (2H, t, J= 7.5, 
CH-13, CH-15), 7.26-7.22 (1H, m, CH-14), 7.16-7.13 (2H, m, CH-19, CH-23), 6.51 (1H, d, J= 
7.6, CH-3), 5.56 (2H, s, CH2-17), 4.84 (2H, d, J= 6.1, CH2-10) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 156.0 (CQ-4), 145.8 (CH-2), 141.3 (CQ-7), 138.8 (CQ-8’), 
135.6 (CQ-11), 132.5 (CQ-18), 129.9 (CH-20, CH-23), 129.5 (CH-24), 129.1 (CH-13, CH-15), 
128.9 (CH-5), 128.3 (CH-6 or CH-14), 128.1 (CH-6 or CH-14), 127.7 (CH-12, CH-16), 127.0 
(CH-19, CH-23), 117.4 (CQ-4’), 117.1 (CH-8), 99.8 (CH-3), 58.4 (CH2-17), 47.0 (CH2-10) 
HRMS (ES+) m/z: Calcd. [M+H]
+ 
359.1315 
 Measured     359.1312 
LRMS (ES+) m/z:   361 (32), 360 (26), 359 (100, [M+H]
+
), 224 (14), 220 (20), 208 (20), 196 
(13), 180 (25), 179 (38) 
IR vmax (neat/cm
-1
): 3178 (N-H), 3087 (Ar C-H), 3057, 3026, 2999, 2939, 2875 (Alkyl C-H), 
1606 (C=N), 1571 (Ar C=C), 1527 
 
 
(E)-N-(1-benzylquinolin-4(1H)-ylidene)pentan-1-amine (21) 
White solid 
 Chemical formula: C21H24N2 
 Molecular Weight: 304.43 g.mol-1 
 Yield: 86% 
 
To a solution of 9 (0.17 g, 0.80 mmol) and NaI (0.15 g, 1.00 mmol) in acetone (5 ml), 
benzyl bromide (0.1 ml, 0.88 mmol) was added and the mixture was heated to reflux 
at 70 oC for 18 hr under Ar atmosphere. The resulting solution was allowed to cool 
at R.T. and was then transferred to a mixture of ice/water (~20 cm3) and NaOH (2M, 
10 ml) while stirring vigorously. The precipitate formed was filtered, washed with 
water (3 x 15 ml) and pentane (2 x 10 ml) and was dried in vacuo to afford pure 21 
(0.21 g, 86%) as white solid.  
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1
H NMR (600 MHz, CDCl3) δ ppm: 8.65 (1H, d, J= 8.2, CH-5), 7.39-7.20 (6H, m, meta Ph-
CH, para Ph-CH, CH-2, CH-6, CH-7), 7.16 (2H, d, J= 7.6, ortho Ph-CH), 7.12 (1H, d, J= 8.5, 
CH-8), 6.14 (1H, d, J= 7.9, CH-3), 5.21 (2H, s, CH2Ph), 3.39 (2H, t, J= 7.5, NCH2), 1.76 (2H, 
qn, J= 7.5, NCH2CH2), 1.47-1.35 (4H, m, CH2CH2CH3), 0.92 (3H, t, J= 7.1, CH3) 
13
C NMR (150 MHz, CDCl3) δ ppm: 154.9 (CQ-4), 140.8 (CH-2), 138.5 (CQ-8’), 135.7 (Ph-
CQ), 131.0 (CH-7), 129.2 (meta Ph-CH), 128.2 (para Ph-CH), 126.3 (ortho Ph-CH), 125.8 
(CH-5), 124.3 (CQ-4’), 124.1 (CH-6), 115.7 (CH-8), 98.9 (CH-3), 56.2 (CH2Ph), 48.8 
(C=NCH2), 30.3 (NCH2CH2), 30.0 (CH2CH2CH3), 22.8 (CH2CH3), 14.3 (CH3) 
HRMS (EI) m/z: Calcd. [M]
+
  304.1934 
   Measured  304.1947 
LRMS (EI) m/z:  304 (27, [M]
+
), 261 (80, [M-CH2CH2CH3]
+
), 247 (100,                               
[M-CH2(CH2)2CH3]
+
), 91 (27, [PhCH2]
+
) 
IR vmax (neat/cm
-1
): 3055 (Ar C-H), 3027, 2950 (Alkyl C-H), 2922, 2851, 1615 (C=N-C), 
1571 (Ar C=C) 
m.p.: 76.5 – 77.5 
o
C 
 
 
[1- (3-Fluoro-benzyl)-1H-quinolin-4-ylidene]-pentyl-amine (22) 
 Pale yellow crystals 
 Chemical Formula: C21H23FN2 
 Molecular weight: 322.43 
 Yield: 71% 
 
 
To a solution of 9 (0.86 g, 4.01 mmol) in acetone (15 ml), 3-fluorobenzyl bromide 
(0.54 ml, 4.40 mmol) and NaI (0.78 g, 4.79 mmol) were added and the mixture was 
heated at 65 °C for 18 h. After cooling to room temperature, DCM (100 ml) was 
added and the resulting mixture was washed with water (2 x 100 ml). The organic 
solution was dried over anh. MgSO4 and evaporated in vacuo. Trituration of the 
remaining residue with petrol, afforded an off-white precipitate. The precipitate was 
dissolved in EtOH (20 ml), KOBut (0.49 g, 4.37 mmol) was added and the resulting 
solution was stirred at room temperature for 15 min. The organic product was 
extracted with DCM (2 x 25 ml), the organic extracts were dried over anh. MgSO4, 
and evaporated to dryness. Recrystallization (pentane, Et2O) afforded 22 as pale 
yellow crystals (0.92 g, 71%). 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.49 (1H, d, J= 8.0, CH-5), 7.33-7.27 (2H, m, CH-7, CH-
15), 7.17 (1H, dd, J= 8.0, 7.2, CH-6), 7.00 (1H, d, J= 8.1, CH-2), 6.99-6.90 (3H, m, CH-8, 
CH-14, CH-16), 6.87 (1H, dt, 
3
JHF= 9.6,
 4
JHH= 2.1, CH-12), 6.05 (1H, d, J= 8.1, CH-3), 5.05 
(2H, s, CH2-10), 3.36 (2H, t, J= 7.5, CH2-17), 1.76 (2H, q, J= 7.5, CH2-18), 1.49-1.36 (4H, m, 
CH2-19, CH2-20), 0.94 (2H, t, J= 7.2, CH3-21) 
13
C NMR (150 MHz, CDCl3) δ ppm: 163.3 (d, 
1
JCF= 247.6, CQ-13), 154.4 (CQ-4), 139.1 (d, 
3
JCF= 6.8, CQ-11), 139.0 (CH-2), 138.5 (CQ-8'), 130.8 (d, 
3
JCF= 8.4, CH-15), 130.2 (CH-7), 
126.0 (CQ-4’), 125.7 (CH-5), 123.4 (CH-6), 121.67 (d, 
4
JCF= 2.9, CH-16), 115.0 (d, 
2
JCF= 
21.2, CH-14), 114.9 (CH-8), 113.2 (d, 
2
JCF= 22.3, CH-12), 99.2 (CH-3), 55.1 (CH2-10), 50.3 
(CH2-17), 31.0 (CH2-18), 30.3 (CH2-19), 22.9 (CH2-20), 14.3 (CH3-21) 
19
F NMR (282 MHz, CDCl3) δ ppm: -112.13 
HRMS (ES-) m/z: Calcd. [M
+
]  322.1845 
   Measured  322.1821 
LRMS (ES-) m/z:  322 (39, [M]
+
), 321(100), 313 (14) 
Experimental 
 
150 
IR vmax (neat/cm
-1
):  2951 (Ar C-H), 2926, 2855 (Aliphatic C-H), 1612 (C=N), 1575, 1542 
m.p.: 64-65 °C 
 
 
N-(1-(3-iodobenzyl)quinolin-4(1H)-ylidene)pentan-1-amine (23) 
Pale yellow solid 
 Chemical formula: C21H23IN2 
 Molecular Weight: 430.33 g.mol-1 
 Yield: 79% 
 
 
To a solution of 9 (0.50 g, 2.33 mmol) in acetone (10 ml), 3-iodobenzylbromide (0.76 
g, 2.56 mmol) and NaI (0.39 g, 2.60 mmol) were added, and the mixture was heated 
at 65 °C for 18 h. After cooling to room temperature, the mixture was poured in ice 
(~100 cm3) and stirred vigorously for 15 min. The precipitate formed was filtered, 
and was washed with water and petrol. The precipitate was dissolved in EtOH (5 
ml), KOBut (0.36 g, 3.21 mmol) was added and the mixture was stirred at room 
temperature for 15 min. The organic products were extracted with DCM (2 x 25 ml). 
The organic extracts were dried over anh. MgSO4 and evaporated to afford 23 as 
pale yellow solid (0.79 g, 79%). 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.55 (1H, dd, J= 8.1, 1.7, CH-5), 7.61 (1H, d, J= 7.7, 1.7, 
CH-19), 7.54 (1H, t, J= 1.7, CH-21) 7.34 (1H, ddd, J= 8.5, 7.1, 1.7, CH-7), 7.20 (1H, dd, J= 
8.1, 7.1, CH-6), 7.12-7.07 (2H, m, CH-2, CH-17), 7.04 (1H, t, J= 7.7, CH-18), 6.96 (1H, d, J= 
8.5, CH-8), 6.07 (1H, d, J= 8.1, CH-3), 5.05 (2H, s, CH2-15), 3.37 (2H, t, J= 7.5, CH2-10), 
1.76 (2H, qn, J= 7.5, CH2-11), 1.48-1.36 (4H, m, CH2-12, CH2-13), 0.93 (3H, t, J= 7.1, CH3-
14) 
13
C NMR (150 MHz, CDCl3) δ ppm: 154.6 (CQ-4), 139.5 (CH-2), 138.6 (Ph-CQ), 138.4 (CQ-
8’), 137.2 (CH-19), 135.1 (CH-21), 130.9 (CH-18), 130.6 (CH-7), 125.8 (CH-5), 125.4 (CQ-4’), 
125.3 (CH-17), 123.8 (CH-6), 115.1 (CH-8), 99.2 (CH-3), 95.1 (CQ-20), 55.0 (CH2-15), 49.8 
(CH2-10), 30.8 (CH2-11), 30.2 (CH2-12), 22.9 (CH2-13), 14.4 (CH3-14) 
HRMS (EI) m/z: Calcd. [M]
+
  430.0906 
   Measured  430.0900 
LRMS (EI) m/z:  430 (38, [M]
+
), 387 (90, [M-CH2CH2CH3]
+
), 373 (100, [M-
HCH2(CH2)2CH3]
+
), 360 (13, [M+H-CH2(CH2)3CH3]
+
), 217 (21, 
[CH2PhI]
+
), 90 (7) 
IR vmax (neat/cm
-1
): 3053 (Ar C-H), 2950, 2913, 2845 (Aliphatic C-H), 2811, 1631 (C=N), 
1606, 1586 (Ar C=C), 1569, 1557 
m.p.: 118 – 119 °C 
 
 
1-benzyl-7-methoxy-4-(pentylamino)quinolin-1-ium bromide (24) 
White powder 
 Chemical formula: C22H26N2O ∙ HBr 
 Molecular weight: 415.38 g.mol-1 
 Yield: 42% 
 
To a solution of 11 (0.43 g, 1.77 mmol) in acetone (15 ml), benzyl bromide (210 µl, 
1.77 mmol) was added and the mixture was heated at 60 °C for 3 h. After cooling to 
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ambient temperature, the mixture was poured into an ice (~ 100 cm3) and NaOH 
(100 ml, 2M) mixture while stirring vigorously. The organic products were extracted 
with DCM (2 x 100 ml), dried over anh. MgSO4 and evaporated in vacuo. To the 
remaining residue, EtOAc (50 ml) was added and the mixture was stirred for 10 min. 
The precipitate formed was filtered, was washed with EtOAc (2 x 50 ml) and petrol 
(2 x 50 ml) and was dried in vacuo to afford 24 as white powder (0.31 g, 42%). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 10.01 (1H, t, J= 5.9, NH
+
), 9.14 (1H, d, J= 9.3, CH-5), 
8.24 (1H, d, J= 7.5, CH-2), 7.36-7.28 (3H, m, meta Ph-CH, para Ph-CH), 7.20 (2H, d, J= 7.9, 
ortho Ph-CH), 7.03 (1H, dd, J= 9.3, 2.5, CH-6), 6.87 (1H, d, J= 2.5, CH-8), 6.36 (1H, d, J= 
7.5, CH-3), 5.71 (2H, s, CH2Ph), 3.78 (3H, s, OCH3), 3.52 (2H, td, J= 7.0, 5.9, NCH2), 1.79 
(2H, q, J= 7.0, NCH2CH2), 1.42-1.31 (4H, m, CH2CH2CH3), 0.89 (3H, t, J= 7.0, CH2CH3) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 163.7 (CQ-7), 155.1 (CQ-4), 145.3 (CH-2), 140.0 (CQ-8’), 
133.9 (Ph-CQ), 129.5 (meta Ph-CH), 128.9 (CH-5 or para Ph-CH), 128.8 (CH-5 or para Ph-
CH), 126.7 (ortho Ph-CH), 116.4 (CH-6), 112.6 (CQ-4’), 99.7 (CH-8), 97.3 (CH-3), 58.4 
(CH2Ph), 56.2 (OCH3), 43.6 (NCH2), 29.2 (CH2CH2CH3), 28.2 (NCH2CH2), 22.5 (CH2CH3), 
14.2 (CH3) 
HRMS (EI) m/z: Calcd. [M]
+ 
334.2040 
 Measured     334.5056 
LRMS (EI) m/z:  335 (8, [M+H]
+
), 334 (32, [M]
+
), 292 (17), 291 (66, [M-CH2CH2CH3]
+
), 
278 (25), 277 (100, [M-CH2(CH2)2CH3]
+
), 264 (13, [M+H-
CH2(CH2)3CH3]
+
), 91 (17, [CH2Ph]
+
) 
IR vmax (neat/cm
-1
): 3458, 3173 (N-H), 3011 (Ar C-H), 2970, 2946 (aliphatic C-H), 1739, 
1614, 1562 (Ar C=C), 1532 
m.p.: 221 - 222 °C 
 
 
(E)-2-acetamido-N-(1-benzyl-7-chloroquinolin-4(1H)-ylidene)ethanaminium 
chloride (25) 
Off white powder 
 Chemical formula: C20H20ClN3O ∙ HCl 
 Molecular Weight: 390.30 g.mol-1 
 Yield: 25% 
 
To a solution of 12 (1.54 g, 5.84 mmol) in DMSO (6 ml), benzyl bromide (0.77 ml, 
6.48 mmol) and Et3N (0.98 ml, 6.97) were added and the resulting solution was 
heated at 110 °C for 24 h. After cooling at room temperature, the mixture was 
poured to an ice (~50 cm3) and NaOH (2M, 50 ml) mixture while stirring vigorously. 
The organic products were extracted with EtOAc (2 x 100 ml) and the organic 
extracts were dried over anh. MgSO4 and evaporated in vacuo. The resulting 
residue was purified via column chromatography using basic Al2O3 as the solid 
phase (EtOAc → 1:9 MeOH:EtOAc). The isolated product was dissolved in a 
mixture of DCM and isopropanol (9:1, 100 ml) and was neutralised to pH 7 with HCl 
(1 M). The organic layer was isolated, dried over anh MgSO4 and evaporated in 
vacuo to afford 25 as the hydrochloride salt as off white solid (0.57 g, 25%). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 10.81 (1H, s, br, NHCH2CH2NHCO), 9.53 (1H, d, J= 9.0, 
CH-5), 8.62 (1H, s, br, NHCOCH3), 8.09 (1H, d, J= 7.5, CH-2), 7.66 (1H, dd, J= 9.0, 2.0, CH-
6), 7.62 (1H, d, J= 2.0, CH-8), 7.45-7.39 (3H, m, meta Ph CH, para Ph CH), 7.15 (2H, dd, J= 
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7.6, 1.9, ortho Ph CH), 6.72 (1H, d, J= 7.5, CH-3), 5.55 (2H, s, CH2Ph), 3.76-3.72 (4H, m, 
NHCH2CH2), 2.06 (3H, s, CH3) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 172.3 (C=O), 156.6 (CQ-4), 145.4 (CH-2), 141.5 (CQ-7), 
138.7 (CQ-8’), 132.4 (CQ-Ph), 130.0 (meta Ph CH), 129.7 (para Ph CH or CH-5), 129.3 (para 
Ph CH or CH-5), 128.5 (CH-6), 126.7 (ortho Ph CH), 117.4 (CQ-4’), 116.8 (CH-8), 99.0 (CH-
3), 58.3 (CH2Ph), 44.4 (NHCH2 or NHCH2CH2), 37.8 (NHCH2 or NHCH2CH2), 23.2 (CH3) 
HRMS (ES+) m/z: Calcd. [M+H]
+ 
354.1373 
 Measured     354.1371 
LRMS (ES+) m/z:  356 (29), 354 (100) 
IR vmax (neat/cm
-1
): 3219 (N-H), 3089 (Ar C-H), 3001, 2942, 2823 (Alkyl C-H), 1661 (C=N-), 
1617, 1579 (Ar C=C), 1545, 1529 
m.p.: 233 - 234 °C 
 
 
(E)-N-(1-benzyl-7-chloroquinolin-4(1H)-ylidene)-2,2,2-trifluoroethanamine (26) 
 
White powder 
 Chemical formula: C18H14ClF3N2 
 Molecular Weight: 350.76 g.mol-1 
 Yield: 73% 
 
To a suspension of 14 (0.12 g, 0.46 mmol) and NaI (0.08 g, mmol) in acetone (4 ml), 
benzyl bromide (0.06 ml, 0.50 mmol) was added and the resulting mixture was 
heated to reflux at 70 oC for 3 h under Ar atmosphere. The solution was allowed to 
cool at R.T. and was then transferred on vigorous stirring, to a mixture of ice/water 
(~20 cm3) and NaOH (2 M, 5 ml). The precipitate formed was filtered, was washed 
with water (3 x 10 ml) and petrol (3 x 10 ml), and dried in vacuo to afford pure 26 
(0.12 g, 73%) as a white solid. 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.51 (1H, d, J= 8.3, CH-5), 7.36 (2H, t, J= 7.4, meta Ph-
CH), 7.32 (1H, t, J= 7.4, para Ph-CH), 7.18-7.14 (3H, m, CH-6, ortho Ph-CH), 7.11 (1H, d, J= 
7.9, CH-2), 7.05 (1H, d, J= 1.3, CH-8), 5.88 (1H, d, J= 7.9, CH-3), 5.08 (2H, s, CH2Ph), 3.82 
(2H, q, 
3
JHF= 9.7, NCH2) 
13
C NMR (150 MHz, CDCl3) δ ppm: 156.6 (CQ-4), 140.2 (CH-2), 139.3 (CQ-8’), 136.8 (CQ-7), 
135.2 (Ph-CQ), 129.4 (meta Ph-CH), 128.4 (para Ph-CH), 127.8 (CH-5), 126.3 (q, 
1
JCF= 
275.7, CF3), 126.2 (ortho Ph-CH), 124.3 (CH-6), 123.9 (CQ-4’), 115.0 (CH-8), 99.0 (CH-3), 
55.8 (CH2Ph), 52.0 (q, 
2
JCF= 30.5, NCH2) 
19
F NMR (282 MHz, CDCl3) δ ppm: -71.23 
HRMS (ES+) m/z: Calcd. [M-H]
+
 351.0876  
   Measured  351.0868 
LRMS (ES+) m/z:  353 (35), 351 (100, [M-H]
+
) 
IR vmax (neat/cm
-1
): 3032 (Ar C-H), 2895 (Alkyl C-H), 2825, 1631 (C=N-), 1600, 1572         
(Ar C=C) 
m.p.: 163 – 164 
o
C 
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(E)-3-((1-benzyl-7-chloroquinolin-4(1H)-ylidene)amino)-4,5-dihydro-1H-
benzo[b]azepin-2(3H)-one (27) 
Yellow powder 
 Chemical formula: C26H22ClN3O 
 Molecular Weight: 427.92 g.mol-1 
 Yield: 49% 
 
 
 
A mixture of 15 (0.10 g, 0.29 mmol) and benzyl bromide (0.05 ml, 0.42 mmol) in 
DMF (1 ml) was heated at 100 °C for 24 h. After cooling to R.T., the mixture was 
poured into an ice (~30 cm3) and NaOH (2 M, 30 ml) mixture while stirring 
vigorously. The precipitate formed was filtered, was washed with water (2 x 50 ml) 
and pentane (2 x 50 ml) and was dried in vacuo. Purification via column 
chromatography (EtOAc → 1:2:20 NEt3:MeOH:EtOAc) followed by trituration with 
Et2O, afforded pure 27 as a yellow solid (0.06 g, 49%). 
1
H NMR (600 MHz, DMSO-d6) δ ppm: 9.74 (1H, s, NH), 8.22 (1H, d, J= 8.7, quin CH-5), 7.64 
(1H, d, J= 8.0, quin CH-2), 7.40 (1H, s, quin CH-8), 7.34 (2H, t, J= 7.6, meta Ph-CH), 7.29-
7.26  (2H, m, bnza CH-6, para Ph-CH), 7.25-7.21 (2H, m, quin CH-6, bnza CH-8), 7.20 (2H, 
d, J= 7.6, ortho Ph-CH), 7.10 (1H, td, J= 7.6, 1.5, bnza CH-7), 7.01 (1H, dd, J= 7.6, 1.5, bnza 
CH-9), 5.60 (1H, d, J= 8.0, quin CH-3), 5.30 (2H, d, J= 4.4, CH2Ph), 4.03 (1H, t, J= 8.9, bnza 
COCH-3), 2.86-2.74 (2H, m, bnza CH2-5), 2.45-2.40 (2H, m, bnza CH2-4) 
13
C NMR (150 MHz, DMSO-d6) δ ppm: 172.7 (CQ=O), 153.6 (quin CQ-4), 141.8 (quin CH-2), 
139.2 (quin CQ-8’), 138.2 (bnza CQ-9’), 136.5 (Ph-CQ), 135.5 (quin CQ-7), 134.3 (bnza CQ-5’), 
129.3 (bnza CH-6), 128.9 (meta Ph-CH), 127.7 (bnza CH-8 and para Ph-CH), 127.2 (quin 
CH-5), 126.4 (ortho Ph-CH), 124.7 (bnza CH-7), 123.3 (quin CH-6), 123.0 (quin CQ-4’), 121.6 
(bnza CH-9), 115.6 (quin CH-8), 99.5 (quin CH-3), 58.5 (bnza CH-3), 54.3 (CH2Ph), 37.5 
(bnza CH2-4), 28.8 (bnza CH2-5) 
HRMS (EI) m/z: Calcd. [M]
+   
 427.1451 
 Measured    427.1458 
LRMS (EI) m/z:  427 (17, [M
+
]), 268 (22, [M+H-Bnza]
+
), 91 (12), 84 (73), 66 (100) 
IR vmax (neat/cm
-1
): 3049 (Ar C-H), 2922, 1676 (C=N-), 1631, 1614, 1599 (Ar C=C), 1549 
m.p.: 220 - 221 °C 
 
 
(7-Chloro-1-pentyl-1H-quinolin-4-ylidene)-phenyl-amine (28) 
 
Bright yellow crystals 
 Chemical formula: C20H21ClN2 
 Molecular Weight: 324.85 g.mol-1 
 Yield: 24% 
 
To a solution of 7 (0.80 g, 3.14 mmol) in THF (20 ml), NaH (60% in mineral oil, 0.19 
g, 4.71 mmol) was added slowly and the mixture was stirred at R.T. for 10 min. 1-
Bromopentane (0.78 ml,  6.28 mmol) was then added and the resulting mixture was 
heated at 65 oC for 3 days. After cooling at R.T., water (75 ml) was slowly added to 
the mixture. The organic products were extracted with EtOAc (3 x 50 ml) and the 
organic extracts were dried over anh. MgSO4. Purification via column 
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chromatography (EtOAc → 1:10 MeOH:EtOAc), followed by recrystallization (Et2O) 
afforded pure 28 as bright yellow crystals (0.25 g, 24%). 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.53 (1H, d, J= 8.7, CH-5), 7.33 (2H, t, J= 7.7, meta Ph-
CH), 7.22 (1H, dd, J= 8.7, 1.9, CH-6), 7.17 (1H, d, J= 1.9, CH-8), 7.02 (1H, t, J= 7.7, para 
Ph-CH), 6.92 (2H, d, J= 7.7, ortho Ph-CH), 6.83 (1H, d, J= 8.0, CH-2) 5.88 (1H, d, J= 8.0, 
CH-3), 3.82 (2H, t, J= 7.3, NCH2), 1.77 (2H, qn, J= 7.3, NCH2CH2), 1.41-1.31 (4H, m, 
CH2CH2CH3) 0.92 (3H, t, J= 6.9, CH3) 
13
C NMR (150 MHz, CDCl3) δ ppm: 154.4 (CQ-4), 152.7 (Ph-CQ), 139.9 (CQ-8’), 139.6 (CH-
2), 137.1 (CQ-7), 129.4 (meta Ph-CH), 128.1 (CH-5), 124.0 (CQ-4’), 123.7 (CH-6), 122.3 
(para Ph-CH), 121.5 (ortho Ph-CH), 114.3 (CH-8), 101.1 (CH-3), 52.5 (NCH2), 29.0 
(CH2CH2CH3), 28.3 (NCH2CH2), 22.4 (CH2CH3), 14.1 (CH3) 
HRMS (EI) m/z: Calcd. [M]
+
 324.1388  
   Measured  324.1395 
LRMS (EI) m/z:  326 (30), 325 (35), 324 (100, [M]
+
), 323 (53), 255 (13), 253 (36, [M-
   CH2(CH2)3CH3]
+
), 218 (12 M-CH2(CH2)3CH3-Cl]
+
) 
IR vmax (neat/cm
-1
): 3072 (Ar C-H), 3022, 2955, 2870 (Alkyl C-H), 2846, 1624 (C=N-), 
1602, 1584 (Ar C=C), 1555 
m.p: 90 - 91 
o
C 
 
 
(E)-N-(7-chloro-1-pentylquinolin-4(1H)-ylidene)-1-phenylmethanamine (29) 
Dark yellow/orange solid 
 Chemical formula: C21H23ClN2 
 Molecular Weight: 338.87 g.mol-1 
 Yield: 92% 
 
To a solution of 8 (0.14 g, 0.52 mmol), in acetone (2 mL), NaI (0.17 g, 1.13 mmol) 
and 1-bromopentane (0.13 ml, 1.01 mmol) were added and the resulting mixture 
was heated to reflux at 65 oC for 32 h. The resulting mixture was allowed to cool at 
R.T and the organic products were extracted with EtOAc, dried over anh. Na2SO4 
and evaporated. Purification via column chromatography (EtOAc → 1:20 
NEt3:EtOAc) afforded pure 29 as a dark yellow/orange solid (0.16 g, 92%). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 8.60 (1H, d, J= 8.7, CH-5), 7.44 (2H, d, J= 7.6, ortho Ph-
CH), 7.32 (2H, t, J= 7.6, meta-Ph-CH), 7.22 (1H, t, J= 7.6, para Ph-CH), 7.16 (1H, dd, J= 8.7, 
1.9, CH-6), 7.13 (1H, d, J= 1.9, CH-8), 6.92 (1H, d, J= 8.0, CH-2), 5.99 (1H, d, J= 8.0, CH-3), 
4.59 (2H, s, CH2Ph), 3.82 (2H, t, J= 7.3, NCH2CH2), 1.77 (2H, qn, J= 7.3, NCH2CH2), 1.41-
1.31 (4H, m, CH2CH2CH3), 0.92 (3H, t, J= 7.0, CH3) 
13
C NMR (150 MHz, CDCl3) δ ppm: 155.1 (CQ-4), 141.8 (Ph-CQ), 139.3 (CQ-8’), 139.3 (CH-
2), 136.5 (CQ-7), 128.4 (meta Ph-CH), 127.8 (CH-5), 127.7 (ortho Ph-CH), 126.4 (para Ph-
CH), 124.3 (CQ-4’), 123.6 (CH-6), 114.2 (CH-8), 99.4 (CH-3), 53.3 (CH2Ph), 52.5 (NCH2), 
29.0 (CH2CH2CH3), 28.3 (NCH2CH2), 22.5 (CH2CH3), 14.1 (CH3) 
HRMS (ES+) m/z: Calcd. [M-H]
+
 339.1628  
   Measured  339.1631 
LRMS (ES+) m/z:  341 (35), 339 (100, [M-H]
+
) 
IR vmax (neat/cm
-1
): 3060 (Ar C-H), 3028, 2947, 2922, 2861 (Alkyl C-H), 1629 (C=N-), 
1596, 1561 (Ar C=C) 
m.p: 93 – 94 
o
C 
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(E)-N-(1-pentylquinolin-4(1H)-ylidene)-1-phenylmethanaminium iodide (30) 
Pale yellow crystals 
Chemical formula: C21H24N2 · HI 
Molecular Weight: 432.34 
Yield: 51% 
 
To a solution of 10 (0.57 g, 2.43 mmol) in acetone (5 ml), 1-bromopentane (0.33 ml, 
2.66 mmol) and NaI (0.44 g, 2.93 mmol) were added and the mixture was heated at 
65 °C for 18 h. After cooling to room temperature, the mixture was poured into an 
ice (~100 cm3) and NaOH (2 M, 100 ml) mixture while stirring vigorously. The 
precipitate formed was washed with water and ether. Recrystallization (CH3CN) 
afforded 30 (0.53 g, 51%) as pale yellow crystals. 
1
H NMR (600 MHz, DMSO) δ ppm: 9.95 (1H, s, br, NH
+
), 8.65 (1H, dd, J= 8.5, 1.5, CH-5), 
8.58 (1H, d, J= 7.5, CH-2), 8.15 (1H, d, J= 8.8, CH-8), 8.03 (1H, ddd, J= 8.8, 7.0, 1.5, CH-7), 
7.79 (1H, dd, J= 8.5, 7.0, CH-6), 7.43 (2H, d, J= 7.6, ortho Ph-CH), 7.37 (2H, t, J= 7.6, meta 
Ph-CH), 7.29 (1H, t, J= 7.6, para Ph-CH), 6.83 (1H, d, J= 7.5, CH-3), 4.80 (2H, s, CH2Ph), 
4.51 (2H, t, J= 7.4, NCH2CH2), 1.78 (2H, q, J= 7.4, NCH2CH2), 1.33-1.22 (4H, m, 
CH2CH2CH3), 0.84 (3H, t, J= 6.7, CH3) 
13
C NMR (150 MHz, DMSO) δ ppm: 155.3 (CQ-4), 146.6 (CH-2), 137.5 (CQ-8’), 137.0 (Ph-
CQ), 133.9 (CH-7), 128.7 (meta Ph-CH), 127.5 (para Ph-CH), 127.3 (ortho Ph-CH), 126.7 
(CH-6), 124.0 (CH-5), 118.5 (CH-8), 118.2 (CQ-4’), 98.8 (CH-3), 53.8 (NCH2CH2), 46.4 
(CH2Ph), 28.5 (NCH2CH2), 28.0 (CH2CH2CH3), 21.8 (CH2CH3), 13.9 (CH3) 
HRMS (CI) m/z: Calcd. [M+H
+
] 305.2012 
   Measured  305.2007 
LRMS (CI) m/z:  305 (100, [M+H]
+
) 
IR vmax (neat/cm
-1
): 3381, 3234 (N-H), 3085 (Ar C-H), 2953, 2927, 2850 (Aliphatic C–H), 
1613 (C=N), 1572 (Ar C=C), 1536 
m.p.: 163 – 165 °C 
 
 
(7-Chloro-1-cyclohex-2-enyl-1H-quinolin-4-ylidene)-pentyl-amine (31) 
Viscous dark yellow/brown oil 
 Chemical formula: C20H25ClN2 
 Molecular weight: 328.88 g.mol-1 
 Yield: 28% 
 
To a suspension of 3 (0.50 g, 2.01 mmol) and NaI (0.35 g, 2.34 mmol) in anhydrous 
DMF (5 ml), 4-bromocyclohexene (2.50 ml, 2.01 mmol) was added and the resulting 
mixture was heated at 80 oC  to reflux for 4 days. The resulting brown solution was 
allowed to cool at R.T. and was then poured into an ice/NaOH (2M) mixture. The 
organic products were extracted with DCM (3 x 15 ml). The organic extracts were 
dried over anh. Na2SO4 and the solvents were evaporated in vacuo. The resulting 
viscous brown residue was purified by flash column chromatography (EtOAc →1:20 
NEt3 : EtOAc) to afford pure 31 as a dark yellow/brown oil (0.18 g, 28%). 
1
H NMR (600 MHz, CDCl3) δ ppm: 9.35 (1H, d, J= 9.0, CH-5), 8.01 (1H, d, J= 7.8, CH-2), 
7.66 (1H, d, J= 1.9, CH-8), 7.55 (1H, dd, J= 9.0, 1.9, CH-6), 6.49 (1H, dtd, J= 10.0, 3.9, 1.8, 
CHCH=CH), 6.37 (1H, d, J= 7.8, CH-3), 5.74 (1H, ddt, J= 10.0, 3.8, 2.2, =CHCH2), 5.24 (1H, 
br, s, NCH), 3.56 (2H, td, J= 7.8, 3.6, NCH2), 2.28-2.24 (1H, m, =CHCH2), 2.23-2.17 (2H, m, 
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=CHCH2, NCHCH2), 1.91-1.85 (1H, m, NCHCH2), 1.84-1.78 (1H, m, =CHCH2CH2), 1.75 (2H, 
qn, J= 7.4, NCH2CH2), 1.64-1.56 (1H, m, =CHCH2CH2), 1.41-1.31 (4H, m, CH2CH2CH3), 0.88 
(3H, t, J= 7.1, CH3) 
13
C NMR (150 MHz, CDCl3) δ ppm: 155.8 (CQ-4), 141.1 (CH-2), 140.3 (CQ-8’), 138.5 (CQ-7), 
137.5 (CHCH=CH), 130.3 (CH-5), 127.3 (CH-6), 123.1 (=CHCH2), 118.6 (CQ-4’), 115.2 (CH-
8), 97.9 (CH-3), 55.8 (NCH), 44.6 (NCH2), 29.2 (CH2CH2CH3 or CH2CH3), 29.0 (NCHCH2), 
27.9 (NCH2CH2), 24.8 (=CHCH2), 22.6 (CH2CH2CH3 or CH2CH3), 18.7 (=CHCH2CH2), 14.2 
(CH3) 
HRMS (ES+) m/z: Calcd. [M-H]
+
  329.1776  
   Measured 329.1785 
LRMS (ES+) m/z:  331 (14), 329 (42, [M-H]
+
), 251 (35), 249 (100)  
IR vmax (neat/cm
-1
): 3024 (C=C-H), 2925 (Alkyl C-H), 2855, 1721 (C=N-), 1598 (Ar 
C=C), 1569 
 
 
(E)-N-(7-chloro-1-(cyclohexylmethyl)quinolin-4(1H)-ylidene)-2-
fluoroethanamine (32) 
Beige solid 
 Chemical formula: C18H22ClFN2 
 Molecular Weight: 320.83 g.mol-1 
 Yield: 27% 
To a solution of 13 (0.10 g, 0.44 mmol), and NaI (0.22 g, 1.47 mmol) in DMF (2 ml), 
bromomethylcyclohexane (0.19 ml, 1.32 mmol) was added and the mixture was 
heated to reflux at 120 oC for 4 days under Ar atmosphere. After cooling at R.T. the 
solution was transferred to a mixture of ice/water (~20 cm3) and NaOH (2M, 5 ml). 
The organic product was extracted with DCM (3 x 15 ml) and the organic extracts 
were dried over anh. Na2SO4 and concentrated in vacuo. Purification via flash 
column chromatography (EtOAc → 1:20 NEt3:EtOAc) afforded pure 32 (0.04 g, 
27%) as a beige powder. 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.45 (1H, d, J= 8.7, CH-5), 7.15 (1H, dd, J= 8.7, 1.8, CH-
6), 7.08 (1H, d, J= 1.8, CH-8), 6.87 (1H, d, J= 8.0, CH-2), 5.90 (1H, d, J= 8.0, CH-3), 4.78 
(2H, dt, 
2
JHF= 47.6, 
3
JHH=5.8, CH2F), 3.62 (2H, d, J= 7.4 Hz, NCH2CH), 3.57 (2H, dt, 
3
JHF= 
25.1, 
3
JHH= 5.8, CH2CH2F), 1.81 (1H, ttq, J= 11.5, 7.4, 3.7, CH(CH2)2), 1.77-1.66 (5H, m, 
cyclohexyl CH2), 1.29-1.11 (3H, m, cyclohexyl CH2), 1.03-0.93 (2H, m, cyclohexyl CH2) 
13
C NMR (150 MHz, CDCl3) δ ppm: 155.7 (CQ-4 ), 139.9 (CH-2), 139.5 (CQ-8’), 136.4 (CQ-7), 
127.5 (CH-5), 124.2 (CQ-4’), 123.5 (CH-6), 114.4 (CH-8), 98.6 (CH-3), 85.1 (d, 
1
JCF= 168.1, 
CH2F), 58.8 (NCH2CH), 50.1 (d, 
2
JCF= 22.5, CH2CH2F), 36.6 (CH(CH2)2), 30.9 (cyclohexyl 
CH2), 26.3 (cyclohexyl CH2), 25.6 (cyclohexyl CH2) 
19
F NMR (282 MHz, CDCl3) δ ppm: -220.43 
HRMS (ES+) m/z: Calcd. [M-H]
+
 321.1534  
   Measured  321.1520 
LRMS (ES+) m/z:  323 (30), 321 (100, [M-H]
+
), 225 (23) 
IR vmax (neat/cm
-1
): 2945 (Aryl C-H), 2841(Alkyl C-H), 1634 (C=N-), 1601, 1572 (Ar 
C=C) 
m.p.: 147-148 
o
C 
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Route B: 
 
Scheme 31. Synthesis of iminodihydroquinolines starting from 4-quinolones. 
Reagents and Conditions: (i) NaH, 0 °C, 15 min (ii) DMF, 80-110 °C, 18-24 h (iii) POCl3, 110
 
°C, 3 h (iv) R
2
-NH2, MeOH, rt, 5-18h (v) CH3CN, 70 °C, 24 h 
N-substituted 4-quinolines 33 - 35: 
1-benzyl-7-chloroquinolin-4(1H)-one (33) 
White crystalline solid 
 Chemical formula: C16H12ClNO 
 Molecular Weight: 269.73 g.mol-1 
 Yield: 57% 
 
To a solution of EYF119 (0.75 g, 4.18 mmol) and NaH (60% in mineral oil, 0.33 g, 
8.35 mmol) in DMF (8 ml), benzyl bromide (1.5 ml, 12.6 mmol) was added under Ar 
atmosphere and the resulting solution was heated at 90 oC for 18 h. After cooling at 
R.T, the solvent was evaporated in vacuo and water (100 ml) was added to the 
remaining residue. The organic products were extracted with DCM (3 x 75 ml) and 
the combined organic extracts were dried over anh. MgSO4 and concentrated in 
vacuo. Purification by flash column chromatography (EtOAc) afforded pure 33 (0.64 
g, 57%) as white crystals. 
 1
H NMR (600 MHz, CDCl3) δ ppm: 8.39 (1H, d, J= 8.5, CH-5), 7.61 (1H, d, J= 7.8, CH-2), 
7.40-7.32 (3H, m, meta Ph-CH, para Ph-CH), 7.31-7.28 (2H, m, CH-6, CH-8), 7.15 (2H, d, J= 
7.7, ortho Ph-CH), 6.33 (1H, d, J= 7.8, CH-3), 5.26 (2H, s, CH2). 
13
C NMR (150 MHz, CDCl3) δ ppm: 177.8 (CQ-4), 143.8 (CH-2), 140.9 (CQ-8’), 138.8 (CH-7), 
134.6 (Ph-CQ), 129.5 (meta Ph-CH), 128.9 (para Ph-CH or CH-5), 128.7 (para Ph-CH or CH-
5), 126.2 (ortho Ph-CH), 125.8 (CQ-4’), 124.6 (CH-6), 115.9 (CH-8), 111.1 (CH-3), 56.6 
(CH2Ph) 
HRMS (EI) m/z: Calcd. [M]
+   
   269.0607 
 Measured      269.0602 
LRMS (EI) m/z:  271 (12), 269 (35, [M]
+
), 91 (100, PhCH2
+
) 
IR vmax (neat/cm
-1
): 3064 (Ar C-H), 3038, 1616 (C=N-), 1598, 1578 (Ar C=C), 1537 
m.p.: 197-198 
o
C 
  
Experimental 
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7-chloro-1-pentylquinolin-4(1H)-one (34) 
White solid 
Chemical formula: C14H16ClNO 
Molecular weight: 249.74 g.mol-1 
Yield: 31% 
To a suspension of EYF119 (0.57 g, 4.76 mmol) in DMF (5 ml), NaH (60% in 
mineral oil, 0.28 g, 7.10 mmol) was added, followed by 1-bromopentane (1.19 ml, 
9.60 mmol) and the resulting mixture was heated at 80 °C for 24 h. After cooling at 
ambient temperature, water (20 ml) was added slowly and the organic products 
were extracted with DCM (3 x 50 ml). The organic extracts were dried over anh. 
MgSO4 and evaporated in vacuo. Purification via column chromatography (2:3 
petroleum ether:EtOAc) afforded  34 as white solid (0.37 g, 31%). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 8.39 (1H, d, J= 8.7, CH-5), 7.49 (1H, d, J= 7.8, CH-2), 
7.39 (1H, d, J= 1.8, CH-8), 7.31 (1H, dd, J= 8.7, 1.8, CH-6), 6.25 (1H, d, J= 7.8, CH-3), 4.04 
(2H, t, J= 7.4, NCH2), 1.84 (2H, q, J= 7.4, NCH2CH2), 1.42-1.31 (4H, m, CH2CH2CH3), 0.92 
(3H, t, J= 6.9, CH3) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 177.6 (CQ-4), 143.5 (CH-2), 140.5 (CQ-8’), 138.6 (CQ-7), 
129.1 (CH-5), 125.9 (CQ-4’), 124.3 (CH-6), 115.2 (CH-8), 110.7 (CH-3), 53.5 (NCH2), 28.9 
(NCH2CH2 or CH2CH2CH3), 28.6 (NCH2CH2 or CH2CH2CH3), 22.4 (CH2CH3), 14.1 (CH3) 
HRMS (ES+) m/z: Calcd. [M+H]
+ 
250.0999 
 Measured     250.0990 
LRMS (ES+) m/z:   252 (20), 250 (83, [M+H]
+
), 182 (20), 180 (100) 
IR vmax (neat/cm
-1
): 3459 (weak, O-H), 3029 (Ar C-H), 2997, 2969, 2958, 2930, 2866 
(aliphatic C-H), 1740 (C=O), 1622 (C=C), 1583, 1542 
m.p.: 82 - 83 °C 
 
 
1-(3-fluorobenzyl)quinolin-4(1H)-one (35) 
White powder 
Chemical Formula: C16H12FNO 
Molecular Weight: 253.28 
Yield: 68% 
 
 
To a solution of 4-quinolinone (1.00 g, 6.89 mmol) and NaH (60% in mineral oil, 0.33 
g, 8.25 mmol) in DMF (8 ml), 3-fluorobenzyl bromide (0.85 ml, 6.93 mmol) was 
added under an atmosphere of argon and the resulting solution was heated at 110 
°C for 18 h. After cooling to ambient temperature, the mixture was concentrated in 
vacuo and water (100 ml) was added to the remaining residue. The organic products 
were extracted with DCM (3 x 100 ml) and the combined organic extracts were 
washed with sat. LiCl (50 ml) and water (2 x 100 ml), were dried over anh. MgSO4 
and were concentrated in vacuo. Trituration of the remaining precipitate with ether, 
afforded 35 (0.12 g, 68%) as white powder. 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.46 (1H, dd, J= 8.2, 1.3, CH-5), 7.62 (1H, d, J= 7.7, CH-
2), 7.54 (1H, ddd, J= 8.4, 7.0, 1.3, CH-7), 7.35 (1H, ddd, J= 7.0, 8.2, 1.3, CH-6), 7.31 (1H, td, 
3
JHH= 8.2, 
4
JHF= 5.9, CH-15), 7.24 (1H, dd, J= 8.4, 1.3, CH-8), 7.00 (1H, td, 
3
JHH= 8.2, 
3
JHF= 
8.2, 
4
JHH= 2.6, CH-14), 6.91 (1H, dd, J=  8.2, 1.7, CH-16), 6.84 (1H, ddd, 
3
JHF= 9.4, 
4
JHH= 
2.6, 1.7, CH-12), 6.34 (1H, d, J= 7.7, CH-3), 5.30 (2H, s, CH2) 
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13
C NMR (150 MHz, CDCl3) δ ppm: 178.4 (CQ-4), 163.4 (d, 
1
JCF= 248.9, CQ-13), 143.7 (CH-
2), 140.1 (CQ-8’), 137.9 (d, 
3
JCF= 6.9, CQ-11), 132.5 (CH-7), 131.1 (d, 
3
JCF= 8.3, CH-15), 
127.5 (CQ-4’), 127.3 (CH-5), 124.0 (CH-6), 121.7 (d, 
4
JCF= 3.0, CH-16), 116.0 (CH-8), 115.5 
(d, 
2
JCF= 21.2, CH-14), 113.3 (d, 
2
JCF= 22.2, CH-12), 110.8 (CH-3), 56.1 (d, 
4
JCF= 2.1, CH2) 
HRMS (EI) m/z: Calcd. [M]
+  
253.0903 
 Measured     253.0904 
LRMS (EI) m/z: 254 (8), 253 (43, [M
+
]), 110 (7), 109 (100, [M-CH2Ph-F]
+
), 86 (17), 84 (30), 
83 (9) 
IR vmax (neat/cm
-1
): 3079 (Ar C-H), 2960, 1622 (C=O), 1614, 1587 (Ar C=C), 1551 
 
 
 
4-iminodidydroquinolines 1, 36 - 40: 
 
(E)-N-(1-benzyl-7-chloroquinolin-4(1H)-ylidene)pentan-1-amine (1) 
Pale yellow crystalline solid 
 Chemical formula: C21H23ClN2 
 Molecular Weight: 338.87 g.mol-1 
 Yield: 51% 
 
A solution of 33 (0.25 g, 0.93 mmol) in POCl3 (4 ml), was heated to reflux for 1.5 h. 
After cooling at R.T., the mixture was evaporated in vacuo, and the resulting residue 
was triturated with ether. The resulting precipitate was dissolved in MeOH (2 ml), 
amylamine (0.57 ml, 4.90 mmol) was added dropwise and the solution was stirred 
R.T. for 3 h. The solution was poured into an ice (~30 cm3) and NaOH (2 M, 20 ml) 
mixture while stirring vigorously. The precipitate formed was filtered, was washed 
with water (2 x 20 ml) and pentane (2 x 20 ml) and dried in vacuo. Recrystallisation 
(CHCl3) afforded pure 1 (0.16 g, 51%) as pale yellow crystals. 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.41 (1H, d, J= 8.5, CH-5), 7.35 (2H, t, J= 7.5, meta Ph-
CH), 7.27-7.30 (1H, t, J= 7.5, para Ph-CH), 7.18 (2H, d, J= 7.5, ortho Ph-CH), 7.09 (1H, dd, 
J= 8.5, 2.1, CH-6), 6.99-6.94 (2H, m, CH-2, CH-8), 6.02 (1H, d, J= 8.2, CH-3), 5.02 (2H, s, 
CH2Ph), 3.32 (2H, t, J= 7.4, NCH2CH2), 1.74 (2H, qn, J= 7.4,  NCH2CH2), 1.47-1.36 (4H, m, 
CH2CH2CH3), 0.93 (3H, t, J= 7.0, CH3) 
13
C NMR (150 MHz, CDCl3) δ ppm: 153.7 (CQ-4), 139.7 (CH-2), 139.1 (CQ-8’), 136.2 (CH-7), 
135.7 (Ph-CQ), 129.3 (meta Ph-CH), 128.2 (para Ph-CH) 127.2 (CH-5), 126.2 (ortho Ph-CH), 
124.5 (CQ-4’), 123.6 (CH-6), 114.8 (CH-8), 99.7 (CH-3), 55.5 (CH2Ph), 50.3 (NCH2CH2), 31.0 
(NCH2CH2), 30.2 (CH2CH2CH3), 22.9 (CH2CH3), 14.3 (CH3) 
HRMS (ES+) m/z: Calcd. [M+H]
+ 
339.1628 
 Measured  339.1633 
LRMS (ES+) m/z:  341 (50), 340 (33), 339 (100, [MH]
+
) 
IR vmax (neat/cm
-1
):  3032 (Ar C-H), 2951, 2917 (Alkyl C-H), 2840, 1632 (C=N-), 1595, 1566     
( Ar C=C) 
m.p.: 93 – 94 
o
C 
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(E)-1-benzyl-7-chloroquinolin-4(1H)-one O-phenyl oxime (36) 
Pale brown crystals 
 Chemical formula: C22H17ClN2O 
 Molecular weight: 360.84 g.mol-1 
 Yield: 74% 
 
 
A solution of 33 (0.48 g, 1.78 mmol) in POCl3 (5 ml), was heated at 100 °C for 2 h. 
The solution was cooled to ambient temperature, DCM (5 ml) was added and the 
mixture was evaporated in vacuo. DCM (5 ml) was added and the mixture was 
evaporated again. The remaining residue was dissolved in MeOH (2 ml), and a 
freshly prepared solution o-phenylhydroxylamine in DCM (*), was added dropwise. 
The mixture was heated at 60 °C for 2 h and at ambient temperature for 18 h, and 
was then poured onto an ice (~ 100 cm3) and NaOH (100 ml, 2 M) mixture while 
stirring vigorously. The organic products were extracted with EtOAc (2 x 100 ml), 
and the organic extracts were dried over anh. MgSO4 and evaporated in vacuo. 
Purification via flash column chromatography (EtOAc), followed by recrystallization 
(Et2O) afforded 36 as pale brown crystals (0.48 g, 74%). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 8.30 (1H, d, J= 8.7, CH-5), 7.37 (2H, t, J= 7.5, CH-20, 
CH-22), 7.34-7.30 (5H, m, CH-12, CH-13, CH-15, CH-16, CH-21), 7.19 (2H, d, J= 7.5, CH-
19, CH-23), 7.12 (1H, dd, J= 8.7, 2.0, CH-6), 7.00 (1H, d, J= 2.0, H-8), 6.99-6.97 (1H, m, 
CH-14), 6.93 (1H, d, J= 8.0, CH-2), 6.57 (1H, d, J= 8.0, CH-3), 5.02 (2H, s, CH2-17) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 160.3 (CQ-11), 149.4 (CQ-4), 139.1 (CQ-8’), 139.0 (CH-
2), 136.4 (CQ-7), 135.4 (CQ-18), 129.4 (CH-13, CH-15 or CH-20, CH-22), 129.3 (CH-13, CH-
15 or CH-20, CH-22), 128.3 (CH-21), 126.2 (CH-19, CH-23), 126.0 (CH-5). 123.8 (CH-6), 
121.2 (CH-14), 118.7 (CQ-4’), 115.0 (CH-8), 114.5 (CH-12, CH-16), 96.8 (CH-3), 55.6 (CH2-
17) 
HRMS (EI) m/z: Calcd. [M]
+  
360.1024 
 Measured     360.1026 
LRMS (EI) m/z:  362 (32), 360 (100, [M]
+
), 270 (14), 269 (49, [M-CH2Ph]
+
), 267 (64, [M-
OPh]
+
), 241 (11), 141 (28), 86 (45), 84 (71) 
IR vmax (neat/cm
-1
): 3067 (Ar C-H), 3030, 1634 (C=N), 1593 (aromatic C=C), 1584, 1557, 
1542 
m.p.: 93 - 94 °C 
 
 
O-phenylhydroxylamine (*) 
 
To a solution of o-phenylhyroxylamine hydrochloride (0.52 g, 3.57 mmol) in DCM (2 
ml) and H2O (1 ml), Na2CO3 (1.96 ml, 2 M) was added and the mixture was stirred at 
ambient temperature for 30 min. DCM (10 ml) was added and the organic layer was 
separated, dried over anh. MgSO4 and concentrated to a volume of 3-4 ml. 
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Benzyl-[1-(3-fluoro-benzyl)-1H-quinolin-4-ylidene]-amine (37) 
Off white crystalline solid 
 Chemical formula: C23H19FN2 
 Molecular weight: 342.42 g.mol-1 
 Yield: 57% 
 
 
A solution of 35 (0.25 g, 1.00 mmol) in POCl3 (3 ml), was heated to reflux for 2 h. 
After cooling to ambient temperature, DCM (2 x 20 ml) was added the mixture was 
evaporated in vacuo. The remaining residue was triturated with ether. The resulting 
precipitate was dissolved in MeOH (1 ml), benzylamine (1.00 ml, 9.21 mmol) was 
added dropwise and the solution was stirred at room temperature for 18 h. The 
solution was poured into an ice (~50 cm3) and NaOH (2 M, 50 ml) mixture while 
stirring vigorously. The precipitate formed was filtered, was washed with water and 
petrol and was dried in vacuo. Recrystallisation (Et2O) afforded 37 (0.20 g, 57%) as 
off white crystals. 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.64 (1H, dd, J= 8.1, 1.7, CH-5), 7.50 (2H, d, J= 7.9, CH-
19, CH-23), 7.37-7.32 (3H, m, CH-7, CH-20, CH-22), 7.30 (1H, td, 
3
JHH= 8.0, 
4
JHF= 5.8, CH-
15), 7.25-7.18 (2H, m, CH-6, CH-21), 7.03 (1H, d, J= 8.1, CH-2), 7.00-6.94 (3H, m, CH-8, 
CH-14, CH-16), 6.88 (1H, ddd, 
3
JHF= 9.5,
 4
JHH= 2.5, 1.7, CH-12), 6.10 (1H, d, J= 8.1, CH-3), 
5.07 (2H, s, CH2-10), 4.65 (2H, s, CH2-17) 
13
C NMR (150 MHz, CDCl3) δ ppm: 163.3 (d, 
1
JCF= 247.6, CQ-13), 155.5 (CQ-4), 142.1 (CH-
2), 139.3 (CQ-8’), 139.0 (d, 
3
JCF= 6.8, CQ-11), 138.5 (CH-21), 130.8 (d, 
3
JCF= 8.3, CH-15), 
130.3 (CQ-18), 128.3 (CH-20, CH-22), 127.8 (CH-19, CH-23), 126.3 (CH-7), 126.1 (CQ-4’), 
125.9 (CH-5), 123.5 (CH-6), 121.7 (d, 
4
JCF= 2.9, CH-16), 115.1 (d, 
2
JCF= 21.1, CH-14), 115.0 
(CH-8), 113.2 (d, 
2
JCF= 22.3, CH-12), 99.5 (CH-3), 55.2 (CH2-10), 53.6 (CH2-17) 
19
F NMR (282 MHz, CDCl3) δ ppm: -111.67 
HRMS (ES+) m/z: Calcd. [M+H]
+ 
343.1611 
 Measured     343.1838 
LRMS (ES+) m/z: 344 (33), 343 (100, [M+H]
+
]), 304 (12), 302 (12), 210 (7), 196 (5) 
IR vmax (neat/cm
-1
): 3056 (Ar C-H), 3022, 2848 (Aliphatic C-H), 1629 (C=N), 1589 (Ar C=C), 
1571 
m.p.: 118 - 119 °C 
 
 
[1-(3-Fluoro-benzyl)-1H-quinolin-4-ylidene]-phenyl-amine (38) 
Bright yellow crystalline solid 
 Chemical formula: C22H17FN2 
 Molecular weight: 328.39 g.mol-1 
 Yield: 88% 
 
 
 
A solution of 35 (0.70 g, 2.76 mmol) in POCl3 (10 ml), was heated to reflux for 2 h. 
After cooling to ambient temperature, DCM (2 x 20 ml) was added the mixture was 
evaporated in vacuo. The remaining residue was triturated with ether. The resulting 
precipitate was dissolved in MeOH (2 ml), aniline (1.39 ml, 15.22 mmol) was added 
dropwise and the solution was stirred at room temperature for 4 h. The solution was 
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poured into an ice (~50 cm3) and NaOH (2 M, 50 ml) mixture while stirring 
vigorously. The organic products were extracted with EtOAc (2 x 100 ml), were dried 
over anh. MgSO4 and evaporated in vacuo. Purification via column chromatography 
(EtOAc) followed by recrystallisation (CHCl3) afforded 38 (0.80 g, 88%) as bright 
yellow crystals. 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.61 (1H, dd, J= 8.1, 1.7, CH-5), 7.41 (1H, ddd, J= 8.6, 
7.2, 1.7, CH-7), 7.35 (2H, t, J= 7.8, CH-19, CH-21), 7.31 (1H, td, 
3
JHH= 8.0, 
4
JHF= 5.8, CH-
15), 7.28-7.24 (1H, m, CH-6), 7.06-7.01 (2H, m, CH-14, CH-20), 7.00-6.95 (5H, m, CH-2, 
CH-8, CH-16, CH-18, CH-22), 6.88 (1H, ddd, 
3
JHF= 9.5,
 4
JHH= 2.5, 1.7, CH-12), 5.99 (1H, d, 
J= 8.0, CH-3), 5.09 (2H, s, CH2-10) 
13
C NMR (150 MHz, CDCl3) δ ppm: 163.3 (d, 
1
JCF= 247.7, CQ-13), 154.8 (CQ-4), 152.9 (CQ-
17), 139.8 (CQ-8’), 139.1 (CH-2), 138.8 (d, 
3
JCF= 6.8, CQ-11), 131.1 (CH-7), 130.9 (d, 
3
JCF= 
8.3, CH-15), 129.3 (CH-19, CH-21), 126.4  (CH-5), 125.5 (CQ-4’), 123.8 (CH-6), 122.3 (CH-
20), 121.7 (d, 
4
JCF= 2.8, CH-16), 121.5 (CH-18, CH-22), 115.2 (CH-8), 115.1 (d, 
2
JCF= 21.2, 
CH-14), 113.2 (d, 
2
JCF= 22.4, CH-12), 101.3 (CH-3), 55.3 (CH2-10) 
19
F NMR (282 MHz, CDCl3) δ ppm: -111.26  
HRMS (ES-) m/z: Calcd. [M]
+  
327.1298 
 Measured     327.1297 
LRMS (ES-) m/z: 328 (48, [M
+
]), 327 (100), 319 (14), 261 (27) 
IR vmax (neat/cm
-1
): 3064 (Ar C-H), 3012, 1629 (C=N), 1609, 1585 (Ar C=C), 1553 
m.p.: 138 - 141 °C 
 
 
N-(1-Benzyl-7-chloro-1H-quinolin-4-ylidene)-benzenesulfonamide (39) 
White crystals 
Chemical formula: C22H17ClN2O2S 
Molecular weight: 408.90 g.mol-1 
Yield: 70% 
 
 
To a suspension of 33 (0.50 g, 1.85 mmol) in CH3CN (10 ml), benzenesulfonyl 
isocyanate (0.49 ml, 3.66 mmol) was added and the resulting mixture was heated at 
70 °C for 24 h. After cooling at ambient temperature, MeOH (5 ml) was added and 
the mixture was stirred for five min. The precipitate formed was filtered, was dried in 
vacuo and recrystallized (CHCl3, DCM) to afford 39 (0.53 g, 70%) as white 
crystalline solid. 
1
H NMR (CDCl3, 600 MHz) δ ppm: 8.60 (1H, d, J= 8.9, CH-5), 8.08 (2H, dd, J= 8.1, 1.6, 
ortho Ph-CH), 7.70 (1H, d, J= 7.7, CH-2), 7.55-7.44 (4H, m, meta Ph-CH, para Ph-CH, CH-
3), 7.40-7.35 (4H, m, meta Bz-CH, para Bz-CH, CH-8), 7.33 (1H, dd, J= 8.9, 1.9, CH-6), 7.12 
(2H, dd, J= 7.7, 1.7, ortho Bz-CH), 5.38 (2H, s, CH2) 
13
C NMR (150 MHz, CDCl3) δ ppm: 161.0 (CQ-4), 143.5 (Ph-CQ), 143.4 (CH-2), 139.6 (CQ-7 
or CQ-8’), 139.5 (CQ-7 or CQ-8’), 133.6 (Bz-CQ), 131.7 (para Ph-CH), 129.7 (meta Bz-CH), 
129.3 (CH-5), 129.1 (para Bz-CH), 128.7 (meta Ph-CH), 126.7 (ortho Ph-CH), 126.4 (ortho 
Bz-CH), 126.2 (CH-6), 123.6 (CQ-4’), 115.8 (CH-8), 106.3 (CH-3), 57.4 (CH2) 
HRMS (EI) m/z: Calcd. [M]
+  
408.0694 
 Measured     408.0699 
LRMS (EI) m/z:   410 (23), 408 (57, [M]
+
), 346 (18), 344 (53), 343 (15), 91 (100, 
[CH2Ph]
+
) 
IR vmax (neat/cm
-1
): 3076 (Ar C-H), 3026, 2970, 1741 (S=O), 1603 (C=C), 1537, 1528 
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m.p.: 231 - 232 °C 
 
 
(E)-N-(7-chloro-1-pentylquinolin-4(1H)-ylidene)benzenesulfonamide (40) 
  White feathery solid 
 Chemical formula: C20H21ClN2O2S 
 Molecular weight: 388.91 g.mol-1 
 Yield: 85% 
 
To a suspension of 34 (0.07 g, 0.28 mmol) in CH3CN (2 ml) benzenesulfonyl 
isocyanate (75.0 µl, 0.56 mmol) was added and the resulting mixture was heated at 
70 °C for 24 h. After cooling to ambient temperature, MeOH (2 ml) was added and 
the mixture was evaporated in vacuo. The remaining residue was purified via 
column chromatography (2:3 petroleum ether:EtOAc) followed by recrystallization 
(CHCl3) to afford 40 (93 mg, 85%) as white feathery solid. 
1
H NMR (CDCl3, 600 MHz) δ ppm: 8.61 (1H, d, J= 8.9, CH-5), 8.07-8.04 (2H, m, ortho Ph-
CH), 7.59 (1H, d, J= 7.6, CH-2), 7.51-7.45 (3H, m, meta Ph-CH, para Ph-CH), 7.44 (1H, d, 
J= 1.6, CH-8), 7.38 (1H, d, J= 7.6, CH-3), 7.37 (1H, dd, J= 8.9, 1.6, CH-6), 4.16 (2H, t, J= 
7.6, NCH2), 1.84 (2H, q, J= 7.6, NCH2CH2), 1.41-1.30 (4H, m, CH2CH2CH3), 0.91 (3H, t, J= 
7.0, CH3) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 160.9 (CQ-4), 143.5 (Ph-CQ), 143.0 (CH-2), 139.6 (CQ-7 
or CQ-8’), 139.0 (CQ-7 or CQ-8’), 131.6 (para Ph-CH), 129.5 (CH-5), 128.7 (meta Ph-CH), 
126.7 (ortho Ph-CH), 126.0 (CH-6), 123.7 (CQ-4’), 115.1 (CH-8), 106.2 (CH-3), 54.3 (NCH2), 
28.8 (NCH2CH2, CH2CH2CH3), 22.3 (CH2CH3), 14.0 (CH3) 
HRMS (EI) m/z: Calcd. [M]
+  
388.1007 
 Measured     388.1001 
LRMS (EI) m/z:  390 (27), 388 (73, [M]
+
), 326 (31), 325 (38), 324 (100), 323 (62), 253 (15), 
84 (17), 77 (16) 
IR vmax (neat/cm
-1
): 2970 (Ar C-H), 2950, 2928, 2869 (aliphatic C-H), 1741 (S=O), 1617 
(C=N), 1601 (C=C), 1539, 1531 
m.p.: 143 – 144 °C 
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Route C: 
 
 
Scheme 32. Synthesis of iminodihydroquinolines 55 and 56 from 2,4-dichlorobenzoic acid. 
Reagents and conditions: (i) (COCl)2, DMF (cat.), DCM, rt, 2h, quant. (ii) ethyl 3-(N,N-
dimethylamino)acrylate, NEt3, CH3CN, 70 °C, 3-5 h (iii) NH2-R
2
, 70 °C, 18 h (iv) NaH, THF, 
reflux, 4-6.5 h (v) NaOH, THF/EtOH (6:1), 50-60 °C, 6 h (vi) HCl (aq.), biphenyl ether, 260 
°C, 7 h (vii) POCl3, 100 °C, 2 h (viii) n-pentylamine, rt, 2-3 h. 
 
2,4-Dichloro-benzoyl chloride (50) 
Yellow oil 
 Chemical formula: C7H3Cl3O 
 Molecular Weight: 209.46 g.mol-1 
 Yield: quantitative 
To a solution of 2,4-dichlorobenzoic acid (5.05 g, 26.28 mmol) in DCM (300 ml) 
under an atmosphere of argon, oxalyl chloride (2.75 ml, 31.52 mmol) was added 
followed by DMF (4 drops) and the solution was stirred at ambient temperature for 2 
h. The solvents were evaporated in vacuo, and to the remaining residue toluene was 
added (150 ml) and the mixture was evaporated again to afford 50 as yellow oil 
(5.45 g, quantitative). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 8.07 (1H, d, J= 8.6, CH-6), 7.51 (1H, d, J= 2.1, CH-3), 
7.40 (1H, dd, J= 8.6, 2.1, CH-5) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 164.2, 140.9, 135.2, 134.8, 131.6, 131.0, 127.6 
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Ethyl 2-(2,4-dichlorobenzoyl)-3-(phenylamino)acrylate (52a) 
Beige solid 
 Chemical formula: C18H15Cl2NO3 
 Molecular weight: 364.22 g.mol-1 
 Yield: 31% 
 Mixture of stereoisomers: 77:33 (52a:52a”) 
To a solution of CH3CN (40 ml) and NEt3 (14.94 ml, 0.11 mmol), ethyl 3-(N,N-
dimethylamino)acrylate (5.75 ml, 40.17 mmol) and 50 (5.61 g, 26.78 mmol) were 
added, and the resulting mixture was heated at 70 °C for 3 h under argon 
atmosphere. After cooling at ambient temperature, aniline (2.44 ml, 26.78 mmol) 
was added and the mixture was heated at 70 °C for 18 h further. After cooling at 
ambient temperature, H2O (40 ml) and CH3CN (40 ml) were added and the resulting 
mixture was stirred for 15 min. The organic products were extracted with EtOAc (3 x 
100 ml), and the organic products were dried over anh. MgSO4 and evaporated in 
vacuo. Purification via column chromatography (1:5 petroleum ether:EtOAc) 
afforded 52a as beige solid (3.03 g, 31%). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 12.71 (1H, d, J= 13.2, NH), 11.26 (1H, d, J= 13.8, NH”), 
8.67 (1H, d, J=14.1, C=CH”), 8.65 (1H, d, J=13.6, C=CH), 7.46-7.39 (2H, m, meta Ph-H, 
meta Ph-H”), 7.38 (1H, d, J= 2.0, CH-3), 7.37 (1H, d, J= 2.0, CH-3”), 7.31-7.18 (5H, m, CH-5, 
CH-5”, CH-6, CH-6”, ortho Ph-H, ortho Ph-H”, para Ph-H, para Ph-H”), 4.04 (2H, q, J= 7.0, 
CH2), 4.01 (2H, q, J= 7.3, CH2”), 1.02 (3H, t, J= 7.2, CH3), 0.88 (3H, t, J= 7.2, CH3”) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 193.5 (CQO), 190.5 (CQO), 168.5(CQO), 166.5(CQO), 
153.3 (CH), 152.7 (CH), 141.2 (CQ), 140.9 (CQ), 138.7 (CQ), 138.6 (CQ), 135.0(CQ), 134.9 
(CQ), 130.9 (CQ), 130.1 (CH), 130.0 (CH), 129.2 (CH), 129.0 (CH), 128.9 (CH), 128.3 (CH),, 
127.0 (CH), 126.9 (CH), 126.4 (CH), 126.0 (CH), 118.2 (CH), 117.8 (CH), 103.4 (CQ), 103.3 
(CQ), 60.4 (CH2), 60.2 (CH2), 13.9 (CH3), 13.5 (CH3) 
HRMS (EI) m/z:  Calcd. [M]
+
 363.0423 
 Measured 363.0427 
LRMS (EI) m/z:  365 (7), 363 (10, [M]
+
), 330 (26), 328 (83, [C18H15ClNO3]
+
), 300 (25), 
284 (27), 282 (86), 175 (62), 173 (100, [C7H3Cl2NO]
+
), 145 (34, 
[C6H3Cl2]
+
) 
m.p.: 74 - 75 °C 
 
 
3-Cyclohexylamino-2-(2,4-dichloro-benzoyl)-acrylic acid ethyl ester (52b) 
White solid 
 Chemical formula: C18H21Cl2NO3 
 Molecular weight: 370.27 g.mol-1 
 Yield: 61% 
 Mixture of stereoisomers: 83:17 (52b:52b”) 
To CH3CN (5 ml), Et3N (1.33 ml, 9.54 mmol), ethyl 3-(N,N-dimethylamino)acrylate (0.51 
ml, 3.58 mmol), and 50 (0.50 g, 2.39 mmol) were added and the resulting mixture 
was heated at 70 °C for 5 h under argon atmosphere. After cooling at ambient 
temperature, cyclohexylamine (0.28 ml, 2.39 mmol) was added and the mixture was 
heated at 70 °C for 18 h further. After cooling at ambient temperature, H2O (10 ml) 
was added and the resulting mixture was stirred for 15 min. The resulting precipitate 
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was filtered, was washed with a solution of H2O and CH3CN (1:1, 100 ml) and dried 
in vacuo to afford 52b as white solid (0.54 g, 61%). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 11.11 (1H, s, br, NH), 9.60 (1H, s,br, NH”), 8.27 (1H, d, 
J=14.8, C=CH”), 8.18 (1H, d, J=14.2, C=CH), 7.34 (1H, d, J=1.9, CH-3), 7.33 (1H, d, J=1.9, 
CH-3”), 7.21-7.25 (1H, m, CH-5, CH-5"), 7.16 (1H, d, J=8.2, CH-6”), 7.13 (1H, d, J=8.2, CH-
6), 3.96 (2H, q, J=7.1, CH2CH3), 3.91 (2H, q, J=7.1, CH2”CH3), 3.29-3.40 (1H, m, 
NHCH(CH2)2), 1.96-2.06 (2H, m, CH2), 1.77-1.87 (2H, m, CH2), 1.62-1.69 (1H, m, CH2), 
1.33-1.53 (4H, m, CH2), 1.19-1.30 (1H, m, CH2), 0.96 (3H, t, J=7.1, CH3), 0.82 (3H, t, J=7.1, 
CH3”) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 192.3 (CQO), 190.2 (CQO), 168.8 (CQO), 166.9 (CQO), 
159.0 (CH), 158.8 (CH), 142.0 (CQ), 141.5 (CQ), 134.3 (CQ), 134.2 (CQ), 131.1 (CQ), 130.8 
(CQ), 128.9 (CH), 128.8 (CH), 128.6 (CH), 128.1 (CH), 126.8 (CH), 126.7 (CH), 100.4 (CQ), 
100.0 (CQ),  59.9 (CH2), 59.6 (CH2), 59.1 (CH), 58.9 (CH), 33.8 (CH2), 33.7 (CH2), 25.1 
(CH2), 24.5 (CH2), 14.0 (CH3), 13.5 (CH3) 
HRMS (CI) m/z:  Calcd. [M]
+
 370.0977 
 Measured 370.0971 
LRMS (CI) m/z:  372 (66), 370 (100, [M]
+
), 334 (51), 324 (40, C16H16Cl2NO2
+
) 
IR vmax (neat/cm
-1
):  3211 (NH), 3078 (C=C-H), 2981 (Ar-H), 2935 (CH2, CH3), 2857 (–CH), 
1670 (C=O), 1612 (C=C) 
m.p.: 124 - 125 °C 
 
 
7-Chloro-4-oxo-1-phenyl-1,4-dihydro-quinoline-3-carboxylic acid (53a) 
White crystalline solid 
 Chemical formula: C16H10ClNO3 
 Molecular weight: 299.71 g.mol-1 
 Yield: 58% 
 
To a solution of NaH (60% in mineral oil, 0.50 g, 12.48 mmol) in THF (70 ml), 52a 
(3.03 g, 8.32 mmol) was added slowly and the mixture was heated at 65 °C for 4 h 
under an atmosphere of argon. The resulting mixture was cooled to ambient 
temperature, and was neutralised to pH 7 by addition of acetic acid (glacial). The 
solution was evaporated in vacuo, and to the remaining residue water (200 ml) was 
added. The precipitate formed was filtered and was re-dissolved in a mixture of THF 
(60 ml) and EtOH (10 ml). NaOH (6.24 ml, 2M) was added, and the resulting 
solution was heated at 60 °C for 5 h. The solvents were evaporated in vacuo and 
water (200 ml) was added to the remaining residue. The aqueous layer was acidified 
to pH 3 by HCl (1M) addition. The organic products were extracted with DCM (3 x 
100 ml), and the organic extracts were dried over anh. MgSO4 and evaporated in 
vacuo to afford 53a as white solid (2.70 g, 58%). 
1
H NMR (DMSO-d6, 600 MHz) δ ppm: 14.76 (1H, s, br, COOH), 8.73 (1H, s, CH-2), 8.44 
(1H, d, J= 8.7, CH-5), 7.77-7.68 (6H, m, Ph-CH, CH-6), 7.04 (1H, d, J= 1.9, CH-8) 
13
C NMR (DMSO-d6, 150 MHz) δ ppm: 177.6 (CQ-4), 165.4 (COOH), 149.9 (CH-2) 141.9 
(CQ-8’), 139.6 (CQ-Ph), 139.0 (CQ-7), 130.7 (CH-6 or para Ph-CH), 130.5 (meta Ph-CH), 
128.1 (CH-5), 127.5 (ortho Ph-CH), 126.9 (CH-6 or para Ph-CH), 123.9 (CQ-4’), 118.1 (CH-
8), 108.6 (CH-3) 
HRMS (ES+) m/z: Calcd. [M+H]
+ 
300.0427 
 Measured  300.0433 
LRMS (ES+) m/z: 302 (33), 300 (100, [M+H]
+
), 256 (12), 254 (25, [M-COOH]
+
), 191 (10) 
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IR vmax (neat/cm
-1
): 3072 (Ar C-H), 2623 (broad, O-H), 1726 (C=O), 1602 (C=N), 1585         
(Ar C=C), 1551, 1536, 1501 
m.p: > 250 °C 
 
 
7-Chloro-1-cyclohexyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid (53b) 
White powder 
 Chemical formula: C16H16ClNO3 
 Molecular Weight: 305.76 g.mol-1 
 Yield: quantitative 
 
To a solution of 52b (0.06 g, 0.18 mmol) in THF (6 ml) and EtOH (1 ml), NaOH (0.14 
ml, 2 M) was added, and the mixture was heated at 60 oC for 6 h. The solvents were 
evaporated in vacuo and to the remaining residue water (150 ml) was added. The 
aqueous layer was acidified to pH 3 with HCl (1 M) and the organic products were 
extracted with DCM (3 x 100 ml). The organic extracts were dried over anh. MgSO4 
and evaporated to afford 53b as white solid (0.05 g, quantitative). 
1
H NMR (CDCl3, 600 MHz) δ ppm:
 
14.79 (1H, s, COOH), 8.89 (1H, s, CH-2), 8.51 (1H, d, J= 
8.6, CH-5), 7.69 (1H, d, J= 1.7, CH-8), 7.54 (1H, dd, J= 8.6, 1.7, CH-6), 4.45 (1H, tt, J= 11.9, 
3.2, NCH(CH2)2), 2.19 (2H, d, J= 11.9, cyclohexyl CH2-2, cyclohexyl CH2-6), 2.12-2.05 (2H, 
m, cyclohexyl CH2-3, cyclohexyl CH2-5), 1.92-1.79 (3H, m, cyclohexyl CH2-2, cyclohexyl 
CH2-4, cyclohexyl CH2-6), 1.60 (2H, qt, J= 13.5, 3.5, cyclohexyl CH2-3, cyclohexyl CH2-5), 
1.34 (1H, qt, J= 13.3, 3.9, cyclohexyl CH2-4) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 176.6 (CQ-4), 167.0 (CQOOH), 144.8 (CH-2), 140.9 (CQ-
7 or CQ-8’), 140.5 (CQ-7 or CQ-8’), 129.3 (CH-5), 126.9 (CH-6), 125.3 (CQ-4’), 115.8 (CH-8), 
109.4 (CQ-3), 60.8 (NCH(CH2)2), 33.0 (cyclohexyl CH2-2, cyclohexyl CH2-6), 25.9 (cyclohexyl 
CH2-3, cyclohexyl CH2-5), 25.2 (cyclohexyl CH2-4) 
HRMS (CI) m/z: Calcd. [M+H]
+ 
306.0897 
 Measured     306.0904 
LRMS (CI) m/z:  308 (31), 306 (100, [M+H]
+
) 
IR vmax (neat/cm
-1
): 3084 (Ar C-H), 2936, 2863 (alkyl C-H), 2658 (broad O-H), 1714 (C=O), 
1604, 1555 (Ar C=C), 1534, 1501 
m.p.: > 250 °C 
 
 
7-Chloro-1-phenyl-1H-quinolin-4-one (54a) 
Pale pink solid 
 Chemical formula: C15H10ClNO 
 Molecular weight: 255.70 g.mol-1 
 Yield: 18% 
 
A mixture of 53a (1.48 g, 4.68 mmol) and HCl (0.47 ml, 10 M) was heated in 
biphenyl ether (16 g) at 260 °C for 7 h. The solution was allowed to cool to ~ 40 °C, 
and petroleum ether (200 ml) was added while stirring vigorously. The precipitate 
formed was filtered, was washed with petroleum ether (2 x 100 ml) and was dried in 
vacuo. Purification via flash column chromatography (EtOAc → 1:19 MeOH:EtOAc) 
afforded 54a (0.21 g, 18%) as pale pink solid.  
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1
H NMR (CDCl3, 600 MHz) δ ppm:
 
8.41 (1H, d, J= 8.7, CH-5), 7.69-7.59 (4H, m, CH-2, meta 
Ph-CH, para Ph-CH), 7.42-7.38 (2H, m, ortho Ph-CH), 7.36 (1H, dd, J= 8.7, 1.9, CH-6), 7.01 
(1H, d, J= 1.9, CH-8), 6.59 (1H, d, J= 8.0, CH-3) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 177.2 (CQ-4), 143.7 (CH-2), 142.1 (CQ-8’), 140.7 (Ph-
CQ), 139.0 (CQ-7), 130.8 (para Ph-CH), 130.2 (meta Ph-CH), 128.4 (CH-5), 127.5 (ortho Ph-
CH), 125.3 (CH-6), 124.5 (CQ-4’), 117.1 (CH-8), 110.5 (CH-3) 
HRMS (EI) m/z: Calcd. [M]
+ 
255.0445 
 Measured  255.0440 
LRMS (EI) m/z: 257 (30), 255 (100, [M]
+
), 229 (11), 227 (37), 191 (12), 165 (13), 110 
(11), 96 (14), 78 (14, [M+H-Ph]
+
) 
m.p.: 192-193 °C 
 
 
7-Chloro-1-cyclohexyl-1H-quinolin-4-one (54b) 
Beige powder 
 Chemical formula: C15H16ClNO 
 Molecular Weight: 261.75 g.mol-1 
 Yield: 24% 
 
A mixture of 53b (2.61 g, 8.53 mmol) and HCl (0.86 ml, 10 M) in biphenyl ether (25 
g) was heated at 260 oC for 7 h. The solution was allowed to cool to ~40 °C, and 
petrol was added (200 ml), while stirring vigorously. The precipitate formed was 
filtered, was washed with petrol and was dried in vacuo. Purification via flash column 
chromatography (EtOAc → 1:1:18 NEt3:MeOH:EtOAc) afforded 54b (0.54 g, 24%) 
as beige solid. 
1
H NMR (CDCl3, 600 MHz) δ ppm:
 
8.42 (1H, d, J= 8.7, CH-5), 7.71 (1H, d, J= 8.0, CH-2), 
7.51 (1H, d, J= 1.8, CH-8), 7.32 (1H, dd, J= 8.7, 1.8, CH-6), 6.30 (1H, d, J= 8.0, CH-3), 4.27 
(1H, tt, J= 11.8, 3.5, NCH(CH2)2), 2.12 (2H, d, J= 11.8, cyclohexyl CH2-2, cyclohexyl CH2-6), 
2.05-1.98 (2H, m, cyclohexyl CH2-3, cyclohexyl CH2-5), 1.89-1.82 (1H, m, cyclohexyl CH2-4), 
1.69  (2H, qd, J= 12.5, 3.5, cyclohexyl CH2-2, cyclohexyl CH2-6), 1.57 (2H, qt, J= 13.2, 3.5, 
cyclohexyl CH2-3, cyclohexyl CH2-5), 1.30 (1H, qt, J= 13.2, 4.0, cyclohexyl CH2-4) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 177.2 (CQ-4), 140.9 (CQ-8’), 138.7 (CQ-7), 138.4 (CH-2), 
129.2 (CH-5), 126.0 (CQ-4’), 124.1 (CH-6), 114.5 (CH-8), 110.8 (CH-3), 58.8 (NCH(CH2)2), 
32.8 (cyclohexyl CH2-2, cyclohexyl CH2-6), 26.0  (cyclohexyl CH2-3, cyclohexyl CH2-5), 25.5 
(cyclohexyl CH2-4) 
HRMS (EI) m/z: Calcd. [M]
+ 
261.0915 
 Measured  261.0922 
LRMS (EI) m/z:  263 (6), 261 (25, [M]
+
), 182 (19), 181 (38), 180 (51), 179 (100, [M+H-
cyclohexyl]
+
), 152 (12), 151 (19), 150 (25) 
IR vmax (neat/cm
-1
): 3471, 3074 (Ar C-H), 2933, 2858 (alkyl C-H), 1628 (C=O), 1589 (Ar 
C=C), 1538 
m.p.: 130-131 °C 
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(E)-7-chloro-N-pentyl-1-phenylquinolin-4(1H)-imine (55) 
Pale brown crystalline solid (needles) 
 Chemical formula: C20H21ClN2 
 Molecular weight: 324.85 g.mol-1 
 Yield: 96% 
 
A solution of 54a (0.22 g, 0.84 mmol) in POCl3 (4 ml), was heated at 100 
oC for 2 h. 
The resulting solution was cooled to ambient temperature, DCM (4 ml) was added 
and the resulting mixture was evaporated in vacuo. DCM (4 ml) was added and the 
mixture was evaporated again. To the remaining residue, n-pentylamine (0.54 ml, 
4.66 mmol) was added dropwise and the mixture was stirred at ambient temperature 
for 2 h. The resulting solution was poured into an ice (~ 50 cm3) and NaOH (50 ml, 2 
M) mixture while stirring vigorously. The organic products were extracted with EtOAc 
(2 x 100 ml) and the organic extracts were dried over anh. MgSO4 and evaporated 
in vacuo. Purification via flash column chromatography using basic Al2O3 as the 
solid phase (EtOAc → 1:9 MeOH:EtOAc), followed by recrystallization (MeOH) 
afforded 55 as pale brown crystalline solid (0.26 g, 96%). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 8.41 (1H, d, J= 8.8, CH-5), 7.56 (2H, t, J= 7.6, meta Ph-
CH), 7.50 (1H, t, J= 7.6, para Ph-CH), 7.34 (2H, d, J= 7.6, ortho Ph-CH), 7.12 (1H, dd, J= 
8.8, 1.8, CH-6), 6.96 (1H, d, J= 8.1, CH-2), 6.72 (1H, d, J= 1.8, CH-8), 6.06 (1H, d, J= 8.1, 
CH-3), 3.36 (2H, t, J= 7.5, NCH2), 1.75 (2H, q, J= 7.5, NCH2CH2), 1.47-1.35 (4H, m, 
CH2CH2CH3), 0.93 (3H, t, J= 7.1, CH3) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 153.5 (CQ-4), 141.7 (Ph-CQ), 140.7 (CQ-8’), 138.0 (CH-
2), 135.8 (CQ-7), 130.5 (meta Ph-CH), 129.0 (para Ph-CH), 127.9 (ortho Ph-CH), 127.0 (CH-
5), 123.8 (CH-6), 115.8 (CH-8), 99.5 (CH-3), 50.4 (NCH2), 31.0 (NCH2CH2), 30.2 
(CH2CH2CH3), 22.9 (CH2CH3), 14.4 (CH3), [CQ-4’, hidden] 
HRMS (EI) m/z: Calcd. [M]
+ 
324.1388 
 Measured  324.1392 
LRMS (EI) m/z: 324 (13, [M]
+
), 283 (13), 281 (41, [M-CH2CH2CH3]
+
), 269 (29), 267 
(100, [M-CH2(CH2)2CH3]
+
), 254 (14, [M-CH2(CH2)3CH3+H]
+
), 86 (17), 84 
(29) 
IR vmax (neat/cm
-1
): 3038 (Ar C-H), 2959, 2930, 2841, 2812 (aliphatic C-H), 1634 (C=N), 
1595 (Ar C=C), 1572, 1549 
m.p.: 78-79 °C 
 
 
(E)-7-chloro-1-cyclohexyl-N-pentylquinolin-4(1H)-imine hydrochloride (56) 
White solid 
 Chemical formula: C20H27ClN2 ∙ HCl 
 Molecular weight: 367.36 g.mol-1 
 Yield: 68% 
 
A solution of 54b (0.29 g, 1.11 mmol) in POCl3 (4 ml), was heated at 100 °C for 2 h. 
The resulting solution was cooled to ambient temperature, DCM (4 ml) was added 
and the mixture was evaporated in vacuo. DCM (4 ml) was added and the mixture 
was evaporated again. To the remaining residue, n-pentylamine (0.71 ml, 6.11 
mmol) was added dropwise and the mixture was stirred at ambient temperature for 3 
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h. The resulting solution was poured into an ice (~ 50 cm3) and NaOH (2M, 50 ml) 
mixture while stirring vigorously. The organic products were extracted with EtOAc (2 
x 100 ml) and the organic extracts were dried over anh. MgSO4 and evaporated in 
vacuo. Purification via flash column chromatography using basic Al2O3 as the solid 
phase (EtOAc → 1:9 EtOAc:MeOH), followed by recrystallization (CHCl3) afforded 
56 as white solid (0.27 g, 68%). 
1
H NMR (CDCl3, 600 MHz) δ ppm:
 
11.36 (1H, t, J= 7.0, =NH
+
), 9.61 (1H, d, J= 9.0, CH-5), 
8.13 (1H, d, J= 7.8, CH-2), 7.67 (1H, d, J= 1.9, CH-8), 7.61 (1H, dd, J= 9.0, 1.9, CH-6), 6.52 
(1H, d, J= 7.8, CH-3), 4.49 (1H, tt, J= 11.9, 3.7, NH(CH2)2), 3.59 (2H, q, J= 7.0, =NCH2), 2.18 
(2H, d, J= 11.7 cyclohexyl CH2-2, cyclohexyl CH2-6), 2.10-2.03 (2H, m, cyclohexyl CH2-3, 
cyclohexyl CH2-5), 1.92-1.85 (cyclohexyl CH2-4), 1.84-1.73 (4H, m, =NCH2CH2, cyclohexyl 
CH2-2, cyclohexyl CH2-6), 1.62 (2H, qt, J= 13.1, 3.7, cyclohexyl CH2-3, cyclohexyl CH2-5), 
1.42-1.29 (5H, m, CH2CH2CH3, cyclohexyl CH2-4),  0.87 (3H, J= 7.1, CH3) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 155.2 (CQ-4), 140.9 (CQ-7), 140.3 (CH-2), 138.6 (CQ-8’), 
130.1 (CH-5), 127.7 (CH-6), 117.6 (CQ-4’), 115.3 (CH-8), 98.5 (CH-3), 60.7 (NCH(CH2)2), 
44.0 (=NCH2), 33.1 (cyclohexyl CH2-2, cyclohexyl CH2-6), 29.3 (CH2CH2CH3), 27.9 
(=NCH2CH2), 25.9 (cyclohexyl CH2-3, cyclohexyl CH2-5), 25.2 (cyclohexyl CH2-4), 22.5 
(CH2CH3), 14.2 (CH3) 
HRMS (CI) m/z: Calcd. [M+H]
+ 
331.1940 
 Measured  331.1949 
LRMS (EI) m/z:  333 (33), 331 (100, [M+H]
+
), 289 (6), 287 (17, [M-CH2CH2CH3]
+
), 275 
(7), 273 (23, [M-CH2(CH2)2CH3]
+
), 191 (8) 
IR vmax (neat/cm
-1
): 3371 (N-H), 2992 (Ar C-H), 2926, 2853 (Alkyl C-H), 1606 (C=N), 1581 
(Ar C=C), 1525 
m.p: 231 - 232 °C 
 
 
 
 
 
Scheme 33. Synthesis of iminodihydroquinoline 61 from 4-fluoro-2-chloroacetophenone. 
Reagents and conditions: (i) N,N-dimethylformamide dimethyl acetal, toluene, reflux, 24 h (ii) 
3-fluorobenzyl amine, acetic acid, 60 °C, 8 h (iii) NaH, DMF, 80 °C, 3 h (iv) POCl3, 100 °C, 
2.5 h (v) n-pentylamine, MeOH, rt, 5 h. 
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(E)-1-(2-chloro-4-fluorophenyl)-3-(dimethylamino)prop-2-en-1-one (58) 
Yellow/brown viscous oil 
 Chemical Formula: C11H11ClFNO 
 Molecular weight: 227.66 
 Yield: 61% 
To a solution of 4-fluoro-2-chloroacetophenone (1.79 g, 10.40 mmol) in toluene (15 
ml), N,N-dimethylformamide dimethyl acetal (1.65 ml, 12.42 mmol) was added and 
the resulting solution was heated to reflux at 110 °C for 24 h under an atmosphere 
of argon. After cooling to room temperature the solution was evaporated in vacuo 
and the remaining residue was purified by column chromatography (1:1 petroleum 
ether:EtOAc → EtOAc) to afford 58 as yellow/brown viscous oil (1.45 g, 61%). 
1
H NMR (600 MHz, CDCl3) δ ppm: 7.40 (1H, br, CH-6), 7.12 (1H, dd, J= 8.7, 2.7, CH-3), 6.98 
(1H, td, J= 8.3, 2.5, CH-5), 5.35 (1H, d, J= 12.5, CHN(CH3)2), 3.10 (3H, s, br, CH3), 2.88 (3H, 
s, br, CH3) 
13
C NMR (150 MHz, CDCl3) δ ppm: 162.5 (d, 
1
JCF = 256.4, CQ-4), 132.1 (d, 
3
JCF= 10.6, CQ-
2), 130.5 (d, 
3
JCF= 9.0, CH-6), 117.4 (d, 
2
JCF= 23.1, CH-3), 114.0 (d, 
2
JCF= 21.2, CH-5), 45.3 
(CH3), 37.3 (CH3) 
HRMS (CI) m/z: Calcd. [M+H]
+
  228.0586 
 Measured   228.0586 
LRMS (CI) m/z:  230 (33), 231 (21), 228 (100, [M+H]
+
), 227 (22), 212 (9), 210 (26), 193 
(33, [M-Cl]
+
), 157 (10, [M- C=CN(CH3)2]
+
), 98 (14, [COC=CN(CH3)2]
+
) 
IR vmax (neat/cm
-1
): 3042 (Ar C-H), 3019, 2920, 2805 (aliphatic C-H), 1640 (C=O), 1578 (Ar 
C=C), 1538 
 
 
(E)-1-(2-chloro-4-fluorophenyl)-3-((3-fluorobenzyl)amino)prop-2-en-1-one (59) 
Viscous orange oil 
 Chemical Formula: C16H12ClF2NO 
 Molecular weight: 307.72 
 Yield: 48% 
 
 
To a mixture of 58 (1.28 g, 5.62 mmol) in acetic acid (20 ml), 3-fluorobenzyl amine 
(0.47 ml, 5.69 mmol) was added and the mixture was heated at 60 °C for 8 h. After 
cooling to room temperature, the solution was evaporated in vacuo and the 
remaining residue was purified by column chromatography (2:3 petroleum 
ether:EtOAc) to afford 59 as viscous orange oil (0.84 g, 48%). 
1
H NMR (600 MHz, CDCl3) δ ppm: 10.43 (1H, s, br, NH-10), 7.51 (1H, dd, 
3
JHH= 8.6, 
4
JHF= 
6.2, CH-6), 7.34 (1H, ddd, 
3
JHH= 9.2, 7.8, 
4
JHF= 5.5, CH-16), 7.12 (1H, dd, 
3
JHF= 8.6, 
4
JHH= 
2.5, CH-3), 7.08 (1H, dd, 
3
JHH= 7.3, 
4
JHH= 1.8, CH-17), 7.03-6.98 (3H, m, CH-5, CH-13, CH-
15), 6.97-6.94 (1H, m, CH-9), 5.47 (1H, d, J= 7.4, CH-8), 4.46 (2H, d, J= 6.0, CH2-11) 
13
C NMR (150 MHz, CDCl3) δ ppm: 190.3 (CQ-7), 163.2 (d, 
1
JCF= 247.7, CQ-4 or CQ-14), 
162.8 (d, 
1
JCF= 252.8, CQ-4 or CQ-14), 154.1 (CH-9), 140.1 (d, 
3
JCF= 6.9, CQ-12), 137.0 (d, 
4
JCF= 3.5, CQ-1), 132.3 (d, 
3
JCF= 10.5, CQ-2), 131.0 (d, 
3
JCF= 9.1, CH-6), 130.6 (d, 
3
JCF= 8.3, 
CH-16), 122.9 (d, 
4
JCF= 3.0, CH-16), 117.7 (d, 
2
JCF= 24.8, CH-3), 115.0 (d, 
2
JCF= 20.9, CH-13 
or CH-15), 114.4 (d, 
2
JCF= 21.8, CH-13 or CH-15), 114.1 (d, 
2
JCF= 21.0, CH-5), 93.3 (CH-8), 
52.4 (d, 
4
JCF= 2.0, CH2-11) 
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HRMS (ES-) m/z: Calcd. [M-H]
-
  306.0497 
 Measured  306.0497 
LRMS (ES-) m/z:  308 (33), 306 (100, [M-H]
-
) 
IR vmax (neat/cm
-1
): 3269 (N-H), 3063 (Ar C-H), 2919, 2851 (aliphatic C-H), 1630 (C=O), 
1589 (Ar C=C) 
 
 
7-Fluoro-1-(3-fluoro-benzyl)-1H-quinolin-4-one (60) 
Yellow solid 
 Chemical formula: C16H11F2NO 
 Molecular weight: 271.27 g.mol-1 
 Yield: 14% 
 
 
To a solution of 59 (0.84 g, 2.72 mmol) in DMF (15 ml) cooled to 0 °C, NaH (60% in 
mineral oil, 0.11 g, 2.75 mmol) was added portion wise. The mixture was then 
heated at 80 °C for 3 h.  After cooling to room temperature, water was added (150 
ml). The organic products were extracted with EtOAc (2 x 100 ml), and the organic 
extracts were dried over anh. MgSO4 and evaporated in vacuo. The remaining 
residue was purified by column chromatography (EtOAc -> 1:9 MeOH:EtOAc) to 
afford 60 as yellow solid (0.10 g, 14%). 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.47 (1H, dd, 
3
JHH= 8.8, 
4
JHF= 6.5, CH-5), 7.60 (1H, d, J= 
7.8, CH-2), 7.35 (1H, ddd, 
3
JHH= 8.3, 7.8, 
4
JHF= 5.9, CH-15), 7.08 (1H, td, 
3
JHF= 8.8, 
3
JHH= 
8.8, 
4
JHH= 2.3, CH-6), 7.03 (1H, td, 
3
JHF= 8.3, 
3
JHH= 8.3, 
4
JHH= 1.8, CH-14), 6.92 (1H, dd, J= 
7.8, 1.8, CH-16), 6.89 (1H, dd, 
3
JHF= 10.6, 
4
JHH= 2.3, CH-8), 6.84 (1H, dt, 
3
JHF= 9.4, 
4
JHH= 
1.8, CH-12), 6.34 (1H, d, J= 7.8, CH-3), 5.24 (2H, s, CH2-10) 
13
C NMR (150 MHz, CDCl3) δ ppm: 177.6 (CQ-4), 165.1 (d, 
1
JCF= 252.1, CQ-7), 163.4 (d, 
1
JCF= 248.7, CQ-13), 143.9 (CH-2), 141.6 (d, 
2
JCF= 11.6, CQ-8’), 137.2 (d, 
3
JCF= 6.9, CQ-11), 
131.3 (d, 
3
JCF= 8.4, CH-15), 130.3 (d, 
3
JCF= 10.7, CH-5), 124.1 (CQ-4’), 121.6 (d, 
4
JCF= 3.1, 
CH-16), 115.8 (d, 
2
JCF= 21.0, CH-14), 113.2 (d, 
2
JCF= 22.4, CH-12), 112.8 (d, 
2
JCF= 22.8, CH-
6), 111.2 (CH-3), 102.2 (d, 
2
JCF= 26.6, CH-8), 56.2 (CH2-10) 
19
F NMR (282 MHz, CDCl3) δ ppm: -104.93, -111.23 
HRMS (EI) m/z: Calcd. [M]
+
 271.0803 
 Measured 271.0793 
LRMS (EI) m/z:  272 (10), 271 (58, [M]
+
), 109 (100, [CH2PhF]
+
), 107 (10) 
IR vmax (neat/cm
-1
): 3079 (Ar C-H), 3055, 2920, 2850 (aliphatic C-H), 1629, 1605, 1576 
m.p.: 129-131 °C 
 
 
[7-Fluoro-1-(3-fluoro-benzyl)-1H-quinolin-4-ylidene]-pentyl-amine 
hydrochloride (61) 
White powder 
 Chemical formula: C21H22F2N2 ∙ HCl 
 Molecular Weight: 376.88 g.mol-1 
 Yield: 50% 
 
A solution of 60 (0.10 g, 0.37 mmol) in POCl3 (3 ml), was heated to reflux for 2.5 h. 
After cooling to room temperature, the mixture was evaporated in vacuo, DCM (2 x 
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20 ml) was added and the mixture was evaporated again. The remaining residue 
was triturated with ether. The resulting precipitate was dissolved in MeOH (2 ml), 
amylamine (0.23 ml, 1.98 mmol) was added dropwise and the solution was stirred at 
room temperature for 5 h. The solution was poured into an ice (~30 cm3) and NaOH 
(2 M, 30 ml) mixture while stirring vigorously. The organic products were extracted 
with DCM (2 x 100 ml), the organic extracts were dried over anh. MgSO4 and were 
evaporated in vacuo. Trituration with Et2O afforded the hydrochloride salt 61 (70 mg, 
50%) as white powder. 
1
H NMR (600 MHz, CDCl3) δ ppm: 11.36 (1H, br, s, NH
+
), 9.59 (1H, dd, 
3
JHH= 9.4, 
4
JHF= 5.6, 
CH-5), 8.32 (1H, d, J= 7.5, CH-2), 7.35 (1H, td,
 3
JHH= 8.2, 
4
JHF= 5.7, CH-15), 7.29-7.25 (1H, 
m, CH-6), 7.16 (1H, dd, 
3
JHF= 9.9, 
4
JHH= 2.5, CH-8), 7.04 (1H, td, 
3
JHF= 8.2, 
3
JHF= 8.2, 
4
JHH= 
2.2, CH-14), 6.96 (1H, dt, J= 8.2, 2.2, CH-16), 6.85 (1H, dt, 
3
JHF= 8.9,
 4
JHH= 2.2, CH-12), 6.50 
(1H, d, J= 7.5, CH-3), 5.67 (2H, s, CH2-10), 3.61-3.55 (2H, m, CH2-17), 1.82 (2H, q, J= 7.4, 
CH2-18), 1.45-1.31 (4H, m, CH2-19, CH2-20), 0.89 (3H, t, J= 7.1, CH3-21) 
13
C NMR (150 MHz, CDCl3) δ ppm: 165.5 (d, 
1
JCF= 257.6, CQ-7), 163.4 (d, 
1
JCF= 249.5, CQ-
13), 155.7 (CQ-4), 145.8 (CH-2), 139.8 (d, 
3
JCF= 11.8, CQ-8’), 135.8 (d, 
3
JCF= 7.6, CQ-11), 
131.5 (d, 
3
JCF= 8.3, CH-15), 131.3 (d, 
3
JCF= 9.8, CH-5), 122.1 (d, 
4
JCF= 2.9, CH-16), 116.4 (d, 
2
JCF= 20.9, CH-14), 116.2 (d, 
2
JCF= 23.9, CH-6), 115.6 (CQ-4’), 113.6 (d, 
2
JCF= 22.7, CH-12), 
103.3 (d, 
2
JCF= 26.4, CH-8), 98.2 (CH-3), 57.6 (CH2-10), 44.2 (CH2-17), 29.3 (CH2-19), 28.0 
(CH2-18), 22.5 (CH2-20), 14.1 (CH3-21) 
19
F NMR (282 MHz, CDCl3) δ ppm: -110.64, -99.87 
HRMS (CI) m/z: Calcd. [M
+
]  340.1746 
 Measured  340.1745 
LRMS (CI) m/z:  342 (95), 341 (77), 340 (100, [M]
+
), 297 (23, [M-CH2CH2CH3]
+
), 283 
(27, [M-CH2(CH2)2CH3]
+
), 233 (19), 109 (11), 85 (17, 
[CH2(CH2)3CH3]
+
) 
IR vmax (neat/cm
-1
): 3167 (N-H), 3020 (Ar C-H), 2929, 2871 (aliphatic C-H), 1613 (C=N), 
1584 (Ar C=C), 1561, 1546 
m.p.: 239 - 240 °C 
 
  
Experimental 
 
174 
8.1.2. Synthesis of N-substituted-4-imino-1,4-dihydro-
naphthyridines 
 
 
 
Scheme 34. Synthesis of the naphthyridine 69. 
Reagents and conditions: (i) (COCl)2, DMF (cat.), DCM, rt, 2 h (ii) Ethyl 3-(N,N-
dimethylamino)acrylate, NEt3, CH3CN, 65 °C, 3.5 h (iii) Benzylamine, 70 °C, 18 h (d) NaH, 
THF, 50 °C, 4 h (iv) NaOH, THF, 60 °C, 3 h (v) HCl (aq.), biphenyl ether, 280 °C, 7 h (vi) 
POCl3, 110 °C, 2 h (vii) n-pentylamine, rt → 18 h, 80 °C → 6 h. 
 
3,5-Dichloro-pyridine-2-carbonyl chloride (63) 
Pale brown needles 
 Chemical formula: C6H2Cl3NO 
 Molecular Weight: 210.44 g.mol-1 
 Yield: quantitative 
To a solution of 3,5-dichloro-2-pyridine carboxylic acid (3.34 g, 17.42 mmol) in DCM 
(300 ml), oxalyl chloride (1.83 ml, 20.98 mmol) was added followed by DMF (3 
drops), and the mixture was stirred at R.T. for 2 h. The solvents were evaporated in 
vacuo, toluene (100 ml) was added and the mixture was evaporated again to afford 
63 as pale brown solid (3.65 g, quantitative yield). 
1
H NMR (CDCl3, 500 MHz) δ ppm: 8.60 (1H, d, J=2.0, CH-6), 7.90 (1H, d, J=2.0, CH-4) 
13
C NMR (CDCl3, 125 MHz) δ ppm: 165.9 (CQ=O), 146.9 (CH-6), 144.6 (CQ-2), 138.8 (CH-4), 
136.5 (CQ-3 or CQ-5), 132.4 (CQ-3 or CQ-5) 
HRMS (EI) m/z: Calcd. [M-Cl]
+  
173.9513 
 Measured  173.9518 
LRMS (EI) m/z:  176 (68), 174 (100, [M-Cl]
+
), 148 (45), 146 (70, [M-COCl]
+
), 112 (26), 
110 (39) 
IR vmax (neat/cm
-1
): 3068 (Ar C-H), 1760 (C=O), 1710, (C=N-), 1556 (Ar C=C), 1527 
m.p.: 58 - 59 °C 
 
  
Experimental 
 
175 
3-Benzylamino-2-(2,4-dichloro-benzoyl)-acrylic acid ethyl ester (65) 
White crystalline solid 
 Chemical formula: C18H16Cl2N2O3 
 Molecular Weight: 379.24 g.mol-1 
 Yield: 45% 
Mixture of stereoisomers: 83:17 (65:65”) 
To a solution of NEt3 (6.63 ml, 45.38 mmol) in CH3CN (20 ml), ethyl-3,3-
dimethylaminoacrylate (2.55 ml, 17.81 mmol) and 63 (2.50 g, 11.88 mmol) were 
added and the mixture was heated at 65 °C for 3.5 h. After cooling to R.T., 
benzylamine (1.30 ml, 11.88 mmol) was added and the mixture was heated again at 
65 °C for 18 h. After cooling at R.T., H2O (30 ml) was added, and after 15 min of 
stirring the mixture was allowed to stand for 45 min. The precipitate formed was 
filtered, was washed with a mixture of CH3CN and H2O (1:1) (3 x 100 ml), and was 
dried in vacuo to afford 65 as a white solid (2.03 g, 45%). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 11.28 (1H, s, br, NH), 9.84 (1H, s, br, NH”), 8.42 (1H, d, 
J= 13.0, CHNH”), 8.41 (1H, d, J= 2.0, CH-6), 8.40 (1H, d, J= 2.3, CH-6”), 8.26 (1H, d, J= 
14.1, CHNH), 7.44-7.33 (3H, m, meta Ph-H, meta Ph-H”, para Ph-H, para Ph-H”), 7.31-7.27 
(2H, m, ortho Ph-H, ortho Ph-H”), 4.64 (2H, d, J= 6.6, CH2Ph), 4.63 (2H, d, J= 6.3, CH2Ph”), 
3.98 (2H, q, J= 7.1, CH2CH3), 3.88 (2H, q, J= 7.2, CH2CH3”), 0.99 (3H, t, J= 7.2, CH3), 0.77 
(3H, t, J= 7.1, CH3”) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 191.0 (CQ), 188.6 (CQ), 168.2 (CQ), 166.2 (CQ), 161.5 
(CH), 160.8 (CH), 156.8 (CQ), 156.0 (CQ), 145.6 (CH), 145.4 (CH), 136.5 (CH), 136.4 (CH), 
135.5 (CQ), 135.3 (CQ), 131.2 (CQ), 131.1(CQ), 129.3 (CQ), 128.7 (CH), 127.8 (CH), 127.7 
(CH), 127.6 (CQ), 100.1 (CQ), 99.5 (CQ), 60.0 (CH2), 59.7 (CH2), 54.4 (CH2), 54.3 (CH2), 14.1 
(CH3), 13.6 (CH3) 
HRMS (ES+) m/z: Calcd. [M+Na]
+  
401.0436 
 Measured  401.0434 
LRMS (ES+) m/z:  401 (11, [M+Na]
+
), 335 (72), 333 (100, [M-OCH2CH3]
+
) 
IR vmax (neat/cm
-1
): 3197 (N-H), 3029, (Ar C-H), 2978, 2931, 1686 (C=O), 1620, (C=N-), 
1571 (Ar C=C) 
m.p.: 130 - 131 °C 
 
 
1-Benzyl-7-chloro-4-oxo-1,4-dihydro-[1,5]naphthyridine-3-carboxylic acid ethyl 
ester (66) 
Yellow powder 
 Chemical formula: C18H15ClN2O3 
 Molecular Weight: 342.78 g.mol-1 
 Yield: 94% 
 
To a solution of 65 (2.00 g, 5.27 mmol) in THF (50 ml) cooled at 0 °C, NaH (60% in 
mineral oil, 0.30 g, 7.38 mmol) was added slowly and the mixture was heated at 50 
°C for 4 h. The mixture was quenched at ambient temperature by the dropwise 
addition of acetic acid (glacial, 1 ml). The solvent was evaporated in vacuo, and the 
remaining residue was taken up in water (200 ml). The precipitate formed was 
filtered, was washed with water (2 x100 ml) and was dried in vacuo to afford 66 as 
yellow powder (1.69 g, 94%).  
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1
H NMR (CDCl3, 600 MHz) δ ppm: 8.70 (1H, d, J= 2.0, CH-6), 8.55 (1H, s, CH-2), 7.68 (1H, 
d, J= 2.0, CH-8), 7.46-7.33 (3H, m, meta Ph-CH, para Ph-CH), 7.17 (2H, d, J= 7.9, ortho Ph-
CH), 5.37 (2H, s, CH2Ph), 4.40 (2H, q, J= 7.2, CH2CH3), 1.40 (3H, t, J= 7.2, CH3) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 172.8 (CQ-4), 164.8 (CQOOCH2), 149.5 (CH-2), 146.9 
(CH-6), 141.9 (CQ-4’ or CQ-7), 136.8 (CQ-8’), 134.9 (CQ-4’ or CQ-7), 133.1 (Ph-CQ), 129.9 
(meta Ph-CH), 129.3 (para Ph-CH), 126.2 (ortho Ph-CH), 124.5 (CH-8), 114.7 (CQ-3), 61.5 
(CH2CH3), 57.3 (CH2Ph), 14.3 (CH3) 
HRMS (ES+) m/z: Calcd. [M+Na]
+  
365.0699 
 Measured  365.0687 
LRMS (ES+) m/z:  367 (34), 365 (100, [M+Na]
+
), 345 (34), 343 (97, [M+H]
+
), 315 (22), 132 
(18) 
IR vmax (neat/cm
-1
): 3075, 3052 (Ar C-H), 2925, 2853 (Alkyl C-H), 1721 (C=O), 1631 (C=N-
), 1608, 1576 (Ar C=C), 1528 
m.p.: 200 - 204 °C (dec.) 
 
 
1-Benzyl-7-chloro-4-oxo-1,4-dihydro-[1,5]naphthyridine-3-carboxylic acid (67) 
Beige powder 
 Chemical formula: C16H11ClN2O3 
 Molecular Weight: 314.72 g.mol-1 
 Yield: 90% 
 
A mixture of 66 (1.66 g, 4.84 mmol) and NaOH (1 M, 5.33 ml) in THF (50 ml), was 
heated to 60 °C for 3 h. After cooling to ambient temperature the solvent was 
evaporated in vacuo and the remaining residue was dissolved in water (50 ml). The 
aqueous solution was washed with DCM (2 x 50 ml) and was acidified to pH 5 by 
addition of HCl (aq. 37 %). The precipitate formed was filtered, was washed with 
water (2 x 100 ml) and was dried in vacuo to afford 67 as a beige solid (1.37 g, 
90%). 
1
H NMR (600 MHz, DMSO-d6) δ ppm: 14.95 (1H, s, COOH), 9.28 (1H, s, CH-2), 8.93 (1H, d, 
J= 2.0, CH-6), 8.55 (1H, d, J= 2.0, CH-8), 7.37 (2H, t, J= 7.3, meta Ph-CH), 7.34-7.24 (3H, 
m, ortho Ph-CH, para Ph-CH), 5.89 (2H, s, CH2) 
13
C NMR (150 MHz, DMSO-d6) δ ppm: 177.1 (CQ-4), 165.6 (CQOOH), 150.6 (CH-2), 147.6 
(CH-6), 139.2 (CQ-4’) 137.7 (CQ-8’), 134.8 (Ph-CQ or CQ-7), 134.7 (Ph-CQ or CQ-7), 129.1 
(meta Ph-CH), 128.3 (para Ph-CH), 126.9 (ortho Ph-CH), 126.4 (CH-8), 111.3 (CQ-3), 55.9 
(CH2Ph) 
HRMS (ES+) m/z: Calcd. [M+H]
+  
315.0536 
 Measured  315.0539 
LRMS (ES+) m/z:  339 (18), 337 (73, [M+Na]
+
), 334 (48), 317 (31), 315 (100, [M+H]
+
), 132 
(60) 
IR vmax (neat/cm
-1
): 3016 (Ar C-H), 2920, 2849 (Alkyl C-H), 1729 (C=O), 1612 (C=N-), 1578 
(Ar C=C), 1551, 1524, 1507 
 
  
Experimental 
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1-benzyl-7-chloro-1,5-naphthyridin-4(1H)-one (68) 
Orange/brown powder 
 Chemical formula: C15H11ClN2O 
 Molecular Weight: 270.71 g.mol-1 
 Yield: 74% 
 
To a mixture of 67 (0.50g, 1.59 mmol) in biphenyl ether (15 g), HCl (36%, 0.32 ml) 
was added and the mixture was stirred at ambient temperature for 10 min. The 
mixture was then heated at 280 °C for 7 h. The resulting solution was cooled at 40 
°C and petroleum ether (150 ml) was added while stirring vigorously. The precipitate 
formed was filtered and was washed with petrol (2 x 100 ml). Purification via column 
chromatography (EtOAc → 1:2:17 NEt3:MeOH:EtOAc) to afford 68 as a brown 
powder (0.32g, 74%). 
1
H NMR (600 MHz, DMSO-d6) δ ppm: 8.64 (1H, d, J= 2.0, CH-6), 8.25 (1H, d, J= 2.0, CH-8), 
8.23 (1H, d, J= 7.8, CH-2), 7.35 (2H, t, J= 7.7, meta Ph-CH), 7.29 (1H, t, J= 7.7, para Ph-
CH), 7.21 (2H, t, J= 7.7, ortho Ph-CH),  6.37 (1H, d, J= 7.8, CH-3), 5.55 (2H, s, CH2) 
13
C NMR (150 MHz, DMSO-d6) δ ppm: 175.4 (CQ-4), 145.4 (CH-2), 144.7 (CH-6), 139.6 (CQ-
4’) 137.5 (CQ-8’), 135.7 (Ph-CQ), 133.1 (CQ-7), 129.0 (meta Ph-CH), 128.0 (para Ph-CH), 
126.4 (ortho Ph-CH), 125.1 (CH-8), 112.6 (CH-3), 54.5 (CH2Ph) 
HRMS (CI) m/z: Calcd. [M+H]
+  
271.0638 
 Measured  271.0632 
LRMS (CI) m/z:  273 (15), 271 (37, [M+H]
+
), 245 (23), 218 (75), 91 (100) 
IR vmax (neat/cm
-1
): 3025 (Ar C-H), 2975, 2942, 2879 (Alkyl C-H), 2735, 2600, 2528, 2494, 
1622, 1575 (Ar C=C), 1524 
 
 
(E)-N-(1-benzyl-7-(pentylamino)-1,5-naphthyridin-4(1H)-ylidene)pentan-1-
aminium chloride (69) 
Brown solid 
 Chemical formula: C25H34N4  ∙  HCl 
 Molecular Weight: 427.02 g.mol-1 
 Yield: 59% 
 
A solution of 68 (0.28 g, 1.02 mmol) in POCl3 (5 ml), was heated to reflux at 110 °C 
for 2 h. After cooling at ambient temperature, the mixture was evaporated in vacuo, 
DCM (50 ml) was added and the mixture was evaporated again. The remaining 
residue was triturated with ether. To the resulting precipitate amylamine (6.00 ml, 
0.05 mol) was added dropwise, and the solution was stirred R.T. for 18 h and at 80 
°C for 6 h further. The solution was poured into an ice (~30 cm3) and NaOH (2 M, 20 
ml) mixture while stirring vigorously. The organic products were extracted with DCM 
(2 x 50 ml), the organic extracts were dried over anh. MgSO4 and were evaporated 
in vacuo. Purification via flash column chromatography (EtOAc → 1:2:7 
NEt3:MeOH:EtOAc) afforded 69 as a brown solid (0.26 g, 59%). 
HRMS (ES+) m/z: Calcd. [M+H]
+ 
391.2862 
 Measured  391.2856 
LRMS (EI) m/z:  392 (32), 391 (100, [M+H]
+
) 
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IR vmax (neat/cm
-1
): 3211 (N-H), 3047, 2956 (Ar C-H), 2927, 2857 (Alkyl C-H), 1622 (C=N-), 
1601, 1578 (Ar C=C), 1546, 1523 
m.p.: 160 - 161 °C 
 
 
 
 
Scheme 35. Synthesis of naphthyridine 82. 
Reagents and conditions: (i) Di-tert-butyl dicarbonate, LiHMDS, THF, -5–0 °C, 2 h (ii) n-BuLi, 
HMPA, THF, -78 °C, 1 h (iii) -78 °C, 1.5 h (iv) HCl (aq.), 100 °C, 3 h (v) CH3COOH, 125 °C, 
1.5 h (vi) Benzyl bromide, K2CO3, DMF, 80 °C, 3 h (vii) POCl3, 110 °C, 1.5 h (viii) n-
pentylamine, MeOH, rt, 18 h. 
 
tert-butyl (4-chloropyridin-2-yl)carbamate (77) 
White powder 
 Chemical formula: C10H13ClN2O2 
 Molecular Weight: 228.67 g.mol-1 
 Yield: 77% 
To a solution of LiHMDS (48.0 mmol, 1M in THF) cooled at -5 oC under Ar 
atmosphere, a solution of 4-chloro-pyridine-2-amine (3.70 g, 28.9 mmol) in THF (50 
ml) was added and the mixture was stirred at -5 oC for 5 min. A solution of di-
tertbutyl-dicarbonate (4.40 g, 20.0 mol) in THF (40 ml) was then added, and the 
resulting mixture was stirred at 0 oC for 2 h. The resulting solution was allowed to 
warm to R.T and the solvents were evaporated in vacuo. To the resulting residue, 
water was added (100 ml) and the pH of the solution was adjusted to 6 by the slow 
addition of HCl (1M). The organic products were extracted with EtOAc (3 x 75 ml), 
the combined organic extracts were washed with NaHCO3 (1M) (2 x 100 ml), water 
(2 x 100 ml) and brine (100 ml), were dried over anh. MgSO4 and were evaporated 
in vacuo. The resulting precipitate was triturated with MeOH (2 x 20 ml) and dried in 
vacuo to afford pure 77 as white powder (3.52 g, 77%). 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.54 (1H, s, br, NH), 8.18 (1H, d, J= 5.5, CH-6), 8.07 (1H, 
d, J= 1.8, CH-3), 6.96 (1H, dd, J= 5.5, 1.8, CH-5), 1.54 (9H, s, (CH3)3) 
13
C NMR (150 MHz, CDCl3) δ ppm: 153.4 (CQ=O or CQ-2), 152.4 (CQ=O or CQ-2), 148.5 
(CH-6), 146.0 (CQ-4), 118.9 (CH-5), 112.6 (CH-3), 81.6 (CQ(CH3)3) 28.4 ((CH3)3) 
HRMS (EI) m/z: Calcd. [M]
+  
228.0660 
 Measured   228.0663 
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LRMS (EI) m/z:  230 (10), 228 (25, [M]
+
), 174 (14), 172 (39, [M+H-C(CH3)]
+
), 157 (18), 
155 (55, [M-OC(CH3)]
+
), 130 (32), 128 (100, [M+H-COOC(CH3)]
+
), 
114 (8), 112 (27, [M-NHCOOC(CH3)]
+
), 27) 
IR vmax (neat/cm
-1
): 3057 (Ar C-H), 3021, 2973 (alkyl C-H), 2921, 2847, 1719 (C=O), 
1574 (C=N-), 1512 (Ar C=C) 
m.p.: 145 - 146 
o
C 
 
 
4-chloro-1,8-naphthyridine (79) 
Brown amorphous solid 
 Chemical formula: C8H5ClN2 
 Molecular Weight: 164.59 g.mol-1 
 Yield: 39% 
To a solution of 77 (3.78 g, 16.5 mmol) in THF (50 ml) cooled at -78 oC under Ar 
atmosphere, HMPA (5.30 ml, 38.4 mmol) was added, followed by n-Buli (15 ml, 
2.5M in hexane) and the resulting solution was stirred at -78 oC for 1 h. 3-
Dimethylaminoacrolein (1.66 ml, 16.5 mmol) was then added dropwise and the 
resulting mixture was stirred at -78 oC for 1.5 h. The reaction was quenched by the 
dropwise addition of HCl (2M, aq.) to pH 8. The organic layer was separated and 
then extracted with HCl (2 M, aq) (2 x 40 ml). The acidic extracts were heated to 
reflux for 3 h. After cooling at R.T, K2CO3 (anh., 40 g) was added, and the resulting 
mixture was extracted with EtOAc (3 x 10 ml), decanting the organic extracts. The 
organic extracts were dried over anh. MgSO4, and evaporated. Purification by 
column chromatography (EtOAc → 1:20 MeOH:EtOAc) afforded pure 79 as brown 
solid (1.05 g, 39%). 
1
H NMR (600 MHz, CDCl3) δ ppm: 9.17 (1H, dd, J= 4.2, 2.0, CH-7), 9.04 (1H, d, J= 4.7, CH-
2) 8.64 (1H, dd, J= 8.4, 2.0, CH-5), 7.63 (1H, dd, J= 8.4, 4.2, CH-6), 7.61 (1H, d, J= 4.7, CH-
3) 
13
C NMR (150 MHz, CDCl3) δ ppm: 156.4 (CQ-8’), 154.5 (CH-7), 153.2 (CH-2), 143.4 (CQ-4), 
134.1 (CH-5), 123.2 (CH-6), 122.4 (CH-3), 121.9 (CQ-4’) 
HRMS (EI) m/z: Calcd. [M]
+   
 164.0136 
 Measured    164.0137 
LRMS (EI) m/z:  166 (32), 164 (100, [M]
+
), 129 (38, [M-Cl]
+
), 102 (43), 75 (16) 
IR vmax (neat/cm
-1
): 3362, 3029 (Ar C-H), 1623, (C=N-), 1585 (Ar C=C), 1546, 1516 
m.p.: 52 - 53 
o
C 
 
 
1,8-naphthyridin-4(1H)-one (80) 
Brown amorphous solid 
 Chemical formula: C8H6N2O 
 Molecular Weight: 146.15 g.mol-1 
 Yield: 92% 
A solution of 79 (0.74 g, 4.48 mmol) in glacial acetic acid (1.85 ml) was heated to 
reflux at 125 oC for 1.5 h. After cooling at R.T, Et2O (100 ml) was added and the 
precipitate formed was filtered, was washed with Et2O (2 x 50 ml) and pentane (2 x 
50 ml), and was dried in vacuo. Recrystallization (CHCl3, MeOH) afforded pure 80 
(0.60 g, 92%) as brown solid.  
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1
H NMR (600 MHz, DMSO-d6) δ ppm: 13.52 (1H, s, br, NH), 8.92 (1H, dd, J= 4.4, 2.0, CH-7), 
8.59 (1H, dd, J= 8.1, 2.0, CH-5), 8.35 (1H, d, J= 7.2, CH-2), 7.59 (1H, dd, J= 8.1, 4.4, CH-6), 
6.65 (1H, d, J= 7.2, CH-3) 
13
C NMR (150 MHz, DMSO-d6) δ ppm: 175.1 (CQ-4), 154.6 (CH-7), 149.8 (CQ-8’), 143.2 
(CH-2), 134.4 (CH-5), 121.4 (CH-6), 118.53 (CQ-4’) 108.4 (CH-3) 
HRMS (EI) m/z: Calcd. [M]
+ 
146.0475 
 Measured  146.0478 
LRMS (EI) m/z:  146 (100, [M]
+
), 118 (48, [M-CO]
+
), 91 (18), 78 (19) 
IR vmax (neat/cm
-1
): 3225, 3029 (Ar C-H), 2844, 2780, 1593 (Ar C=C), 1510 
m.p: 207 - 211 
o
C (dec.) 
 
 
1-benzyl-1,8-naphthyridin-4(1H)-one (81) 
Light brown powder 
 Chemical formula: C15H12N2O 
 Molecular Weight: 236.27 g.mol-1 
 Yield: 80% 
 
To a solution of 80 (0.51 g, 3.42 mmol) in DMF (5 ml), K2CO3 (0.57 g, 4.12 mmol) 
was added and the mixture was stirred at rt for 10 min. Benzyl bromide (0.42 ml, 
3.54 mmol) was then added and the resulting mixture was stirred at 80 oC for 3 h. 
After cooling at R.T., the mixture was poured onto an ice (~50 cm3) and NaOH (2M, 
30 ml) mixture and was stirred for 10 min. The organic products were extracted with 
DCM (2 x 100 ml), the organic extracts were dried over MgSO4 and were evaporated 
in vacuo. The crude residue was purified by column chromatography (EtOAc →1:10 
MeOH:EtOAc) to afford pure 81 as a tan solid (0.66 g, 80%). 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.75-8.70 (2H, m, CH-5, CH-7), 7.75 (1H, d, J= 7.8, CH-
2), 7.36 (1H, dd, J= 7.9, 4.6, H-6), 7.35-7.28 (3H, m, meta Ph-CH, para Ph-CH), 7.24 -7.28 
(2H, m, ortho Ph-CH), 6.38 (1H, d, J= 7.8, CH-3), 5.62 (2H, s, CH2) 
13
C NMR (150 MHz, CDCl3) δ ppm: 178.8 (CQ-4), 152.6 (CH-5 or CH-7), 150.1 (CQ-8’), 143.2 
(CH-2), 136.4 (Ph-CQ), 136.2 (CH-5 or CH-7), 129.2 (meta Ph-CH), 128.3 (para Ph-CH), 
127.6 (ortho Ph-CH), 121.9 (CQ-4’), 120.1 (CH-6), 111.5 (CH-3), 53.0 (CH2Ph) 
HRMS (EI) m/z: Calcd. [M]
+  
236.0944 
 Measured  236.0948 
LRMS (EI) m/z:  236 (59, [M]
+
), 91 (100, [PhCH2
+
]) 
IR vmax (neat/cm
-1
): 3057 (Ar C-H), 2988, 1641, 1616, 1578 (Ar C=C), 1549 
m.p.: 124 - 126 
o
C 
 
 
(1-Benzyl-1H-[1,8]naphthyridin-4-ylidene)-pentyl-amine (82) 
Dark orange needles/crystals 
 Chemical formula: C20H23N3 
 Molecular Weight: 305.42 g.mol-1 
 Yield: 90% 
 
A solution of 81 (0.53 g, 2.23 mmol) in POCl3 (8 ml) was heated to reflux at 110 
oC 
for 1.5 h. After cooling at R.T., DCM (10 ml) was added, and the solvents were 
evaporated in vacuo. The resulting residue was dissolved in MeOH (8 ml), 
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amylamine (0.52 ml, 4.47 mmol) was added dropwise and the mixture was stirred at 
R.T. for 18 h. The mixture was poured into an ice (~50 cm3) and NaOH (2M, 30 ml) 
mixture and was stirred for 10 min. The organic products were extracted with DCM 
(3 x 100 ml), the organic extracts were dried over anh. MgSO4 and were evaporated 
in vacuo. Purification via flash column chromatography (EtOAc → 1:20 NEt3:EtOAc), 
followed by recrystallisation (petroleum ether) afforded pure 82 as an orange solid 
(0.61 g, 90%). 
1
H NMR (600 MHz, CDCl3, heated at 60 
o
C) δ ppm: 8.74 (1H, m, CH-7), 8.45 (1H, dd, J= 
5.5, 1.9, CH-5), 7.35-7.25 (5H, m, Ph-CH), 7.11 (1H, dd, J= 7.9, 4.6, CH-6), 7.03 (1H, d, J= 
8.2, CH-2), 6.02 (1H, d, J= 8.2, CH-3), 5.37 (2H, s, CH2Ph), 3.36 (2H, t, J =7.2, NCH2), 1.76 
(2H, qn, J= 7.2, NCH2CH2), 1.50-1.38 (4H, m, CH2CH2CH3), 0.96 (3H, t, J= 7.2, CH3) 
13
C NMR (150 MHz, CDCl3, RT) δ ppm: 154.8 (CQ), 149.8 (CH), 149.7 (CQ), 138.0 (CH), 
137.6 (CQ), 134.1 (CH), 128.8 (CH), 127.7 (CH), 127.4 (CH), 121.1 (CQ), 119.2 (CH), 100.1 
(CH), 51.7 (CH2), 50.5 (CH2), 30.9 (CH2), 30.2 (CH2), 22.9 (CH2), 14.3 (CH3) 
HRMS (EI) m/z: Calcd. [M]
+  
305.1886 
 Measured  305.1893 
LRMS (EI) m/z:  305 (6, [M]
+
), 262 (13, [M-CH2CH2CH3]
+
), 248 (22, [M-CH2 (CH2)2CH3]
+
), 
158 (10), 130 (9), 91 (100, [PhCH2
+
]) 
IR vmax (neat/cm
-1
): 3063 (Ar C-H), 3026, 2950, 2923, 2856, 2838 (Alkyl C-H), 2809, 1630, 
1588 (Ar C=C), 1570 
m.p.: 52 - 53 
o
C 
 
 
 
8.1.3. Synthesis of N9-substitued-6-aminoaryl-purines and N-
substituted-4-imino-1,4-dihydro-pyridines 
 
 
Scheme 36. Synthesis of purines 93 and 94. 
Reagents and conditions: (i) NaH, DMF, rt, 24 h (ii) Aniline, NEt3, n-pentanol, 110 °C, 24 h 
(iii) Benzylamine, EtOH, reflux, 3 h 
 
  
Experimental 
 
182 
Pentyl 4-methylbenzenesulfonate 
Colourless oil 
 Chemical formula: C12H18O3S 
 Molecular weight: 242.33 g.mol-1 
 Yield: 57% 
To a solution of tosyl chloride (4.75 g, 24.91 mmol) in DCM (15 ml) cooled at 0 °C, 
pentan-1-ol (1.22 ml, 11.27 mmol) and pyridine (5 ml, 61.82 mmol) were added and 
the mixture was stirred at ambient temperature for 48 h. DCM was added until the 
cloudy solution turned clear. The solution was then washed with KHSO4 (2 M, aq) (2 
x 150 ml), with NaHCO3 (1 M, aq), (2 x 150 ml) and brine (2 x 150 ml). The 
combined organic layers were dried over anh. MgSO4 and evaporated in vacuo. 
Purification via flash column chromatography (petroleum ether → 1:19 
Et2O:petroleum ether) afforded pentyl 4-methylbenzenesulfonate as colourless oil 
(1.56 g, 57%). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 7.78 (2H, d, J= 8.3, ortho Ph-CH), 7.34 (2H, d, J= 8.3, 
meta Ph-CH), 4.01 (2H, t, J= 6.7, OCH2), 2.44 (3H, s, Ph-CH3), 1.63  (2H, q, J= 6.7, 
OCH2CH2), 1.32-1.17 (4H, m, CH2CH2CH3), 0.84 (3H, t, J= 7.0, CH2CH3) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 144.8 (CQ-SO2), 133.3 (Ph-CQ-CH3), 129.9 (meta Ph-
CH), 128.0 (ortho Ph-CH), 70.9 (OCH2), 28.6 (OCH2CH2), 27.6 (CH2CH2CH3), 22.2 
(CH2CH3), 21.8 (Ph-CH3), 14.1 (CH2CH3) 
HRMS (CI) m/z: Calcd. [M+H]
+ 
243.1055 
 Measured  243.1057 
LRMS (CI) m/z: 485 (100), 397 (30), 243 (24) 
IR vmax (neat/cm
-1
): 2958 (Ar C-H), 2932, 2871 (aliphatic C-H), 1598 (Ar C=C) 
 
 
6-Chloro-9-pentyl-9H-purine (91) 
Light yellow oil 
Chemical formula: C10H13ClN4 
Molecular weight: 224.69 g.mol-1 
Yield: 48% 
To a solution of 6-chloropurine (0.56 g, 3.62 mmol) in DMF (15 ml), NaH (60% in 
mineral oil, 0.16 g, 4.17 mmol) was added followed by EYF162 (1.00 g, 4.13 mmol). 
The mixture was stirred at ambient temperature for 24 h. DCM (50 ml) was added 
and the resulting solution was washed with water (3 x 30 ml) and sat. LiCl (2 x 20 
ml). The organic solution was dried over anh. MgSO4 and evaporated in vacuo. 
Purification via column chromatography (EtOAc) afforded 91 as yellow oil (0.39 g, 
48%). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 8.74 (1H, s, CH-2), 8.11 (1H, s, CH-8), 4.28 (2H, t, J= 
7.3, NCH2), 1.92 (2H, q, J= 7.3, NCH2CH2), 1.40-1.28 (4H, m, CH2CH2CH3), 0.88 (3H, t, J= 
7.1, CH3) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 152.0 (CH-2), 151.9 (CQ-4), 151.1 (CQ-6), 145.2 (CH-8), 
131.7 (CQ-5), 44.7 (NCH2), 29.7 (NCH2CH2), 28.8 (CH2CH2CH3), 22.2 (CH2CH3), 14.0 (CH3) 
HRMS (EI) m/z: Calcd. [M]
+ 
224.0823 
 Measured  224.0821 
Experimental 
 
183 
LRMS (EI) m/z: 226 (21), 224 (66, [M]
+
), 209 (15, [M-CH3]
+
), 195 (41, [M-CH2CH3]
+
), 
182 (16, [M-CH2CH2CH3]
+
), 169 (30), 168 (100), 167 (73, [M-
CH2(CH2)2CH3]
+
), 154 (73, [M+H-pentyl]
+
) 
IR vmax (neat/cm
-1
): 3073 (Ar C-H), 2957, 2931, 2864 (aliphatic C-H), 1591 (Ar C=C), 1556 
 
 
9-pentyl-N-phenyl-9H-purin-6-amine (93) 
White crystalline solid 
Chemical formula: C16H19N5 
Molecular weight: 281.36 g.mol-1 
Yield: 75% 
 
To a solution of 91 (0.35 g, 1.58 mmol) in n-pentanol (5 ml), aniline (0.29 ml, 3.18 
mmol), and NEt3 (0.88 ml, 6.31 mmol) were added and the resulting mixture was 
heated at 110 °C for 24 h, under argon atmosphere. The resulting mixture was 
concentrated in vacuo and was purified via column chromatography (1:4 petroleum 
ether:EtOAc) followed by recrystallization (CHCl3, Et2O) to afford 93 as white 
crystalline solid (0.33 g, 75%). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 8.55 (1H, s, CH-2), 7.82 (CH-8), 7.80 (2H, d, J= 7.7, ortho 
Ph-CH), 7.75 (1H, s, br, NH), 7.39 (2H, t, J= 7.7, meta Ph-CH), 7.11 (1H, t, J=7.4, para Ph-
CH), 4.22 (2H, t, J= 7.3, NCH2), 1.92 (2H, q, J= 7.3, NCH2CH2), 1.40-1.29 (4H, m, 
CH2CH2CH3), 0.90 (3H, t, J= 7.1, CH3) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 152.9 (CH-2), 152.4 (CQ-6), 149.8 (CQ-4), 140.7 (CH-8), 
138.8 (Ph-CQ), 129.2 (meta Ph-CH), 123.7 (para Ph-CH), 120.5 (CQ-5), 120.4 (ortho Ph-CH), 
44.2 (NCH2), 30.0 (NCH2CH2), 28.9 (CH2CH2CH3), 22.3 (CH2CH3), 14.0 (CH3) 
HRMS (ES+) m/z: Calcd. [M+H]
+ 
282.1719 
 Measured  282.1719 
LRMS (ES+) m/z: 283 (20), 282 (100, [M+H]
+
), 213 (10), 212 (68), 180 (13), 164 (9) 
IR vmax (neat/cm
-1
): 3281 (N-H), 3199, 3050 (Ar C-H), 2952, 2930, 2868 (aliphatic C-H), 
1736, 1624 (Ar C=C), 1574 
m.p.: 113-114 °C 
 
 
N-benzyl-9-pentyl-9H-purin-6-amine (94) 
White powder 
Chemical formula: C17H21N5 
Molecular weight: 295.39 g.mol-1 
Yield: 90% 
To a solution of 91 (0.45 g, 2.00 mmol) in ethanol (15 ml), benzylamine (1.08 ml, 
10.00 mmol), was added and the resulting mixture was heated at 70 °C, under 
argon atmosphere for 3 h. The resulting mixture was concentrated in vacuo and was 
purified by column chromatography (1:5 petroleum ether:EtOAc) followed by 
recrystallization (CHCl3) to afford 94 as white solid (0.53 g, 90%). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 8.43 (1H, s, br, CH-2), 7.66 (1H, s, br, CH-8), 7.39 (2H, d, 
J= 7.6, ortho Ph-CH), 7.33 (2H, t, J= 7.6, meta Ph-CH), 7.28 (1H, t, J= 7.6, para Ph-CH), 
6.21 (1H , s, br, NH), 4.87 (2H, s, br, CH2Ph), 4.17 (2H, t, J= 7.3, NCH2), 1.88 (2H, q, J= 7.3, 
NCH2CH2), 1.40-1.27 (4H, m, CH2CH2CH3), 0.89 (3H, t, J= 7.2, CH3) 
Experimental 
 
184 
13
C NMR (CDCl3, 150 MHz) δ ppm: 154.8 (CQ-6), 153.2 (CH-2), 149.4 (CQ-4), 139.9 (CH-8), 
138.6 (Ph-CQ), 128.8 (meta Ph-CH), 127.9 (ortho Ph-CH), 127.6 (para Ph-CH), 119.9 (CQ-5), 
44.7 (CH2Ph), 44.0 (NCH2), 30.0 (NCH2CH2), 28.9 (CH2CH2CH3), 22.3 (CH2CH3), 14.0 (CH3) 
HRMS (EI) m/z: Calcd. [M]
+ 
295.1792 
 Measured  295.1791 
LRMS (EI) m/z:  296 (18), 295 (100, [M]
+
), 294 (21), 280 (8, [M-CH3]
+
), 252 (5, [M-
CH2CH2CH3]
+
), 239 (11), 238 (16, [M-CH2(CH2)2CH3]
+
), 224 (10, [M-
CH2(CH2)3CH3]
+
), 106 (7, [NH2CH2Ph]
+
) 
IR vmax (neat/cm
-1
): 3268 (N-H), 3222, 3195, 3147, 3062, 3034 (Ar C-H), 2949, 2929, 2870 
(aliphatic C-H), 1620 (Ar C=C), 1581, 1538 
m.p.: 78 - 79 °C 
 
 
 
 
Scheme 37. Synthesis of pyridine 97. 
Reagents and conditions: (i) n-Pentylamine, 110 °C, 48 h (ii) Benzyl bromide, NaI, acetone, 
reflux, 8 h. 
 
N-pentylpyridin-4-amine (96) 
Beige crystals 
 Chemical formula: C10H16N2 
 Molecular Weight: 164.25 g.mol-1 
 Yield: 51% 
A solution of 4-chloropyridine hydrochloride (2.50 g, 16.65 mmol) in amylamine 
(10.64 ml, 0.09 mol) was heated to reflux at 110 °C for 48 h. After cooling to R.T, the 
solution was poured on ice (~50 cm3) while stirring vigorously. The organic products 
were extracted with DCM (2 x 100 ml) and the organic extracts were dried over anh. 
MgSO4, and were evaporated in vacuo. Purification via column chromatography 
(EtOAc → 1:5:20 NEt3:MeOH:EtOAc) afforded pure 96 as beige crystals (1.40 g, 
51%). 
1
H NMR (CDCl3, 500 MHz) δ ppm: 8.16 (2H, dd, J= 5.0, 1.6, CH-2, CH-6), 6.41 (2H, dd, J= 
5.0, 1.6, CH-3, CH-5), 4.24 (1H, s, br, NH), 3.12 (1H, td, J= 7.2, 5.5, NHCH2), 1.61 (2H, qn, 
J= 7.2, NHCH2CH2), 1.40-1.33 (4H, m, CH2CH2CH3), 0.91 (3H, t, J= 6.8, CH3) 
13
C NMR (CDCl3, 125 MHz) δ ppm: 153.6 (CQ-4), 149.9 (CH-2, CH-6), 107.5 (CH-3, CH-5), 
42.7 (NHCH2), 29.2 (NHCH2CH2 or CH2CH2CH3), 28.9 (NHCH2CH2 or CH2CH2CH3), 17.6 
(CH2CH3), 14.1 (CH3) 
HRMS (EI) m/z: Calcd. [M]
+  
164.1308 
 Measured  164.1310 
LRMS (EI) m/z:  164 (22, [M]
+
), 107 (100, [M-CH2(CH2)2CH3]
+
) 
IR vmax (neat/cm
-1
): 3230 (N-H), 3138, 3026 (Ar C-H), 2995, 2927, 2862 (Alkyl C-H), 1603 
(C=N-), 1531 (Ar C=C) 
m.p.: 63 - 64 °C  
Experimental 
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N-(1-benzylpyridin-4(1H)-ylidene)pentan-1-amine hydroiodide (97) 
White crystals 
Chemical formula: C17H22N2 ∙ HI  
Molecular Weight: 382.28 g.mol-1 
Yield: 62% 
 
 
A mixture of 96 (1.00 g, 6.09 mmol), benzyl bromide (0.79 ml, 6.69 mmol) and NaI 
(1.09 g, 7.30 mmol) in acetone (5 ml), was heated to reflux at 65 °C for 8 h. After 
cooling to R.T, the mixture was poured in an ice (~50 cm3) and NaOH (2M, 50 ml) 
mixture while stirring vigorously. The organic products were extracted with DCM (2 x 
100 ml). The organic extracts were dried over anh. MgSO4, and evaporated in 
vacuo. Purification via flash column chromatography (EtOAc → 1:5:20 
NEt3:MeOH:EtOAc) followed by recrystallization (propan-2-ol) afforded 97 as the 
hydroiodide salt as white crystals (1.44 g, 62%). 
1
H NMR (CDCl3, 600 MHz) δ ppm: 8.68 (1H, t, J= 6.7, NH), 8.16 (1H, dd, J= 7.4, 2.0, CH-2), 
8.06 (1H, dd, J= 7.4, 2.0, CH-6), 7.60 (1H, dd, J= 7.4, 2.9, CH-5), 7.39-7.29 (5H, m, Ph-CH), 
6.55 (1H, dd, J= 7.4, 2.9, CH-3), 5.43 (2H, s, CH2Ph), 3.23 (2H, q, J= 6.7, NCH2CH2), 1.73 
(2H, qn, J= 6.7, NCH2CH2), 1.43-1.20 (4H, m, CH2CH2CH3), 0.85 (3H, t, J= 7.1, CH3) 
13
C NMR (CDCl3, 150 MHz) δ ppm: 157.1 (CQ-4), 143.0 (CH-2), 140.6 (CH-6), 133.9 (Ph-
CQ), 129.6 (ortho Ph-CH or meta Ph-CH), 129.5 (para Ph-CH), 128.6 (ortho Ph-CH or meta 
Ph-CH), 111.5 (CH-5), 105.5 (CH-3), 61.0 (CH2Ph), 43.4 (NHCH2), 29.2 (CH2CH2CH3), 27.9 
(NHCH2CH2), 22.4 (CH2CH3), 14.1 (CH3) 
HRMS (CI) m/z: Calcd. [M+H]
+  
255.1861 
 Measured  255.1859 
LRMS (CI) m/z:  255 (100, [M+H]
+
) 
IR vmax (neat/cm
-1
): 3210 (N-H), 3125, 3043 (Ar C-H), 3016, 2948, 2924, 2862 (alkyl C-H), 
1641 (C=N-), 1575 (Ar C=C), 1551, 1517 
m.p.: 108 - 109 °C 
 
 
8.1.4. Synthesis of sulfonium salt 100 
 
Scheme 38. Synthesis of the sulfonium salt 100. 
Reagents and conditions: (i) 4-methoxythiophenol, Pd2(dba)3, DPEPhos, 
t
BuOK, toluene, 
100 °C, 3 h (ii) 99, Cu(II) benzoate, TFSA, chlorobenzene, 125 °C, 2.5 h. 
 
N-(1-(3-iodobenzyl)quinolin-4(1H)-ylidene)pentan-1-amine (23) 
Synthesis described in page 148.  
Experimental 
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(1-[3-(4-Methoxy-phenylsulfanyl)-benzyl]-1H-quinolin-4-ylidene)-pentyl-amine, 
(98) 
 
Yellow oil 
 Chemical formula: C28H30N2OS 
 Molecular Weight: 442.62 g.mol-1 
 Yield: 63% 
 
 
In a flame dried, three-necked round bottom flask, Pd2dba3 (19 mg, 0.02 mmol), 
DPEPhos (23 mg, 0.04 mmol) and toluene (35 ml) were added and the resulting 
solution was stirred under an atmosphere of argon for 10 min. 23 (0.89 g, 2.07 
mmol), 4-methoxythiophenol (254 μl, 2.07 mmol) and KtOBu (0.28 g, 2.49 mmol) 
were added and the mixture was heated at 100 °C for 3 h. The mixture was cooled 
to room temperature, was passed over a pad of celite and was evaporated in vacuo. 
The resulting residue was purified by column chromatography using basic Al2O3 as 
the solid phase (EtOAc → 3:17 MeOH:EtOAc) to afford 98 as viscous yellow oil 
(0.57 g, 63%). 
Note: 98 and 100 have very similar Rf values therefore their separation using 
standard chromatographic means is not feasible; the reaction needs to proceed to 
completion for isolation of pure product. 
1
H NMR (600 MHz, CDCl3) δ ppm: 9.22 (1H, dd, J= 8.2, 1.4, CH-5), 7.99 (1H, d, J= 7.6, CH-
2), 7.64–7.53 (2H, m, CH-6, CH-7), 7.34-7.30 (3H, m, CH-8, CH-24, CH-28), 7.18 (1H, t, J= 
7.8, CH-18), 7.02 (1H, dt, J= 7.8, 1.8, CH-19), 6.84 (2H, d, J= 8.9, CH-25, CH-27), 6.83-6.80 
(1H, m, CH-17), 6.77 (1H, t, J= 1.8, CH-21), 6.32 (1H, d, J= 7.6, CH-3), 5.40 (2H, s, CH2-15), 
3.83 (3H, s, CH3-30), 3.52 (2H, t, J= 7.5, CH2-10), 1.78 (2H, qn, J= 7.5, CH2-11), 1.43-1.33 
(4H, m, CH2-12, CH2-13), 0.91 (3H, t, J= 7.0, CH3-14) 
13
C NMR (150 MHz, CDCl3) δ ppm: 160.5 (CQ-26), 156.2 (CQ-4), 144.5 (CH-2), 141.5 (CQ-
16), 137.7 (CQ-8’), 136.3 (CH-24, CH-28), 134.9 (CQ-20), 133.6 (CH-7), 130.0 (CH-18), 127.8 
(CH-5), 127.3 (CH-19), 126.8 (CH-6), 124.5 (CH-21), 123.1 (CH-17), 122.2 (CQ-23), 119.5 
(CQ-4’), 116.5 (CH-8), 115.3 (CH-25, CH-27), 97.8 (CH-3),  57.2 (CH2-15), 55.6 (CH3-30), 
44.5 (CH2-10), 29.4 (CH2-12), 27.9 (CH2-11), 22.6 (CH2-13), 14.2 (CH3-14) 
HRMS (EI) m/z: Calcd. [M]
+
  442.2079 
 Measured 442.2081 
LRMS (EI) m/z: 442 (69, [M]
+
), 399 (100, [M-CH2CH2CH3]
+
), 385 (70, [M-
HCH2(CH2)2CH3]
+
), 371 (16, [M-CH2(CH2)2CH3]
+
), 229 (20), 213 (9) 
IR vmax (neat/cm
-1
): 3207, 3052 (Ar C-H), 2950, 2921, 2847 (Aliphatic C-H), 1619 (C=N), 
1588 (Ar C=C), 1569 
 
  
Experimental 
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(E)-bis(4-methoxyphenyl)(3-((4-(pentylimino)quinolin-1(4H)-
yl)methyl)phenyl)sulfonium trifluoromethanesulfonate (100) 
 
Yellow oil 
Chemical formula: C36H37F3N2O5S2 
Molecular weight: 698.82 g.mol-1 
Yield: 32% 
 
 
 
 
To a solution of 98 (0.22 g, 0.49 mmol) in chlorobenzene (2.5 ml), 
trifluoromethanesulfonic acid (41 μl, 0.47 mmol) was added and the solution was 
stirred at room temperature for 10 min. Bis(4-methoxyphenyl)iodonium triflate (0.20 
g, 0.40 mmol) and copper (II) benzoate dihydrate (13 mg, 0.04 mmol) were then 
added and the mixture was heated at 125 °C for 2.5 h under an atmosphere of 
argon. After cooling to room temperature, Et2O (10 ml) was added and the top layer 
was decanted. The resulting dark brown residue was purified by column 
chromatography (CHCl3 → 1:9 MeOH:CHCl3). The oil obtained was diluted in DCM 
(20 ml) and was washed twice with NaOH (2M, 20 ml). The organic layer was dried 
over anh. MgSO4 and evaporated in vacuo to afford 100 as viscous pale yellow oil 
(0.90 g, 32%). 
1
H NMR (600 MHz, CDCl3) δ ppm: 8.47 (1H, dd, J= 8.1, 1.5, CH-5), 7.57 (1H, t, J= 7.8, CH-
18), 7.53 (4H, d, J= 9.1, CH-24, CH-28, CH-32, CH-36), 7.52-7.49 (1H, m, CH-17), 7.45 (1H, 
dq J= 8.0, 1.2, CH-19), 7.33-7.28 (2H, m, CH-2, CH-7), 7.27-7.25 (1H, m, CH-21), 7.17 (1H, 
ddd, J= 8.1, 7.1, 1.1, CH-6), 7.09 (4H, d, J= 9.1, CH-25, CH-27, CH-33, CH-35), 6.91 (1H, 
dd, J= 8.4, 1.1, CH-8), 6.02 (1H, d, J= 8.1, CH-3), 5.29 (2H, s, CH2-15), 3.88 (6H, s, CH3-30, 
CH3-38), 3.33 (2H, t, J= 7.4, CH2-10), 1.74 (2H, qn, J= 7.4, CH2-11), 1.47-1.35 (4H, m, CH2-
12, CH2-13), 0.93 (3H, t, J= 7.1, CH3-14) 
13
C NMR (150 MHz, CDCl3) δ ppm: 164.7 (CQ-26, CQ-34), 154.3 (CQ-4), 141.1 (CQ-16), 
140.2 (CH-2), 138.0 (CQ-8’), 133.2 (CH-24, CH-28, CH-32, CH-36), 131.9 (CH-17 or CH-18), 
131.8 (CH-17 or CH-18), 130.6 (CH-7), 129.0 (CH-19), 127.8 (CH-21), 127.1 (CQ-20), 125.7 
(CH-5), 125.1 (CQ-4’), 123.7 (CH-6), 121.0 (CQ, q, 
1
JCF = 319.9, CF3), 117.4 (CH-25, CH-27, 
CH-33, CH-35), 115.2 (CH-8), 113.6 (CQ-23, CQ-31), 99.3 (CH-3), 56.2 (CH3-30, CH3-38), 
54.5 (CH2-15), 49.6 (CH2-10), 30.7 (CH2-11), 30.2 (CH2-12), 22.9 (CH2-13), 14.3 (CH3-14) 
19
F NMR (282 MHz, CDCl3) δ ppm: -78.23 
HRMS (EI) m/z: Calcd. [M]
+
  549.2576 
 Measured  549.2571 
LRMS (EI) m/z:  549 (5, [M]
+
), 491 (12), 442 (55, [M-PhOCH3]
+
), 399 (90, [M-PhOCH3-
CH2CH2CH3]
+
), 385 (69, [M+H-PhOCH3-CH2(CH2)2CH3]
+
), 371 (17, [M-
PhOCH3-CH2(CH2)3CH3]
+
), 246 (100, [S(PhOCH3)2]
+
, 231 (34), 214 
(23), 84 (23) 
IR vmax (neat/cm
-1
): 3060 (Ar C-H), 2925, 2848 (Aliphatic C-H), 1631 (C=N), 1586 (Ar 
C=C), 1572 
 
  
Experimental 
 
188 
Bis(4-methoxyphenyl)iodonium trifluoromethanesulfonate (99) 
Light brown oil 
Chemical formula: C15H14F3IO5S 
Molecular weight: 490.23 g.mol-1 
Yield: 80% 
To a solution of iodine (0.52 g, 2.0 mmol) and 3-chloroperbenzoic acid (0.8 g, 4.6 
mmol) in DCM (15 ml) were added anisole (0.68 g, 6.2 mmol) and para-
toluenesulfonic acid monohydrate (1.2 g, 6.3 mmol), and the mixture was stirred for 
15 min at 40 °C. The red solution was cooled to 0 °C (ice bath) and 
trifluoromethanesulfonic acid (0.35 ml, 4 mmol) was added. The red slurry was 
stirred for 1 h at room temperature, diluted with DCM and purified by column 
chromatography (DCM: diethyl ether = 2: 1, DCM, DCM: methanol = 96: 4). The 
product was obtained as a light brown oil (1.2 g, 80%). 
1
H NMR (600 MHz, DMSO-d6) δ ppm: 8.12 (4H, d, J= 9.0, ortho Ph-H), 7.06 (4H, d, J= 9.0, 
meta Ph-H), 3.79 (6H, s, OCH3) 
13
C NMR (150 MHz, DMSO-d6) δ ppm: 161.8 (CQ para Ph), 136.9 (CH ortho Ph), 120.7 (CQ, 
q, 
1
JCF= 321.3, CF3), 117.4 (CH meta Ph), 106.2 (CQ Ph), 55.7 (OCH3) 
19
F NMR (282 MHz, DMSO-d6) δ ppm: -78.2 
HRMS (EI) m/z: Calcd. [M]
+
  341.0039 
 Measured  341.0031 
 
  
Experimental 
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8.1.5. Radiochemistry 
 
[18F]N-(1-(3-Fluorobenzyl)quinolin-4(1H)-ylidene)pentan-1-amine ([18F]22) 
[18F]Fluoride (650 MBq) in water was trapped on a Sep-Pak® QMA cartridge, 
released with a solution (0.5 ml) of Kryptofix 222 (30 mM) and potassium 
bicarbonate (30 mM) in acetonitrile: water (85:15). After removing the solvent by 
heating at 90 °C under a stream of nitrogen, acetonitrile (0.5 ml) was added, and the 
distillation was continued at 90 °C. This procedure was repeated and the reaction 
vial was subsequently capped. Compound 100 (5 mg) dissolved in DMSO (0.5 ml) 
was subsequently added and the mixture was stirred at 120 °C for 15 minutes. After 
cooling, the reaction was quenched with water (1.5 ml) and purified by radio-HPLC 
using an Agilent Zorbax® 300SB-C18 column (250 × 9.4 mm) at room temperature 
and with a flow rate of 3 ml/min. The mobile phase consisted of water and methanol, 
each containing 0.5% TFA. The radioactive product was isolated using a gradient 
starting with 10% methanol content kept constant for 5 min and then increased to 
50%. The methanol content was subsequently raised from 50 to 60% in 10 min, 
further to 63% in 5 min, to 70% in 5 min, and finally to 90% in 5 min. Only the most 
concentrated fraction of the product peak was isolated. The obtained solution was 
diluted with water to a final volume of 20 ml, trapped on a Sep-Pak® SPE C-18 light 
cartridge, and the labelled product was released with ethanol (0.5 ml). After having 
reduced the volume to <0.1 ml under a stream of nitrogen, the solution was diluted 
with saline to give a final ethanol concentration of 5% and sterilized by filtration. 
Quality control was performed on an analytical Agilent Zorbax® 300SB-C18 column 
(150 × 4.6 mm) at room temperature and with a flow rate of 1 ml/min. The mobile 
phase consisted of water and methanol, each containing 0.5% TFA. Gradient elution 
started with 30% methanol content that was kept constant for 5 min, then increased 
to 50%, raised to 60% in 10 min, then further to 63% in 5 min. The radiochemical 
purity of [18F]22 was >98% and the specific activity of the tracer was 2.9 GBq/μmol. 
The identity of the radiochemical product was confirmed by coelution with the non-
radioactive analogue. 
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8.2. Experimental for Chapter 4 
The automated patch clamp electrophysiology study was outsourced to ChanTest 
Corporation. The experimental details below are reported as provided by the 
company. 
Chemicals 
Chemicals were purchased from Sigma-Aldrich unless otherwise noted and were of 
ACS reagent grade purity or higher. Test compound and control solutions were 
prepared fresh daily by diluting stock solutions into a HEPES-buffered physiological 
saline (HB-PS) solution (composition in mM): NaCl, 137; KCl, 4.0; CaCl2, 1.8; MgCl2, 
1; HEPES, 10; Glucose, 10; pH adjusted to 7.4 with NaOH. Test compound and 
control solutions contained 0.3% DMSO and 0.05% F-127. 
 
Cell culture procedures 
Chinese hamster ovarian (CHO) cells were stably transfected with specific human 
Nav1.x channel cDNAs. Cells were cultured in Ham’s F-12 supplemented with 10% 
fetal bovine serum, 100 U/mL penicillin G sodium, 100 g/mL streptomycin sulfate, 
and the appropriate selection antibiotics. Before testing the cells in culture dishes 
these were washed twice with Hank’s Balanced Salt Solution and treated with 
accutase for approximately 20 minutes. Immediately before use in the IonWorks 
QuattroTM system, the cells were be washed with HB-PS to remove the accutase 
and re-suspended in approximately 3 mL of HB-PS. All experiments were performed 
at ambient temperature. 
 
Controls 
Lidocaine was used as hNav1.x positive control.  A solution of HB-PS + 0.3% DMSO 
+ 0.05% F-127 was used as vehicle control; HB-PS provides the appropriate ionic 
composition for in vitro hERG current recording. 
 
Automated patch clamp electrophysiological procedures 
The test compound formulations were loaded in a glass-lined 384-well compound 
plate, and placed in the plate well of IonWorks QuattroTM or IonWorks™ Barracuda 
(Molecular Devices Corporation, Union City CA). Each test compound concentration 
was applied to naïve cells (n  4, where n = the number cells/concentration). 
In preparation for a recording session, intracellular solution was loaded into the 
intracellular compartment of the PPC planar electrode. Cell suspension was pipetted 
into the wells of the PPC planar electrode. After establishment of a whole-cell 
configuration, membrane currents were recorded using patch clamp amplifier in the 
IonWorks QuattroTM or the IonWorks™ Barracuda system. Before digitization, the 
current records were low-pass filtered at one-fifth of the sampling frequency. Block 
of Nav channels was measured using the stimulus voltage pattern described in 
section 4.2. 
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8.3. Experimental for Chapter 5 
The skin-nerve experiments were performed at the UCL Institute of Neurology. 
All animal work was performed in compliance with the United Kingdom Home 
Office’s Animals (Scientific Procedures) Act 1986 and with approval of the University 
College London (UCL) Animal Ethics Committee. 
 
Isolated Nerve Preparation 
The skin-nerve in vitro preparation was used to record electrically evoked A- and C-
fiber sensory nerve compound action potentials (CAP). Female Sprague-Dawley 
rats, weighing 300 to 400 g, were killed by cervical dislocation. The skin of the hind 
limb and the attached saphenous nerve were removed as previously described by 
Reeh et. al.210 The preparation was mounted corium-side up in an organ bath and 
superfused with oxygenated synthetic interstitial fluid (SIF) consisting of 108 mM 
NaCl, 3.5 mM KCl, 3.5 mM MgSO4, 26 mM NaHCO3, 1.5 mM CaCl2, 9.6 mM sodium 
gluconate, 5.55 mM glucose, 7.6 mM sucrose, and 10 mM HEPES, at pH 7.4. The 
temperature of the bath was maintained at 32°C. The proximal end of the nerve was 
isolated from SIF by liquid paraffin. Recordings were obtained with a pair of gold-
wire electrodes, a custom-made low-noise differential amplifier in common rejection 
mode, a low-pass filter of 1 kHz, and a high-pass filter of 1 Hz. A self-sealing 
stainless steel ring (inner diameter, 6 mm; outer diameter, 8 mm) was placed on top 
of a section of the saphenous nerve. In some experiments, the nerve section 
covered by the stainless steel ring was desheathed before the experiment. The 
whole nerve was stimulated using Ag/AgCl electrodes with a non-insulated tip 
diameter of 2 mm (EPO5; World Precision Instruments, Hertfordshire, UK) at a 
frequency of 1 Hz (A -volley) or 0.25 Hz (C-volley), a stimulus width of 0.2 ms (A-
volley) or 2 ms (C-volley), and an intensity of 5 to 20 V. The amplitude of the CAP 
was measured peak-to-peak and expressed as a percentage of control for different 
treatments. Drug solutions were diluted into SIF from 100 μM or 100 mM stock 
solutions in DMSO and warmed to 32°C before the experiment. 
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8.4. Experimental for Chapter 6 
 
A. Pharmacokinetic profiling of [18F]22 using PET/CT 
The study was performed at the UCL Centre of Advanced Biomedical Imaging by 
Dr. Thibault Gendron and Dr. Kerstin Sander. 
All animal work was performed in compliance with the United Kingdom Home 
Office’s Animals (Scientific Procedures) Act 1986 and with approval of the University 
College London (UCL) Animal Ethics Committee. 
Wild-type albino mice (FVB or Balb/C, Charles River Laboratories, UK) were allowed 
to acclimatize for at least one week and were given food and water ad libitum. 
Dynamic PET imaging was performed using a nanoScan® PET-CT system 
manufactured by Mediso (Medical Imaging Systems, Budapest, Hungary). Mice 
were anaesthetized with isoflurane (2% in oxygen) and placed on the preheated bed 
of the scanner (set at 38 °C). The respective radiotracer (5–10 MBq in 100–250 μl 
saline solution) was injected into the tail vein via intravenous cannulation. After 
injection, the catheter was carefully removed. Breathing rate and body temperature 
of the animals were closely monitored during the dynamic PET scans and, if 
necessary, the isoflurane dose was adjusted. Scans were recorded over two hours, 
and the animals were subsequently sacrificed by cervical dislocation. Quantification 
of tissue uptake was carried out using the software package VivoQuant 1.23 
(inviCRO, Boston, USA). 
 
Β. Maximum tolerated dose finding study of 22 in rats 
The study was outsourced to Charles River Laboratories, Wilmington, MA. The 
experimental details reported below are as provided by the company. 
22 was prepared as solution in vehicle on the day of each experiment. The dosing 
vehicle was 5% glucose in HPLC grade water (chemicals purchased by Sigma). 
A total of 5 male Wistar Han rats were received from Charles River Laboratories, 
Raleigh, North Carolina. Following an acclimation period, the animals were assigned 
to the study based on acceptable health as determined by a staff veterinarian. 
Animals were placed into 5 groups of 1 animal per group. Each animal in Groups 1-
5 received the appropriate 22 dose by intravenous administration (tail vein) over an 
approximate 3 minute dosing period. The volume of each dose delivered (mlkg-1) 
was based on each individual animal’s body weight recorded on the morning of dose 
administration. Dosing was performed in five dose sessions each one week apart. 
Body weights were recorded daily for seven days post dosing. Following dosing and 
at the time of each weight collection, the animals were observed for any clinically 
relevant abnormalities. Animals observed as normal had similar heart rate and 
breathing patterns as non-dosed animals.
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